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The excessive prescribing of short-acting beta2-agonists (SABAs), an indicator of poorly controlled 
asthma and a risk factor for asthma attacks, remains problematic despite proliferating guidelines 
for the management of asthma in primary care. Computer decision support alerts are increasingly 
used to influence prescribing behaviour with guidelines recommending clinicians are alerted to 
excessive SABA prescribing and patients subsequently invited for a review of asthma control. The 
aim of this thesis was to determine the effect of an alert to reduce excessive SABA prescribing and 
explore the potential reasons for the alert’s success or failure. 
Phase 1 of the thesis involved a systematic review of the literature on the use of electronic alerts to 
reduce excessive SABA prescribing in primary care. Findings showed limited evidence to support the 
use of an alert to reduce excessive SABA prescribing when delivered as part of a multicomponent 
intervention in an integrated healthcare system. 
Using a retrospective case-control study design, Phase 2 explored the effect of a single component 
alert to reduce SABA prescribing in 132 practices across three Clinical Commissioning Groups in east 
London. Findings showed a small, potentially clinically significant 6% reduction in repeat SABA 
prescribing within 12 months of the SABA alert (P<0.001). 
Phase 3 consisted of qualitative research with asthma experts and primary care staff (n=32), to 
explore the use of an alert to identify excessive SABA prescribing in practice. Using the ‘framework’ 
analysis approach, findings showed varying definitions and perceptions of excessive SABA use and 
inconsistent alert use, influenced by suboptimal design and ambiguous action. Inconsistencies in 
how excessive SABA prescribing is defined, identified and managed by clinicians in practice were 
observed.  
Findings show that alerts to improve SABA prescribing practice have potential to improve asthma 
management and clinical outcomes for people with asthma in primary care. Further research is 
required to determine the impact of an alert on SABA prescribing when optimised and delivered in 
a multicomponent intervention. Future alert interventions require a collaborative effort between 
people with asthma, general practice and wider primary care.   
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This introductory chapter provides a background to the research undertaken and reported in this 
thesis. Section 1.1 discusses the role of short-acting beta2-agonist (SABAs) in the management of 
asthma, the current issues regarding the associated risks and the challenge of defining excessive 
SABA use. Section 1.2 discusses current SABA prescribing practice in relation to evidence-based 
guidelines and the varying roles of primary care staff in asthma management. Section 1.3 explores 
the increasing role of computer decision support system (CDSS) in the management of asthma and 
the associated challenges. Section 1.4 sets out the thesis structure including the research 
question(s), rationale and aims and objectives of the research undertaken. 
 
1.1     Asthma 
 
Asthma is a heterogeneous disease characterised by chronic airway inflammation which manifests 
in variable respiratory symptoms such as wheeze, shortness of breath, chest tightness, cough and 
expiratory airflow limitation.1 Symptoms commonly vary over time and in intensity. When inhaled, 
SABAs activate beta2-adrenergic receptors causing the relaxation of smooth muscle in the lungs 
resulting in dilation and opening of the airways providing relief of asthma symptoms.2 
 
 
1.1.1 Asthma prevalence 
 
Asthma is one of the most common long-term conditions in the world. An estimated 339 million 
people globally are thought to have asthma, with approximately 5.4 million people in the UK 
affected.3,4 Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) 
suggests the UK has one of the highest asthma prevalences in the world.5 Globally an estimated 21% 
of adults and 14% of children experience asthma symptoms.3,6 However in the UK, the lifetime 
prevalence of patient-reported symptoms suggestive of asthma is approximately 29.5 % (18.5 
million people).7 Despite recent analysis suggesting a plateau in new diagnoses of asthma 
particularly in children, the lifetime diagnosis and prescription of asthma-related medication in 
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primary care continues to rise.8 Furthermore, research indicates a disproportionate prevalence in 
the burden of asthma among people of ethnic minority populations. In a review of asthma outcomes 
among ethnic minorities in the UK, Netuveli et al., identified that people with asthma from Black 
and South Asian ethnic backgrounds were at substantially increased risk of hospital admission when 
compared to their White counterparts.12 More recently in their research on asthma prescribing and 
risk of hospital admission in inner city east London, Hull et al., identified that Black and South Asian 




1.1.2 Asthma control 
 
Asthma control is defined as the extent to which the manifestations of asthma can be observed or 
have been reduced or removed by treatment.14,15 Figure 1.1 summarises Bateman et al’s., goals for 
achieving asthma control and reducing future risk.16  Inhaled corticosteroids (ICS) are used in the 
management of asthma to maintain asthma control by suppressing airway inflammation and 
reducing airway hyper-responsiveness. SABA use is both a marker of current asthma control and 
future risk, with frequent and increasing use associated with poor symptom control,17,18 increased 
risk of exacerbations9,19–24 and potentially asthma-related death.25–27 When prescribed at an 
appropriate strength/dose, the regular use of ICS should result in minimal to no asthma symptoms 
and therefore a decreased need, or ideally no need, for SABAs.37  
 




It is estimated that asthma control is suboptimal in over half of the asthma population.28 Poor 
asthma control is primarily due to suboptimal management,29,30 and is associated with a higher risk 
of exacerbations, increased morbidity, mortality and healthcare costs.28,31–33,34 Research has 
consistently reported that both suboptimal ICS use and overuse of SABAs is associated with poor 
outcomes.35 However using prescribing data to infer asthma control is problematic for a number of 
reasons. Prescribing data is a crude surrogate indicator of asthma control that may not accurately 
reflect current use. For example, despite inhaled medication being prescribed, it cannot be assumed 
this was dispensed from pharmacy. Furthermore actual inhaler use based on device actuation and 
delivered dose to the lungs cannot be captured.36–38 Discrepancies also exist between patient-
perceived asthma control and guideline-defined asthma control28 with binary descriptors of asthma 
control as ‘good’ or ‘bad’, ‘’optimal’ or ‘sub-optimal’ not reflective of the continuum of asthma 
care.15 
 
1.1.3 Short-acting beta2-agonists and risk 
 
The use of SABAs in the management of asthma has not been without controversy with two 
“epidemics” of asthma mortality attributed to the adverse effects of SABAs.39 During the mid-1980s 
in New Zealand, three case-control studies reported an increased risk of death among people using 
the short acting beta2-agonist, fenoterol.40–42 Findings suggested an association between the dose 
of and cumulative exposure to beta-agonists in general, rather than the specific compound of 
fenoterol.43,44,45 Between 1970 and 1992 research carried out in nine countries where fenoterol was 
licenced did not indicate any relation between asthma mortality and beta-agonists in general nor 
fenoterol in particular.46 However in 1992, Spitzer et al., examined prescription records in the 
Saskatchewan province in Canada and found an association between inhaled beta-agonists and 
increased risk of death particularly among those prescribed more than two canisters per month of 
fenoterol or salbutamol.27 
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In 1994, a study by Suissa et al., carried out in the Saskatchewan Province, concluded the association 
between inhaled beta-agonists and asthma mortality was observed in those using more than two 
SABAs per month but also with increasing use i.e. a doubling of monthly SABA use, was a major 
predictive factor of adverse outcomes in asthma.26 Other studies have demonstrated that regular 
use of SABAs, fenoterol and salbutamol, accelerated the decline in clinical disease control and lung 
function.39,47 
 
In the 1990s, enquiries in England and Scotland reported an association between increasing SABA 
use and asthma deaths. A review of 50 asthma deaths in England between 1992 and 1994 noted 
that those requiring two or more SABAs monthly were at increased risk 50 In a review of 95 deaths 
from asthma in Scotland between 1994 and 1996, the management of asthma was judged 
inappropriate in 41% of asthma deaths51 with excessive repeat prescribing of SABAs implicated in 
both reports. 
 
In the most recent confidential enquiry into asthma deaths in the UK, the National Review of Asthma 
Deaths (NRAD), further implicated the excessive prescribing of SABAs as a preventable factor in 195 
asthma related deaths.25 Between 2012 and 2013, 39% received more than 12 SABAs in the previous 
year, with 4% having received more than 50 SABAs in the previous year. Despite uncertainty 
regarding the mechanism of action, evidence suggests a risk-benefit paradox of SABAs; that despite 
being used to counteract symptoms of airway inflammation, SABAs may have pro-inflammatory 
effects that enhance, rather than reduce, airway responsiveness.48,49 These consistent findings 
indicate the need for urgent action to  address current prescribing practices and the provision of 















1.1.4 Defining excessive use 
 
The association between SABA use, poor asthma control and risk of exacerbation varies in the 
reporting of the SABA threshold, language and evidence cited in the literature. National asthma 
guidelines devised by the British Thoracic Society in collaboration with the Scottish Intercollegiate 
Guideline Network (BTS/SIGN) state that heavy or increasing SABA use is a risk factor for asthma 
death.52 The international Global Initiative for Asthma (GINA) strategy state that high SABA use is a 
potentially modifiable risk factor for exacerbations.1 BTS/SIGN base use Spitzer et al.,27 Suissa et 
al.,26 and the UK enquires into asthma deaths as described in the previous section as their evidence 
base for recommendations50,51,53,54 whilst GINA base recommendations on evidence from Suissa et al., 
and Turner at al.26,55 BTS/SIGN define poor asthma control as SABA use of more than three times a 
week52 in contrast to GINA guidelines which define poor control as use of SABA more than twice a 
week.1 In comparison, the NRAD recommendations that one SABA inhaler a month, or more than 
six puffs a day, is indicative of poor asthma control far exceeds guideline recommended levels of 
SABA use indicative of sub-optimally controlled asthma.  
 
A number of studies have identified an increased risk of asthma attack and/or hospital admission 
associated with SABA use at much lower levels than one inhaler a month (12 a year). Studies have 
suggested an increased risk associated with use of more than three SABAs a year,56 more than four 
SABAs a year,9 more than five SABAs a year,57 more than six SABAs a year18,58 and more than nine 
SABAs a year.22 More recently Hull et al., identified a progressive risk of hospital admission 
associated with increasing prescription of SABAs; a two-fold increase in risk of admission when 
prescribed more than 3 SABAs in the previous year and more than a three-fold increase in risk if 
prescribed more than 12 SABAs in the previous year.13   
 
Studies have also stratified levels of SABA use and associated risk rather than determining risk based 
on definitive prescribing threshold. Schatz et al. derived an asthma control scale based on four levels 
of SABA use:  between 0-2, 3-6, 7-12 and >12 SABAs a year. Patients prescribed between 3 to 6 
SABAs per year were at greater risk of asthma exacerbations and poorer symptom control, with 
increasing risk when prescribed between 7 to 12 SABAs and more than 12 SABAs a year.18  
In Tavakoli et al’s., analysis of the predictors of SABA use in asthma, they distinguished between 
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excessive and inappropriate SABA use, with excessive defined as using at least 12 SABAs a year 
whilst the inappropriate use of SABAs was interpreted in conjunction with ICS use, as >2 puffs SABAs 
and no ICS per week or 9 SABAs and <=100μg/day of ICS per year.62  A recent ‘Asthma Right Care’ 
initiative from the International Primary Care Respiratory Group (IPCRG)65 has sought to provide 
clarity and consistency in the messaging used to talk about SABAs. Recommendations have called 
for a shift to the term ‘over-reliance’ rather than ‘overuse’ or ‘excessive use’ as the latter holds 
negative connotations that may deter patients from using SABAs when clinically appropriate.  
 
The risks of SABA use have also been defined with the co-prescribing of ICS, with the excessive use 
of SABAs and underuse of ICS use associated with the use of significantly more health care 
resources.22 Lanes et al. concluded that patients who received more than one SABA prescription a 
month the previous year with regular use of inhaled steroids (7+ prescriptions per year), had a 60% 
reduction in risk of asthma death.59 The NRAD inferred an association between the under-use of ICS 
and over-use of SABAs with 49 patients (38%) prescribed fewer than four ICS prescriptions in the 
year before death whilst 103 (80%) were issued with fewer than 12 preventer inhalers in the year 
before death. Furthermore, Hull et al., reported the greatest burden of emergency hospital 
admission for asthma occurred among those prescribed less than 10 ICS inhalers a year with rising 
number of SABAs prescribed associated with risk of hospital admission.13 National and international 
guidelines recommend SABAs are not prescribed in isolation but rather with an appropriate level of 
ICS to achieve and maintain control of asthma symptoms and reduce future risk.1,52   
 
In an assessment of the use of primary care electronic health records in the management of 
respiratory disease, Ryan et al’.,66 define medication prescribing and medication use as two separate 
variables that should be used to identify at-risk patient. This suggests that to improve overall asthma 
control the behaviours of both patient use and clinician prescribing of SABAs should be targeted. 
 
 
1.2   Prescribing 
 
The medication process in primary care is comprised of three stages; medication prescribing 
administration and monitoring, each involving a multidisciplinary team of professionals, informal 
26 
 
carers and patients.67 Prescribing medicines is an inherently risky and often complex task,68 
described by Cribb and Barber as ‘a balance between the right technical properties, what patients 
want and the greater good.’ 69  
 
 
1.2.1 Prescription types 
 
Prescribing occurs in a number of ways in general practice: as an acute prescription for a one-off 
provision of medicine, by repeat prescription for long‐term medication use,70,71 or by repeat 
dispensing commonly managed by a pharmacist.72 Paper prescriptions, otherwise referred to as an 
‘FP10’, are historically the most common prescription type. In 2010 the electronic prescription 
service (EPS) was introduced whereby a prescription is digitally signed by the prescriber and sent via 
a central network (the Spine) to be downloaded in pharmacy. The purpose of EPS was to improve 
the efficiency and safety of prescribing, to improve communication in primary care and reduce 
prescribing workload.72 However the uptake of EPS has been variable with up to 70% of patients 
continuing to be issued prescriptions by paper.73 Despite the purported benefits, the additional 





1.2.2 Repeat prescribing 
 
 
Salbutamol is the most commonly prescribed SABA used for the relief of asthma symptoms.74 It is 
the eleventh most commonly dispensed medication in England, with approximately 22 million items 
dispensed in 2017.75 In a recent report on repeat prescribing in the UK, it was estimated that up to 
80% of all SABAs are issued ‘on repeat,’ with the management of repeat prescriptions accounting 
for 20 per cent of a GPs workload.76 Furthermore, the number of repeat prescriptions issued 
nationally is estimated to have more than doubled from 5.8 to 13.3 items per patient per annum in 
the past two decades.77 
 
Zermansky identified three tasks in repeat prescribing; prescription production, management 
control (authorization, compliance, review date, flagging) and clinical control (authorization, 
periodic review).79 Robust systems for safe and effective repeat prescribing are required78 however 
this is problematic as repeat-prescribing systems vary between practices and require a high degree 
of local tailoring and judgment from frontline staff.71,76 In ethnographic observations of receptionists 
in four general practices, Swinglehurst et al. identified repeat prescribing as a complex technology-
supported social practice, with receptionists heavily involved in the production and quality and 
safety of repeat prescriptions.71 
 
The “error” and “harm” associated with prescribing and medicines management in primary care is 
well documented with reducing preventable harm in repeat prescribing a patient safety priority 
worldwide.80,81 The NRAD identified that of those prescribed SABA in the year before death 97% 
were obtained on repeat prescription.25 This raises concerns regarding the review processes for 
SABA prescribing in primary care,72 with concerns regarding the adequacy of control in the review 
process.71,79 The NRAD recommended that patients who have requested the maximum number of 
SABA approved prescriptions are identified and invited to attend for urgent review.25 In an e-Delphi 
study on the most important safety features of GP computer systems, there was consensus that 
practice staff should be alerted to patients either under-using or over-using their medication.82 A 
systems approach that combines technology interventions, education and improvement to improve 




1.2.3 Role of pharmacists 
 
Almost two decades ago Zermansky highlighted the role of pharmacists in identifying and managing 
high risk repeat prescribing.79 Systematic reviews of pharmacist-led interventions targeted at 
patients and/or prescribers have shown potential to improve medication use processes.84,85 In the 
PINCER trial, general practices were allocated to either (1) simple computer-generated feedback for 
patients identified by at-risk prescribing (control) or (2) a pharmacist-led multifaceted intervention 
composed of feedback, educational outreach, and dedicated support (PINCER).86 Findings showed 
that a multicomponent pharmacist-led intervention reduced a range of medication errors in general 
practices. Most recently, Petty highlighted missed opportunities to improve the quality and safety 
of repeat prescriptions across primary care,76 yet concerns regarding the management of repeat 
prescribing persist and the pharmacist’s role in asthma management remains underutilised.79  
 
The role of community pharmacists in clinical tasks has typically been limited, due in part to national 
contracts which generate the majority of income from dispensing services.76 Since 2015, NHS 
England initiatives have seen an increased role of pharmacists in general practice, mainly to relieve 
GP pressures driven by workforce changes.87 This has increasingly involved the delegation of 
responsibilities for the management of repeat prescriptions and medication reviews from GPs to 
pharmacists. However in a recent review of pharmacist’s intervention in asthma management, 
Crespo-Gonzalez et al. concluded the most common pharmacist interventions continue to be 
patient education and self-management rather than process interventions.88  
 
In 2016, the Murray Review,90 a review into the utilisation of community pharmacy in England 
identified that patients and the public still do not benefit from the full range of skills that community 
pharmacists possess. The review highlighted the underutilised potential for pharmacists in the 
management of long-term conditions including medicines management.  Recommendations 
included the development of Medicines Use Reviews (MURs) into full clinical reviews in community 
pharmacy, to include on-going monitoring and follow-up of patients.90 In Scotland, the role and 
responsibilities of community pharmacists has already been extended to the management of long-
term conditions such as asthma. The Chronic Medications Service (CMS) involves a pharmaceutical 
assessment and care planning to facilitate pharmacist’s monitoring and review of medications. 
Within the CMS, when medication is dispensed by community pharmacists details are sent to the 
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corresponding GP practice and the patient’s Emergency Care Summary; a national shared electronic 
patient record system across NHS Scotland which is automatically updated.91  This gives a more 
accurate picture of medication use based on items dispensed rather than prescribed. 
 
The Pharmaceutical Services Negotiating Committee (PSNC) have proposed similar roles for 
community pharmacists in England.92 This would involve pharmacists being responsible for 
medication adherence issues, undertaking clinical assessments, medicines reviews and checking for 
suspected adverse effects. In a recent Cochrane review on community pharmacist services, the 
impact of pharmacist’s management of long-term conditions, the management of hypertension was 
comparable between pharmacists and GPs.93 Such findings highlight the potential for pharmacist-
led interventions in asthma management as an adjunct or alternative to GP delivered care. However, 
despite recommendations from the Murray Review, the absence of integrated computer systems 
limits the sharing of data between primary care service providers. Furthermore, pharmacist-led 
interventions in asthma management are likely to be dependent on funding, leadership, culture, 
time and the overcoming of professional boundaries between community pharmacists and GPs.  
 
In the past two decades, the purchasing of medications online through either online pharmacies or 
alternative sources has become an increasingly convenient and cost saving way to obtain 
medications. However, there are a number of safety risks linked to the online purchase of medicines 
outside the traditional supply chain, including insufficient clinical supervision, monitoring and lack 
of continuity of care.94 The in online purchasing of medications may therefore limit the opportunity 
for pharmacist-led interventions in asthma management. However, health care professionals, 
particularly pharmacists, are ideally positioned to influence such behaviour and reduce risk of online 






1.2.4 Evidence-based asthma guidelines 
 
BTS/SIGN are the mainstay guidelines for asthma care across the UK.105 However despite the 
increasing evidence base to guide clinical practice, including the recently published National 
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Institute for Health and Care Excellence (NICE) guidelines for the diagnosis, monitoring and 
management of asthma,108,109 application of asthma guidelines into clinical practice remains 
problematic.106,107 It is suggested that inconsistency in guideline recommendations regarding 
appropriate SABA use and prescribing practice sends a contradictory message to clinicians making 
guideline application into practice both challenging and confusing.96 For example, BTS/SIGN 
recommend that SABAs should not be prescribed without an ICS, thus removing SABAs as the first 
step of the commonly recognised 1 to 5 stepwise approach in the pharmacological management of 
asthma.52 In contrast, NICE advise that SABAs can be used in the first step as sole treatment for 
asthma.  
 
Most recently, the NRAD identified a failure among clinicians to adhere to national asthma 
guidelines, in particular the excessive prescription of SABAs, insufficient prescription of ICS and 
failure to recognise patients at current and future risk of asthma attack.25 There may be a number 
of reasons for poor adherence to asthma guidelines in practice including a lack of awareness, lack 
of guideline knowledge, disagreement with guidelines or external or practical barriers such as lack 
of time and limited staff resources.96–99  Continued variability in asthma management across primary 
care has  resulted in increasing calls for one universal guideline to provide coherent and consistent 
advice to clinicians to improve asthma care.110–113 Computer decision support systems (CDSSs) in 
clinical practice have been recommended to increase clinician adherence to evidence-based 




1.3 Computer decision support systems 
 
 
Electronic health records (EHRs) are defined as digitised health record systems that facilitate the 
access, storage, display, and retrieval, printing, and sharing of patient’s health care information.114 
EHRs can be integrated with computer decision support to improve the quality and safety of patient 
care through the use of routinely collected patient data.115 Success of such systems is dependent on 
use, therefore it is important to understand how these systems work in clinical practice.116 
 
 
1.3.1 Defining computer decision support 
 
Wyatt and Spiegelhalter define CDSSs as ‘active knowledge systems which use two or more items 
of patient data to generate case-specific advice.’117 However defining CDSSs is challenging due to 
variability in the features and characteristics of such systems in practice. Over 15 years ago, in 
seminal research on the effective features of decision support, Bates et al., defined CDSSs systems 
as those which provide “passive and active referential information as well as reminders, alerts, and 
guidelines.”118 More recent definitions increasingly reflect higher levels of technical sophistication 
of decision support systems.119 In a step-by-step roadmap for using CDSSs to improve outcomes, 
Osheroff et al. define CDSSs as that which provides “clinicians or patients with computer-generated 
clinical knowledge and patient-related information, that is intelligently filtered or presented at 
appropriate times, to enhance patient care.”104 Therefore important features of such systems are 
not only the type of information and how it is presented but also when it is presented. 
 
CDSSs are either systems that are stand-alone, or more recently integrated with EHRs as 
technological capabilities have increased. Integrated decision support uses routinely recorded 
clinical and demographic data to tailor and target clinician advice for specific populations and 
disease profiles.66 CDSS designs range from simple to more complex systems. A simple system may 
present descriptive text to support clinician decision-making whilst a complex system may include 
patient data integrated with guidelines or protocols.119, CDSSs most commonly include alerts and 
reminders generated from electronic patient data to guide and assist clinical decision-making.121,122  
Sittig et al. identified the majority of CDSSs utilise simple alerts and reminders to assist with decision 
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making.125 However in the literature no clear distinction is made between CDSS “reminders”, 
“alerts”, and “prompts” with these terms often used interchangeably.122  
 
 
1.3.2 Features of effective computer decision support systems 
 
James et al., define effective CDSSs as those which present the right information, in the right format, 
at the right time, without requiring special effort.”126 Kuperman elaborates that effective CDSSs are 
those which utilise real time patient specific EHR data to generate alerts integrated at the point of 
care.127 The importance of CDSS integration streamlined with workflow was first emphasised in 
Bates et al’s., seminal research Ten Commandments for Effective Clinical Decision Support.118 When 
such systems use real time patient data to support clinician decision making, patient’s are 
increasingly likely to receive more appropriate and timely care. Maviglia et al., suggest that level of 
integration with clinical practice will determine the success of alerts but there remains limited 
guidance on where and how CDSSs should be integrated to improve process and patient 
outcomes.128 
 
The clinical workflow concept has evolved from the manufacturing industry which focused on the 
completion of a collection of tasks to accomplish a process.129 In healthcare, workflow describes the 
point at which clinicians are engaged in an activity of interest, such as prescribing medications, 
documenting clinical encounters and ordering investigations.”130 Thorough understanding of the 
clinical workflow processes and when and how to prompt clinicians within workflow strongly 
increases the likelihood of decision support use.118 In a study on decision support and GP prescribing, 
Hayward et al. identified that alerts integrated in-consultation often do not align with prescribing 
workflow, but instead present when prescribing decisions have already been ‘justified, negotiated 
and agreed’ with the patient at various points in the consultation.124 Consideration should be given 
to the technological, clinical, and socio-technical issues that influence clinical decision making when 
designing and implementing CDSSs.120 
 
The presentation of alerts that interrupt workflow, commonly referred to as ‘hard’ or modal alerts, 
have shown a significantly higher effect on outcomes than non-interruptive (passive) reminders, 
soft or non- modal alerts.122,137,145,146 In a review of the literature on drug safety alerts, van der Sijs 
et al., recommend that to facilitate use, alerts should have high specificity and sensitivity and 
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minimise workflow disruption.142 Furthermore, increased user acceptability has been observed 
when alert recommendations could not be ignored.118,145 This suggests that alert success is 
dependent not only on when, where and how alert presents but also on the type of information 
displayed and the ability of the user to act on such information. 
 
Research suggests that success of medication-related decision support is dependent on human 
factor design.143 In a review of human factors in the design and implementation of medication alerts, 
Phansalkar et al, suggested that for alerts to be acted upon, they should present in a clinician’s visual 
field, with alert size, colour, and signal words tailored to indicate level of risk.144 Further suggestions 
include decision support that presents clinically meaningful, pragmatic, evidence based knowledge 
that can be actionable rather than ignored. 127  
 
 
1.3.3 Computer decision support and asthma 
 
Several systematic and narrative reviews have highlighted the potential of CDSSs to improve 
clinician performance and decrease adverse patient outcomes in chronic disease 
management.122,142,147–149 In particular two systematic reviews have focused on the increasing use of 
CDSSs to improve the management of chronic conditions such as asthma.150,151 However, it is unclear 
to what extent decision support has been used to specifically reduce excessive SABA prescribing in 
asthma is unclear.  
 
In a systematic review of CDSSs in the management of asthma, Matui et al.,150 concluded that 
systems were ineffective at improving patient outcomes because they were rarely used,153–155 and 
users were often not compliant with CDSS advice.155,158 However, when systems were used, some 
improvement to clinical outcomes was reported. 152,156 In comparison, in a systematic review on 
CDSSs and asthma in primary care, Fathima et al.,151 concluded that CCDSs comprised of multiple 
components such as reminders and education, have the potential to improve the management of 
asthma when compared to single-target interventions with fewer components. These findings 
echoed research on the effectiveness of CDSSs for other common chronic conditions such as 
diabetes and osteoporosis. 
In a study evaluating the impact of at-risk registers for severe asthma (ARRISA), Smith et al., used 
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alerts to identify people at risk of asthma attack.160 Findings showed the alerts had no significant 
effect on asthma exacerbations, with 70% of end-users reporting that alerts had limited impact on 
the management of identified patients despite the wording, appearance and visibility of alerts being 
customised by practice. Whilst CDSSs alerts are commonly generated in electronic health records to 
improve high-risk medication prescribing,68,161 the alerts in the ARRISA study  were not specific to 
SABA prescribing. Recommendations from the NRAD report and leading asthma charity Asthma UK 
have called for increasing use of CDSSs in the management of asthma prescribing however the use 





Despite advances in technology and design, concerns regarding the usability and relevance of CDSSs 
remain.119 Current research gaps in CDSSs include determining optimal specificity and sensitivity of 
alerts, the personalisation and timing of alerts in the prescribing process and capturing appropriate 
outcome measures from which CDSS success can be measured.121 Furthermore, prescribing 
practices are commonly based on guideline recommended ‘best practice’ that remain open to 
interpretation.127 A predominant issue in CDSS design is clinicians being inundated with alerts of low 
clinical significance resulting in “alert fatigue.”142,163 Coleman et al., define alert fatigue as cognitive 
overload and/or desentisation “resulting from alerts consuming too much time and mental 
energy,”121,165 This increases the chance that prescribing alerts pertinent to patient safety or of 
clinical relevance will be overridden or ignored by clinicians. 142,163,164,166 For example, in a review by 
Van der Sijs et al., clinicians overrode alerts between 49% and 96% of the time.142 Alert fatigue is 
often due to the failure of CDSSs to provide patient specific guidance to clinicians at the appropriate 
time and using an appropriate method of display.167 Creating a clear and concise alert that displays 
sufficient information, as well as facilitating appropriate action, presents many challenges as there 
is no one size fits all approach to decision support systems nor prescribing processes.127 
 
In a review of CDSS functionalities, Jones et al. concluded that insufficient reporting of the 
implementation and context of CDSS use makes it difficult to evaluate why some interventions are 
successful and others are not.168 Systematic reviews often do not differentiate one type of decision 
support from another making the evaluation of individual CDSS components challenging.122,137,168,169 
Furthermore, heterogeneity in study design, clinical setting, study population, software 
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specifications, CDSS workflow integration and process and clinical outcomes is common even when 
evaluating the same drug or disease.147 
 
In a seminal review on the quality and safety of eHealth, Black et al., reported that CDSSs vary on 
multiple dimensions, including levels of sophistication, detail, data source with variable integration 
across health services.120,170  In a subsequent summary of the grand challenges in clinical decision 
support, Sittig et al. emphasised that CDSS use is influenced by the local contexts and healthcare 
settings in which they are applied.124 The majority of CDSS evaluations originate from North America, 
with design and use likely influenced and facilitated by integrated healthcare organisations in an 
insured healthcare system.102,103,118,122,137,167, In contrast, the interoperability of NHS technology 
systems, including the integration of health and social care records, data sharing and digitisation of 
patient records across IT platforms has shown limited large-scale success. However, a number of 
local NHS clinical commissioning groups (CCGs) have successfully moved towards integrated and 
interoperable health care records, with success attributed to the early buy-in and involvement of 
clinicians and the role of digital technology in wider transformation plans.171 The current ability of 
local healthcare providers to achieve such ambitious plans is however likely to be constrained by 













1.4 Study rationale 
 




Despite an increasing number of guidelines for the management of asthma, there is no consensus 
definition on how many SABAs is problematic. In the literature, the reporting of “excessive” SABAs 
is variable in terms of quantity and associated risk. The impact of inconsistent messaging on clinician 
prescribing remains unclear.  Furthermore, asthma management is not restricted to GPs but 
involves members of the wider primary care team including receptionists and pharmacists.  
Increasing evidence shows the potential to improve the management of asthma and prescribing 
practices through CDSSs alerts. However, alerts often do not align with decision-making that occurs 
at various points in clinician workflow. At present the evidence to support the use of alerts in SABA 
prescribing remains unclear.  
 
 
1.4.2  Current problem 
 
 
Recent figures indicate that asthma deaths in England and Wales are the highest on record, with an 
increase of more than 25% from ten years ago (figure 1.2).172 Asthma mortality is however rare 
contributing to less than 1% of all deaths globally.3 Furthermore, the accuracy of death certification 
was highlighted as a potential limitation of the data analysed in the NRAD report, with the cause of 
many deaths incorrectly coded as asthma rather than as a result of comorbid disease.25 Whilst 
asthma deaths remain shocking, the reliability of data and the analysis and interpretation of asthma 












        Source: Office of National Statistics (2018)172 
 
 
Asthma morbidity, defined as the frequency of acute asthma exacerbations, emergency department 
visits and hospitalisations, remains a burden to health care services and patients.7 A study by 
Partridge et al. estimated that 75% of hospital admissions for asthma are preventable, with poor 
prescribing practice a potentially avoidable contributor to both asthma morbidity and mortality.174  
 
Two studies on variations in UK hospitalisation rates for asthma identified increasing rates of  
asthma morbidity among adults and children of Black and South Asian origin.12,180 However, the 
limited  number of UK studies are out-dated having taken place in the 1980-90s and inclusive of only 
three broad ethnic groups, namely: Whites, Blacks and South Asians. Recent research by Sheikh et 
al., suggests that increased hospitalisations among ethnic minorities are likely due to variability in 
asthma knowledge and awareness, greater severity of asthma, and differences in the quality of 
care181 and medication use.182,183 Understanding such variations is challenging, as ethnic minority 
groups remain under-represented in asthma research. 
 
Recommendations have called for innovative strategies for the early detection and prevention of 
asthma attacks in primary care to reduce asthma morbidity and the burden of disease.7 An 
assessment of the impact of CDSSs on asthma mortality is beyond the scope of this thesis. However, 
the role of CDSSs in identifying potentially poor asthma control and the influence of CDSSs on 




1.4.3  Asthma outcomes in east London 
 
In London, asthma prevalence is estimated to be lower than the rest of England ranging between 
3.5% to 5.7% of the population.184,185 However, in three densely populated boroughs in inner city 
east London, mortality from asthma is higher  than that of London and England with a rate of 2.75 
per 1000 asthma deaths in Tower Hamlets, increasing to 5.41 in Hackney and 5.85 in Newham 
(Figure 1.3).186 London has higher hospital admission rates for asthma in comparison to the rest of 
England despite a lower prevalence of asthma.184 Within London, crude hospital admission rates in 
the east London boroughs of Hackney, Newham and Tower Hamlets are above the London average 
(figure 1.4).186 Asthma morbidity disproportionately affects people from ethnic minority 
backgrounds,12 which may account for the poor asthma outcomes in the ethnically diverse and 
transient Inner city east London boroughs. Often concentrated in inner-city areas175,176 ethnic 
minorities often have poorer continuity with healthcare providers,177 less familiarity with primary 
healthcare practitioners178 and are more likely to present to Accident and Emergency Departments 
(AED) as a primary source of care.179 
 
Figure 1. 3 Asthma mortality rate per 1,000 deaths in east London in comparison to London 




Figure 1. 4 Crude hospital admission rates in Hackney, Newham and Tower Hamlets in 






1.4.4  Framing the research question 
 
The rationale for the framing of this thesis as an evaluation of an alert for “excessive” SABA 
“prescribing” is described below: 
 
(i)   “Excessive” SABAs: this is quantified using the pre-defined EMIS Asthma Medicines 
Management alert threshold of three SABAs in three month. The description of this threshold as 
excessive was reflective of the terminology used in the most recent evidence in the NRAD report. 
 
(ii) SABA “prescribing”: SABA prescribing is commonly used as a proxy measure of SABA use with 
terms often used interchangeably in the literature. This is because actual SABA use cannot be 
determined as it is not possible to capture device actuation and drug deposition in the lungs. For the 
purpose of this thesis, the term SABA “prescribing” is not used interchangeably with SABA use, as 




1.5 Aims and Objectives 
 
This thesis aims to address the gaps in the research in the following ways: 
 
 
I. To provide a systematic overview of the literature on the use of CDSS alerts to reduce 
excessive prescribing of SABAs in primary care. 
II. To evaluate the effect of a CDSS alert to reduce SABA prescribing and improve asthma 
management. 
III. To explore the views of asthma experts and primary care staff regarding the use of a CDSS 
alert to reduce excessive SABA prescribing in primary care. 
 
The objectives of this thesis are comprised of the following three contemporaneous stages: 
 
 
Phase 1: A systematic review of the literature on the use of CDSS alerts to reduce excessive SABA 
prescribing and to determine the features of alert systems that have the potential to improve 
process outcomes for healthcare providers and clinical outcomes for people with asthma in primary 
care. 
 
Phase 2: Evaluate the effect of the Asthma Medicines Management alert (SABA alert) on SABA 
prescribing in general practices in east London using a retrospective case-control study design, 
including a subgroup analysis of repeat prescribing and secondary process measures and clinical 
outcomes of asthma care. 
Phase 3: Explore what primary care staff and asthma experts understand by excessive SABA 
prescribing, identify the extent to which the SABA alert is used and the factors influencing its use, 









1.6 Structure of the thesis 
 
Chapter 1 introduces the background to the study placing it in context within current literature, 
highlights the current challenges in identifying and managing excessive SABA prescribing and the 
potential for CDSSs to assist clinicians in practice. This is followed by an outline of the study’s aims 
and objectives of this thesis delivered in three contemporaneous phases. 
 
Chapter 2 sets out the methodology that has been used to inform the design of the thesis. The 
chapter includes a discussion of mixed-methods research traditions and the application of both 
quantitative and qualitative methods appplied in this thesis are described, critiqued and justified. 
 
Chapter 3 reflects Phase 1 of the thesis; a systematic review of the literature on the use of alerts to 
identify and reduce excessive SABA use. Both the systematic review protocol188 and the review 
findings189 have been peer reviewed and published prior to this thesis. Phase 1 addresses gaps in the 
literature regarding the use of alerts specifically for excessive SABA prescribing whilst reviewing the 
impact and the features associated with CDSS alert interventions. 
 
Chapter 4 presents Phase 2 of the thesis, a case-control study evaluating the impact of the EMIS 
Asthma Medicines Management alert (SABA alert) on process measures and clinical outcomes of 
asthma management. This includes an analysis of asthma outcomes of interest at predefined time 
points before and after the introduction of the SABA alert. Findings across three clinical 
commissioning groups (CCGs) in east London were analysed collectively.  
 
Chapter 5 presents Phase 3 of the thesis comprising of a qualitative study with primary care staff 
and asthma experts. This study provides insight on the perceptions of the problem of excessive SABA 
prescribing, highlighting the roles of primary care staff in the identification and management of 
excessive SABA prescribing.  It also addresses how the SABA alert is used in practice including the 
influences and challenges to its use. Phase 3 provides both context and understanding to Phase 2 
findings. 
 
Chapter 6 integrates the contemporaneous findings of Phase 1, 2 and 3 of the thesis. Findings of 
Phase 1 (Systematic Review) and Phase 3 (Qualitative study) are discussed in relation to the findings 
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of Phase 2 (Quantitative study). A number of recommendations for practice are made, including 
discussion of recommendations of further work. The chapter finishes with an overall conclusion, 
summarising the thesis findings in relation to the aims of the research. 
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This chapter outlines a general introduction to the methodology applied in in this thesis. Firstly, a 
description and rationale for the selection of a mixed methods research design is discussed to 
provide context to the thesis. The contribution of patient and public involvement in shaping the 
thesis is described prior to a description of the methods applied in this thesis. A discussion of the 
key philosophical assumptions underlying a particular research tradition precede the presentation 
and justification of the methods applied. The chapter ends with a summary of how the aims and 
objectives of the research project will be met whilst acknowledging some of the potential limitations 
of the methods to be applied. 
 
2.1 General introduction to research methodology 
 
Creswell190 defines methodology as the framework that relates to the entire process of research, 
whilst the research design refers to the plan of action that links the philosophical assumptions to 
specific methods e.g. mixed methods. The methods can be defined as the techniques of data 
collection and analysis, such as a quantitative instruments or qualitative analysis of text data.191 
However, the methodology requires moving beyond descriptions of the research process instead 
critiquing how the research process had been generated and justified and the philosophical 
assumptions that underpin the methods applied. 
 
Philosophical assumptions, described by Guba and Lincoln192 as ‘paradigms’, underpin the 
methodological approach adopted by any researcher, depending on the researcher’s ontological 
and epistemological standpoint. Blaikie193 describes ontology as concerned with what exists, while 
epistemology refers to the possible ways of knowing what exists based on assumptions about what 
there is to know or can be known. Therefore, the researcher approaches a subject with a set of ideas 




Health services research, is defined by Bowling194 as “...an applied field of multi-disciplinary research 
concerned with the relationship between the provision, effectiveness and efficient use of health 
services and the health needs of the people.” This type of research involves either quantitative 
methods, rooted in the natural sciences, qualitative methods, rooted in the social sciences, or a 
mixture of both approaches.191 This chapter describes the methodology used to explore the effect 




2.2 Mixed-methods research design 
 
2.2.1 Defining mixed methods 
 
Mixed methods research, defined as the collecting, analysing, and mixing both quantitative and 
qualitative data in a single study or a series of studies,190 has been described as the “third 
methodological movement” behind that of quantitative and qualitative methods.195 The use of 
mixed methods is increasing in prominence in health services research and particularly in health 
service evaluations.196 
 
There are a number of approaches to mixed methods research based on what is being combined, 
when or where the combination is made and the breadth and purpose of combinations used to 
address the research question.197 Mixed methods can be applied concurrently (at the same time), 
sequentially (one after another) or independently, with data integrated either by design, methods, 
interpretation and reporting or a combination of approaches.198 The most common mixed method 




Figure 2. 1 Main mixed methods design types 
 





2.2.2 Philosophical basis of mixed-methods research 
 
 
Mixed-methods research is not committed to any one philosophy, because one philosophy cannot 
account for the variety of methods used. Instead, mixed-methods research adopts a more pragmatic 
perspective, which is further described below. 
 
 
2.2.2.1     Pragmatism 
 
 
Pragmatism is a middle-ground philosophy that does not seek to address a research ‘truth’ or 
abstract knowledge, but instead seeks to enhance knowledge through the direct enquiry of
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research.200 In pragmatism, there is no all-embracing worldview,201 with Onwuegbuzie and 
Johnston202 noting that a philosophical and methodological pragmatism in mixed methods involves 
inclusive ontological and epistemological dispositions. Creswell191 describes these dispositions as 
worldviews that guide researcher in their quest of knowledge through research. The elements of 
each worldview position, including pragmatism, are presented in figure 2.2. In a pragmatist 
argument for mixed methodology in medical informatics, Scott and Briggs203 view knowledge 
generation as practical rather than theoretical, with methods applied based on the ability to  address 
the research question, rather than methods driven by ontological and epistemological assumptions. 
Pragmatism involves pluralism of methods that despite appearing contradictory; quantitative and 
qualitative methods can complement and enable one to more fully to see his or her world.202 The 
plurality of methods seeks to answer questions through research to improve the world, and in the 
case of this thesis, the world of applied health services research. 
 
 











Mixed methods research can utilise the strengths and counterbalance the weaknesses of 
quantitative and qualitative approaches when addressing complex, multifaceted issues such as 
health services interventions and living with chronic illness.204 Furthermore using a mixed methods 
approach can provide stronger evidence for a conclusion through “convergence and corroboration” 
of findings.199 One of the main criticisms of mixed methods research is that methods should not be 
mixed as they are belong to two separate and incompatible paradigms.190 Combining two methods 
in one study can be time consuming and requires experience and skills in both quantitative and 
qualitative methods. Potential challenges exist in the appropriate integration of data, with difficulty 
in presenting the results of a mixed methods study a barrier to conducting this type of research.205 
 
 
2.2.4 Rationale for a mixed methods design 
 
This thesis was undertaken to explore the effect of an electronic alert at reducing SABA prescribing 
in primary care. Alerts are common features of computer decision support systems in medical 
informatics, defined as “the study and application of methods to improve the management of 
patient data, clinical knowledge, population data.” 206 Medical informatics is described as a “hybrid 
sociotechnical field” encompassing social, technological, and cultural effects, a mixed methods 
approach that is not limited to one method is the most appropriate study design for research in this 
field.207 In this thesis, quantitative research is used to evaluates changes in SABA prescribing and 
secondary clinical and process of care outcome measures following the implementation of an alert 
for excessive SABA prescribing across three CCGs in east London. Qualitative research is used to 
explore the wider issues regarding the use of an alert to identify and manage excessive SABA 
prescribing in primary care. A mixed methods design enables a broader understanding of the role 
of alerts for excessive SABA prescribing, to contribute current literature and gaps in knowledge. 




insight into the use of an alert for excessive SABA prescribing that would not be reflected in a sole 
quantitative study design. 
 
 
2.2.5 Application of mixed methods in this thesis 
 
An embedded mixed methods design (figure 2.3) was applied in this thesis. This involved data 
concurrent data collection with the qualitative study (phase 3) supplemental to the quantitative 
study (phase 2).  The embedded design is a mixed methods design in which one data set provides  a 
supportive, secondary role in a study based primarily on the other data type.190 This design is popular 
in the health sciences whereby quantitative and qualitative approaches are used in tandem and 
embed to provide new insights. The quantitative and qualitative methods were independent of one 
another and integrated in interpretation, in what Onwuegbuzie and Johnston202 define as 
paradigmatic mixing legitimisation. This method seeks to address the challenge of competing 
epistemological and ontological and methodological viewpoints of qualitative and quantitative 
research described further in the individual sections of this chapter. 
This quantitative phase of the thesis involved a retrospective case-control study to determine the 
effect of an alert for excessive SABA prescribing, primarily on SABA prescribing, and secondarily on 
the number of asthma reviews, time to asthma review, ICS, LABA and combination inhaler 
prescribing, exacerbations and primary care consultations. The qualitative phase of the thesis 
involved interviews with primary care staff and asthma experts to explore perspectives of excessive 
SABA use and the role of an alert to reduce excessive SABA prescribing. In addition, observations 
with receptionists were carried out to provide insight into the process for the repeat prescribing of 
SABAs and how excessive SABA prescribing may be identified at this point. Both data sets were 
collected and analysed concurrently, with findings integrated in the interpretation stage. In this way, 
the qualitative work supported the quantitative findings by providing practical context and insight 
into the identification of excessive SABA prescribing and the role of the alert. Greene et al.208 
describe such methods as complementarity (i.e., seeking elaboration, illustration, enhancement, 












2.3 Patient and Public Involvement 
 
The role of Patient and Public involvement (PPI) in applied health research is increasing. PPI involves 
patient’s sharing their views and experiences as contributors to the research process rather than 
being the subject of research.209 Patient and public contributions at an early stage can help clarify 
research questions and ensure the most appropriate people are involved thereby strengthening the 
research.210 Early involvement of PPI, for example through the contributions of an advisory group, 
are more likely to have a positive impact on research compared to late involvement and 
contributions in an oversight capacity.211 
 
Asthma UK Centre for Applied Research (AUKCAR) facilitates patient and public involvement (PPI) 
for researchers to ensure that research affiliated with AUKCAR remains relevant to those affected 
by asthma. The group is comprised of people with asthma, including parents and carers of people 
with asthma who can bring insight and experiences of living with asthma as well as a range of 





It was important that the views of people with asthma were considered in design of the project to 
ensure issues relevant to their asthma care were addressed. The AUKCAR PPI group were consulted 




primary care staff involved in the management of SABAs were included in the study and to ensure 





In March 2015, an open-ended questionnaire was devised with the assistance of the AUKCAR PPI 
lead. The questionnaire was circulated the AUKCAR PPI group by email (Appendix 2.1). Questions 
focused on experiences of SABA use and NRAD25 recommendations for an alert to identify people 
prescribed excessive SABAs. Completed responses were sent directly from PPI members to the lead 
researcher by email. 
 
 
2.3.3 Patient and Public Involvement feedback 
 
 
Responses were received from 13 PPI group members. An overview of points raised is summarised 
below. Responses were collated and summarised into the main points below. 
 
 
SABA use experiences 
 
 
Of the 13 responses, patients described variable use of SABA inhalers, including none, less than one 
SABA a month, one SABA a month or possibly more depending on symptoms. One person responded 
they routinely used two puffs of SABAs between two to four times a day, irrespective of symptoms, 
as this was how they thought it should be used, whilst another person required SABA four times a 
day due to severe asthma. Patients described having contact with the pharmacist, GP and/or asthma 




Requesting repeat prescriptions 
 
 
Responses described repeat prescriptions requests for SABAs were made in either paper or 
electronic format in a process that involved the GP, receptionist and pharmacy. Suggestions to 
improve the process through which SABAs are obtained included integrated computer systems 
between GP and pharmacist so that both could be alerted to high SABA use, improved GP record 
keeping, increased use of the comments section by patients when requesting prescriptions 





An alert for excessive SABA use 
 
 
An alert to identify high SABA use in primary care was welcomed. It was acknowledged that patients 
are often not aware of the problems of high SABA use and different clinicians may process repeat 
prescriptions and SABA use should be brought to their attention. It was suggested that an alert will 
be dependent on the on human factors such as co-operation between practice and patient, and that 
pharmacists should also be alerted to high SABA use, potentially through the electronic prescription 
service. The role of pharmacy was viewed as important as patients do not always need to attend 
the GP but will always need to go to the pharmacy to collect prescriptions. Pharmacy was viewed as 
well placed to highlight high SABA use to a patient and explain the need for review. Respondents 
raised questions regarding the proposed action following a SABA alert. A number of challenges were 
envisaged particularly with potentially limiting SABAs and the difficulty of asthma reviews. 
 
Respondents raised questions regarding the proposed action following a SABA alert. A number of 





• Potential concerns regarding the availability of SABAs for people with difficult to control asthma or 
under specialist care that require above normal use 
• Concerns that if a GP does not prescribe SABAs following an alert the patient may be more at risk 
of an asthma attack than from SABA overuse 
• An alert may not mean excessive SABA use due to a variety of reasons for requesting SABAs 
including lost inhalers, forgotten repeat prescriptions or holiday requests 
• Difficulty in getting patients to attend review, patients may not understand the relevance of 
excessive SABA use 
• Lack of available appointments at suitable times especially if a review needs to be carried out 
within a certain time frame from alert 
• An alert needs to be supportive of users and whether the surgery can offer suitable appointments 
• The alert should not be overridden until the patient has a review carried out 






There were a number of suggestions as to how patients could be followed up following an alert. 
Suggestions included contacting patients by letter, email, text message, phone call to invite for 
asthma review or by prescription message from GP delivered by a range of staff including asthma 
nurse, receptionist or pharmacist. 
 
 
2.3.4 Implications for study 
 
PPI feedback highlighted the variations in SABA use, methods to obtain SABAs, the potential 
challenges of an alert and considerations regarding the management of people identified as 
excessively using SABAs. The original plan for the study was to gather GP perspectives on the use of 
an alert to identify excessive SABA prescribing, as GPs are most likely to hold prescribing
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responsibility. However, as highlighted in feedback, receptionists and in particular pharmacists 
played an important role in how patients currently obtained SABAs. Therefore, it was viewed as 
necessary to include a range of staff in qualitative study to further understand their input into the 
identification of excessive SABA use and to place the use of a SABA alert in a wider primary care 
context. The feedback also helped shape questions for the interview topic guide for primary care 
staff and experts including what constitutes excessive SABA use, how an alert is/could be used to 
identify excessive SABA use and how excessive SABA use is acted upon in practice. Furthermore, PPI 
feedback highlighted the importance of capturing the effect of the alert on repeat SABA prescribing 
in the quantitative study, rather than SABA prescribing alone. 
 
 
2.4 Quantitative research methods 
 
Creswell191 defines quantitative research as the collection of data by numbers to which statistical 
analyses are applied to explain relationships between variables. In this section, an overview of 
quantitative research methodology will be described including experimental and quasi- 





2.4.1 Philosophical assumptions underpinning quantitative research 
 
The collection and analysis of quantitative data assumes that deductive reasoning of defined 
concepts or hypotheses can uncover a truth or reality.194 These assumptions represent a positivist 
paradigm: that which is influenced by health beliefs systems including the ontological, 
epistemological and methodological positions adopted by the researcher.192 Positivism is described 







Positivism is a scientific paradigm based on data and facts with knowledge believed to be absolute 
and value free.212 The ontological position of positivism is one of realism, in which objects have an 
existence independent of and discoverable by the researcher.213 The positivist epistemology is one 
of objectivity, with researchers impartially discovering absolute knowledge about a reality.214 
Methodological positivism refers to a concept of knowledge rooted in science,215 however a true 
objective reality in applied health services research is questionable as it fails to acknowledge the 




2.4.2 Quantitative study designs 
 
There are three main types of quantitative study designs: experimental, quasi-experimental and 
non-experimental. Experimental study designs commonly refer to prospective, randomised, 
controlled trials to determine causality between variables, in contrast to quasi-experimental study 
designs to determine associations between variables.217 Experimental designs are commonly used 
to demonstrate the efficacy of an intervention or treatment through a focused, rigorous process to 
achieve scientific integrity, whilst quasi-experimental designs determine associations but not 
causality due to non-randomisation and are perceived as of lower scientific integrity.217 
 
Non-experimental research designs are commonly observational, either prospective or 
retrospective and descriptive in the reporting of findings. Despite non-experimental designs 
generally perceived as of the lowest scientific rigor, each design has its own merits based on the 
appropriateness of the research design to answer the research question. 
 
 
2.4.2.1     Observational research 
 
 
Observational research in the form of a retrospective case-control study design was applied in this 




2.4.2.1.1 Observational study design 
 
 
An observational study can be defined as one that observes changes or differences in one 
characteristic in relation to changes or differences in other characteristic(s) without interference 
from the researcher.218 Whilst an experimental design provides valuable evidence about treatments 
and interventions, much of clinical or public health knowledge comes from measuring the 
effectiveness of an intervention in ‘real world’ scenarios at the population level through 
observational research.219 A retrospective observational study design was applied to observe the 





2.4.2.1.2 Case-control studies 
 
 
A case-control study involves the selection of two similar populations with shared outcomes in 
which one has been exposed to an intervention and one not.218 This can include matching historical 
data (control group) obtained prior to the implementation of an intervention with post-intervention 
data (case group).220 Matching is often based on similar population characteristics between both 
groups. In this thesis, case-control groups were matched on the basis of excessive SABA use. 
 
Whilst experimental designs are viewed as the most appropriate to evaluate computer decision 
decision, a case-control study design is often the most feasible option for retrospective evaluations. 
In this thesis, a prospective evaluation was not possible and therefore the current design was most 
feasible method with which to address the research question. A case-control design is most useful 
in demonstrating the impacts of an intervention in a limited time-frame hence its use in this multi-
phased thesis.221 Furthermore, the total number of individuals required to obtain adequate power 
in a case–control study is often considerably less than other observational methods, for example 
cohort studies.222 This was deemed an appropriate when  evaluating the  intervention in a 




2.4.2.1.3 Electronic health records in observational research 
 
 
Electronic health record (EHR) data has been used to support observational studies, either as stand-
alone data or following linkage to primary research data or other administrative data sets.223 As 
exposure and outcome data already exist in electronic form for those registered with a general 
practice, the use of EHRs for observational research purposes is increasing.66 Large routine primary 
care data sets offer opportunities and sufficient power to study difficult to reach populations 
including ethnic minority groups.224 However, there is wide variation in how EHR data is utilised and 
reported in observational research. EHR systems usually fail to capture complete and accurate 
clinical information at the point of care due to design limitations and inefficient use of these systems 
by clinicians to document clinical data.101,225 Although EHR-derived data are convenient resources 
for research, they are originally collected for other purposes, and usually suffer from missing or 
incorrect data and potential biases which may impact on data collection and analysis.226–228 
 
 
2.4.3 Statistical analyses 
 
In applied health research normality is more often the exception rather than the norm, with non- 
parametric statistical tests most commonly used in non-normal data.229 Count data, as reflected in 
the quantitative phase of this thesis, is commonly skewed. Histograms were used to confirm skewed 
distribution of SABAs and non-parametric tests were applied. Non-parametric tests place few 
assumptions on the data and therefore outlying observations, that may be problematic in a 
parametric approach, can be dealt with using non-parametric methods. Non-parametric tests 
however may lack power to determine an effect, particularly if the sample size is small.230 The 




2.4.3.1 Median and Interquartile Range 
 
 
The media and interquartile range (IQR) was reported to determine the distribution (centre and 
spread) for continuous variables i.e. prescribing and consultations, rather than the mean and 
standard deviation associated with normally distributed data. The median and IQR was calculated 
to compare continuous outcome measures between the case-control datasets, with the median 
providing a measure of central tendency and the IQR reflecting the spread of the data and variability 
of the sample.231 The median (IQR) provides an overall description of prescribing and consultation 
data including the identification of outlying data and similarities and differences between the case 
and control group. 
 
 
2.4.3.2 Mann-Whitney U test 
 
 
Unlike the parametric t-test that compares the mean of two groups when data is normally 
distributed, the Mann-Whitney U test was used to determine the strength of relationships between 
continuous variables: prescribing and primary care consultations, by comparing the medians 
between the case and control groups.232–234 
 
 
2.4.3.3 Chi Squared test 
 
 
The Chi-squared test was used to compare the distribution of categorical variables (number of 
asthma reviews) between the case and control groups, to determine whether asthma reviews 
increased in response to the alert. However, the test does not address the potential influence of 




2.4.3.4 Regression analysis 
 
 
Regression analysis was used to determine the relationships and strength of associations between 
the dependent variables and independent variables when adjusted for covariates. Using a 
generalised linear regression model (Poisson regression and Binary logistic regression) outcome 
data was adjusted for covariates including age, gender, ethnicity, control group and prescribing in 
the prior time-period. Whilst the Mann- Whitney U test indicates the association between groups 
the strength and direction of associations and confounding effects are not determined. Whilst the 
Mann-Whitney U test reports the positioning of data above or below the median, the magnitude of 
the observation is not taken into account.236 Therefore, for outcomes of interest using count data 
e.g. prescribing and consultations, Poisson regression was used as it assumes a non-normal 
distribution of data. Binary logistic regression was used to analyse the number of asthma reviews, a 




2.4.4 Reliability, validity and rigour in quantitative research 
 
Rigour refers to the extent to which the researchers worked to enhance the quality of the studies. 
In quantitative research, this is achieved through measurement of the validity (internal and external) 
and reliability of studies.237 Internal validity refers to the strength by which observed results are 
attributable to an intervention. There are three biases commonly associated with observational 
studies that affect internal validity including selection bias: when the study population is not 
randomly sampled; information bias: inaccurate assessment of the outcome, the exposure, or 
potential confounding variables; and confounding bias: the exposure to a risk factor that is 
associated with the exposure but not the end point.238,239 Internal validity of a study may be 
compromised by not having a control group or a control group that is not comparable to that of the 
intervention group.240 There, in this study patients identified by the alert as being prescribing 
excessive SABAs (case) were compared to a population matched by excessive SABA prescribing prior 




Internal validity may be threatened by regression to the mean (RTM), which can be defined as a 
statistical phenomenon in which the distribution of a unit of observation moves towards the mean 
following its selection based on extreme measurement.221 RTM may potentially influence the 
findings of the case-control study as SABA prescribing was captured at an excessive point. 
 
External validity involves the ability to generalise results from the study population to the general 
population, to “other persons in other places at other times.”240 The most common threat to 
external validity in observational research comes from sample size obtained from a single 
geographic location or facility. This is acknowledged as a likely limitation due to the focus of the 
research specific to ethnically diverse population and locality. However, due to a lack of real-world 
RCT testing, observational studies an often have greater external validity than experimental designs 
as they can provide insight into real world clinical practice rather than controlled conditions of an 
RCT.241 
 
The use of electronic health record (EHR) data poses potential threats to the validity of observational 
research, otherwise described as data validity; that data reflects what it claims to  represent.242 
However, there are a number of issues regarding the quality of EHR data, including heterogeneity 
in the capture, reporting and assessment of EHR data.243 Whilst the potential for EHR data to inform 
clinical decision making and real-life research in asthma has been highlighted,66 there remains wide 
variation in the approaches used, with limited attention being paid to the validity of the underlying 









Creswell defines qualitative research as: 
 
“an inquiry process of understanding a social or human problem, based on building a 
complex, holistic picture, formed with words, reporting detailed views of informants, and 
conducted in a natural setting.” (Creswell, 1994) 
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However, no one universal definition adequately captures the variation and complexities of 
qualitative research methods. Strauss and Corbin,245 define qualitative research in terms of what it 
is not, for example, as that which produces findings other than through statistical analysis or 
quantification of numerical relationships between variables as in quantitative research. Qualitative 
research is often described as naturalistic and interpretative, concerned with exploring phenomena 
‘from the interior.’246 In this approach, the perspectives and accounts of research participants are a 
starting point from which phenomenon can be explored.247 Researchers utilise participants 
experiences to provide a lens to shape the understanding of the social world.194 
 
 
Qualitative research designs can be classified into three categories: exploratory, descriptive, and 
explanatory research. Explanatory research use research hypotheses to specify the nature and 
direction of the relationships between or among variables being studied to understand why 
phenomena occur. Descriptive studies depict people, products, and situations using one or more 
guiding research questions rather than structured research hypotheses. Exploratory research seeks 
to create hypotheses rather than test them, instead formulating problems and clarify concepts for 
example in response to literature searches, focus group discussions, or case studies.248 
 
The philosophical assumptions of qualitative research are described in the following section prior to 





2.5.1 Philosophical assumptions underpinning qualitative research 
 
Qualitative research comprises different orientations and approaches, various intellectual and 
disciplinary traditions grounded, often, in differing philosophical assumptions.249 The philosophical 
assumptions underpinning qualitative research are often a source of contention within the 




associated with qualitative research. Braun and Clarke250 note there are a number of oppositional 
approaches within the social sciences, contrasting to the mainstream positivist empiricist research 
design and practice of quantitative research. These include four dominant taxonomies that underpin 
qualitative research: the positivist, constructivist, critical and feminist paradigms.251 However, 
Barbour252 notes that distinctions between paradigms are often not clearly defined. As it is not 
possible to define each paradigm within the confines of thesis, the constructivist paradigm specific 








The qualitative study is contextualised by a constructivist/interpretivist paradigm. In an analysis of 
paradigm positions, Guba and Lincoln253 describe the aim of constructivism as to understand. In its 
relation to phenomenology, constructivism assumes that people construct social reality by 
interpreting the world around them. Unlike the positivist philosophy predominant in quantitative 
research where the researcher is completely ‘detached’ from the tangible subject, the ontology of 
constructivism assumes that the researcher is actively engaged in research participant’s 
construction of their ‘social reality.’191 As such, applied health services research involves studying 
the environment that both shapes and is shaped by the research participants within.194 
 
Unlike positivism, the ontology (nature of social reality) of constructivism assumes that ‘social 
reality’ does not exist as a discrete, tangible, measurable ‘fact,’ but that individuals construct a 
subjective ‘social reality’ of multiple meanings.191 In a constructivist epistemology, (the relationship 
between the researcher and the social reality they seek to know), the researcher takes into account 
local contexts and meanings that shape individual’s reality.254 This data is used to identify patterns 









The aim of exploratory research is to gain an increased understanding of an issue or situation for 
which little is known, and from which further in-depth research may be generated.255 Pope and 
May256 describe that qualitative exploration of a topic can complement quantitative work by 
exploring complex behaviours, attitudes, and interactions which quantitative methods cannot. 
Exploratory research can be referred to as interpretive research whereby the intention is to build 
an understanding of an issue rather than prove a theory.255 Constructivists do not generally begin 
with a theory rather they “generate or inductively develop a theory or pattern of meanings.”191 
Atheoretical research in is categorised by Kelly257 as ‘generic qualitative research’ with the aim of 
providing a surface-level analysis or general overview of a topic. Such methods are useful in health 
research, in particular, when examining clinical decision making by exploring both the declared and 
the “implicit or tacit routines and rules” which doctors use.258 Similarly, exploratory qualitative 
research in this thesis enabled a broad analysis of excessive SABA prescribing in primary care 





Sampling in exploratory research can be defined in its broadest sense as the selection of specific 
data sources from which data are collected to address the research objectives.259 Unlike quantitative 
research, qualitative research is more interested in understanding the complex processes behind 
phenomena through a detailed study of a few participants. There are a number of ways in which 
ways in which participants can be selected for inclusion in qualitative research. Four sampling 
strategies are the most commonly used in health services research: convenience sampling, 
purposive sampling, snowballing and theoretical sampling.194 
 
 
Convenience sampling recruits opportunistically based on participant availability.194 This strategy is 
resource-efficient, in terms of saving time, money and efforts, but may have implications for quality 




selects participants who can provide insight specific to the topic of investigation or those with varied 
opinions to enhance the quality and depth of the data.260 Snowballing involves recruiting 
participants with potential characteristics of interest based on the suggestions of others in the 
absence of a clear sampling strategy.194 Theoretical sampling involves the recruitment of 




2.5.3.1 Sampling strategy 
 
 
In exploratory research, pragmatic convenience sampling is common as researchers usually look for 
individuals who are knowledgeable about a topic or process in line with specific purposes in 
accordance with the research objective.261 
 
Asthma ‘experts’ defined as primary or secondary care clinicians who have contributed specifically 
to asthma care at a national or international level were recruited by convenience sampling following 
research team discussion. 
 
A pragmatic decision was made to convenience sample primary care staff specifically from Tower 
Hamlets CCG due to the proximity to the lead researcher due to established networks between 
practices and the Clinical Effectiveness Group (CEG) at QMUL. It is acknowledged that convenience 
sampling may limit findings give the quantitative study was carried out across three CCGs. Therefore 
it is possible the qualitative work may not fully reflect the reasons for alert success or failure to 
reduce excessive SABA prescribing. However as this was exploratory research, the findings in Tower 
Hamlets provide general insight into the topic of alerts to change SABA prescribing behaviour, from 
which specific, in-depth research may be facilitated as a standalone project rather than embedded 
within a quantitatively dominated mixed methods project. The purpose of qualitative research is 
not to determine all there is to know about topic through exhaustive sampling.262,263 A sufficient 
sample size is commonly justified by data “saturation.”264 Originating in grounded theory, Glaser 
and Strauss265 define saturation as something that is reached when new data fails to enhance the 
development of categories. Saturation has been described by Urquhart266, as when no new codes 
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occur in the data. Saturation is often used as a criterion for discontinuing data collection, and/or 
analysis267 and is often used by researchers as an indication of quality.268 However, there are no 
specific guidelines in the literature regarding the appropriate sample size to achieve data saturation 
in qualitative research.269,270 
 
In an analysis on data extensiveness in qualitative research, Sobal271 argues that sample size should 
be guided by principles of data adequacy and appropriateness as well as analytical redundancy. 
However, a balance should be sought between the sample size needed to achieve information 
power in the thematic analysis process and ambition for a larger sample to find out as much as 
possible, rendering data unmanageable and incomprehensible.263 Therefore qualitative data 
collection was guided by that which has already been collected and ended when the ‘new’  did not 
materially add anything to the overall story.245 
 
 
2.5.4 Data collection 
 
Qualitative research relies on textual data rather than numbers to explain phenomena.191,194 The 
three main most common methods to generate data in qualitative research are through interviews, 
ethnography/observational research and (focus) group discussions.272 Interviews are the most 
common qualitative research method. There are three fundamental types of research interviews: 
structured, semi-structured and unstructured.273 Interviews generally involve more than merely 
asking questions to elicit the views and opinions of the participants on a one-to-one basis and may 
also be conducted in groups, in person, on the telephone or by video. 252,274 
 
Research through observation is the main approach of ethnography, which can be described as the 
observation of human behaviour in the natural setting.272 Ethnography observes the sequences of 
human activities in a manner that is open to discovering new data, and then connects observed data 
to local contexts of the study.275 The main aim of observational research in healthcare is to collect 
data on errors, adverse events, near misses, team performance, and organisational culture.276 
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Focus group discussion is common in exploratory health services research.272 A focus group can be 
defined as any group discussion in which the researcher actively encourages and enables group 
interaction.277 However, this method may not the most appropriate for accessing views or attitudes 
of participants due to the group setting. One-to-one interviews are better at generating and 
clarifying narratives than focus groups which are more suitable for studying how views are created 
and modified.252 
 








Semi-structured interviews consist of several key questions that help to define the areas to be 
explored whilst allowing the interviewer or interviewee to pursue an idea or response in more 
detail.273 The interview is often guided by a topic guide, with appropriate prompts to increase the 
depth of interaction.194,252 Researchers conducting exploratory research usually look for individuals 
who are knowledgeable about a topic or process, for example experts in the field of investigation.248 
In classification as an ‘expert,’ it is assumed the person has specific knowledge on the research 
topic.278 In an analysis of interviewing experts, Littig278 notes that experts are those who have a 
certain degree of both formative and/or interpretive power. 
 
There are three different types of expert interviews: exploratory expert interviews, systemising 
expert interviews and theory generating expert interviews.278 Exploratory expert interviews as are 
most commonly used in a field of research with unknowns and therefore deemed appropriate this 
thesis to explore the use of alerts for excessive SABA prescribing. 
 
 
Telephone interviews were conducted to enable access to wide range of experts both nationally and 
internationally that could not have otherwise been reached. Although face-to-face interviews 
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are the dominant interview method in qualitative research, telephone interviewing has become 
increasingly common.279,280 Telephone interviews may be often viewed as inferior methods of data 
collection when compared to those carried out in person.281,282 However research suggests the 
depth and quality of data generated by telephone does not significantly differ from those generated 
by face-to-face interviews.283 
 
Semi-structured face-to-face interviews were carried out in-person with primary care staff, including 
general practitioners (GPs), pharmacists and nurses. In-person interviews gave an added advantage 
of referencing the alert on-screen when in interview. The term focus group has often been construed 
as synonymous with group interviews however they are fundamentally different  in that focus group 
discussions rely on the interactions between participants to generate data whilst group interview 
involves the researcher asking group participants the same question in turn.252 Group interviews 
were facilitated via clinical meetings where necessary, enabling primary care staff to participate in 






Observations are increasingly used to understand and evaluate the delivery of a service.284 In this 
study this involved observations of receptionists in the management of repeat SABA prescriptions. 
As identified In Chapter 1 and in PPI feedback discussed earlier in this chapter, SABAs are commonly 
obtained in through repeat prescribing that relies on reception staff. Observations with clinicians 
carry out repeat prescribing activities may provide increased understanding of the role of an alert 
in this process. An important advantage of observation in this context would be to overcome the 
discrepancy between what people say in interview and what they actually with the SABA alert.285 
However, given the variable uptake of clinician interviews, clinician observations were deemed 
challenging due to added time constraints in practice and the variability of repeat prescribing 
activities. It was anticipated that observations with receptionists as they process and manage repeat 
prescribing activities would be increasingly accessible partly influenced by their
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non-clinical role. Such observational methods analysing the role of receptionists in repeat 
prescribing have been previously carried out71 but not specifically in relation to SABAs. Receptionist 
observations are not intended to provide an in-depth analysis of SABA repeat prescribing but to 
provide a broad understanding of the identification and management of excessive SABA prescribing 
and when, how and by whom an alert may be used. It is envisaged that further in-depth research 
using different methods, for example an ethnography or comparative case study may potentially 
result from the findings. 
 
 
An observation guide was adapted from Spradley’s 9 Dimensions of descriptive observation.286,287 
This provided a focus for observations using the domains of cultural space, objects, acts, activities, 
events, times, actors, goals, and feelings. These categories represent the range of what might be 
observed in any specific social setting, and may carry meaning for the participants in the setting.288 
Descriptive observations are usually carried out observing everything, however as the role of 
receptionists in the repeat prescribing of SABAs was of specific relevance to the research question, 






Thematic analysis is best suited for exploratory studies investigating an area where not much is 
known.289 Braun and Clarke290 define thematic analysis as “a method for identifying, analysing and 
reporting patterns within data,” and as one which does not require the detailed theoretical and 
technological knowledge of other qualitative approaches.290,291 The Framework Method is most 
commonly used for the thematic analysis of semi-structured interview transcripts in applied heath 
research.292 This approach was developed for applied policy research and involves five stages as 
described by Ritchie and Spencer:293 Stage 1-2 Transcription and Familiarisation, Coding Stage 3-4 
Developing a Framework, Stage 5 Applying the framework Stage 6 and 7 Charting and interpreting 
the data. Qualitative research often lacks transparency in relation to the analytical processes 
employed.294,295 Therefore the framework approach was deemed appropriate for systematic 




data “saturation” can be defined as the point at which information has been exhaustively coded.296 
However it is questionable as to whether data can ever be saturated due new ways of interpretation 
from a range of different perspectives. 
 
 
2.5.6 Reliability, validity and rigour in qualitative research 
 
There are fundamental difference in the knowledge derived through a positivist and interpretivist 
paradigm is due to varying ontological and epistemological beliefs.253 The traditional meaning of 
reliability and validity, as described in the quantitative research positivist paradigm, is not 
transferable to qualitative research as unlike quantitative research, qualitative research does not 
seek to measure.297 Lincoln and Guba298 conceptualise traditional quantitative terms of reliability 
and validity as the ‘trustworthiness’ of qualitative research. In this way, internal validity in 
quantitative research is replaced with ‘credibility,’ external validity with ‘transferability’; reliability 
with ‘dependability’; and objectivity with ‘confirmability.’202 A number of steps were taken to ensure 
the trustworthiness of the qualitative research process using the criteria created by Lincoln and 
Guba (1985).298 
 
Credibility has been described as that which addresses the “fit” between respondents’ views and 
the researcher’s representation of them.299 Reflections on the credibility of the qualitative research 
process were made using Noble and Smith’s (2015) nine-step strategy for ensuring credibility.300 
These include acknowledging personal biases which may influence findings, acknowledging biases 
in sampling; good record keeping; comparing and contrasting similarities the data, including rich 
and thick verbatim descriptions of participants’ accounts to support findings; demonstrating clarity 
in thought processes during data analysis and subsequent interpretations; engaging with other 
researchers to reduce research bias, respondent validation and data triangulation. To enhance 
qualitative research credibility, personal biases have been acknowledged through reflexivity 
(Chapter 6). Clarity in the thought processes during data analysis and interpretations have been 
demonstrated in an illustrative example of the use of the Framework Method in Appendix 5.6. Data 
was compared and contrasted to identify similarities and differences, for example, in definitions and 
perceptions of excessive SABA use. A mixture of rich and thick verbatim descriptions of participants’ 
accounts have been analysed and reported; the coding and analytical framework was reviewed by 
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an independent researcher who acted as second coder. 
 
Transferability has been defined as the degree to which, not just findings but their context, can be 
transferred to other contexts or settings so that the behaviour and experiences of participants 
become meaningful to an outsider.298,301 This is often achieved through ‘thick description’ of the 
participants and the research process.302 The participants and processes described in the qualitative 
study may be transferable to further research on alerts in primary care prescribing for asthma or 
other conditions, with the context of the complexities of SABA prescribing and asthma management 
possibly transferable to the management of other long-term conditions. 
 
Dependability describes the stability and consistency of findings over time, in particular whether a 
person external to the research process would agree the process was carried out in a reasonable 
manner.298 This involves the provision of a transparent research process including rationale for 
decisions taken including those related to sampling and reflective thoughts.302 To ensure consistency 
in the research process, transcripts were coded following multiple reflections of interview audio as 
well as comparing and contrasting audio with the number of the interviews transcribed by Penguin 
Transcription services. Furthermore, an independent researcher coded three transcripts, with codes 
compared and the emerging themes reviewed and reflected upon over two visits. 
 
Confirmability is concerned with the neutrality of the research process, for example that data and 
interpretations of the findings are clearly derived from the data and not influenced by researcher 
perspectives or experiences.298,302 Whilst the use of an independent coder also influenced the 
confirmability of the research process, researchers are encouraged to embrace ‘subjectivity’ 
through reflexive practice, to acknowledge the emotional influence of a researcher’s personal and 
professional background the analysis and interpretation of data.252,303 Nowell et al.,291 propose  that 
trustworthiness of qualitative analysis be achieved through Lincoln and Guba’s298 four criteria for 
trustworthiness with the addition of audit trails and reflexivity. A reflexive account detailing the 
research student’s professional and personal background and experience of the research process is 




2.6 Chapter summary 
 
In this chapter, the philosophical basis of quantitative and qualitative research in mixed methods 
was described. The apparent inadequacy of either quantitative or qualitative research designs to 
sufficiently answer applied health services research questions was highlighted in this chapter. The 
pragmatic advantage of mixed-methods research to harness the individual strengths, whilst 
overcoming the individual weaknesses of both quantitative and qualitative research, was presented. 
The chapter outlined the rationale for choosing a mixed-methods research design with emphasis on 
how individual methods were applied to address the research question. Further descriptions of the 




Chapter 3. The use of electronic alerts in primary 
care computer systems to reduce excessive 
prescribing of short-acting beta2-agonists for people 








Following the National Review of Asthma Deaths (NRAD) identification that of 195 deaths from 
asthma between 2012 and 2013, 39% were prescribed more than 12 SABAs in the previous year 
whilst 4% were prescribed more than 50 SABAs in the same time period, the electronic surveillance 
of prescription refill frequency was recommended to alert clinicians to people with asthma 
prescribed excessive quantities of SABAs.25 
 
 
Computer decision support systems (CDSSs), defined as by Wyatt and Spiegelhalter as ‘active 
knowledge systems which use two or more items of patient data to generate case-specific advice’ 
have the potential to influence prescribing behaviour.117 General practice computer systems 
increasingly use reminders and alerts for preventative care and disease management137,304 including 
more recently for asthma.150,151 
 
 
Evidence shows that CDSSs do not consistently improve prescribing behaviour and clinical 
outcomes119 and whilst CDSSs have many assumed benefits, the empirical evidence to support is 
often weak and inconsistent. Furthermore it is unclear to what extent electronic alerts have been 




Representing Phase 1 of thesis, this chapter will determine the evidence for the use of electronic 
alerts to reduce excessive SABA prescribing in primary care, review the characteristics of 
interventions that have the potential to reduce excessive SABA prescribing and provide an evidence 
base for Phase 2 and Phase 3 of the thesis. 
 
 
3.1.2 Review aim 
 
This review aims to provide a systematic overview of the use of electronic alerts to identify 
excessive prescribing of SABAs in primary care. 
 
 
3.1.3 Review objectives 
 
The objectives of Phase 1 of the thesis were to: 
 
1. Evaluate the effectiveness of electronic alerts to reduce excessive SABA prescribing in primary 
care by: 
 
a) Identifying studies that used electronic alerts generated by excessive SABA prescribing 
 
b) Establishing the impact of an alert on process outcomes for healthcare providers and clinical 
outcomes for people with asthma 
 
2. Determine the features of alert systems that have the potential to improve process outcomes 
for healthcare providers and clinical outcomes for people with asthma by: 
 
a) Reviewing intervention design and delivery 
 
 






The systematic review was registered on PROSPERO (International Prospective Register of 
Systematic Reviews) with identifier CRD 42016035633. Systematic review methods were 
documented in a published review protocol.188 
 
 
3.2.1 Database selection 
 
The literature was identified from the following database sources: Medline, Embase, Cinahl, Scopus 
and Cochrane Library (Cochrane Reviews, Other Reviews, Trials, Methods Studies, Technology 
Assessments, Economic Evaluations, Cochrane Groups). 
 
These database sources were chosen following: 
 
 
● Discussion with study supervisors and guidance from Queen Mary University Faculty Liaison 
Librarian for Medicine & Dentistry. 
● Peer review feedback prior to the acceptance of the systematic review for publication. 
● A combination of the database searches used in two previous systematic reviews on clinical 
decision support systems for asthma.150,151 
 
 
3.2.2 Search strategies 
 
Search terms were based on the database search methods for the Cochrane Airways Group 
Specialised Register. On-going and unpublished trials were searched for using the following 
websites. Due to variability in the design and reporting of CDSSs for prescribing practice,164 the 
search strategy was deliberately broad to ensure the screening of studies with interventions that 




3.2.3 Study inclusion criteria 
 
Studies were considered for inclusion according to the PICOS criteria (population, intervention, 
control, outcomes and study design) which is a widely known strategy for framing a research 
question. 
 
(P) - Participants 
 
 
Studies that delivered care to adults and/or children with asthma, in a primary care setting. Primary 
care was defined as healthcare delivered in a community setting, most commonly in general 
practice, by a clinician, nurse or pharmacist. Non-clinical staff, including administrators and/or 
receptionists were also included. 
 
(I) - Intervention 
 
 
CDSSs were defined as ‘active knowledge systems which use two or more items of patient data to 
generate case-specific advice.’117 Studies were included if they incorporated a CDSS alert in the 
management of asthma. The intervention search strategy was purposely broad to facilitate 
screening of individual papers within which an alert triggered to excessive SABA prescribing may not 
have been explicitly reported. Alerts used in secondary or tertiary care, for other respiratory 
conditions that were not asthma were excluded. 
 
(C) - Comparator 
 
 
The comparator was ‘usual care.’ 
 
 
(O) - Outcomes 
 
 
Our primary outcome of interest was excessive SABA prescribing. Excessive prescribing of SABA was 
assessed on a study-defined basis. Secondary outcomes of interest included additional measures of 
prescribing and process of care (future SABA and ICS prescribing, ICS/SABA prescribing ratio, 




outcomes (asthma exacerbations with/without oral steroids, unscheduled primary and secondary 
care asthma consultations, asthma control). 
 
(S) - Study design 
 
 
Randomised controlled trials (RCTs), in any language, carried out between 1990-2016, were 
included. The cornerstone of clinical research on interventions is generally considered that of 
RCTs,305 with systematic reviews of RCTs considered the most rigorous way to evaluate intervention 
effectiveness.305,306  
 
The decision to set 1990 as the earliest date for study inclusion was based upon a) the search dates 
used for previous systematic reviews on clinical decision support systems for asthma150,151 and b) 
the introduction of the general practice contract in 1990, that encouraged the role of computers to 
facilitate the capture of care delivery data for which GPs could be reimbursed and remunerated for 
delivery of care. 
 
 
3.2.4 Validity assessment 
 
The data extraction and quality appraisal of the studies were conducted simultaneously. 
 
 
Quality assessment of studies was undertaken using the Critical Appraisal Skills Programme (CASP) 
tool for Randomized controlled trials.307 The Cochrane Collaboration’s seven-step criteria approach 
for assessing risk of bias in randomised trials308 as described in section eight of the Cochrane 
Handbook for Systematic Reviews of Interventions was used to assess the risk of bias of included 
studies. The primary researcher and second reviewer (AD) independently appraised the quality and 
risk of bias in the four studies included in the systematic review whilst carrying out data extraction 








Using a piloted data extraction form the primary researcher and an independent researcher 
independently extracted the following data from included trials: country, setting, funding, study 
design, healthcare professional and patient population, features of the CDSS intervention, 
description of the control group, outcome measures, results and risk of bias assessment. Data 
extraction tables were compared and discussed without disagreement. The items selected for data 
extraction were based on the Cochrane Collaboration data extraction form for RCTs.309 As alerts may 
form part of a CDSS intervention it is important to consider other components of an intervention in 
which an alert may be one part. 
 
3.2.6 Data syntheses 
 
 
The systematic review protocol was published prior to screening studies for inclusion.188 The 
protocol stated that a meta-analysis would be carried out, if possible, and heterogeneity in 
outcomes between studies would be determined using the I-squared statistic as described in the 
Cochrane Handbook for Systematic Reviews of Interventions.309 Furthermore where possible, 
subgroup analyses would be performed on age categories as defined by BTS/SIGN.52 However due 
to the small number of studies identified for inclusion in this review and the variability in outcomes 
reported it was not possible to carry out a meta-analysis and sub-group analyses. Therefore a 
narrative synthesis approach was followed. 
 
3.2.7 Reporting assessment 
 
 










3.3.1 Search results 
 
Table 3.1 presents a breakdown of the number of studies identified from each of the electronic 
databases. In addition, three studies were further identified from reference lists of included studies. 
 
 
Table 3. 1 Database search results 
 
 Electronic Database Searched    Number of identified studies 
 MEDLINE  455 
 CINAHL  19 
 Embase  94 
 Cochrane  196 
 Scopus  1268 




3.3.2 Study selection and exclusion 
 
 
The combined database searches yielded 2032 studies with three studies from additional sources. 
There were 1453 studies remaining following the removal of 582 duplicates. To determine whether 
CDSS alerts for asthma were triggered by the prescribing or dispensing of SABAs, the titles and 
abstracts of the identified papers were screened. As they did not include an alert triggered on 
excessive SABA prescribing or dispensing, 1444 studies were excluded. The remaining 9 studies that 
potentially included an alert for SABA prescribing were screened by full-text.  Where there was 
reporting uncertainty, authors of included studies were contacted by email to clarify intervention 
design and characteristics. 5 studies were excluded; 2 following author’s intervention clarification, 
1 was not randomised and 1 was not asthma specific. Figure 3.1 PRISMA flowchart details the step-
















































Records identified through 
database searching 
(n = 2032) 
Additional records identified 
through other sources 
(n = 3) 
Records after duplicates removed 
(n = 1453) 
Records excluded 
(n = 1444) 
Records screened 




(n = 5) 
Full-text articles 
assessed for eligibility 
(n = 9) 
Author contacted (n=2) 
Not Randomised (n=1) 
Not asthma specific (n=1) 
Included 




3.3.3 Validity assessment 
 
The terms quality, validity, and bias are used interchangeably in the systematic review literature to 
describe methodological conditions and the appraisal of internal validity of studies.309,311 Studies 
were included irrespective of quality status as studies rated as “low quality” because of 
methodological flaws or lack of reporting may nevertheless generate new insights whilst ‘high’ 
quality studies do not guarantee interpretation and insight to inform practice.312 Cochrane 
Collaboration’s assessments of internal validity of randomised trials is concerned with how well the 
study was designed and executed to prevent systematic errors or bias due to study design, conduct, 
analysis, interpretation, or reporting.311 The risk of bias in the studies included in this review was 
assessed using the Cochrane Risk of Bias Tool308 and reported in Table 3.2. All but one of the four 







Table 3. 2 Risk of bias assessment of included studies 
 
 
 Study  Selection bias  Allocation 
 Concealment                              
bias       
 Performance     
bias 
Detection bias  Attrition bias  Selective  
reporting 
 Other bias  Overall  
risk 





Yes: attrition rate 








 Eccles  No No No No No No No A-Low 
 Zeiger  No No No No No No No A-Low 
 Tamblyn  No No No No No No No A-Low 
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3.3.4 Study characteristics 
 
Four RCTs were conducted between 2001 and 2015; two recent studies by Tamblyn et al. 313 and 
Zeiger et al.314 (published in 2014 and 2015) were carried out within integrated healthcare 
systems in the United States and Canada respectively, whilst two older studies by 
McCowan156and Eccles153 (published in 2001 and 2002) were carried out with the National 
Health Service (NHS) in the United Kingdom. Study duration ranged from between 6 months,156 




3.3.5 Population characteristics 
 
Three of the four studies included people with asthma under-18 years of age. In two of the three 
studies the lower age for inclusion ranged from 5 years of age313 and 12 years of age314 whilst 
not reported in the third.156 No studies stratified findings by age range. Method of defining 
asthma status varied between studies. In older studies by McCowan et al.156 and Eccles et al.153 
the methods used to identify patients with asthma within an EHR were not clearly specified. This 
included patients on an asthma register,156 and patients identified from computerised searches 
for relevant (unspecified) codes for asthma diagnosis, management, and drug treatment.153 In 
the two recent studies by Tamblyn et al.313 and Zeiger et al.314 ICD-9 code 493 was used to 
determine asthma diagnosis. In Zeiger et al. an ICD-9 was required within at least the previous 
3 years and at least one ICS dispensed in prior 6 months,314 with health insurance a prerequisite 
for patients in both studies. Both study and population characteristics of studies are presented 
















Time scale Inclusion Criteria Exclusion criteria 
 McCowan  
(2001, UK) 
Cluster RCT 46 practice 
clusters 













50% of doctors using EMIS or AAH 
Meditel system to view clinical 
















Patients aged 12- 56 years with 
physician diagnosed asthma; 
(ICD-9 code 493) in previous 
3 years, >=7 SABAs dispensed, 
continuous health-plan 
membership and pharmacy 
benefit in the prior year, >=1 ICS 
canister dispensed in prior 6 
months 
Co-morbidities: COPD, 
emphysema, Cystic Fibrosis, 
chronic bronchitis, bronchiectasis, 
Churg Strauss syndrome, Wegener 
granulomatosis, Sarcoidosis, 
pulmonary hypertension, steroid-
dependant asthma, Omalizumab in 
prior 3 




Cluster RCT 81 physician 
clusters 
4,447 patients 33 months >5 years, asthma diagnosis 
(ICD9 code 493), provincial 
drug plan insured 
COPD diagnosis (ICD-9 
Code: 492, 44, 496) 
 RCT, randomised control trial; COPD, chronic obstructive pulmonary disease, ICD, international classification of diseases; SABAs, short-acting beta2-agonists; 
 ICS, inhaled corticosteroid 
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3.3.6  Intervention characteristics 
 
Table 3.4 summarises the intervention features in which an electronic alert was delivered. A 
multicomponent intervention was used in each of the four included studies, with an alert being 
one of a number of features. Methods of alerting included computerised prompts,153,156 a ‘real-
time’ electronic message to physicians314 and a ‘dashboard’ alert.313 No study included an 
electronic alert as a sole intervention. 
 
 
 Table 3. 4 Summary of Intervention features 
 
Features in addition to alert McCowan Eccles Zeiger Tamblyn 
Guideline decision support X X  X 
Allergy Specialist referral   X  
Asthma nurse home-care monitoring    X 
Self-management plan X   X 
Patient advice sheet X X   
Patient information letter   X  
 
 
Due to the heterogeneity of CDSS design, function and reporting in the literature, a detailed 
description of intervention characteristics of the 4 included studies is presented in Appendix 3.1 
adapted from the framework for reporting of CDSSs used by Kawamoto et al.137 and the 
computer decision support system taxonomy used by Berlin et al.315 This Includes descriptions 
of intervention context, knowledge source, decision support type, delivery, workflow and 
auxillary features of the interventions used within included studies. 
 
3.3.6.1  Context and function 
 
 
The aims of the intervention in McCowan et al.,156 Eccles et al.153 and Tamblyn et al.313 focused 
on the impact of an intervention on broad asthma management whilst aim of Zeiger et al.314 was 
to reduce excessive SABA use. The alert in McCowan et al., Eccles et al. and Tamblyn et al. 
presented in consultation whilst in Zeiger et al., the clinician was alerted in ‘real-time’ at point 
of excessive SABA dispensing from pharmacy.314 Potential barriers to the use of the intervention 
were reported in three of the four studies. In McCowan et al., alert presentation was dependent 
on clinician data entry however as this was a stand-alone system separate
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from the EHR double data-entry would have been required.156 In Eccles et al., alerts initially 
presented when a patient’s EHR was entered but this was changed to presenting when a 
relevant morbidity code for asthma was entered.153 However as the codes were not reported in 
the study there is uncertainty as to when and how an alert may have presented. In Zeiger et al. 
an electronic message within the electronic medical record system was sent to a patient’s 
primary care provider when a patient with excessive SABA use was identified from SABA 
dispending records.314 In Tamblyn et al., the alert presented when a patient’s EHR was entered 
and therefore was not specific to asthma.313 None of the interventions in the four included 
studies were delivered in conjunction with behaviour change programmes. 
 
3.3.6.2  Knowledge and data source 
 
 
A range of guidelines relevant at time of study, were used as the knowledge base for 
intervention design and delivery. This ranged from British Asthma Guidelines,156 National 
Asthma Education & Prevention Programme (NAEPP) guidelines and Global Initiative for Asthma 
guideline314 and Canadian consensus guidelines.313 In one study, evidence based guidelines for 
asthma were developed and reported elsewhere.153,316 In two studies alerts  were driven by data 
derived within the patient EHR,153,313 whilst one study relied on data being manually entered 
onto a separate programme.156 In one study, the alert was generated in response to pharmacy 
data contained within a research data warehouse within the Kaiser Permanente integrated 
healthcare system.314 In two studies generic alerts were generated in response to pre-
determined scenarios within the CDSS,153,156 whilst in the two recent studies within integrated 
healthcare systems, alerts were personalized to patients.313,314 
 
3.3.6.3  Decision support and information delivery 
 
 
In McCowan et al.,156 the decision support was a system based on a combination of asthma 
guidelines, clinical scenarios and reminders, clinical presentation as determined by the data 
manually entered at consultation including SABA use, would trigger a series of prompts related 
to scenarios predetermined within the CDSS. The decision support was delivered on a floppy 
disk to be installed on participants Microsoft Windows compatible computer desktop and that 
had to be opened separately to the EHR for use in asthma consultations 
 
In Eccles et al.,153 a CDSS provided contextualized prompts triggered when relevant asthma 
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codes were entered on the EHR. Asthma management and prescribing suggestions were 
presented based on guidelines, clinical scenarios and health record information. The CDSS was 
accessible from within the main computerised operating system used by clinicians however the 
guideline recommendations presented as a separate pathway that required clinicians to leave 
the EHR. It is unclear what type of information presented to clinicians within  consultation or 
whether the recommendations prompted the clinician to access the separate pathway for the 
guideline. It is unclear what specific advice was presented to clinicians in regards to SABA use 
however the system offered suggestions for management that included prescribing 
recommendations. 
 
Zeiger et al.,314 used real-time identification, notification, and facilitated allergy specialist 
referral for excessive SABA users. The intervention was delivered within the Kaiser Permanente 
Southern California (KPSC) managed care organisation (MCO) that utilises integrated electronic 
medical record systems and an electronic registry linked to dispensing data and hospital data 
for health insured patients. When excessive SABA use was determined at time of dispensing, the 
patient’s clinician was explicitly informed of excessive SABA use at that point. An electronic 
message was generated to the clinician with the following information: 
 
“Your patient (Name, MR #) was recently identified with uncontrolled asthma based on being 
dispensed a seventh canister of albuterol within the past year. Kaiser Permanente and other 
groups have documented that this amount of use of albuterol is a sign of uncontrolled asthma 
and is associated with an increased rate of future asthma ED visit and/or hospitalizations. ” 
(Zeiger et al. 2014, p.456, appendix E1). 
 
 
The message also stated the patient had been recommended by letter to take (or restart) regular 
ICS. Clinicians were advised if the patient had been referred to an allergy clinic and were 
encouraged to contact their clinician regarding asthma care. Therefore the message to clinicians 
was not at point of care and did not require action as patient letter and allergy referral were 
facilitated within the study. 
 
Tamblyn et al.,313 used a dashboard alert (figure 3.2) that presented upon identifying a
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patient’s asthma as out-of-control. This was determined by daily update of SABA prescriptions 
dispensed and physician visit information from the regional health insurance database. The alert 
presented within the EHR informing clinicians of a patient’s poor asthma control. The clinician 
could access the patient’s asthma profile, enroll the patient on a home care support and 
monitoring programme or close the alert. The patient’s asthma profile contained information 
on current medications, level of SABA use, respiratory-related emergency department visits, 
symptoms and impact on daily activities, as well as prescribing recommendations and an 
optional action plan. In the studies in which the intervention facilitated referral to an allergy 










3.3.6.4  Auxillary features 
 
 
User involvement in the intervention development in McCowan et al.,156 consisted of a steering 
group consisting of GPs with an interest in asthma reviewing the project over an 18- month 
period. In Eccles et al.,153 user involvement in CDSS design was not reported however, user 
feedback was obtained after 4 months of the study resulting in an alteration to the method of 
intervention presentation however it is not clear what type of information was obtained, how it 
was obtained and how it was used. A usage log within the computer recorded when the 
guidelines were used but reasons for (non) engagement was not reported.  
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In three studies patients were targeted by the intervention. In McCowan et al.,156 an optional 
asthma action plan and advice sheet was available, whilst in Tamblyn et al.,313 an asthma action 
plan was automatically generated by the CDSS when recommendations were accepted by a 
clinician however use remained at clinician discretion. This was in contrast to Zeiger et al.,314 in 
which patient letters were generated by administrative outreach in a managed healthcare 
organisation removing the need for clinician action. Education and training were reported in two 
of the four studies. McCowan et al.,156 reported that ‘online help’ was accessible from within the 
CDSS programme and an installation booklet and user guide were also provided. In Eccles et 
al.,153 two members from Intervention practices were sent to a one-day workshop on how to 
use the CDSS. 
 
 
3.3.7  Defining excessive SABA prescribing 
 
 
Due to the variety of definitions of excessive SABA use identified in Chapter 1 Introduction, 
excessive SABA prescribing was determined by study definition. There was a lack of uniformity 
in the definition and description of excessive SABA prescribing between the four studies 
reviewed. Tamblyn et al.313 defined excessive SABA use as was defined as the dispensing of more 
than the equivalent of 250 doses of the most commonly prescribed FABA, salbutamol 100 mcg, 
in a 3-month period. However, Zeiger et al.314 defined excessive SABA use as the dispensing of 7 
SABAs per year, equating to 4 puffs of SABA per day per year. 
 
In both Tamblyn et al.313 and Zeiger et al.314 SABAs were referenced in terms of excessive use, 
however the aim of this review was to determine the effect of CDSS on excessive SABA 
prescribing. Variations in framing the problem of SABA use/prescribing was described in Chapter 
1 with SABA use and SABA prescribing used interchangeably in the literature. Howwever, SABA 
use cannot accurately be captured and can only be assumed by SABA prescribed/dispensed 





A summary of findings is presented in Table 3.5. A detailed description of findings by study can 





Table 3. 5 Summary of review outcome findings 
 
 





































  +/-   +/- + +/- + +/-  
 Eccles 
 2002 
 +/- +/-     +/- +/-   
 Zeiger 
 2014 
+ + +/-  +   +/-  +/-  
 Tamblyn 
 2015 
   +       + 
 + positive effect; +/- no effect; SABA, short-acting beta2- agonist; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist  
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 Study CDSS use Process outcomes of 
interest 
Clinical outcomes of interest Interpretation 
 McCowan   
2001 
Not reported No between-group 
difference in number of 
patients prescribed 
maintenance therapy based 
on British asthma guidelines 
step; p= 0.51. No between- 
group difference in number 
of patients attending practice 
initiated asthma reviews OR 
0.69 (CI 0.21- 
2.21). 
Fewer exacerbations reported in the intervention group; 
12/147 (8%) in comparison to the control group 57/330 
(17%); OR 0.43 (CI 0.21-0.85). Fewer patients prescribed 
oral steroids for an exacerbation; 7/147 (5%) of the 
intervention group compared to 35/330 (11%) of the 
control group OR 0.42 (CI 0.14-1.29). Fewer primary care 
consultations initiated by patients; 22% intervention 
group compared to 34% control group, OR 0.59 (0.37- 
0.95). No between group difference in hospital 
admissions; OR 0 (CI 0-3.44); or emergency department 
visits; OR 0 (CI 0-9.16). 
Of the 46 practices registered to participate, 
21 were randomised but only 5 completed 
the trial due to software problems. 
Patients treated with CDSS initiated less 
asthma consultations and were less likely to 
experience an exacerbation. However it was 
not clear how exacerbation was defined. 
The CDSS was not integrated and usage rate 
was not captured. 










difference in numbers of 




differrence in numbers of 
ICS prescribed; OR 0.95 (CI 
0.78-1.16). 
No between-group difference in number of 
consultations for asthma OR 0.94 (CI 0.81-1.08). 
No between-group difference in number of patients 
prescribed oral steroids before and after OR 1.0 (CI 0.82- 
1.22). 
Cluster study design with practices as the unit 
of randomisation, consisted of two arms, 
asthma and angina each acting as control for 
the opposite arm. Data analysed 12 months 
before and after. A high number of practices 
participated (62); prescribing data was 
obtained from 1139 patients (intervention) 
and 1385 (controls). Process of care data was 
obtained from 1200 patients treated with the 
intervention and 1163 controls. Intervention 
had no effect on process or clinical outcomes. 
Median intervention usage was zero. Data 
was analysed on an intention to treat basis. 
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Table 3.6. Detailed description of findings (continued) 
 
Study CDSS use Process outcomes of interest Clinical outcomes of interest Interpretation 
 Zeiger  
2014 
Not reported Less patients in the intervention group 
dispensed excessive SABA: 50.7% vs 57.1% 
control group; RR 0.89, p= 0.007 (CI 0.82- 
0.97) and increased time to be dispensed 
SABA excessively; HR 0.80; p=<0.001 (CI 
0.71-0.91). Greatest effects seen in those 
with no prior asthma specialist care. 
Reduction in SABAs dispensed to 
intervention group at 3 months p= 0.002, 6 
months p= <0.001, 12 months p= <0.001. 
Increase in ICS-LABA inhalers dispensed to 
intervention patients without prior asthma 
specialist care; 3 months p= 0.004, 6 
months p=<0.001,12 months p= 0.03. 
No between group difference in number of 
patients with an exacerbation requiring oral 
steroids; p= 0.71, either with or without prior 
specialist asthma care; p= 0.38 vs p= 0.83. No 
between group difference in number of 
patients with an asthma exacerbation 
requiring >= two oral steroid courses; p= 0.55, 
either with or without prior specialist asthma 
care; p= 0.89 vs p= 0.50.No between group 
difference in number of asthma ED visits 
and/or hospitalisation; p= 0.96, either with or 
without prior specialist asthma care; p= 0.55 
vs p= 0.66. 
Real-time outreach intervention in the 
Kaiser Permanente Southern California 
(KPSC) managed healthcare system. 
Usual care included KSPC extensive 
integrated asthma care management. 
The intervention reduced excessive 
SABA use, and ICS/LABA use. Greatest 
effect was seen in the subgroup of 
patients without prior asthma specialist 
care. Physician engagement was not 
captured Multicomponent intervention 
included a clinician message, patient 
letter and allergy referral. 
 Tamblyn 
2015 
Physicians did not 
use the CDSS 
intervention 
‘Asthma Decision 





Increased ICS-SABA mean ratio in the 
intervention group; mean difference= 0.27 
p= 0.034 (CI 0.02–0.51); 
Reduction in out of control asthma events in 
the intervention group rate difference - 
8.7/100 PY; p= 0.29 (CI -24.7, 7.3). Greatest 
effects in the sub-group with out-of-control 
asthma when beginning the study. Rate 
difference: -28.4, p= 0.04 (CI -55.6, -1.2); 
Greatest reduction in the subgroup with out- 
of-control asthma at beginning of the study 
when treated with CDS alone had Rate 
difference: -36.9/100 PY; p= 0.01. 
81 physicians were randomised to 
‘asthma decision support;’ 2,273 
patients treated with the intervention, 
2174 controls. intervention increased 
mean ratio ICS-SABA use and reduced 
the rate of out-of-control episodes. 
Greatest effect in the subgroup of 
patients with out-of-control asthma at 
study entry treated by CDS alone. In 60% 
of out-of-control visits the decision 
support was not utilised. 
 CI 95% confidence intervals, SABA short acting beta2-agonist, ICS inhaled corticosteroid, LABA long acting beta2-agoinst, RCT randomised control trial, I 
 Intervention, C Control, OR Odds ratio, RR risk ratio, ED emergency department, PY patients per year, CDSS computer decision support system, HR Hazard Ratio 
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3.3.8.1 Primary outcome 
 
 
3.3.8.1.1 Excessive SABA prescribing 
 
 
Zeiger et al.,314 reported a reduction in the number of patients being dispensed excessive SABAs 
(p = 0.007) and an increase in length of time between SABA prescriptions (p = < 0.001). These 
effects were noted in the subgroup of patients without prior asthma specialist care who received 
the intervention (p = < 0.001). Tamblyn et al.,313 reported excessive SABA (expressed as fast-
acting b-agonist) dispensing as a composite primary outcome, the rate of out-of-control asthma 
episodes, which included emergency department (ED) attendances and hospitalisations. It was 




3.3.8.2 Secondary outcomes 
 
3.3.8.2.1 SABA prescribing 
 
Zeiger et al.,314 reported a reduction in the number of SABAs dispensed at 3 months (p = < 0.001), 
6 months (p = < 0.001) and 12 months (p = < 0.001) in the subgroup of patients without prior 
specialist asthma care. Eccles et al.,153 reported no significant effect of a computerised decision 
support system on SABA prescription in the 12 months before and after the intervention (odds 
ratio (OR) 1.04, 95% CI 0.83–1.31). 
 
3.3.8.2.2 ICS prescribing 
 
Zeiger et al.,314 reported no difference in the number of patients dispensed ICS (not as a 
combination inhaler), whilst Eccles et al.,153 reported no difference in the number of patients 
prescribed ICS before and after the intervention. McCowan et al.,156 reported no between- 
group difference in maintenance prescribing patterns and no difference in the proportion of 
patients classified by management step. 
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3.3.8.2.3 ICS-SABA prescribing ratio 
 
Tamblyn et al.,313 reported an increase in the ratio of ICS-SABAs dispensed (mean difference 
0.27, p = 0.03; 95% CI 0.02–0.51) with higher ratios reported in both subgroups of patients 
whose asthma was controlled and out of control at the start of the study. Zeiger et al.,314 
reported a controller (ICS) to total medication ratio of greater or equal to 0.5 at 3, 6 and 12 
months, in particular for those without prior asthma specialist care. As the ICS to total 
medication ratio was calculated by the number of ICS canisters or 30-day supplies of oral 
controller medications dispensed, divided by the total number of controller units and SABA 
inhalers, it was not possible to determine the ICS-SABA ratio specifically. 
 
 
3.3.8.2.4 ICS/LABA prescribing 
 
 
Zeiger et al.,314 reported an increase in the number of patients in the subgroup without prior 
asthma specialist care dispensed an ICS-LABA inhaler at 3 months (p = 0.004), 6 months 
(p = < 0.001) and 12 months (p = 0.03). 
 
 
3.3.8.2.5 Asthma reviews 
 
McCowan et al.,156 reported no reduction in the number of patients attending practice- initiated 
asthma reviews. This was not reported by other studies. 
 
3.3.8.2.6 Asthma exacerbations 
 
 
Exacerbations were determined by study-defined parameters, as described in the protocol. This 
was due to the variation in definitions of exacerbations in the literature on asthma. McCowan 
et al.,156 observed a reduction in asthma exacerbations, with 8% of patients who received the 
intervention reporting an acute asthma exacerbation compared to 17% in the control group (OR 
0.42; 95% CI 0.21-0.85). However, there was no difference in the use of oral steroids to manage 
these attacks in the intervention and control group. Zeiger et al.,314 reported no difference in 
the numbers of patients prescribed oral steroids for an exacerbation irrespective of prior asthma 
specialist care status. Neither McCowan et al., nor Zeiger et al., explicitly defined an asthma 
exacerbation. Eccles et al.,153 reported no difference in the numbers of patients prescribed oral 
steroids before and after the intervention but did not specifically report asthma exacerbations. 
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3.3.8.2.7 Unscheduled consultations for asthma 
 
Eccles et al.,153 found no between-group reduction in the number of primary care asthma 
consultations, whilst McCowan et al.,156 reported that patients who received the intervention 
initiated fewer primary care consultations (OR 0.59; 95% CI 0.37–0.95). However neither study 
clarified whether consultations were scheduled or unscheduled. Both McCowan et al.,156 and 
Zeiger et al.,314 reported no effect of the intervention on AED attendances or hospitalisations for 
asthma. Tamblyn et al.,313 reported AED visits and hospitalisations for asthma as a composite 
outcome defined as ‘rate of out-of-control asthma episodes,’ therefore secondary care 
consultations for asthma could not be specifically determined. 
 
 
3.3.8.2.8 Asthma control 
 
Tamblyn et al.,313 reported a reduction in the rate of out-of-control asthma events, defined as a 
composite outcome of excessive SABA use, AED attendance and hospitalisations for asthma, in 
the sub-group of patients whose asthma was out-of-control at the beginning of the study (mean 
difference −28.4, p = 0.04; 95% CI −55.6, −1.2). When stratified by intervention component, the 
rate of out-of-control asthma events further reduced when patients were treated with CDSS 
alone (rate difference (RD) −36.9/100 per year, p = 0.01) in comparison to those threated with 
both CDSS and the asthma home care monitoring programme (rate difference -28.4, p = 0.04; 





3.4.1 Summary of findings 
 
 
Given the few studies identified, the evidence to support the use of alerts to reduce excessive 
SABA prescribing in primary care is limited but promising. This review found that electronic 
alerts, when delivered as a multicomponent intervention have the potential to successfully 
identify and reduce excessive SABA prescribing. The greatest effect on SABA prescribing 
occurred in well-resourced integrated health care systems with access to referral to 






3.4.2 Comparison with the literature 
 
Our findings support previous research on the use of computer decision support for long-term 
conditions including asthma, chronic obstructive pulmonary disease, diabetes and osteoporosis 
which found that interventions consisting of multiple components are associated with greater 
improvement in outcomes than single-target interventions with fewer components.130,150,317 
 
The McMaster group’s meta-regression explored the features of CDSSs associated with system 
‘effectiveness’.102 They found that stand-alone programs, for example in McCowan et al.,156 as 
well as advice directed at both health-care practitioners and patients, and requiring users to 
enter an explanation for any overrides of system recommendations was associated with better 
patient outcomes.102 Standalone programmes are more likely to be used in older studies such 
as McCowan et al.,156 with more recent studies by Tamblyn et al.,313 and Zeiger et al.,314 using 
integrated CDSS to improve asthma outcomes. Matui et al.,150 note that use of standalone 
programmes risks poor user engagement with CDSS however integrated CDSSs do not guarantee 
engagement, as reflected in low user rates in Tamblyn et al.313 In two studies in which CDSS 
engagement was reported, users failed to engage with decision support,153 whilst in another, 
clinicians failed to interact with the CDSS in approximately 60% of cases.313 However it is not 
clear whether levels of engagement were consistent between clinicians and whether clinician 
interaction declined over time. There may be valid reasons to account for the variability in 
decision support engagement which include technical design of the CDSS, the setting in which 
the system is deployed and the characteristics of users and the patients treated.119 User 
engagement of 40% in Tamblyn et al.,313 in comparison to almost no engagement in Eccles et 
al.,153 is likely due to the increased ease of use associated with more recent, sophisticated 
decision support integrated within a comprehensive EHR system that accesses pharmacy, as well 
as primary and secondary care data. 
 
The two studies that showed greatest effects on outcomes of interest in this review were those 
carried out recently (in the past three years), in which decision support was integrated 
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with EHRs.313,314 In contrast to McMaster group findings, these findings support the evidence, as 
described in Chapter 1, that computer decision support integrated with clinician workflow is 
associated with improved outcomes.122,137,141 Zeiger et al’s.,314 findings that a multicomponent 
alert intervention can reduce excessive SABA use, supports the evidence that electronic health 
records and electronic messaging in an integrated health care system increases clinician 
adherence to evidence-based guidelines.318 The identification and reduction of excessive SABA 
use in Zeiger et al.,314 was facilitated by alerts that were not restricted to point-of-care 
presentation. Such methods of alerting may offer a solution to the dilemma that automatic 
provision of decision support at point of decision making neither guarantees clinician uptake  or 
engagement119 nor predicts improvements in process of care or patient outcomes.102 
 
As described in Chapter 1, alerts integrated within EHRs may interrupt clinician workflow and 
result in “alert fatigue” with up to 96% of alerts over ridden or ignored.142 Following user 
feedback, Eccles et al.,153 altered decision support to trigger when a clinician entered a relevant 
morbidity code rather than being automatically activated upon entering a patient’s medical 
record. Whilst this may have been an attempt to minimise alert fatigue it did not improve CDSS 
user interaction. It is likely that very low CDSS interaction reflected clinical guidelines being 
located in a separate system not supported within clinician workflow. 
 
In a non-randomised study by Cho et al,319 used a CDSS to classify asthma severity based on 
symptoms, FEV1 or PEFR and medication use, including SABAs. If asthma severity was 
aggravated compared to a previous visit the CDSS presented a warning message in consultation, 
advising that medications should be changed according to current asthma severity and that 
referral to an asthma specialist should be considered. The CDSS resulted in fewer prescriptions 
for beta2-agonists (p=0.02) however it is unclear whether this was short or long acting beta2-
agonists or both. Furthermore the change in prescribing was not quantified and it is unclear 
whether the warning message contained direct advice on SABA prescribing. 
 
In a non-controlled before and after study by Wong et al.,320 notifying providers of their patients 
with excessive SABA use resulted in reduced SABA prescriptions. The intervention involved 
written or verbal confirmation by the prescriber for all new prescriptions for more than one 
SABA per month prior to pharmacist dispensing. Pharmacists manually alerted clinicians by fax 
and follow-up telephone call. This included guideline recommendations for appropriate SABA 
use and requested a reduction of SABA prescribed to less than or equal to one inhaler per 
month, if the prescriber judged it appropriate.  
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This resulted in a reduction in the percentage of people prescribed more than one SABA per 
month between year one and year two (22.9% vs 9.7%, P <0.01), with 67% receiving less than 
one SABA per month during year two. For example Wong et al.320 highlight the potential role of 
pharmacists that has been absent from the four studies included in this review. 
 
None of the four included studies reported using qualitative methods to complement 
intervention design despite the potential to influence intervention RCT design and delivery.321 
Such methods may optimise alert design, improve clinician interaction with decision support 
and aid the interpretation of results in future. 
 
 
3.4.3 Outcome reporting 
 
The recent Lancet commission on redefining airways disease highlighted the underutilised 
potential for the use of EHRs containing clinical, laboratory, and health utilisation data for 
asthma research in primary care.322 However asthma clinical research often lacks standardised 
outcomes, with variability in clinical definitions of asthma and disease severity, control and 
attacks/exacerbations.323,324 In their scoping review of defining asthma outcomes using EHR 
data, Al Sallakh et al.,244 note that variability and underreporting make it difficult to assess the 
validity of studies and compare their findings. Such inconsistent definition, measurement and 
reporting of asthma outcomes therefore makes it challenging to determine the effects of one 
intervention over another in practice. 
 
For example in two previous systematic reviews of the literature on CDSS for asthma by Matui 
et al.150 and Fathima et al.,151 the reporting of both clinical and process outcomes varied across 
the included studies. As described in Chapter 1 there are variations in how SABA use is defined 
in the literature. Definitions of excessive SABA use also varied between Tamblyn et al.,313 and 
Zeiger et al.314 as described in section 3.4.7. The reporting of inhaled steroid use varied between 
the studies. In Zeiger et al.314 both ICS prescribing and ICS/LABA combination inhaler prescribing 
were captured. Whilst in Tamblyn et al.,313 the ICS-to-SABA ratio was reported, in McCowan et 
al.,156 ICS prescribing was reported by British asthma guidelines step and in Eccles et al.,153 the 
separate prescribing of inhaled steroids and LABAs was reported. 
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ICS-to-SABA ratio has been used as a measure of quality of asthma care and a marker for deficits 
in asthma treatment and potential risk in a number of studies in the literature.326,327 Despite 
identifying the excessive prescribing of SABAs and under prescribing of ICS as a marker of risk 
and a contributor to asthma deaths, NRAD,25 like BTS/SIGN52 do not specify an ICS/SABA ratio 
threshold as indicative of poor asthma control. Challenges are likely to arise in the accurate 
capture of ICS data within EHRs given the variations ICS in dose equivalence resulting from 
increased generic prescribing112 and the prescribing of combination inhalers including as 
maintenance and reliever therapy (MART). This may present challenges for the standardisation 
of endpoints and comparison of outcomes between future studies. 
 
Surprisingly asthma reviews were reported in only one of the four studies included in the 
systematic review despite being fundamental to asthma self-management.325 It may be that 
asthma reviews are not a routinely captured outcome measure due to the challenge of 
translating process measures into improvements in patient outcomes.328 In Zeiger et al.,314 
patients using excessive SABAs without prior specialist asthma care were invited for an allergy 
specialist review however only a minority of intervention patients recommended availed of the 
allergy review. Patients were also contacted by letter and advised to initiate follow-up with their 
primary care doctor however, these follow-ups were not reported.  
 
There are wide variations in the definition and reporting of asthma exacerbations in the 
literature329 and in a recent scoping review by Al Sallakh et al.,244 on EHR data and asthma 
outcomes. There were variations in the reporting of exacerbations in the studies included in this 
systematic review. Zeiger et al,314 defined an exacerbation as least one oral steroid course, or 
two or more courses with exacerbations considered distinct when separated by at least 30 days. 
Tamblyn et al.,313 did not explicitly report asthma exacerbations as an outcome measure instead 
reporting on out-of-control asthma events characterized by three components: an AED 
attendance, hospitalization and/or excessive SABA use in the past three months. However 
Tamblyn et al’s., definition of out-of-control asthma as a composite outcome may reflect an 
uncertainty in defining an exacerbation as a progressive worsening of symptoms in comparison 
to that which requires AED attendance or hospitalization. In a review to determine a consensus 
definition for asthma exacerbations, Fuhlbrigge et al.330 found no dominant definition of 
“exacerbation” in the literature but noted that the three components were
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commonly used: (1) systemic use of corticosteroids, (2) asthma-specific emergency department 
visits or hospitalization, and (3) SABA use. However the use of oral steroids was notably absent 
from Tamblyn et al’s., definition. Fuhlbrigge et al.,330 argue that each component adds 
independent information about a patient’s underlying condition recommending that variables 
used to determine an exacerbation where reported as a composite outcome are also reported 
as single indicators. Despite two of the three components in Tamblyn et al’s definition of out-
of-control asthma reflective of Fulhbrigge’s, definition of an exacerbation, exacerbation rates 
could not be determined due to the individual components of asthma control not fully reported. 
In McCowan et al.156 an exacerbation was determined as such if reported by a clinician, however 
it was not clear how the clinician’s reporting was derived. Oral steroid prescribing did not reflect 
an exacerbation, instead used to determine how a reported exacerbation was managed. In 
Eccles et al.153 an exacerbation was not specifically defined however was determined by steroid 
prescribing before and after CDSS use. 
 
Each of the four studies included in the systematic review included unscheduled consultations 
for asthma as an outcome measure. However the definition of unscheduled consultation varied 
across studies. Both McCowan et al.,156 and Eccles et al.153 reported on the number of primary 
care asthma consultations, however neither study clarified whether consultations were 
scheduled or unscheduled. Both McCowan et al.,156 and Zeiger et al.,314 reported and/or AED 
attendances or hospitalisations for asthma. Tamblyn et al.,313 reported AED visits and 
hospitalisations for asthma as a composite outcome defined as ‘rate of out-of-control asthma 
episodes,’ as previously discussed, therefore asthma related secondary care contacts could not 
be specifically determined. 
 
3.4.4 Strengths and limitations 
 
 
As interventions to improve prescribing volumes/rates do not necessarily result in more 
‘appropriate’ prescribing or improved patient outcomes,119 both process and clinical outcomes 
were assessed in this review. Due to variations in the definition and reporting of asthma 
outcomes in studies using EHR data as identified by Al Sallakh et al.,244 selection and reporting 
bias was reduced by including study defined outcome definitions in this review. Few studies met 
our inclusion criteria, with only one study reporting our primary outcome of interest therefore 
due to the limited number of published reports of randomised controlled trials in our analyses, 
there may be possibility of publication bias or selective reporting.  
Interventions in the two older studies by McCowan et al.,156 and Eccles et al.,153 were poorly 
99  
described which may have limited our interpretation of the findings. We were unable to conduct 
a meta- analysis due to heterogeneity in intervention design and outcomes evaluated. Due to 
poor reporting, no conclusions could be drawn on health economic impact. 
 
The inclusion of only RCTs is a potential limitation of this review. It has been suggested that 
population-based intervention studies using health information technology are less likely to be 
randomised.314 This may account for the few RCTs identified for inclusion in this review (n=4). 
Furthermore, the design, delivery and understanding of complex interventions requires a multi-
method research approach to facilitate the rigorous assessment and interpretation of results.306 
Understanding of issues pertaining to the effectiveness of CDSSs is unlikely to be achieved 
through analysis of RCTs alone.331 It has been suggested that in topic areas where the number 
of patients is limited or the evidence is conflicting, systematic reviews offer the benefit of 
collating evidence from a variety of sources.305,332 Therefore excluding non-RCTs has potentially 
limited our understanding of the use of CDSSs for SABA prescribing and findings should be 





There is some evidence that electronic alerts integrated with EHRs and delivered as part of a 
multicomponent intervention can reduce excessive SABA prescribing. Due to variations in health 
care systems, intervention designs and outcomes measured, further research is required to 
determine the effects of alerts on excessive SABA prescribing in a publically funded health 
system. Future research should determine the point at which novel alerts will most effectively 





3.6.1    Implications for clinical practice 
 
There is an increased focus on the digitalisation of the NHS in an attempt to improve safety and 
quality of care,333 with recommendations from both NRAD and Asthma UK calling for national 
use of electronic alerts to identify excessive prescribing of SABAs in the UK.25,334 Due to the few 
studies identified in this review, the role of alerts to reduce excessive SABA prescribing in the 
UK’s publically funded NHS remains unclear. Integrated care can take many forms involving 
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collaboration between policy providers and commissioners and between service providers, 
however benefits arise primarily when clinical teams and services are brought together and 
incentives are aligned to support service improvement.318 It is likely that a combination of 
design, technical capabilities and variety of intervention components, when delivered in an 
integrated health care system, facilitated the improvements to SABA prescribing and asthma 
management identified in recent studies. However due to organisational, management, policy 
and financial barriers and the increasing politicisation of the NHS, it remains challenging to 
deliver such improvements in a publicly funded health care system such as the NHS.335  
 
 
3.6.2   Implications for future research 
 
This review identifies a number of areas where potential exists and where further research is 
recommended. In the UK, 78% of bronchodilators are issued on repeat prescription76 yet 
research fails to address the use of alerts at this point in the prescribing process. Furthermore, 
two studies from the UK, carried out over a decade ago, did not integrate interventions within 
EHRs, in contrast to more recent studies from North America. Future research should consider 
novel ways to deliver SABA alerts as a sole intervention and/or as part of a multicomponent 
intervention in primary care. Furthermore, the point in the prescribing process at which a SABA 
alert will have greatest impact should be explored. Interventions should be trialled both in and 
outside of the consultation to target clinicians and people with asthma.  
 
Findings highlight the potential of multicomponent CDSS interventions to reduce SABA 
prescribing and improve asthma management. Further potential to explore the effect of a single 
component CDSS intervention on SABA prescribing as no such studies were identified. Given the 
limited number of RCTs on this topic, future study design and evaluation such not be restricted 








Standardised methods for the design and reporting of CDSS interventions in asthma are 
recommended to enable a thorough evaluation of process and clinical outcomes. An explicitly 
defined outcome set that includes standardised endpoints, e.g., excessive SABA use and asthma 
exacerbations may help the translation of research findings into clinical practice. In studies using 
CDSSs to improve the management of asthma, asthma reviews be included as an important 
process outcome measure.  
 
Findings support the recommendations of as Kawamoto et al.,137 and Berlin et al.,315 that studies 
use a taxonomy or framework to theoretically underpin the design and reporting of interventions 
including the implementation processes and health economics outcomes associated with CDSS-
based alerts. This should include the enhanced reporting of EHR interventions through the use 
of the RECORD and STROBE statements336 Future studies should consider mixed methods 
designs that incorporate qualitative methods before, during and/or after an RCT as 
recommended by O’Cathain et al.,321 End-users should be involved in the design of alerts to 
optimise interventions purpose, usability and trial design. Such methods may help determine 
the barriers and facilitators to alert usage in practice, as well as assisting in the development of 
alerts that are transferable to the real-world clinical setting.
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Chapter 4. An electronic alert to reduce excessive 
prescribing of short-acting beta2-agonists for 
people with asthma in general practice in east 
London: a retrospective case-control study using 








4.1.1 Recap of context 
 
 
This chapter represents Phase 2 of the thesis; a retrospective case-control study of electronic 
health care record (EHR) data to evaluate the effectiveness of a single component alert 
intervention to reduce SABA prescribing.  This follows Phase 1 findings that when delivered as 
part of a multicomponent intervention CDSS alerts show limited potential to reduce excessive 
SABA prescribing. No studies in the review evaluated an alert as a single component intervention 
nor assessed the impact of an alert at reducing repeat prescriptions of SABAs. As such, the 
evidence to support alerts in the identification and management of excessive SABA prescribing 
remains unclear.  
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In 2015, EMIS Health, national providers of general practice software systems, collaborated with 
Asthma UK to devise and implement an alert to improve identify and improve problematic 
prescribing in asthma. The Asthma Medicines Management alert* was developed to identify 
people prescribed excessive SABAs, high long-acting beta- agonists (LABAs) or long-acting 
muscarinic antagonist (LAMA) use and/or the prescribing of LABAs/LAMAs without concomitant 
inhaled corticosteroids (ICS) (figure 4.1). The SABA alert identifies patient’s prescribed more 
than three SABA prescriptions in a three-month period and activates upon opening of a patient’s 
EHR. The alert was made active in EMIS web practices on 17th June 2015. The original intention 
of this study had been to work collaboratively with EMIS to prospectively evaluate an alert to 
identify excessive SABA prescribing in primary care. However, 6 months after commencing the 
PhD, EMIS implemented the SABA alert resulting in the retrospective evaluation of the SABA 

























* Referred to hereafter as SABA alert 
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Figure 4.2 presents the SABA alert as displayed in the EHR. The SABA alert automatically presents 
at the bottom right hand corner of the EHR screen, in what is referred to as the ‘pop- up’ box or 
the ‘QOF’ box. The QOF is a pay-for-performance system incentivising disease-specific 
performance targets. This was introduced on 1 April 2004 as part of the General Medical Services 
(GMS) contract for general practice. There are currently three QOF asthma indicators that 
present in this box; asthma diagnosis, smoking status and annual asthma review. The QOF box 
is however not restricted to QOF indicators and a range of other outstanding areas of patient 
care present in this box and are commonly referred to as alerts, reminders, ‘flags or pop-ups. 
Once the SABA prescribing threshold has been triggered the SABA alert remains in the QOF box 
until the protocol criteria is no longer met. The SABA alert was devised on the assumption that 
only one SABA device is issued at a time however it is not uncommon for two SABA devices to 










This study aimed to test the following hypotheses: 
 
 
The null hypothesis 
The Asthma Medicines Management alert will have no effect on SABA prescribing in the 12-
months post trigger date. 
 
The alternative hypothesis 
The Asthma Medicines Management alert will have an effect on SABA prescribing in the 12-
months post trigger date. 
 
 
4.1.4 Aims and Objectives 
 
 
The aim of Phase 2 of the thesis was to determine the effectiveness of an electronic alert at 
reducing SABA prescribing among people with asthma prescribed excessive SABAs in primary 
care. 
 
The objectives of Phase 2 of the thesis were to: 
 
 
1. Evaluate the effect of the Asthma Medicines Management alert on the primary outcome of 
SABA prescribing at 12 months following the alert intervention using a historically controlled 
case-control study design. 
 
2. Determine the effect of the Asthma Medicines Management alert on secondary outcomes: 
process measures (number of asthma reviews, time to asthma review, ICS/LABA prescribing, 
combination inhaler prescribing) and clinical outcomes (exacerbations, primary care 
consultations) of asthma care. 
 






4.2.1 Study design 
 
4.2.1.1 Case-control study design 
 
A case-control study design was used to determine the effects of an alert on outcomes of 
interest by comparing two population groups identified by excessive SABA prescribing: those 
identified following the implementation of an alert intervention (intervention group) and those 
historically matched as having been prescribed excessive SABAs prior to the alert intervention 
(control group). The study design is presented in figure 4.3. The choice of retrospective case-
control design was influenced by two factors (1) convenience; by utilising a readily available data 
source in the locality within which the researcher was based, and (2) time; a prospective study 
would have exceeded both doctorate funding and timeframe for completion. 
The intervention group were those identified as having been prescribed excessive SABAs in a 12-
month period after the alert intervention (17th June 2015 to 17th June 2016) and the historical 
controls were those identified as having been prescribed excessive SABAs in a 12-month period 
before the alert intervention (17th June 2013 to 17th June 2014). The date of study entry for each 
patient was the date on which excessive SABA prescribing first occurred i.e. the point at which 
a third prescription for SABAs was generated. Patient and practice data was extracted and 
anonymised by the Clinical Effectiveness Group (CEG) at QMUL prior to being obtained by the 
researcher hence data analysis at practice and patient level was not possible. As practice 
characteristics were not analysed, cluster adjustment by general practice not required and a 
paired analysis between the intervention and control groups was not possible.  Despite being 
identified by two distinct time-periods, patients may have been included in both intervention 




























12 months before 12 months after 
17 June 2013  17 June 2014 17 June 2015 17 June 2016 
 
 
Assessment period Assessment period 
12 months after 
Intervention 
group 
12 months after 
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4.2.1.2 Sample size and power 
 
 
Sample size and power was calculated using Chi-square test and interpreted using Cohen’s 
statistical power analyses.338 A Queen Mary University of London statistician was consulted 
throughout this study and assisted with power calculations. 
 
An original power calculation was based on Hull et al’s. study of asthma prescribing in the same 
three east London CCGs with a population of 35,864 asthma patients.13 Based on approximately 
30,000 patients in each arm of the study at 80% power and 5% significance, it was estimated 
that a very small effect size of 0.011 could be detected in the case-control study in Phase 2 of 
this thesis. In clinical terms, this equated to the detection of an estimated 0.03% difference in 
those prescribed >3 SABAs between the intervention and control group in the 12 months 
following the excessive prescribing trigger. However, on further review, the inclusion criteria in 
Hull et al. were those with a QOF read code set for asthma diagnosis rather than our subset of 
interest; those prescribed excessive SABAs.  
Following preliminary data collection, 18,244 patients met the Phase 2  study inclusion criteria 
reported in section 4.2.2.3. Therefore at 80% power and 5% significance it was re-estimated that 
a minimum effect size of 0.02 could be detected. However following data analysis, there was a 
1.69% difference in those prescribed >3 SABAs in the intervention and control group in the 12 
months following the excessive prescribing trigger. This meant the actual effect size was 0.015 
and when compared to the estimated power calculation, the study was underpowered at 52%. 
To increase power, data was adjusted for covariates: age, ethnicity and SABA prescribing prior. 
Based on the evidence that each significant covariate adjusted for variation can add 
approximately 10% power,339 the study was approximately powered at 82%. 
Socio-economic status as determined by indices of multiple deprivation (IMD2010) was not 








4.2.2 Study population 
 
4.2.2.1 Study setting 
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The study included data from 132 primary care practices using EMIS web general practice 
computer software in three ethnically diverse boroughs in east London: Tower Hamlets (n=37), 
Hackney (n=43) and Newham (n=52).  This constituted a combined GP registered population of 
approximately 1 million. Practices were automatically included due to the data sharing 
agreements between general practice in east London and the Clinical Effectiveness Group (CEG) 
at QMUL.  
 
4.2.2.2 Patient demographics 
 
Anonymised demographic data including age, gender and ethnicity were extracted. Ethnicity 
was self-reported, recorded at the practice either during registration or routine consultation. 
Ethnic categories were based on the UK 2011 census codes for ethnicity340 and condensed into 
five major categories: White (British, Irish, other White), Black (Black African, Black Caribbean, 
Black British, other Black and mixed Black) and South Asian (Bangladeshi, Pakistani, Indian, Sri 
Lankan, British Asian, other South Asian or mixed Asian). Coding category ‘other’ was used to 
describe people who self-identify as White persons not of English, Welsh, Scottish or Irish ethnic 
groupings as referenced in census data. Ethnic category ‘not stated’ refers to unknown ethnicity 
or not reported/missing data. Appendix 4.1 details how the ethnicity categories were refined 
into the three categories used in this study.  
 
4.2.2.3 Inclusion and exclusion criteria 
 
 
Four rules were generated used to search the EHR to determine patients eligible for inclusion 
based on the following criteria: 
 
Rule 1: Patients aged between 5 and 75 years  
 
Rule 2: Asthma in the previous 12 months 
 
Patients were defined by the QOF Read code diagnosis of asthma.341 Table 4.1 includes the 
expanded cluster list of codes for QOF Asthma diagnosis. 
 




A SABA prescription was defined as any SABA included in the Asthma Medicines Management 
alert protocol as listed in Table 4.2. 
 
Rule 4: Excluding COPD 
 
Patients who had a diagnosis of COPD as identified by the QOF Read code set342 were excluded 
from the study. 
 
 Table 4. 1 Expanded QOF codes for Asthma diagnosis 
 
 
Read Code Code description 
173A. Exercise induced asthma 
H3120 Chronic asthmatic bronchitis 
H33.. Asthma 
H330. Extrinsic (atopic) asthma 
H3300 Extrinsic asthma without status asthmaticus 
H3301 Extrinsic asthma with status asthmaticus 
H330z Extrinsic asthma NOS 
H331. Intrinsic asthma 
H3310 Intrinsic asthma without status asthmaticus 
H3311 Intrinsic asthma with status asthmaticus 
H331z Intrinsic asthma NOS 
H332. Mixed asthma 
H334. Brittle asthma 
H335. Chronic asthma with fixed airflow obstruction 
H33z. Asthma unspecified 
H33z0 Status asthmaticus NOS 
H33z1 Asthma attack 
H33z2 Late-onset asthma 
H33zz Asthma NOS 
H3B Asthma-chronic obstructive pulmonary disease overlap syndrome 
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The main outcome of interest was SABA prescribing at 12 months following the SABA alert. The 
definition of excessive SABA use was based on the Asthma UK Medicines Management alert 
definition of high SABA use as three SABA prescriptions in a three-month period. As SABA may 
be issued on a variety of prescription types including by acute or repeat, the date and type of 
SABA prescription was captured and included in sub-group analysis. 
SABA Name, Dosage and Quantity 
Asmasal 95micrograms/dose Clickhaler (Focus Pharmaceuticals Ltd) 
Bricanyl 500micrograms/dose Turbohaler (AstraZeneca UK Ltd) 
Easyhaler Salbutamol sulfate 100micrograms/dose dry powder inhaler (Orion Ltd) 
Easyhaler Salbutamol sulphate 100micrograms/dose dry powder inhaler (Orion Ltd) 
Salamol 100micrograms/dose Easi-Breathe inhaler (Teva UK Ltd) 
Salamol 100micrograms/dose inhaler CFC free (Teva UK Ltd) 
Salamol Easi-Breathe Cfc-Free Breath-Actuated Inhaler 100 micrograms/puff 
Salbulin Novolizer 100micrograms/dose inhalation powder (Meda Pharma Ltd) 
Salbutamol Accuhaler 200 micrograms/dose and 
Salbutamol Breath-Actuated Inhaler (Cfc-Free) 100 micrograms/dose 
Salbutamol Breath-Actuated Inhaler (Cfc-Free) 100 micrograms/dose~(c13U.) 
Salbutamol Cfc-Free Inhaler 100 micrograms/puff 
Salbutamol Cfc-free inhaler 100 micrograms/puff~(c13J.) 
Salbutamol 100micrograms/dose breath actuated inhaler CFC free 
Salbutamol 100micrograms/dose dry powder inhaler 
Salbutamol 100micrograms/dose inhaler CFC free 
Salbutamol 200micrograms/dose dry powder inhaler 
Salbutamol 95micrograms/dose dry powder inhaler 
Terbutaline 500micrograms/dose dry powder inhaler 
Ventolin 100 micrograms/dose Evohaler (GlaxoSmithKline UK Ltd) 
Ventolin 200 micrograms/dose Accuhaler (GlaxoSmithKline UK Ltd) 
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The number of asthma reviews and time to review were defined by the following QOF Read code 
set: 66YJ (Asthma annual review) 66YK (Asthma follow-up), 66YQ (Asthma monitoring by a 
nurse), 66YR (Asthma monitoring by a doctor), 8B3j (Asthma medication review) and 9OJA 
(Asthma monitoring check done).341 
 
The number of asthma reviews and time to asthma review were analysed at 0-3 months and 3-
6 month time points only as deemed more likely to be clinically significant than a review carried 
out at a later point. No review data was captured in the prior time period and therefore the 
potential influence of having had a review prior to the alert trigger was not explored. 
 
 
ICS, LABA and Combination inhaler prescribing 
 
 
The types of ICS, LABA and Combination inhalers included in the study are presented in 
appendices: ICS (appendix 4.2), LABAs (appendix 4.3) and Combination inhalers (appendix 4.4). 
Spacer prescriptions were not included.  
 
Decision-making regarding the choice of inhalers for inclusion was guided by a variety of sources: 
(i) the British National Formulary for prescribing (ii) MIMs online; a prescribing and clinical 
reference for general practice, (iii) Hull et al’s study on asthma prescribing in the same 





An asthma exacerbation was defined as any oral steroid prescription type as listed in appendix 
4.5. This definition was based on Al Sallakh et al’s.244 scoping review of asthma outcomes using 
electronic health record data, which identified this as a commonly used definition of an 
exacerbation in a number of studies.
343–350  Oral steroid prescriptions were assumed to be 
prescribed for the treatment of an asthma exacerbation as prescribing for alternative purposes 
could not be determined in the data set. Exacerbations were primarily analysed at 0-12 months 
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Primary care consultations were captured using the following consultation types readily 
available within the EHR: Administration note, discussion with colleague, discussion with other 
professional, emergency appointment, emergency consultation, extended hours consultation, 
externally entered note, face to face consultation, face to face consultation with relative/carer, 
GP surgery, home visit note, nursing home visit note, other note, telephone call from a patient, 
telephone call from a relative/carer, telephone call to a patient, telephone call to a 
relative/carer, telephone consultation, telephone triage encounter, third party consultation, 
urgent consultation, walk-in clinic. Asthma-specific consultations could not be determined as 
data is routinely coded by consultation type and not for presenting reason/condition. Primary 
care consultations were primarily analysed at 0-12 months post excessive prescribing trigger 
date but not in the prior time period. 
 
4.2.3.3 Sub group analyses 
 
 
Outcomes were explored by time period 0-3, 3-6 and 6-12 months, with the exception of asthma 
reviews, and by acute and repeat prescription type. Subgroup analysis by various time point was 
deemed appropriate to account for likely regression to the mean in the 0-3 months following  
SABA prescribing being identified at an extreme (excessive) point.  
 
Sub-group analysis by prescription type was explored as SABAs are commonly obtained by 
repeat prescription. This data would be used to complement qualitative findings of Phase 3 on 
the roles of primary care staff in SABA prescribing.  
 
It was assumed that characteristics and prescribing practice between the three CCGS in east 








4.2.4  Data collection and management 
 
Data collection and management was facilitated by a data analyst from the CEG at QMUL. 
 
The CEG has data sharing agreements with general practices in Hackney, Newham and Tower 
Hamlets to access aggregated and anonymised patient data for research purposes. The CEG is 
linked with both EMIS and the NHS N3 network, the national broadband network for the NHS, 
enabling the CEG to search and extract general practice data. Data were extracted on secure N3 
terminals using EMIS-Web and processed using Microsoft Excel and Access. 
 
To ensure accuracy of the data, the study methods underwent multiple revisions from June 
2016, supported by a data analyst, with final data extraction carried out in December 2017.  
 
 
4.2.4.1  Identifying alert trigger date 
 
As the SABA alert was not coded within the EHR at time of activation, it was not possible to 
automatically determine patients for whom the SABA alert activated. An Excel search was 
written to identify patients prescribed excessive SABAs within the intervention and control 
group periods. Of those eligible for inclusion, patients prescribed at least 3 SABAs in a 90-day 
period were identified. The date on which a third SABA prescription was generated was taken 
as the point at which the SABA alert would have triggered for that patient and was the point 
from which all outcomes of interest were measured. 
 
Data was saved and imported into Access alongside patient demographics and outcomes of 
interest. The SABA alert date was imported from Excel to Access. Using the anonymised patient 
identifier, data was merged to provide one line patient level data. All data searches were carried 
out by the data analyst and the searches can be found in Appendix 4.6 (intervention group) and 
Appendix 4.7 (control group). 
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4.2.4.2  Inhaled steroid data  
 
 
Until May 2009 all doses of ICS in the BTS/SIGN asthma guidelines were referenced against 
beclometasone dipropionate equivalent (BDP) given via chlorofluorocarbon metered dose 
inhalers (CFC-MDIs). Most recent BTS/SIGN guidelines52 no longer refer to BDP equivalent 
dosage. However, there is no gold standard comparator of ICS dosage, and BDP equivalent is 
often used as the reference standard when comparing ICS in terms of their potency.105 
  
Due to complexities of calculating BDP equivalent prescribing of inhaled steroids in clinical 
practice, the ICS prescribing data captured could not be analysed within the study timeframe 
and was therefore omitted.   
 
 
4.2.5 Statistical analyses and reporting 
 
Statistical analyses were performed using IBM SPSS Statistics 24. All statistical analyses were 
carried out and analysed by the lead researcher and checked by the QMUL statistician. The 
statistician provided advice regarding all statistical tests and reviewed all results. 
 
The statistical tests applied were a result of data not normally distributed. Distribution of data 
was determined by reviewing frequency tables and histograms for count data. No formal test 
was carried out to determine distribution due to challenges of using statistical tests to 
determine normality in a large dataset. Non-parametric tests were used to determine the 
relationship between prescribing and consultations (Mann Whitney-U test) and the numbers 
of asthma reviews carried out in the intervention and control groups (Chi-Squared test). A 
mixed effects regression model was applied to collective CCG data. Prescribing and 
consultation data were analysed using Poisson regression, whilst a  binary regression was 
applied to the number of asthma reviews.  
 
The following covariates were adjusted for potential baseline imbalance: age, gender, 
ethnicity and prescribing in the equivalent timeframe prior to the alert (where applicable). 
The median (IQR) was reported alongside Mann-Whitney P-values as despite suggestions that 
the actual distribution of the data does not matter,353 differences in spread may sometimes 
be as clinically important as differences in medians.236 The relationship between independent 
and dependent variables is commonly misreported as causal, therefore data adjusted using 
regression analysis has been reported as indicative of correlation not causation.354 The 
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direction and strength of effect was determined using Adjusted Beta (β), Exp β (adjusted odds 
ratio) and the reliability of the effect determined by a 95% confidence interval (95% CI) and 
P- value. 
 
Multiple testing of the primary outcome of interest SABA prescribing data was pre-specified. 
Subgroup analysis by time point was due to data being identified at an extreme point (excessive 
SABA prescribing) with regression to the mean likely in the 0-3 months following the alert. To 
account for multiple testing, Bonferroni adjustment was applied and the cut-off for a statistical 
significant effect of the intervention on SABA prescribing was reduced from P<0.05 to P<0.016. 
 
 
4.2.6 Ethical considerations 
 
Ethical approval was not required as aggregated, anonymised patient-level data was reported 
in this study. All GPs in the participating east London practices consented to the use of 
practice anonymised patient data through pre-existing data-sharing agreements with the 
CEG. 
 
4.2.7 Validity and reliability of data 
 
This study has been reported  in line with the STROBE statement (Reporting of Observational 
Studies in Epidemiology) and the RECORD statement (Reporting of studies Conducted using 
Observational Routinely collected health Data.336 Both checklists can be found in appendix 
4.8. 
As optimal reporting should include complete code lists, detailed algorithms and validity 
assessment,244 code lists and algorithms are presented in appendices 4.1-4.7. 
 
Quality checks were carried out manually to ensure the purported date of alert for excessive 
SABA prescribing was accurately captured by the Excel search. This involved reviewing the 







The primary outcome of SABA prescribing in the 12 months following the alert intervention 
is presented below. Secondary outcomes are reported: number of asthma reviews and time 
to review, number of exacerbations as determined by prednisolone prescribing, and primary 
care consultations. Exploratory sub group analyses were carried out by time point and by 
prescription type. Both SABA and prednisolone prescribing were adjusted for prior and post 
excessive SABA prescribing trigger point. Primary care consultations and asthma reviews prior 
to the date of excessive SABA prescribing were neither captured nor adjusted for in both 
intervention and control groups. ICS, LABA and Combination inhaler prescribing data was 
collected but not reported for reasons explained in section 4.2.4.2. Data was adjusted for 
covariates: age, gender and ethnicity. Ethnicity was adjusted for collectively and reported by 
ethnic category where statistically significant. 
 
 
4.3.1 Population characteristics 
 
 
A total of 18,244 were included in the study. Table 4.3 presents a comparison of patient 
characteristics between the intervention and control group. Patients were evenly distributed 
between groups by age and ethnicity however there was a higher number of patients in the 
intervention than control group with more females than males. 
 
Table 4. 3  Characteristics of included patients 
 
 Patient demographics  Control Group  Intervention group 
 Number of patients  8691  9553 
 Age  41.93 (SD 19.338)  42.17 (SD 19.344) 
 Gender  Female  5351 (56%)  4717 (54%) 
 Male  4202 (44%)  3974 (46%) 
 Ethnicity  White  3338 (34.94%)  3128 (35.99%) 
 Black  1723 (18.04%)  1582 (18.2%) 
 South Asian  3787 (39.64%)  3401 (39.13%) 
 Other  445 (4.66%)  358 (4.12%) 




The mean age of patients was 42.1 years (+/-SD 19.3). Figure 4.4 presents the age distribution 
of patients. There were two notable clusters of children/adolescents and older age peaking 
between 50-60 years, with the study population consisting of more females (55.2%) than 
males (44.8%). The majority of patients were of South Asian ethnicity (39.4%), followed by 
those of White ethnicity (35.4%) and Black ethnicity (18.1%). 
 





4.3.2 Distribution of data 
 
Histograms were used to review the distribution of SABA prescribing in the intervention 
group (figure 4.5) and control group (figure 4.6). Both histograms show uneven spread and 
skewed data reflective of non-normal distribution and therefore non-parametric tests were 
applied in this study. 
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4.3.3 Primary outcome 
 
4.3.3.1 SABA prescribing: 0-12 months 
 
The median and interquartile Range (IQR) of SABAs prescribed in the intervention and control group 
at 0-12 months prior and post SABA prescribing trigger is presented in Table 4.4. The median number 
of SABA inhalers prescribed was similar between groups. 
 
 
 Table 4. 4 Number of SABA prescribed in the control and intervention groups at 12 months before 
and after the intervention group (SABA alert) and at 12 months before and after the historical 
control group (no SABA alert). Reported as Median and Interquartile Range (IQR). 
 
 
 Number of SABA inhalers prescribed 
 (Months)  
 Control group  Intervention group 
 Median (IQR)   Median (IQR) 
 0-12 mo nth prior   7 (5-11)  7 (5-11) 
 0-12 month post  7 (4-11)  7 (4-11) 
   
 
 
A comparison between the distributions of SABAs prescribed in the 0-12 months prior and post 
excessive prescribing trigger between groups was carried out to determine the spread of data. 
This is presented in Table 4.5. In the 0-12 months prior to the SABA prescribing trigger, a greater 
proportion of the population in the intervention group were prescribed >12 SABA in comparison 
to control group, however in the 12 months post SABA prescribing trigger the opposite was 
observed. Furthermore a greater proportion of the intervention group were prescribed no SABAs 
at 0-12 months post SABA prescribing trigger when compared to the control group.  
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Table 4. 5 Comparison of SABA prescribing at 0- 12 months before and after the intervention 
group (SABA alert) and at 0-12 months before and after the historical control group (no SABA 
alert). 
 
* Derived from Mann-Whitney test 
 
The effect of covariate adjustment on SABA prescribing in the 12 months post SABA prescribing 
trigger is presented in table 4.6.  In the intervention group, SABA prescribing reduced by 7% in 
the 12 months following the alert (AOR 0.938, 95% CI 0.927-0.947, P<0.001). SABA prescribing 
reduced by 4% in the Black population (AOR 0.964, 95% CI 0.949 – 0.980, P<0.001), 3% in the 
South Asian population (AOR 0.972, 95 % CI 0.949–0.980, P<0.001) and by 4% in those of Other 
ethnicity (AOR 0.961, 95% CI 0.935–0.989, P=0.006). SABA prescribing was associated with 
increasing age however, despite statistical significance being achieved the small size of effect 
suggests a negligible association between age and SABA prescribing that is not clinically significant 
(AOR 1.002, 95% CI 1.002 – 1.003, P<0.001). There was no association between gender and SABA 
prescribing as reflected in an effect size of almost zero (AOR 0.994, 95% CI 0.983 – 1.005, P=0.283). 
Those prescribed excessive SABAs in the 12 months prior had a 7% chance of being prescribed 
excessive SABAs in the 12 months post prescribing trigger (AOR 1.073, 95% CI 1.072 – 1.074, 
P<0.001).  There was no significant variance in SABA prescribing across individual CCGs to account 
for changes to SABA prescribing (σ2 0.001, 95% CI 0.000 - 0.005, σ= 0.333). 
 SABA prescribing 
 0-12 months prior 
 Control group (N%)  Intervention group (N%)  P-value* 
 3 (alert trigger)  824 (9.5%)  810 (8.1%)  0.001 
 4-6  2865 (33.0%)  3055 (30.4%) 
 7-12  3907 (45.0%)  4447 (44.3%) 
 >12  1095 (12.5%)  1732 (17.2%) 
 SABA prescribing 
 0-12 months post 
 Control group (N%)  Intervention group (N%)  P-value* 
 0  111 (1.3%)  149 (1.6%)  <0.001 
 1-3  1400 (16.1%)  1674 (17.5%) 
 4-6  2406 (27.7%)  2850 (29.8%) 
 7-12  3851 (44.3%)  4108 (43.0%) 
 >12  923 (10.6%)  772 (8.1%) 
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Table 4. 6 Poisson mixed effects model with SABA prescribing at 0-12 months as a dependent  
variable adjusted for covariates.1 
 
 
 Factors  Adjusted β5 (95% CI)  Exp β / OR (95% CI)  P-value 
 Age  0.002 (0.002 - 0.003)  1.002 (1.002 – 1.003)  <0.001 
 Gender2 (Female)  -0.006 (-0.017, 0.005)  0.994 (0.983 – 1.005)  0.283 
 Ethnicity3  Black  -0.036 (-0.052, -0.020)  0.964 (0.949 - 0.980)  <0.001 
 South Asian  -0.028 (-0.041, -0.016)  0.972 (0.959 - 0.984)  <0.001 
 Other  -0.039 (-0.067, -0.011)  0.961 (0.935 - 0.989)  0.006 
 Not stated  0.001 (-0.036, 0.037)  1.001 (0.964 - 1.037)  0.975 
 SABA 0-12 months prior  0.071 (0.070-0.072)  1.073 (1.072 – 1.074)  <0.001 
 Group (Intervention)4  -0.064 (-0.075, -0.054)  0.938 (0.927 – 0.947)  <0.001 
 Random effect  Estimated σ2 (95% CI)   P-value 
 CCG Variance  0.001 (0.000 – 0.005)   0.333 
1 adjusted for age, gender, ethnicity and SABA prescribing prior 




4.3.3.2 SABA prescribing: 0-3 months 
 
The median and IQR of SABAs prescribed in the intervention and control group at 0-3 months 
prior and post SABA prescribing trigger is presented in Table 4.7. The median number of SABA 
inhalers prescribed in the 0-12 months was similar in both groups. 
 
Table 4. 7 Number of SABA prescribed in the control and intervention groups at 0-3 months 
before and after the intervention group (SABA alert) and at 0-3 months before and after the 
historical control group (no SABA alert). Reported as Median and Interquartile Range (IQR). 
 
 
Number of SABA inhalers prescribed  
(Months) 
 Control group  Intervention group 
 Median (IQR)  Median (IQR) 
 0-3 month prior  3 (3-3)  3 (3-3) 




Table 4.8 compares the distribution of SABAs prescribed in the 0-3 months prior and post SABA 
prescribing trigger in the intervention and control group. In the 0-3 months prior to the SABA 
prescribing trigger, a higher proportion of people were prescribed between 4-6 SABAs in the 
intervention group than control group. However in the 0-3 months post SABA prescribing trigger, 
the opposite was observed with a higher proportion of the control group prescribed 4-6 SABAs 
than the intervention group. 
 
 
Table 4. 8 Comparison of SABA prescribing at 0-3 months before and after the intervention group 
(SABA alert) and at 0-3 months before and after the historical control group (no SABA alert) 
 
* Derived from Mann-Whitney test 
 
 
The effect of covariate adjustment on SABA prescribing in the 0-3 months post SABA prescribing 
trigger is presented in table 4.9. When adjusted for prescribing in the control group, there was a 
2% reduction in SABA prescribing the 0-3 months post excessive prescribing trigger however this 
was not statistically significant (AOR 0.983, 95% CI 0.961-1.006, P=0.148). When adjusted for 
ethnicity, a 4% reduction in SABA prescribing was observed in the Black (P=0.026) and South Asian 
population (P=0.006) and an 8% reduction in those of Other ethnicity (P=0.007). SABA prescribing 
was associated with increasing age however, despite achieving statistical significance the small 
effect size suggests a negligible association between age and SABA prescribing that is not clinically 
significant (AOR 1.004, 95% CI 1.004 – 1.005, P<0.001). 
 SABA prescribing                                      
0-3 months prior 
Control group (N%) 
 
 Intervention group (N%) 
 
 P-value* 
 3 (alert trigger)  7175 (82.6%)  7776 (81.4%)  0.165 
 4-6  1481 (17%)  1735 (18.2%) 
 7-12  35 (0.4%)  42 (0.4%) 
 >12  0 (0%)  0 (0%) 
 SABA prescribing 
 0-3 months post 
 Control group (N%)  Intervention group (N%) 
 
 P-value* 
 0  1478 (17.0%)  1633 (17.1%)  0.044 
 1-3  6820 (78.5%)  7538 (78.9%) 
 4-6  377 (4.3%)  355 (3.8%) 
 7-12  14 (0.2%)  26 (0.2%) 
 >12  2 (0%)  1 (0%) 
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Despite a 2% reduction in SABA prescribing among females, the relationship between gender and 
SABA prescribing was not statistically significant (AOR 0.979, 95% CI 0.955-1.002, P=0.069). Those 
prescribed excessive SABAs in the 0-3 months prior had a 30% chance of being prescribed 
excessive SABAs in the 0-3 months post prescribing trigger (AOR 1.308, 95% CI 1.291-1.324, 
P<0.001). There was no significant variance in SABA prescribing across individual CCGs to account 
for changes to SABA prescribing (σ2 0.007, 95% CI 0.001 - 0.051, σ= 0.324). 
 
Table 4. 9 Poisson mixed effects model with SABA prescribing at 0-3 months as a dependent variable 
adjusted for covariates1 
 
1 adjusted for age, gender, ethnicity and SABA prescribing prior 




4.3.3.3 SABA prescribing: 3-6 months 
 
The median and IQR of SABAs prescribed in the intervention and control group at 3-6 months 
prior and post SABA prescribing trigger is presented in Table 4.10. The median number of SABA 
inhalers prescribed in the 3-6 months was similar in both groups. 
 
 
 Factors  Adjusted β (95% CI)  Exp β / OR (95% CI)  P-value 
 Age  0.004 (0.004 – 0.005)  1.004 (1.004 – 1.005)  <0.001 
 Gender2 (Female)  -0.021 (-0.045, 0.002)  0.979 (0.955 – 1.002)  0.069 
 Ethnicity3    Black  -0.037 (-0.070, -0.004)  0.963 (0.932 – 0.996)  0.026 
 South Asian  -0.038 (-0.065, -0.011)  0.962 (0.937 – 0.989)  0.006 
 Other  -0.081 (-0.140, -0.022)  0.922 (0.869 – 0.978)  0.007 
 Not stated  -0.074 (-0.152, 0.003)  0.928 (0.858 – 1.003)  0.061 
 SABA 0-3 months prior  0.269 (0.256 – 0.281)  1.308 (1.291 – 1.324)  <0.001 
 Group (Intervention)4  -0.017 (-0.039, 0.006)  0.983 (0.961 – 1.006)  0.148 
 Random effect  Estimated σ2 (95% CI)   P-value 
 CCG Variance  0.007 (0.001 – 0.051)   0.324 
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 Table 4. 10 Number of SABA prescribed in the control and intervention groups at 3-6 months 
before and after the intervention group (SABA alert) and at 3-6 months before and after the 
historical control group (no SABA alert). Reported as Median and Interquartile Range (IQR). 
 
 Number of SABA inhalers prescribed   
(Months) 
 Control group  Intervention group 
 Median (IQR)   Median (IQR) 
 3-6 months prior  1 (0-2)  1 (0-2) 
 3-6 months post  2 (1-3)  2 (1-3) 
  
 
Table 4.11 compares the distributions of SABAs prescribed in the 3-6 months prior and post SABA 
prescribing trigger in the intervention and control group. In the 3-6 months prior, a higher 
proportion of people in the control group were prescribed no SABAs prescribed in comparison to 
the intervention group. However in the 3-6 months post SABA prescribing trigger, the opposite 
was observed with a higher proportion of the intervention group prescribed no SABAs in 
comparison to the control group. 
 
Table 4. 11 Comparison of SABA prescribing at 3-6 months before and after the intervention group 
(SABA alert) and at 3-6 months before and after the historical control group (no SABA alert). 
 
 SABA prescribing 
 3-6 months prior 
 Control group (N%) 
 
 Intervention group (N%) 
 
 P-value* 
 0  2516 (29.0%)  2571 (26.9%)  <0.001 
 1-3  5678 (65.3%)  6436 (67.4%) 
 4-6  473 (5.4%)  531 (5.6%) 
 7-12  23 (0.3%)  15 (0.1%) 
 >12  1 (0%)  0 (0%) 
 SABA prescribing 
 3-6 months post 
 Control group (N%) 
 
 Intervention group (N%)  P-value* 
 0  1308 (15.1%)  1544 (16.2%)  0.002 
 1-3  6605 (76.0%)  7282 (76.2%) 
 4-6  749 (8.6%)  701 (7.3%) 
 7-12  29 (0.3%)  24 (0.3%) 
 >12  0 (0%)  2 (0%) 
  * Derived from Mann-Whitney test  
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The effect of covariate adjustment on SABA prescribing in the 3-6 months post SABA prescribing 
trigger is presented in table 4.12. When adjusted for the control group, SABA prescribing reduced 
by 4% in the 3-6 months post excessive prescribing trigger  (AOR 0.955, 95% CI 0.935-0.976, 
P<0.001). SABA prescribing reduced by 5% in the Black population (P=0.001) and by 4% in the 
South Asian population  (P=0.002). SABA prescribing was associated with increasing age however, 
despite being statistically significant the small effect size suggests a negligible association 
between age and SABA prescribing that is not clinically significant (AOR 1.002, 95% CI 1.002-1.003, 
P<0.001). SABA prescribing reduced by 1% among females in the 3-6 months post excessive 
prescribing trigger however this was not statistically significant (AOR 0.988, 95% CI 0.966-1.010, 
P=0.288). Those prescribed excessive SABAs in the 3-6months prior to trigger date had a 21% 
chance of being prescribed excessive SABAs in the 3-6 months post prescribing trigger (AOR 1.216, 
95% CI 1.208- 1.226, P<0.001). There was no significant variance in SABA prescribing across 




Table 4. 12 Poisson mixed effects model with SABA prescribing at 3-6 months as a dependent 
variable adjusted for covariates1 
 
1 adjusted for age, gender, ethnicity and SABA prescribing prior 
2 reference males, 3 reference White population, 4 reference control group 
 Factors  Adjusted β (95% CI)  Exp β / OR (95% CI)  P-value 
 Age  0.002 (0.002 – 0.003)  1.002 (1.002 – 1.003)  <0.001 
 Gender2 (Female)  -0.012 (-0.034, 0.010)  0.988 (0.966 – 1.010)  0.288 
 Ethnicity3 Black  -0.051 (-0.082, -0.020)  0.950 (0.921 – 0.980)  0.001 
South Asian  -0.039 (-0.064, -0.014)  0.961 (0.938 – 0.986)  0.002 
Other  -0.042 (-0.097, 0.013)  0.958 (0.907 – 1.013)  0.131 
Not stated  -0.020 (-0.092, 0.053)  0.980 (0.912 – 1.054)  0.593 
 SABA 3-6 months prior  0.196 (0.189 – 0.204)  1.216 (1.208 – 1.226)  <0.001 
 Group4 (Intervention)  -0.046 (-0.067, -0.024)  0.955 (0.935 – 0.976)  <0.001 
 Random effect  Estimated σ2 (95% CI)   P-value 
 CCG Variance  0.001 (0.000 – 0.010)   0.350 
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4.3.3.4 SABA prescribing: 6-12 months 
 
The median and IQR of SABAs prescribed in the intervention and control group at 6-12 months 
prior and post SABA prescribing trigger is presented in Table 4.13. The median number of SABA 
inhalers prescribed prior and post SABA prescribing trigger was similar between both groups. 
However fewer SABAs were prescribed in the intervention group than control group in the 6-12 
months post SABA prescribing trigger.   
 
 
Table 4. 13 Number of SABA prescribed in the control and intervention groups at 6-12 months 
before and after the intervention group (SABA alert) and at 3-6 months before and after the 
historical control group (no SABA alert). Reported as Median and Interquartile Range (IQR). 
 
 Number of SABA inhalers prescribed 
 (Months) 
 Control group  Intervention group 
 Median (IQR)  Median (IQR) 
 6-12 months prior  3 (1-5)  3 (1-5) 
 6-12 months post  4 (2-6)  3 (2-5) 
    
 
Table 4.14 compares the distributions of SABAs prescribed between groups in the 6-12 months 
prior and post SABA prescribing trigger. In the 6-12 months prior, a higher proportion of people 
in the control group had no SABAs prescribed in comparison to the intervention group. However 
in the 6-12 months post, the opposite was observed with a higher proportion of the intervention 
group prescribed no SABAs or 1-3 SABAs in comparison to the control group. Furthermore, a 
greater proportion of the control group population were prescribed 4-6 or 7-12 SABAs in the 6-
12 months post SABA prescribing trigger in comparison to the intervention group.  
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Table 4. 14 Comparison of SABA prescribing at 6-12 months before and after the intervention 
group (SABA alert) and at 6-12 months before and after the historical control group (no SABA 
alert) 
 
 SABA prescribing 
 6-12 months prior 
 Control group (N%) 
 
 Intervention group (N%) 
 
 P-value* 
 0  1259 (14.5%)  1250 (13.1%)  <0.001 
 1-3  3931 (45.2%)  4347 (45.5%) 
 4-6  2626 (30.2%)  2957 (31.0%) 
 7-12  858 (9.9%)  978 (10.2%) 
 >12  17 (0.2%)  21 (0.2%) 
 SABA prescribing 
 6-12 months post 
 Control group (N%)  Intervention group (N%) 
 
 P-value* 
 0  492 (5.7%)  727 (7.6%)  0.014 
 1-3  3564 (41.0%)  4338 (45.4%) 
 4-6  3484 (40.0%)  3490 (36.5%) 
 7-12  1124 (13.1%)  970 (10.1%) 
 >12  27 (0.2%)  28 (0.3%) 
* Derived from Mann-Whitney test 
 
The effect of covariate adjustment on SABA prescribing in the 6-12 months post SABA prescribing 
trigger is presented in table 4.15. When adjusted for the control group, SABA prescribing reduced 
by 9% in the 6-12 months post SABA prescribing trigger  (AOR 0.912, 95% CI 0.898-0.925, P<0.001). 
When adjusted for covariates, SABA prescribing reduced by 4% among the Black population 
(P<0.001), by 3% in the South Asian population (P=0.001) and by 6% in those of Other ethnicity 
(P=0.04). SABA prescribing was associated with increasing age (AOR 1.003, 95% CI  1.002-1.003, 
P<0.001) but not gender  (AOR 0.999, 95% CI  0.984 – 1.015, P=0.905). Despite being statistically 
significant, the small effect size suggests the association between age and SABA prescribing is not 
clinically significant. Those prescribed excessive SABAs in the 6-12 months prior to SABA 
prescribing trigger had a 10% chance of being prescribed excessive SABAs in the 6-12 months post 
(AOR 1.102, 95% CI 1.099-1.106, P<0.001). There was no significant variance in SABA prescribing 
across individual CCGs to account for changes to SABA prescribing at 6-12 months (σ2 0.000, 95% 
CI 0.000 -0.002, σ=0.446). 
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Table 4. 15 Poisson mixed effects model with SABA prescribing at 6-12 months as a dependent 
variable adjusted for covariates1 
 
1 adjusted for age, gender, ethnicity and SABA prescribing prior 
2 reference males, 3 reference White population, 4 reference control group 
 
 
4.3.4 Secondary outcomes 
 
4.3.4.1 Asthma reviews 
 
The number of reviews and time to review were analysed at 0-3 months and 3-6 months post 
SABA prescribing trigger and not 6-12 months. 
 
4.3.4.1.1 Number of people having an asthma reviews at 0-3 months 
 
The number of asthma reviews carried out between groups 0-3 months following post SABA 
prescribing trigger is presented in Table 4.16. There was a significant difference in the number of 
asthma reviews between groups, with a higher proportion of reviews in the intervention group 






 Factors  Adjusted β (95% CI)  Exp β / OR (95% CI)  P-value 
 Age  0.003 (0.002 – 0.003)  1.003 (1.002-1.003)  <0.001 
 Gender2 (Female)  -0.001 (-0.016, 0.015)  0.999 (0.984 – 1.015)  0.905 
 Ethnicity3  Black  -0.043 (-0.065, -0.021)  0.957 (0.937-0.979)  <0.001 
 South Asian  -0.034 (-0.051, -0.016)  0.966 (0.950-0.984)  0.001 
 Other  -0.057 (-0.096, -0.018)  0.944 (0.908-0.982)  0.004 
 Not stated  -0.010 (-0.061, 0.041)  0.990 (0.940-1.041)  0.706 
 SABA 6-12 months prior  0.098 (0.095 – 0.101)  1.102 (1.099 – 1.106)  <0.001 
 Group4 (Intervention)  -0.092 (-0.107, -0.077)  0.912 (0.898-0.925)  <0.001 
 Random effect  Estimated σ2 (95% CI)   P-value 
 CCG Variance  0.000 (0.000 – 0.002)   0.446 
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Table 4. 16 Number of people having had an asthma review in the intervention and control 
group at 0-3 months 
 
 Asthma Review 
 0-3 months post 
 Control group (N%)  Intervention group (N%)  P-value* 
 Yes 1809 (20.8%)  2182 (22.8%) 0.001 
 No 6882 (79.2%)  7371 (77.2%) 
* Derived from Mann-Whitney test 
 
 
The effect of covariate adjustment on asthma reviews in the 0-3 months post SABA prescribing 
trigger is presented in table 4.17. 
 
Table 4. 17 Binary mixed effects model with number of people having had an asthma review at 
0-3 months as an independent variable adjusted for covariates1 
 
1 adjusted for age, gender, ethnicity 
2 reference males, 3 reference White population,4 reference control group 
 
 
When adjusted for the control group, the number of asthma reviews in the intervention group 
increased by 12% (AOR 1.120, 95% CI 1.043- 1.202, P=0.002). When adjusted for ethnicity, the 
number of asthma reviews increased by 12% in the Black population (P=0.044) and 19% in the 
South Asian population (P<0.001). The number of asthma reviews was positively associated with 
increasing age however despite being statistically significant the small effect size is likely to be 
clinically insignificant (AOR 1.005, 95% CI 1.003-1.007, P<0.001).  
 Factors  Adjusted β (95 % CI)  Exp β / OR (95 % CI)  P-value 
 Age  0.005 (0.003-0.007)  1.005 (1.003-1.007)  <0.001 
 Gender2 (Female)  0.069 (-0.003, 0.142)  1.071 (0.997-1.152)  0.060 
 Ethnicity3 Black  0.106 (0.003-0.208)  1.111 (1.003-1.231)  0.044 
South Asian  0.175 (0.090-0.261)  1.191 (1.094-1.298)  <0.001 
Other  0.171 (0.003-0.345)  1.186 (1.003-1.411)  0.054 
Not stated  0.027 (0.206-0.260)  1.027 (1.228-1.296)  0.821 
 Group4 (Intervention)  0.114 (0.043-0.184)  1.120 (1.043-1.202)  0.002 
 Random effect  Estimated σ2 (95% CI)   P-value 
 CCG Variance  0.018 (0.002 – 0.146)   0.348 
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There was a non-statistically significant 7% increase in asthma reviews among females in 
comparison to males (AOR 1.071, 95% CI 0.997-1.152, P=0.060).  There was no significant variance 
in number of asthma reviews across individual CCGs to account for differences in number of 
asthma reviews at 0-3 months (σ2 0.018, 95% CI 0.002 -0.146, P=0.348). 
 
4.3.4.1.2 Number of asthma reviews: 3-6 months 
 
 
The number of asthma reviews carried out at 3-6 months following post SABA prescribing trigger is 
presented in Table 4.18. There was no significant between-group difference in the number of 
people having an asthma review at 3-6 months (P=0.370) (Table 4.18). 
 
 
Table 4. 18 Number of people having had an asthma review in the intervention and control 
group at 3-6 months 
 
 Asthma Review  
3-6 months post 
 Control group (N%)  Intervention group (N%)  P-value* 
 Yes  1917 (22.1%)  2160 (22.6%) 0.370 
 No  6774 (77.9%)  7393 (77.4%) 
* Derived from Mann-Whitney test 
 
 
The effect of covariate adjustment on asthma reviews in the 3-6 months post SABA prescribing 
trigger is presented in table 4.19. When adjusted for the control group, there was a 3% statistically 
non-significant increase in the number of asthma reviews in the intervention group (AOR 1.028, 
95% CI 0.985- 1.102, P=0.430).  When adjusted for ethnicity, the number of asthma reviews 
increased by 17% in the South Asian population only (P<0.001). There was a positive association 
between increasing and the number of asthma reviews however despite being statistically 
significant the small effect size is not clinically significant (AOR 1.005, 95% CI 1.003-1.007, 
P<0.001). There was a statistically significant 12% increase in asthma reviews among females in 
comparison to males (AOR 1.120, 95% CI 1.042-1.204, P=0.002).  There was no significant variance 
in number of asthma reviews across individual CCGs to account for differences in number of 
asthma reviews carried out (σ2 0.030, 95% CI 0.004-0.234, P=0.338). 
133  
Table 4. 19 Binary mixed effects model with number of people having had an asthma review at 
3-6 months as an independent variable adjusted for covariates1 
 
 Factors  Adjusted β (95 % CI)  Exp β / OR (95 % CI)  P-value 
 Age  0.005 (0.003-0.007) 1.005 (1.003-1.007)  <0.001 
 Gender2 (Female)  0.114 (0.042-0.186) 1.120 (1.042-1.204)  0.002 
 Ethnicity3   Black  -0.030 (-0.123, 0.072) 0.970 (0.884-1.074)  0.562 
 South Asian  0.158 (0.073-0.242) 1.171 (1.075-1.273)  <0.001 
Other  0.044 (-0.136, 0.224) 1.044 (0.872-1.251)  0.632 
 Not stated  0.203 (-0.043, 0.449) 1.225 (0.957-1.566)  0.106 
 Group4 (Intervention)  0.028 (-0.042, 0.098) 1.028 (0.958-1.102)  0.430 
 Random effect  Estimated σ2 (95% CI)   P-value 
 CCG Variance  0.030 (0.004-0.234)   0.338 
1 adjusted for age, gender, ethnicity 




4.3.4.1.3 Time to review: 0-3 months 
 
The median time to asthma review in the 3 months post SABA prescribing trigger was 48 days 
(IQR 22-70) in the control group and 46 days in the intervention group (IQR 23-69). There was no 
significant difference in the time to review between both groups at 3 months (P=0.762). Figure 
4.7 shows the time to review between groups at 0-3 months. 
 
When adjusted for the control group, no effect on time to asthma review was observed in the 
intervention group at 0-3 months post SABA prescribing trigger (Adjusted β 0.010, SE 0.032, 
P=0.753). Neither gender (β 0.015, SE 0.033, P=0.635), nor ethnicity (P=0.856), was associated 
with time to review at 0-3 months. Asthma reviews occurred in those of younger age however 
this is likely to be clinically insignificant given the small effect size. (β -0.002, SE 0.001, P=0.030). 
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Figure 4. 7 The proportion of asthma reviews carried out in the intervention and 








4.3.4.1.4 Time to review: 3-6 months 
 
The median time to asthma review at 3-6 months post SABA prescribing trigger was 133 days 
(IQR 112-156) in the control group and 134 days in the intervention group (IQR 112-158). 
There was no significant difference in the time to review between both groups at 3-6 months 
(P=0.409). Figure 4.8 shows the time to review between intervention and control group at 3-
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Figure 4. 8 The proportion of asthma reviews carried out in the intervention and control 







When adjusted for the control group, no effect on time to review was observed in the 
intervention group at 3-6 months post SABA prescribing trigger (Adjusted β -0.027, SE 0.031, 
P=0.384). Neither gender (Adjusted β 0.010, SE 0.032, P=0.765) nor age (Adjusted β 0.001, 
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4.3.4.2 Asthma exacerbations 
 
 
4.3.4.2.1 Prednisolone prescribing: 0-12 months 
 
 
Table 4.20 compares the distribution of prednisolone prescribing between groups in the 12 
months prior and post SABA prescribing trigger, with the majority of the control and 
intervention groups not prescribed prednisolone. Differences in prednisolone prescribing 
between groups in the 12 months prior to the SABA prescribing trigger was not statistically 
significant (P=0.75), however, a statistically significant difference was observed in the 12 
months post (P=0.032). 
 
Table 4. 20 Comparison of prednisolone prescribing at 0-12 months before and after the 
intervention group (SABA alert) and at 0-12 months before and after the historical control 
group (no SABA alert). 
 
 Prednisolone courses prescribed 
 0-12 months prior 
 Control group 
 (N%)  
 Intervention group 
 (N%) 
 P-value* 
 0  6835 (78.6%)  7414 (77.6%)  0.075 
 1  1043 (12.0%)  1189 (12.4%) 
 2  391 (4.5%)  421 (4.4%)  
 3  169 (1.9%)  214 (2.2%) 
 >3  253 (3.0%)  315 (3.3%) 
 Prednisolone courses prescribed 
 0-12 months post 
 Control group 
 (N%) 
 Intervention group 
 (N%) 
 P-value* 
 0  6926 (79.7%)  7487 (78.4%)  0.032 
 1  977 (11.2%)  1149 (12.0%) 
 2  343 (3.9%)  408 (4.3%) 
 3  168 (1.9%)  177 (1.8%) 
 >3  277 (3.2%)  332 (3.5%) 
* Derived from Mann-Whitney test 
 
 
The effect of covariate adjustment on prednisolone prescribing in the 0-12 months post SABA 






 Table 4. 21 Poisson mixed effects model with prednisolone prescribing at 0-12 months as 
a dependent variable adjusted for covariates1 
 
 Factors  Adjusted β (95 % CI)  Exp β / OR (95% CI)  P-value 
 Age  0.014 (0.013 – 0.016)  1.014 (1.013 – 1.016)  <0.001 
 Gender2 (Female)  0.248 (0.203 – 0.293)  1.281 (1.225 – 1.340)  <0.001 
 Ethnicity3   Black  -0.063 (-0.124, -0.003)  0.938 (0.883 – 0.997)  0.041 
 South Asian  -0.094 (-0.142, -0.046)  0.910 (0.867 – 0.955)  <0.001 
 Other  -0.189 (-0.302, -0.075)  0.827 (0.739 – 0.927)  0.001 
 Not stated  -0.005 (-0.156, 0.145)  0.995 (0.855 – 1.156)  0.943 
 Prednisolone 0-12m prior  0.111 (0.110 – 0.113)  1.117 (1.116 – 1.119)  <0.001 
 Group4 (Intervention)  -0.012 (-0.054, 0.029)  0.988 (0.947 – 1.029)  0.561 
1 adjusted for age, gender, ethnicity and prednisolone prescribing prior 
2 reference males, 3 reference White population, 4 reference control group 
 
 
When adjusted for the control group, the intervention had no effect on prednisolone 
prescribing in the 12 months post SABA prescribing trigger (AOR 0.988, 95% CI 0.947 – 1.029, 
P=0.561). Following covariate adjustment for ethnicity, prednisolone prescribing reduced by 
6% among the Black population (P=0.041), by 9% in the South Asian population (P<0.001) 
and by 16% in those of Other ethnicity (P=0.001). In contrast, female gender was positively 
associated with prednisolone prescribing (AOR 1.281, 95% CI 1.225 – 1.340, P<0.001) with 
those prescribed prednisolone prior to the SABA trigger 12% more likely to be prescribed 
prednisolone post SABA prescribing trigger (AOR 1.117, 95% CI 1.116 – 1.119, P<0.001). 
Prednisolone prescribing was positively associated with increasing age however despite 
being statistically significant the small effect size is not clinically significant (AOR 1.014, 95% 
CI 1.013-1.016, P<0.001). No significant variance in prednisolone prescribing was observed 
across individual CCGs to account for differences at 0-12 months (σ2 0.018, 95% CI 0.002 -
0.146, P=0.348). 
 
4.3.4.2.2 Prednisolone prescribing: 0-3 months 
 
Table 4.22 compares the distribution of prednisolone prescribing between groups in the 0-3 
months prior and post SABA prescribing trigger. There was no difference in prednisolone 
prescribing observed between groups in the 0-3 months prior (P=0.297) and post (P=0.558) 
SABA prescribing trigger.  
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Table 4. 22 Comparison of prednisolone prescribing at 0-3 months before and after the 
intervention group (SABA alert) and at 0-3 months before and after the historical control 
group (no SABA alert) 
 
 Prednisolone courses prescribed 
 0-3 months prior 
 Control group 
 (N%) 
 Intervention group 
 (N%) 
 P-value* 
 0  7703 (88.6%)  8498 (89.0%)  0.297 
 1  705 (8.1%)  712 (7.5%) 
 2  177 (2.0%)  213 (2.2%) 
 3  65 (0.7%)  69 (0.7%) 
 >3  41 (0.5%)  61 (0.5%) 
 Prednisolone courses prescribed 
 0-3 months post 
 Control group 
 (N%) 
 Intervention group 
 (N%) 
 P-value* 
 0  8048 (92.6%)  8807 (92.2%)  0.558 
 1  447 (5.1%)  522 (5.5%) 
 2  135 (1.6%)  145 (1.5%) 
 3  36 (0.4%)  50 (0.5%) 
 >3  25 (0.1%)  29 (0.1%) 
* Derived from Mann-Whitney test 
 
 
The effect of covariate adjustment on prednisolone prescribing in the 0-3 months post SABA 
prescribing trigger is presented in table 4.23.  When adjusted for the control group, the 
intervention had no effect on prednisolone prescribing at 0-3 months (AOR 1.008, 95% CI 
0.969-1.048, P=0.695). Following covariate adjustment, neither ethnicity nor female gender 
was associated with prednisolone prescribing in the 0-3 months post SABA prescribing 
trigger. However, prednisolone prescribing prior was associated with a 33% increase in 
prednisolone prescribing post SABA alert trigger (AOR 1.327, 95% CI 1.312-1.341, P<0.001). 
There was a statistically significant association between age and prednisolone prescribing 
(AOR 1.002, 95% CI 1.001-1.003, P<0.001) however the small effect size suggests the 
association is not clinically significant. Variance between CCGs was tested however 
convergence of the data in the Hessian matrix was not possible due to low numbers of 
prednisolone prescribed within the 0-3 months between CCGs.  
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Table 4. 23 Poisson mixed effects model with prednisolone prescribing at 0-3 months as a 
dependent variable adjusted for covariates1 
 
 
Factors  Adjusted β (95 % CI)  Exp β / OR (95% CI)  P-value 
 Age  0.002 (0.001 – 0.003)  1.002 (1.001 – 1.003)  <0.001 
 Gender2 (Female)  0.008 (-0.033, 0.048)  1.008 (0.967 – 1.049)  0.708 
 Ethnicity3    Black  -0.002 (-0.059, 0.056)  0.998 (0.942 – 1.057)  0.955 
 South Asian  0.032 (-0.013, 0.078)  1.032 (0.987 – 1.081)  0.165 
 Other  0.065 (-0.032, 0.163)  1.067 (0.968 – 1.177)  0.190 
 Not stated  0.069 (-0.058, 0.197)  1.071 (0.943 – 1.217)  0.288 
 Prednisolone 0-3m prior  0.283 (0.272 - 0.294)  1.327 (1.312 – 1.341)  <0.001 
 Group4 (Intervention)  0.008 (-0.031, 0.047)  1.008 (0.969 – 1.048)  0.695 
1 adjusted for age, gender, ethnicity and prednisolone prescribing prior 









A comparison in prednisolone prescribing between groups in the 3-6 months prior and post 
SABA prescribing trigger is presented in Table 4.24. There were significant differences in 
prednisolone prescribed between groups in the 3-6 months prior (P=0.011) and 3-6 months 
post trigger (P=0.049.) Count data indicates that in both the 3-6 months prior and post trigger 
less prednisolone was prescribed in the control group in comparison to the intervention 
group. In contrast, the proportion of the population having one or two courses of 
prednisolone prescribed was higher in the intervention group at both 3-6 months prior and 
post SABA prescribing trigger. 
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Table 4. 24 Comparison of prednisolone prescribing at 3-6 months before and after the 
intervention group (SABA alert) and at 3-6 months before and after the historical control 
group (no SABA alert) 
 
 Prednisolone courses prescribed 
 3-6 months prior 
 Control group 
 (N%) 
 Intervention group 
 (N%) 
 P-value* 
 0  8094 (93.1%)  8804 (92.2%)  0.011 
 1  438 (5.0%)  540 (5.7%) 
 2  99 (1.1%)  117 (1.2%) 
 3  29 (0.3%)  58 (0.6%) 
 >3  31 (0.2%)  34 (0.3%) 
 Prednisolone courses prescribed 
 3-6 months post 
 Control group 
 (N%) 
 Intervention group 
 (N%) 
 P-value* 
 0  7994 (92.0%)  8707 (91.1%)  0.049 
 1  491 (5.6%)  619 (6.5%) 
 2  117 (1.3%)  141 (1.5%) 
 3  53 (0.6%)  49 (0.5%) 
 >3  36 (0.4%)  37 (0.3%) 
* Derived from Mann-Whitney test 
 
 
The effect of covariate adjustment on prednisolone prescribing in the 3-6 months post SABA 
prescribing trigger is presented in table 4.25.  When adjusted for the control group, the 
intervention had no effect on prednisolone prescribing (AOR 1.008, 95% CI 0.969-1.048, 
P=0.695). When adjusted for the control group, prednisolone prescribing reduced by 8% the 
3-6 months post SABA prescribing trigger (AOR 0.924, 95% CI 0.890-0.960, P<0.001). 
Following covariate adjustment, a 6% reduction in prednisolone prescribing was observed 
among those of Black ethnicity (AOR 0.938, 95% CI 0.886-0.993, P=0.028) and a 10% 
reduction was observed among those of Other ethnicity (AOR 0.895, -95% CI 0.808-0.992, 
P=0.035). In contrast, prednisolone prescribing increased by 6% in those of South Asian 
ethnicity in the 3-6 months following the SABA prescribing trigger (AOR 1.063, 95% CI 1.018-
1.110, P=0.006). There was a statistically significant increase in prednisolone prescribing with 
increasing age, however the extremely small effect size suggests this is not clinically 
significant (AOR 1.006, 95% CI 1.005-1.007, P<0.001). There was no association between 
prednisolone prescribing and gender (AOR 1.024, 95% CI 0.984-1.065, P=0.236). 
Prednisolone prescribing prior was associated with a 33% increase in prednisolone 
prescribing post SABA prescribing trigger (AOR 1.327, 95% CI 1.311- 1.344, P<0.001). CCG 
variance was tested however convergence of the data in the Hessian matrix was not possible 
due to low numbers of prednisolone prescribed in the 3-6 months between CCGs. 
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Table 4. 25 Poisson mixed effects model with prednisolone prescribing at 3-6 months as a 
dependent variable adjusted for covariates1 
 
 
 Factors  Adjusted β (95% CI)  Exp β / OR (95% CI)  P-value 
 Age  0.006 (0.005 – 0.007)  1.006 (1.005 – 1.007)  <0.001 
 Gender2 (Female)  0.024 (-0.016, 0.063)  1.024 (0.984 – 1.065)  0.236 
 Ethnicity3 Black  -0.064 (-0.120, -0.007)  0.938 (0.886 – 0.993)  0.028 
South Asian  0.062 (0.018 – 0.105)  1.063 (1.018 – 1.110)  0.006 
Other  -0.110 (-0.212, -0.008)  0.895 (0.808 – 0.992)  0.035 
Not stated  0.113 (-0.011, 0.236)  1.119 (0.989 – 1.266)  0.074 
 Prednisolone 3-6m prior  0.283 (0.271 – 0.296)  1.327 (1.311 – 1.344)  <0.001 
 Group4 (Intervention)  -0.078 (-0.116, -0.040)  0.924 (0.890-0.960)  <0.001 
1 adjusted for age, gender, ethnicity and prednisolone prescribing prior 
2 reference males, 3 reference White population, 4 reference control group 
 
 
4.3.4.2.4 Prednisolone prescribing: 6-12 months 
 
 
Table 4.26 compares prednisolone prescribing between groups in the 6-12 months prior and 
post SABA prescribing trigger. There was a significant difference in prednisolone prescribed 
between groups in the 6-12 months post trigger (P=0.006) but not in the prior 6-12 months 
(P=0.089). The proportion of the population prescribed no courses or one to two courses of 





Table 4. 26 Comparison of prednisolone prescribing at 6-12 months before and after in the 
intervention group (SABA alert) and at 6-12 months before and after in the historical 
control group (no SABA alert) 
 
 Prednisolone courses prescribed 
 6-12 months prior 
 Control group 
 (N%) 
 Intervention group 
 (N%) 
 P-value* 
 0  7694 (88.5%)  8328 (87.2%)  0.089 
 1  635 (7.3%)  788 (8.2%) 
 2  179 (2.1%)  227 (2.4%) 
 3  81 (0.9%)  90 (0.9%) 
 >3  102 (1.0%)  120 (1.2%) 
 Prednisolone courses prescribed 
 6-12 months post 
 Control group 
 (N%) 
 Intervention group 
 (N%) 
 P-value* 
 0  7520 (86.5%)  8185 (85.7%)  0.006 
 1  755 (8.7%)  859 (9.0%) 
 2  218 (2.5%)  284 (3.0%) 
 3  81 (0.9%)  74 (0.8%) 
 >3  117 (1.1%)  143 (1.6%) 
* Derived from Mann-Whitney test 
 
 
The effect of covariate adjustment on prednisolone prescribing in the 6-12 months post SABA 
prescribing trigger is presented in table 4.27.  When adjusted for the control group, the 
intervention had no effect on prednisolone prescribing at 6-12 months (AOR 1.037, 95 % CI 
0.980-1.099, P=0.200). When adjusted for covariates, an 11% reduction in prednisolone 
prescribing among those of Black ethnicity (AOR 0.893, 95% CI 0.821-0.970, P=0.008), a 18% 
reduction among those of South Asian ethnicity (AOR 0.815, 95% CI0.762-0.872, P<0.001) 
and a 21% reduction among those of Other ethnicity (AOR 0.791, 95% CI 0.677-0.924, 
P=0.003) was observed. Prednisolone prescribing was associated with increasing age (AOR 
1.014, 95% CI 1.012-1.015, P<0.001), prednisolone prescribing prior (AOR 1.223, 95% CI 
1.217-1.228, P=<0.001) and female gender (AOR 1.347, 95% CI 1.266-1.434, P<0.001). There 
was no significant variance across the three CCGs to account for differences in prednisolone 
prescribing in the 6-12 months post SABA prescribing trigger (σ2 0.003, 95% CI 0.000 – 0.031, 
P=0.408). 
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Table 4. 27 Poisson mixed effects model with prednisolone prescribing at 6-12 months as a 
dependent variable adjusted for covariates1 
 
 Factors  Adjusted β (95% CI)  Exp β / OR (95% CI)  P-Value 
 Age  0.014 (0.012 – 0.015)  1.014 (1.012 – 1.015)  <0.001 
 Gender2 (Female)  0.298 (0.236 – 0.361)  1.347 (1.266 – 1.434)  <0.001 
 Ethnicity3  Black  -0.113 (-0.197, -0.030)  0.893 (0.821 – 0.970)  0.008 
 South Asian  -0.204 (-0.271, -0.136)  0.815 (0.762 – 0.872)  <0.001 
 Other  -0.234 (-0.390, -0.078)  0.791 (0.677 – 0.924)  0.003 
 Not stated  -0.003 (-0.204, 0.199)  0.997 (0.815 – 1.220)  0.979 
 Prednisolone 6-12m prior  0.202 (0.197 – 0.206)  1.223 (1.217 – 1.228)  <0.001 
 Group4 (Intervention)  0.037 (-0.020, 0.095)  1.037 (0.980 – 1.099)  0.200 
 Random effect  Estimated σ2 (95% CI)   P-value 
 CCG Variance  0.003 (0.000 – 0.031)   0.408 
1 adjusted for age, gender, ethnicity and prednisolone prescribing prior 






4.3.4.3 Primary care consultations 
 
 
4.3.4.3.1 Primary care consultations: 0-12 months 
 
 
Table 4.28 compares the distribution of primary care consultations between groups in the 0-
12 months post SABA prescribing trigger.  An increased proportion of the intervention group 
did not consult in the 12 months post SABA prescribing trigger in comparison to the control 
group. However, an increased proportion of the intervention group had between 1-3 
consultations in comparison to the control group. This was in contrast to a lower proportion 
of the intervention group consulting between 7-10 and >10 times in comparison to the 
control group. The effect of covariate adjustment on primary care consultations in the 0-12 
months post SABA prescribing trigger is presented in table 4.29.   
144  
Table 4. 28 Comparison of primary care consultations at 0-12 months after in intervention 
group (SABA alert) and at 0-12 months after in the historical control group (no SABA alert) 
 
 Primary care consultations     
0-12 months post 
 Control group (N%)  Intervention group (N%)  P-Value* 
 0  3068 (35.3%)  3647 (38.2%)  <0.001 
 1-3  3170 (36.5%)  3476 (36.4%) 
 4-6  1298 (15.0%)  1295 (13.6%) 
 7-10  709 (8.2%)  701 (7.3%) 
 >10  446 (5.0%)  434 (4.5%) 




Table 4. 29 Poisson mixed effects model with primary care consultations at 0-12 months as 
a dependent variable adjusted for covariates1 
 
 Factors  Adjusted β (95% CI)  Exp β / OR (95% CI)  P-value 
 Age  0.015 (0.014 – 0.015)  1.015 (1.014 – 1.015)  <0.001 
 Gender2 (Female)  0.284 (0.265 – 0.302)  1.328 (1.303 – 1.352)  <0.001 
 Ethnicity3 Black  -0.109 (-0.136, -0.083)  0.896 (0.872 – 0.920)  <0.001 
South Asian  0.079 (0.059 – 0.100)  1.082 (1.060 – 1.105)  <0.001 
Other  -0.128 (-0.174, -0.081)  0.879 (0.840 – 0.922)  <0.001 
Not stated  -0.208 (-0.279, -0.137)  0.812 (0.756 – 0.871)  <0.001 
 Group4 (Intervention)  -0.083 (-0.101, -0.066)  0.920 (0.903 – 0.936)  <0.001 
 Random effect  Estimated σ2 (95% CI)    
 CCG Variance  1   
1 adjusted for age, gender, ethnicity 
2 reference males, 3 reference White population, 4 reference control group 
 
 
When adjusted for the control group, an 8% reduction in consultations was observed in the 
intervention group in the 12 months post SABA prescribing trigger  (AOR 0.920, 95% CI 0.903- 
0.936, P<0.001). When adjusted for covariates, a 10% reduction in primary care consultations 
among those of Black ethnicity (AOR 0.896, 95% CI 0.872 – 0.920, P<0.001), a 12% reduction 
among those of Other ethnicity (AOR 0.879, 95% CI 0.840 – 0.922, P<0.001) and a 19% 
reduction among those with ethnicity not stated (AOR 0.812, 95% CI 0.756 – 0.871, P<0.001) 
was observed. 
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In contrast an increase in consultations was associated with age (AOR 1.015, 95% CI 1.014-
1.015, P<0.001), female gender (AOR 1.328, 95% CI 1.303-1.352, P<0.001) and South Asian 
ethnicity (AOR 1.082, 95% CI 1.060 – 1.105, P<0.001). Heterogeneity between CCGs was 




4.3.4.3.2 Primary care consultations: 0-3 months 
 
Table 4.30 compares the distribution of primary care consultations between groups in the 0-
3 months post SABA prescribing trigger.  There was an increased proportion of the 
intervention group not consulting in the 0-3 months post SABA prescribing trigger in 
comparison to the control group.  
 
Table 4. 30 Comparison of primary care consultations at 0-3 months after in intervention 
group (SABA alert) and at 0-12 months after in the historical control group (no SABA alert) 
 
 
 Primary care consultations  
0-3 months post 
 Control group (N%)  Intervention group (N%)  P-Value* 
 0  4857 (55.9%)  5646 (59.1%)  <0.001 
 1-3  3292 (37.9%)  3348 (35.1%) 
 4-6  452 (5.2%)  450 (4.7%) 
 7-10  76 (1.0%)  89 (0.9%) 
 >10  14 (0.1%)  20 (0.1%) 




The effect of covariate adjustment on primary care consultations in the 0-3 months post 
SABA prescribing trigger is presented in table 4.31.  When adjusted for the control group, an 
8% reduction in consultations was observed in the intervention group  (AOR 0.924, 95% CI 
0.895-0.952, P<0.001). When adjusted for covariates, an 8% reduction in primary care 
consultations among those of Black ethnicity (AOR 0.917, 95% CI 0.876-0.960, P<0.001) and 
a 28% reduction among those with ethnicity not stated (AOR 0.720, 95% 0.632-0.819, 





In contrast an increase in consultations was associated with age (AOR 1.014, 95% CI 1.013-
1.014, P<0.001), female gender (AOR 1.282, 95% CI 1.242-1.324, P<0.001) and South Asian 
ethnicity (AOR 1.110, 95% CI 1.071- 1.151, P<0.001). There was no significant variance in 
consultations across individual CCGs to account for covariate influence at 0-3 months post 
SABA prescribing trigger (σ2 0.017, 95% CI 0.002-0.125, P=0.322). 
 
Table 4. 31 Poisson mixed effects model with primary care consultations at 0-3 months as a 
dependent variable adjusted for covariates1 
 
 Factors  Adjusted β (95% CI)  Exp β / OR (95% CI)  P-value 
 Age  0.014 (0.013 – 0.014)  1.014 (1.013 – 1.014)  <0.001 
 Gender2 (Female)  0.249 (0.217 – 0.281)  1.282 (1.242 – 1.324)  <0.001 
 Ethnicity3   Black  -0.086 (-0.132, -0.040)  0.917 (0.876 – 0.960)  <0.001 
 South Asian  0.105 (0.069 – 0.141)  1.110 (1.071 – 1.151)  <0.001 
 Other  -0.079 (-0.159, -0.000)  0.924 (0.852 – 1.000)  0.050 
 Not stated  -0.328 (-0.458, -0.199)  0.720 (0.632 – 0.819)  <0.001 
 Group4 (Intervention)  -0.079 (-0.110, -0.049)  0.924 (0.895 – 0.952)  <0.001 
 Random effect  Estimated σ2 (95% CI)   P-value 
 CCG Variance  0.017 (0.002 – 0.125)   0.322 
1 adjusted for age, gender, ethnicity 




4.3.4.3.3 Primary care consultations: 3-6 months 
 
Table 4.32 compares the distribution of primary care consultations between groups in the 3-
6 months post SABA prescribing trigger. An increased proportion of the intervention group 
did not consult in the 3-6 months post SABA prescribing trigger in comparison to the control 




Table 4. 32 Comparison of primary care consultations at 3-6 months after in intervention 
group (SABA alert) and at 0-12 months after in the historical control group (no SABA alert) 
 
 Primary care consultations  
3-6 months post 
 Control group (N %)  Intervention group (N %)  P-Value* 
 0  5172 (59.5%)  6055 (63.4%)  <0.001 
 1-3  3043 (35.0%)  3004 (31.5%) 
 4-6  398 (4.6%)  414 (4.3%) 
 7-10  71 (0.8%)  68 (0.7%) 
 >10  5 (0.0%)  12 (0.1%) 
* Derived from Mann-Whitney test 
 
 
The effect of covariate adjustment on primary care consultations in the 3-6 months post 
SABA prescribing trigger is presented in table 4.33 
 
 
Table 4. 33 Poisson mixed effects model with primary care consultations at 3-6 months 
as a dependent variable adjusted for covariates1 
 
1 adjusted for age, gender, ethnicity 
2 reference males, 3 reference White population, 4 reference control group 
 Factors  Adjusted β (95% CI)  Exp β / OR (95% CI)  P-value 
 Age  0.014 (0.013 – 0.015)  1.014 (1.013 – 1.015)  <0.001 
 Gender2 (Female)  0.279 (0.245 – 0.313)  1.321 (1.277 – 1.367)  <0.001 
 Ethnicity3  Black  -0.104 (-0.153, -0.055)  0.901 (0.858 – 0.946)  <0.001 
 South Asian  0.107 (0.069 – 0.145)  1.112 (1.071 – 1.156)  <0.001 
 Other  -0.184 (-0.272, -0.096)  0.831 (0.761 – 0.908)  <0.001 
 Not stated  -0.105 (-0.230, 0.020)  0.900 (0.794 – 1.020)  0.100 
 Group4 (Intervention)  -0.101 (-0.134, -0.069)  0.903 (0.874 – 0.933)  <0.001 
 Random effect  Estimated σ2 (95% CI)   P-value 
 CCG Variance  0.036 (0.005 – 0.256)   0.320 
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When adjusted for the control group, a 10% reduction in consultations was observed in the 
intervention group (AOR 0.903, 95% CI 0.874-0.933, P<0.001). When adjusted for covariates, 
a 10% reduction in primary care consultations among those of Black ethnicity (AOR 0.901, 
95% CI 0.858-0.946, P<0.001) and a 17% reduction among those of Other ethnicity (AOR 
0.831, 95% CI 0.761-0.908,P<0.001) was observed. The number of consultations at 3-6 
months was positively associated with increasing age (AOR 1.014, 95% CI 1.013-1.015, 
P<0.001), female gender (AOR 1.321, 95% CI 1.277-1.367, P<0.001) and South Asian ethnicity 
(AOR 1.112, 95% CI 1.071-1.156, P<0.001). There was no significant variance in consultations 
across individual CCGs to account for covariate influence at 3-6 months post SABA 




4.3.4.3.4 Primary care consultations: 6-12 months 
 
Table 4.34 compares the distribution in primary care consultations between groups in the 6-
12 months post SABA prescribing trigger. An increased proportion of the intervention group 
did not consult in the 6-12 months post SABA prescribing trigger in comparison to the control 
group. Furthermore a lower proportion of the intervention group consulted on between 1-3 
occasions in the 6-12 months post SABA prescribing trigger in comparison to the control 
group.  
 
Table 4. 34 Comparison of primary care consultations at 6-12 months after in intervention 
group (SABA alert) and at 0-12 months after in the historical control group (no SABA alert) 
 
 Primary care consultations  
6-12 months post 
 Control group (N %)  Intervention group (N %)  P-Value* 
 0  5444 (62.6%)  6125 (64.1%)  0.012 
 1-3  2402 (27.6%)  2552 (26.7%) 
 4-6  601 (7.0%)  648 (6.8%) 
 7-10  194 (2.3%)  176 (1.9%) 
 >10  50 (0.4%)  52 (0.5%) 
* Derived from Mann-Whitney test 
 
 
The effect of covariate adjustment on primary care consultations in the 6-12 months post 
SABA prescribing trigger is presented in table 4.35.  When adjusted for the control group, a 
7% reduction in consultations was observed in the intervention group (AOR 0.930, 95% CI 
0.903-0.956, P<0.001).  
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When adjusted for covariates, a 12% reduction in primary care consultations among those of 
Black ethnicity (AOR 0.875, 95% CI 0.838-0.913, P<0.001), a 12% reduction among those of 
Other ethnicity (AOR 0.879, 95% CI 0.816-0.948, P=0.001) and a 17% reduction among those 
with ethnicity not stated (AOR 0.826, 95% CI 0.737-0.928, P=0.001) was observed. The 
number of consultations at 6-12 months was positively associated with increasing age (AOR 
1.016 95% CI 1.015-1.017, P<0.001), female gender (AOR 1.374, 95% CI 1.332-1.417, P<0.001) 
and those of South Asian ethnicity (AOR 1.036, 95% CI 1.002-1.072, P=0.035). There was no 
significant variance in consultations across individual CCGs to account for covariate influence 
(σ2 0.040, 95% CI 0.006 - 0.286, P=0.319). 
 
Table 4. 35 Poisson mixed effects model with primary care consultations at 6-12 
months as a dependent variable adjusted for covariates1 
 
1 adjusted for age, gender, ethnicity 











Factors  Adjusted β (95% CI)  Exp β / OR (95% CI)  P-value 
Age  0.016 (0.015 – 0.017)  1.016 (1.015 – 1.017)  <0.001 
Gender2 (Female)  0.318 (0.287 – 0.349)  1.374 (1.332 – 1.417)  <0.001 
 Ethnicity3  Black  -0.133 (-0.176, -0.090)  0.875 (0.838 – 0.913)  <0.001 
 South Asian  0.036 (0.002 – 0.070)  1.036 (1.002 – 1.072)  0.035 
 Other  -0.128 (-0.203, -0.053)  0.879 (0.816 – 0.948)  0.001 
 Not stated  -0.190 (-0.305, 0.074)  0.826 (0.737 – 0.928)  0.001 
 Group4 (Intervention)  -0.072 (-0.101, -0.044)  0.930 (0.903 – 0.956)  <0.001 
 Random effect  Estimated σ2 (95% CI)   P-value 




4.3.5 Repeat prescribing 
 
 
In the total study population, 81% (14,776) of SABAs were prescribed by repeat prescription in 
comparison to 9.3% (1,700) on acute prescription (Figure 4.9). 
 




Exploration of subgroup analyses by prescription type identified a 6% reduction in SABA 
repeat prescriptions issued in the 0-12 months post SABA prescribing trigger (Adjusted β -
0.059, 95% CI - 0.047,  -0.071/AOR 0.942, 95% CI 0.931 - 0.954, P<0.001). No effect on acute 
SABA prescribing was observed (Adjusted β -0.031, 95% CI 0.011, -0.074/AOR 0.969, 95% CI 
0.928 -1.011, P=0.153). 
 
When analysed by time point, repeat SABA prescribing reduced at 3-6 months (Adjusted β -
0.050, 95% CI -0.073,  -0.026/AOR 0.951, 95% CI 0.929-0.974, P<0.001) but not acute SABA 
prescribing (Adjusted β 0.021, 95% CI -0.064, 0.107 /AOR 1.021, 95% CI 0.938-1.113, 
P=0.622). A 6-1 months post SABA prescribing trigger, a statistically significant reduction in 
repeat SABA prescribing (Adjusted β -0.081, 95% CI -0.098, -0.065/AOR 0.922, 95% CI 0.906-
0.937, P<0.001) and acute prescribing (Adjusted β -0.069, 95% CI -0.129, -0.009/AOR 0.933, 
95% CI 0.878-0.991, P=0.024) was observed. 
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4.4 Summary of findings 
 
Table 4.36 details a summary of outcomes by time point following covariate adjustment.  
 
In the 0-12 months following the SABA prescribing trigger, SABA prescribing reduced by 6%, 
(AOR 0.938, 95% CI 0.927-0.947, P<0.001). This was reflected in a 6% reduction to repeat 
SABA prescribing (AOR 0.942, 95% CI 0.931 - 0.954, P<0.001), but not acute prescribing (AOR 
0.969, 95% CI 0.928 - 1.011, P=0.153). No effect on prednisolone prescribing was observed 
(AOR 0.988, 95% CI 0.947 – 1.029, P=0.561), however primary care consultations reduced by 
8% (AOR 0.920, 95% CI 0.903-0.936, P<0.001). 
 
When explored by time point, there was no change in SABA prescribing was observed at 0-3 
months post SABA prescribing trigger (AOR 0.983, 95%CI 0.961-1.006, P=0.148). However 
the number of asthma reviews increased by 12% (AOR 1.120, 95% CI 1.043-1.202, P=0.002). 
There was no change in prednisolone prescribing (AOR 1.008, 95% CI 0.969-1.048, P=0.695) 
however consultations reduced by 8% (AOR 0.924, 95% 0.865-0.952, P<0.001). 
 
At 3-6 months post SABA prescribing trigger, SABA prescribing reduced by 4% (AOR 0.955, 
95% CI 0.935- 0.976, P<0.001). When analysed by prescription type, SABA repeat prescribing 
reduced by 5% (AOR 0.951, 95% CI 0.929 – 0.974, P<0.001) but no effect was observed on 
acute prescribing (AOR 1.021, 95% CI 0.938-1.113, P=0.622). Exacerbations reduced by 8% 
(AOR 0.924, 95% CI 0.890- 0.960, P<0.001), and consultations reduced by 10% (AOR 0.903, 
95% CI 0.874-0.933, P<0.001). 
 
At 6-12 months post SABA prescribing trigger, SABA prescribing reduced by 9% (AOR 0.912, 
95% CI 0.898-0.925, P<0.001). When analysed by prescription type, repeat SABA prescribing 
reduced by 8% (AOR 0.922, 95% CI 0.906 - 0.937, P<0.001) and acute SABA prescribing 
reduced by 7% (AOR 0.933, 95% CI 0.878-0.991, P=0.024). There was no change in 
prednisolone prescribing (AOR 1.037, 95% CI 0.980-1.099, P=0.200) however primary care 




Following covariate adjustment at 0-12 months post SABA prescribing trigger, SABA 
prescribing was associated with increasing age (p<0.001), Black ethnicity (p<0.001), South 
Asian ethnicity (p<0.001), Other ethnicity (p=0.006) and SABA prescribing prior (p<0.001).  At 
0-3 months, SABA prescribing was associated with increasing age (p<0.001), Black ethnicity 
(p=0.026), South Asian ethnicity (p=0.006), Other ethnicity (p=0.007) and SABA prescribing 
prior (p<0.001).  At 3-6 months following the alert, SABA prescribing was associated with 
increasing age (p<0.001), Black ethnicity (p=0.001), South Asian ethnicity (p=0.002) and SABA 
prescribing prior (p<0.001). At 6-12 months following the alert, SABA prescribing was 
associated with increasing age (p<0.001), Black ethnicity (p<0.001), South Asian ethnicity 





Table 4. 36 Summary results of adjusted analyses* by time point 
 
 Outcomes  0-12 months  0-3 months  3-6 months  6-12 months 
 AOR (95% CI)  P-Value  AOR (95% CI)  P-Value  AOR (95% CI)  P –Value  AOR 95% CI  P-Value 
 SABA prescribing  0.938 (0.927-0.947)  <0.001  0.983 (0.961-1.006)  0.148  0.955 (0.935-0.976)  <0.001  0.912 (0.898-0.925)  <0.001 
 Number of asthma 
 reviews 
   1.120 (1.043-1.202)  0.002  1.028 (0.958-1.102)  0.430     
 Exacerbations  0.988 (0.947-1.029)  0.561  1.008 (0.969-1.048)  0.695  0.924 (0.890-0.960)  <0.001  1.037 (0.980-1.099)  0.200 
 Consultations  0.920 (0.903-0.936)  <0.001  0.924 (0.895-0.952)  <0.001  0.903 (0.874-0.933)  <0.001  0.930 (0.903-0.956)  <0.001 
   Adjusted B (SE)  P-Value  Adjusted B (SE)  P-Value  
 Time to review    0.010 (0.032)  0.753  - 0.027 (0.031)  0.384 




4.5.1  Main findings 
 
This study demonstrates a small but potentially clinically significant 6% reduction in repeat 
SABA prescribing in the 12 months following the SABA prescribing alert intervention 
(P<0.001). This provides evidence from which to reject the null hypothesis as set out in 
section 4.1.3. The evidence to support a SABA prescribing alert is strengthened by the 
observed 12% increase in asthma reviews at 0-3 months (P=0.002), and a 4% reduction in 
SABA prescribing (p<0.001) and an 8% reduction in exacerbations (p<0.001) in the 
subsequent 3-6 months. However no change in SABA prescribing was observed in the 
immediate 0-3 months following the alert intervention. This may reflect a reluctance or 
inability among clinicians to alter SABA prescribing without first assessing asthma control and 
clinical need. This suggests that asthma reviews act as a catalyst for SABA prescribing change. 
At 6-12 months SABA prescribing reduced by 9% (p<0.001) however no change in 
prednisolone prescribing was observed (p=0.200). The relationship between SABA 
prescribing and exacerbations remains unclear. It is not possible to comment further on the 
relationship between these two variables without acknowledging the role of ICS prescribing 
which unfortunately was absent from the study. These findings highlight the importance of 
assessing the co-prescription of ICS and SABAs to determine inappropriate prescribing 
practice and potentially at-risk patients.  
 
 
4.5.2  Strengths and limitations 
 
4.5.2.1  Strengths 
 
This study is based on asthma cases from a multi-ethnic population of approximately one 
million GP-registered patients. Findings may be representative of primary care practices in 
ethnically diverse, inner city populations delivering care using EMIS web computer systems. 
Utilising the CEG data network avoided potential selective bias of practice ‘opt-in.’ Potential 
confounding effects of prescribing changes over time were considered by analysing data at 
three time points within a 12-month period whilst adjusting for covariates. To aide 
transparency and reproducibility full lists of clinical codes and algorithm to identify patient 
eligibility have been reported. Strengths also include the large data set and automatic data 




4.5.2.2     Limitations 
 
In the hierarchy of evidence, observational study designs such as case-control studies are 
commonly viewed as producing lower quality evidence than those using an RCT or cohort 
study design. An RCT is the recommended method to evaluate computer decision support 
interventions125 however this was not possible given the intervention had already been 
implemented by EMIS without the researcher’s knowledge. Furthermore an RCT would not 
have been achievable within the thesis timeframe given the volume of work required for the 
mixed methods concurrent phases. An interrupted time series (ITS) analysis; often used to 
evaluate retrospective changes to prescribing following an intervention,356, may have been a 
more appropriate design to determine changes to SABA prescribing before and after the 
alert intervention. However as the date and time of SABA alert activation was not coded 
within the EHR, a flaw in system design, it would not have been possible to identify those 
specifically prescribed excessive SABAs using an ITS analysis. Instead changes to SABA 
prescribing for the asthma population as a whole would have been captured.  
 
It was not possible to utilise patient identifiable data for the purpose of this research as 
highlighted in section 4.2.1.1. page 107. Therefore patients may potentially have been 
included in both the case and control groups. This may have resulted in an overestimation 
of intervention effect given that: (1) similarities in patient characteristics in case and control 
groups could not be adjusted for, and (2) the positive impact of an intervention is more likely 
to be observed when evaluated closer to its point of implementation, particularly as the 
study did not extend beyond 12 months. It was not possible to capture asthma quality 
improvement initiatives and SABA prescribing practices at local level between 2013 and 
2016. Therefore the potential influence and impact  of such practices on SABA prescribing 
could not  be accounted for. 
 
Results were likely subject to regression to the mean (RTM) as SABA prescribing was 
identified at an extreme point on first measurement. Given the alert was triggered by 
excessive SABA prescribing in a three month period, RTM in the 0-3 months following the 
alert was likely. Therefore, following primary analysis of data at 0-12 months, additional time 
points were selected to analyse the effect of time on alert use. A non-differential bias of 
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SABA prescribing RTM was however observed in both the intervention and control group 
increasing the validity of findings compared to possible differential biases. Analysis was 
strengthened by the measurement of data at 3-6 months and 6-12 months to reduce the 
impact of RTM. Multiple testing of SABA prescribing at three time points (0-3, 3-6 and 6-12 
months) in addition to analysis at 0-12 months was a potential limitation. To strengthen 
findings, Bonferroni adjustment was applied and the P value cut-off for statistical significance 
was reduced from P<0.05 to P<0.016. Statistically significant findings remained so following 
Bonferroni adjustment. 
 
The inappropriate use of asthma medications is a major contributor to uncontrolled asthma 
in inner-city, ethnically diverse populations such as east London.11,367  The interdependent 
relationship between ethnicity, socio-economic status and asthma prescribing has been 
acknowledged at various points in this thesis. However as socio-economic status was not 
captured in the study, it was not possible to explore the confounding effect of socio-
economic status as a predictor of SABA use alongside ethnicity. 
 
There are a number of weaknesses in the study due to the limitations of EHR data. It was not 
possible to determine dose equivalent prescribing of the various SABA and ICS inhaler types 
included in the study. Due to intervention configuration, it is possible that more than one 
SABA inhaler was prescribed per prescription and that number of SABA inhalers prescribed 
was underestimated. The SABA alert was configured to include patients on the asthma 
register, determined as any QOF Read code for asthma diagnosis. Such a definition included 
‘H3B Asthma-chronic obstructive pulmonary disease overlap syndrome’ (ACOS) and as such 
SABA use may have been overestimated. It is also possible the SABA alert triggered on more 
than one occasion in the 12 months of the study however it was not possible to detect this 
within the data set. 
 
Prednisolone prescribing was assumed to be for the treatment of an exacerbation of asthma 
but may have been prescribed for other clinical reasons. Exacerbations were not 
distinguished between one another, with the dose and duration of prednisolone prescribing 
not captured. Multiple prednisolone prescriptions within a 30-day period may have reflected 
the same exacerbation but were counted as separate events. Unlike prescribing outcomes, 
the number of consultations carried out in the prior 0-3, 3-6, 6-12 months was not captured 




4.5.3  In relation to the literature 
 
Of the four RCTs included in a systematic review of the literature in Phase 1 of this thesis, 
Zeiger et al.,314 reported a reduction in the number of patients dispensed excessive SABAs 
(<7 SABAs per year) within 12 months following the intervention (P=0.007). A reduction in 
SABA dispensing was also observed at 3 months (P<0.001), 6 months (P<0.001) and 12 
months (P<0.001). Findings in this study indicate that an alert intervention can reduce SABA 
prescribing, therefore echoing the findings of Zeiger at al.,314 as reported in Phase 1 
systematic review. However, the multicomponent intervention in Zeiger et al., included 
patient referral to an allergy specialist. Interestingly, a reduction in SABA prescribing at 3 
months in Zeiger et al.314 coincided with earlier time to allergy specialist review, occurring an 
average of 36 days post excessive SABA dispensing. This was in contrast to findings in this 
study in which there was no effect on time to asthma review, occurring an average of 46 days 
following the SABA prescribing trigger. This may reflect challenges in obtaining an asthma 
review in primary care, when compared to quicker time to specialist hospital review in an 
insured healthcare system.  
 
In Zeiger et al.,314 the intervention failed to reduce exacerbations despite reducing SABA 
prescribing. However Zeiger et al.,314 defined exacerbations as distinct episodes separated by 
at least 30 days, whilst no distinction was made between exacerbations in this study. 
Therefore multiple courses of prednisolone reported in this study may have been indicative 
of one exacerbation. In Zeiger et al.,314 the lack of reduction in exacerbations was likely due 
to the poor uptake of allergy specialist reviews. Similarly, in this study, poor review uptake 
was also problematic with 77% of patients identified by the SABA prescribing trigger not 
having an asthma review. This highlights potential challenges in practice follow-up of patients 
therefore limiting the opportunity to improve asthma control and reduce risk of  asthma 
attack. Asthma review uptake may be influenced by patient and HCP discrepancies in 
perceived and actual asthma control,357,358 with patients less inclined to attend review if they 








The use of CDSSs to change prescribing behaviour is challenging due to heterogeneity in the 
type of decision support used and the broad scope of clinical outcomes reported in the 
literature. Each of the four studies in Phase 1’s systematic review included an alert as part of 
a multicomponent intervention, with no study using a single component alert intervention, 
such as the SABA alert. For example, the intervention in Zeiger et al.,314 included 
communication with patients by letter, advising either to attend an allergy referral that had 
been automatically generated in response to the intervention or advising to initiate follow-
up with their primary care doctor. A multicomponent intervention may aide the timely review 
of patients thereby facilitating a reduction in SABA prescribing. This offers potential 
explanation for the lack of effect of a sole SABA alert intervention at reducing exacerbations 
in the present study. A more complex intervention beyond a sole SABA alert intervention may 
have greater potential to improve SABA prescribing and reduce exacerbations. This may 
require an intervention that not only targets the prescriber at the point of prescribing, but 
targets and requires action from multiple members of the primary care team. Further insight 
as to what such an intervention may entail is explored in the qualitative research in the next 
phase of the thesis. 
 
In Phase 1’s systematic review, McCowan et al.,156 was the only one of four studies to capture 
asthma reviews as an outcome measure, but found no difference in practice initiated reviews. 
This was likely due to the intervention not being integrated with the general practice 
computer system resulting in poor user engagement. Studies by Garg et al.,122 Kawamoto et 
al.,137 and Fillmore et al.,141 recommend that to best influence prescribing behaviour alerts 
should not only be integrated with general practice software but should be aligned with 
workflow at point of decision-making. However as decision-making occurs at all points of 
workflow this may be challenging in practice.123 In the Phase 1 study by Eccles et al.,153 the 
alert presented centrally on the computer screen upon opening of a patient record, however 
following clinician feedback this was changed to present only when a relevant code was 
entered by clinicians. This was an attempt to minimise interruption to clinician workflow, yet 
no effect on SABA prescribing was observed. In this study, the SABA alert did not present at 
the point of prescribing but presented in the QOF box at the bottom right hand corner of the 




 In two studies evaluating a computerised reminder system in hospital, Dexter et al.,145 and 
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Overhage et al.,359 reported that reminders placed at the bottom of the screen for optional 
clinician engagement had no effect in outcomes.359  Conversely the SABA alert  in this study 
may have minimised alert fatigue and cognitive overload by presenting in the QOF box rather 
than centrally on-screen within workflow. The option to view the SABA alert at the discretion 
of the clinician may have increased user acceptance and recommended action. Alternatively, 
the position of the SABA alert in the QOF box may have dissuaded clinicians from engaging 
with the intervention or not being aware of its presence. In Chapter 1, Swinglehurst et al.,71 
described repeat prescribing as a complex process requiring collaboration between general 
practice staff, in particular receptionists and GPs. As the majority of SABAs in this study were 
obtained by repeat prescription, the influence of the variability in the roles, process and 
management of repeat prescriptions at practice level will be explored through qualitative 
research in the next phase of the thesis. 
 
Research suggests that CDSSs not restricted to general practice can improve prescribing 
behaviour. In the PINCER trial86 a computerised pharmacist-led intervention composed of 
feedback and educational outreach effectively reduced prescribing errors. This RCT 
compared pharmacists delivering computerised feedback about potential prescribing errors 
to GPs, in comparison to simple GP decision support for at-risk patients in general practice. 
In a non-controlled before and after study by Wong et al.,320 pharmacists manually alerted 
clinicians to excessive SABA prescribing (more than 1 SABA per month) by fax and follow-up 
telephone call. Pharmacists provided guideline recommendations for appropriate SABA use 
and requested GPs reduce SABA prescribing. This resulted in 1,230 people (67%) receiving 
less than 1 SABA per month in the subsequent 12 months (P<0.01). However, this 
intervention had no effect on asthma hospitalisations, AED visits, and oral corticosteroid use. 
Wong et al.,320 highlight the potential benefit of interventions in the management of asthma 
that engage the wider primary care team.  
 
 
In Zeiger et al.314 the success of the intervention at reducing excessive SABA dispensing was 
attributed in part to the integration of EHR, pharmacy and secondary care data in a managed 
health care organisation whereby the intervention was delivered in conjunction with 
comprehensive asthma management initiatives as standard care. In the present study, the 
three CCGs are among the highest QOF achieving nationally.360 However recent evidence to 
support QOF indicators in the improvement of quality of care is variable. In a recent review 
of QOF by NHS England it was reported that indicators do not necessarily demonstrate quality 
of care,363 whilst in Lester et al’s.,364 qualitative study with health care professionals, QOF was 
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perceived as a tick-box exercise. In contrast, recent evidence by Minchin et al.,365 has 
suggested the removal of financial incentives is associated with an immediate decline in 
performance on quality measures and care delivery. In a recent analysis on health care 
improvement, Braithwaite et al.,366 argued that changing behaviours of those within health 
care systems requires consideration of the influence of local strategies. High QOF 
performance in the study population is likely influenced by quality improvement initiatives 
facilitated by the CEG. However, the extent to which the role of the CEG influences standard 
asthma care in the 3 CCGs of interest in comparison to CCGs outside of inner city east London 
remains unclear.  
 
Ethnic minority groups are more likely to live in deprived neighbourhoods often in inner-city 
areas such as the east London population included in this study. Asthma morbidity 
disproportionately affects people from ethnic minority backgrounds,12 however the majority 
of data on asthma and ethnicity comes from the United States (US) health insured system 
afforded by a majority White population.11,368,369 In the two North American studies in Phase 
1’s systematic review, the largest proportion of the study population in Zeiger et al.314 was of 
White background, whilst in Tamblyn et al.,313 ethnicity was not reported. Socio-economic 
status is a proxy measure for lower income, inferior housing, poor neighbourhood social 
structures and differential exposures to environmental risks and stressors, that are 
inextricably linked to ethnicity.367 However, despite being important social determinants of 
health; race and socio-economic status are often overlooked in research. In this Phase 2 study 
in inner-city east London, the SABA alert was associated with a reduction in SABA prescribing 
among those of Black and South Asian ethnicity. Unfortunately as socio-economic status was 
not captured alongside ethnicity further research is required to explore the association 
between ethnicity, socio-economic status and SABA prescribing in the east London asthma 
population.  
 
A study by Griffiths et al.,154 carried out in the same east London population  identified 
variability in the management of asthma between ethnicities, with the South Asian 
population more commonly managing exacerbations without prophylactic ICS or systemic 
corticosteroids. Furthermore in a recent analysis on the factors associated with consultation 
rates in general practice in England, Mukhtar et al.,370 reported that primary care consultation 
rates varied by ethnicity, with patients of Asian ethnicity consulting more frequently than the 
White population. However, reasons to account for such findings were not explored. 
Similarly, this study identified an association between higher numbers of consultations and 
161  
South Asian ethnicity, in contrast to fewer consultations among with those of Black ethnicity. 
Further exploration is required to identify the relationship between ethnicity and asthma 
self-management behaviours and health beliefs among ethnic minorities that may influence 






This retrospective case-control study in an ethnically diverse inner city population identified 
a statistically and potentially clinically significant reduction in SABA prescribing following a 
SABA prescribing alert intervention. This adds to the systematic review findings in Phase 1 
that a single component alert intervention has the potential to reduce SABA prescribing. The 
reduction in SABA prescribing appears to result from asthma reviews initiated in response to 
the SABA alert rather than a reduction in SABA prescribing at point of alert presentation. An 
asthma review facilitates an in-person assessment of asthma control and management from 
which asthma prescribing can then be optimised. The mechanisms through which the SABA 
alert facilitates an asthma review, including where in workflow the alert is identified and how 
and by whom the alert is acted upon remains unclear. Such issues cannot be captured in 
quantitative data alone. Qualitative research is required to explore quantitative findings from 
an end-user perspective. Current findings highlight the potential of a SABA alert intervention 
to support primary care staff in the identification and management of patients with poor 




4.5.5  Implications for practice and future research 
 
Findings have identified that an alert intervention can reduce SABA prescribing however it is 
not clear how this reduction occurs in response to the SABA alert. Qualitative research is 
required to understand the socio-technical factors influencing the use of the SABA alert. This 
includes determining when, how and whom engages with the SABA alert in particular within 
the repeat prescribing process and how this translates into a reduction in SABA prescribing.   
 
Future exploratory qualitative research should determine whether (1) the SABA alert meets 
the needs of end-users in practice and (2) how the alert could be optimised to improve the 
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identification of at-risk patients and improve asthma prescribing. The findings of the 
qualitative study in Phase 3, carried out contemporaneously to this study, will be used to 
complement the quantitative findings of this study. Furthermore findings will help optimise 
a future alert intervention prior to feasibility testing in a suitably powered prospective study. 
Furthermore, an optimised intervention should be tested in CCGs with less high performing 
QOF metrics to determine whether there is greater potential for improvements in SABA 
prescribing and asthma management than those identified in this study. Further research to 
determine the relationship between ICS and SABA prescribing to improve the identification 
of at-risk patients is required. 
 
Heterogeneity in the reporting of asthma outcome and CDSS interventions makes it challenging 
to determine the effectiveness of the SABA alert in this study in comparison to similar studies 
using CDSS-linked EHR data. Further research is required in the standardisation of outcome 
measures to determine the effectiveness of CDSSs interventions for the management of 




Chapter 5. A qualitative study on electronic alerts 
to reduce excessive prescribing of short-acting 
beta2-agonists for people with asthma: the views 







5.1.1 Recap of context 
 
This chapter represents Phase 3 of the thesis, in which qualitative research was carried out 
with primary care staff and asthma experts to explore their views on an alert to reduce 
excessive SABA prescribing. The rationale was to provide context to Phase 2 findings and to 
provide a broad understanding of the problem and scope of an alert for excessive SABA 
prescribing in primary care. The chapter begins with a recap of the study rationale, and 
outlines the aims and specific objectives of the qualitative study. A description of the 
methods applied in data generation and analysis are then presented, before findings are 






In 2015, following recommendation by NRAD25 and leading asthma charity Asthma UK,334 
general practice computer software providers, EMIS Health, designed and implemented the 
‘Asthma Medicines Management alert’ to identify excessive SABA prescribing in EMIS web- 
using primary care practices in England. 
 
Whilst CDSSs are increasingly used to improve prescribing practice in the management of 
asthma, it was unclear to what extent CDSSs alerts had been used to reduce excessive SABA 
prescribing. In Phase 1 of the thesis, a systematic review of the evidence on the use of CDSS 
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alerts in asthma to reduce excessive SABA prescribing identified the potential of alerts to 
reduce excessive SABA prescribing when delivered as a multicomponent intervention. 
However, of the two studies systematically reviewed that captured user engagement, Eccles 
et al.153 reported that engagement with the CDSS was poor with several instances of zero 
interaction, whilst in Tamblyn et al.,313 clinicians failed to interact with the CDSS in 
approximately 60% of cases. These findings support the evidence that availability of CDSS do 
not guarantee user engagement,119 with alerts often ignored or overridden by users.125,142,166 
In evaluations of CDSSs for the management of hypertension and diabetes in primary care, 
Hetlevik et al.,375 reported low user engagement in 12% of case. Qualitative work reported 
difficulties in CDSS design and time-consuming procedures as reasons for low engagement. 
However, research often overlooks the relationship between system and user as a potential 
reason for the success or failure of CDSSs to influence prescribing behaviour.102 This was 
reflected in the absence of qualitative research in Eccles et al.153 and Tamblyn et al.313 
incorporating qualitative work within RCTs to determine reasons for low levels of 
engagement with CDSSs. 
 
In Phase 2 of the study (Chapter 4), the SABA alert had a variable effect SABA prescribing 
across three CCGs in east London however; an observational study design alone does not 
help understand reasons for intervention success or failure. Few research topics in clinical 
decision-making can be sufficiently understood through quantitative research alone,376 with 
qualitative research to complement quantitative findings increasingly recommended.321,377 
As described in Chapter 1, CDSSs should present the right information, in the right format, at 
the right time, without requiring special effort.”126 Yet it is unclear what users perceive as the 
right information, format and time for a SABA alert and how this may impact the use of the 
current SABA alert. 
 
 
5.1.3 Aims and objectives 
 
 
The aim of this study was to explore the views of asthma experts and primary care staff on 
the use of alerts, in particular the SABA alert, to reduce excessive SABA prescribing in primary 
care. 
 
The objectives of Phase 3 of the thesis were to: 
 
 
● Identify clinician’s perceptions of excessive SABA prescribing 
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● Determine the role of an alert to identify excessive SABA prescribing 
 
 
● Identify the factors influencing the use of a SABA alert 
 
 
● Explore the roles and relationships between primary care staff in the identification and 





Recruitment and data collection for the qualitative study took place between May 2015 and 
Sept 2016 as outlined in the following sections. 
 
 
5.2.1 Research design 
 
As discussed in Chapter 2, theory influences research design, including the development of 
research questions and underpins methodology thereby influencing how data are analysed 
and interpreted.257,378 
 
According to Kelly’s classification of the role of theory in qualitative research,257 this study 
can be described as ‘generic qualitative research’ within the field of applied health research 
and did not use an explicit theoretical model. With respect to methodology, an empirical 
approach was applied to this qualitative research to generate a surface understanding of 
clinician’s perceptions of excessive SABA use and the role of alerts in identifying excessive 
use. The analysis was focused on generating knowledge as a basis for provoking a wider 
debate about clinicians’ responses to SABA use and informing future research and 
development of alerts to identify excessive use of SABAs in primary care. 
 
This study was informed by background literature on the use of alerts (Chapter 1), patient 
perspectives from the PPI group feedback (Chapter 2), evidence on the use of alerts for 
excessive SABA prescribing (Phase 3) and research team experience as clinicians: the lead 
researcher is clinically active respiratory nurse in a tertiary referral centre and Asthma UK, 
one research team member who was recent editor of the UK’s leading respiratory journal 
and two of whom contributed to NRAD. 
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5.2.2 Defining participants 
 
Participants were classified into two groups of either primary care staff or asthma experts. 
Primary care staff were defined as those involved in the delivery of day-to-day asthma care 
in primary care either clinically as general practitioners (GPs), nurses or pharmacists, or non- 
clinically as receptionists. Asthma experts were defined as primary or secondary care 
clinicians who have contributed specifically to asthma care at a national or international level. 
 
 




5.2.3.1 Sample size 
 
 
Following consideration of the issues regarding data saturation and information power, an 
initial approximate sample size of between 25-35 participants was suggested. This sample 
size was decided upon so as to not to limit the scope of the data thereby ensuring the study 
aims were met, yet not stretched so far as to lose significance.267 Final sample size was based 
on the richness of the data as determined through a continuous process of data analysis and 
reflection of study aims rather than when the subjective concept of data saturation has been 
achieved. Concepts of data saturation and sample size in qualitative research have been 
discussed in Chapter 2. 
 
 
5.2.3.2 Participant recruitment 
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5.2.3.2.1 Primary care staff 
 
Primary care staff were recruited with the assistance of the Clinical Effectiveness Group (CEG) 
at Queen Mary University London (QMUL). The CEG is a unit funded by Clinical 
Commissioning Groups, GP Confederations, Public Health and research grants, to support 
general practices to improve care delivery and patient outcomes in primary care. Using well-
established data- sharing networks, the CEG leads and collaborates on research with GP 
practices in east London. The rationale for sampling via the CEG was that practices may be 
more receptive to a local approach to research participation given the already established 
working relationship. 
 
A purposive sample of fourteen primary care practices in the ethnically diverse borough of 
Tower Hamlets in east London was determined. A CEG facilitator, whose role was to  liaise  
with practices in the facilitation of training, determined fourteen practices as research 
receptive to participate. 
 
Practice managers were initially approached by a clinical lead from the CEG individually via 
email to raise awareness of the project and to invite practices to participate. The researcher 
initiated follow-up contact within one week by telephone call to the practice for the attention 
of the practice manager. If contact had not been established, a third attempt was made later 
that week by telephone call to the practice and an email sent to the practice manager. 
Receptionists and pharmacists were identified through snowball sampling within practices 
once access had been established. Of the fourteen practices contacted, eight GPs, two 
nurses, two pharmacists and seven reception staff agreed to take part (Practices 1-3). One 
GP  (Practice 4) was recruited following referral from a participating GP in Practice 2. 
 
 
5.2.3.2.2 Asthma Experts 
 
Discussion was initiated among research team members to identify clinicians who have 
significantly contributed to asthma care at national and international levels. The rationale for 
the inclusion of asthma experts is described in Chapter 2. Using purposive sampling, 13 
experts were identified for study inclusion and invited via email to participate. 
Communication was initiated by team members, as expert peers, and followed up by the lead 
researcher via email. 
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5.2.3.3 Participant characteristics 
 
Age group, gender and field of expertise was categorised for all participants. Participant 
demographics are presented in Table 5.1. Of 32 participants, 8 were GPs (4 male/4 female), 
13 were asthma experts (10 male/3 female), 2 were pharmacists (female), 2 were nurses 
(female) and 7 were reception staff (female). Participants were categorised as greater than 
50 years of age (n=17), between 35-49 years (n=9) or under 35 years of age (n=6). 
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1 GP GP 1 35-49 M 
2 GP GP 2 >50 F 
3 GP GP 3 35-49 F 
4 GP GP 4 35-49 M 
5 GP GP 5 <35 M 
6 GP GP 6 35-49 M 
7 GP GP 7 35-49 F 
8 GP GP 8 <35 F 
9 Nurse practitioner Nurse 1 >50 F 
10 Nurse Nurse 2 35-49 F 
11 Community Pharmacist Community pharmacist <35 F 
12 Practice pharmacist Practice pharmacist <35 F 
13 Receptionist Receptionist 1 >50 F 
14 Receptionist Receptionist 2 >50 F 
15 Receptionist Receptionist 3 >50 F 
16 Receptionist Receptionist 4 <35 F 
17 Receptionist Receptionist 5 35-49 F 
18 Receptionist Receptionist 6 <35 F 
19 Receptionist Receptionist 7 35-49 F 
20 Expert (Primary care, UK) Expert 1 >50 M 
21 Expert (Hospital care, UK) Expert 2 >50 M 
22 Expert (Primary care, UK) Expert 3 >50 M 
23 Expert (Hospital care, UK) Expert 4 >50 M 
24 Expert (Hospital care, UK) Expert 5 >50 M 
25 Expert (Primary care, Int) Expert 6 >50 M 
26 Expert (Hospital care, EU) Expert 7 >50 F 
27 Expert (Primary care, UK) Expert 8 >50 F 
28 Expert (Primary care, EU) Expert 9 35-49 F 
29 Expert (Primary care, Int) Expert 10 >50 M 
30 Expert (Primary care, EU) Expert 11 >50 M 
31 Expert (Primary care, EU) Expert 12 >50 M 
32 Expert (Hospital care EU) Expert 13 >50 M 
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5.2.4   Ethical considerations 
 
Ethical approval was given by Queen Mary, University of London, Ethics of Research 
Committee and the Health Research Authority (appendix 5.2). 
 
 
5.3 Data collection 
 
Written informed consent was obtained from primary care staff (appendix 5.3) and 





An interview topic guide was constructed for use in all interviews (appendix 5.4). 
 
 
5.3.1.1 Primary care staff 
 
Face-to-face semi-structured interviews were carried out by the lead researcher, with five 
GPs, two pharmacists, two nurses and a group discussion with three GPs in a clinical meeting. 
Interviews lasted no more than 30 minutes with the average length of interview 21 minutes. 
All interviews were audio recorded and transcribed verbatim. All observations were 





Semi-structured interviews were carried out by the lead researcher with thirteen asthma 
experts via telephone. The average length of interview was 27 minutes. Interview data was 
recorded on digital voice recorder and transcribed verbatim. Of the twenty-five interviews,  
the lead researcher transcribed fifteen interviews and ten were transcribed by Queen Mary 
University of London verified Penguin Transcription services. The researcher validated the 
transcripts completed by the transcription specialist by comparing transcripts with the 





The lead researcher carried out non-participant observations with reception staff when 
processing of repeat prescriptions. This included receptionists from two practices: three 
receptionists from one practice (3 visits, 6.5 hours) and four receptionists from another (4 
visits, 9.5 hours). Average visit length of observation per visit was approximately 2.3 hours. 
Visits to both practices coincided with repeat prescribing activities. An observation guide of 
issues to consider was adapted from Spradley’s 9 Dimensions of descriptive observation286,287 
(appendix 5.5). Repeat prescribing observations were approached, “without any particular 
orientation in mind, instead with the general question, “What is going on here?.”286 Initial 
notes were made during observations and written-up as field notes by the lead researcher  
who collected the data. Data was anonymised and numbered to record only the roles of the 
participants. 
 
5.4 Data analysis 
 
This section introduces thematic analysis using the Framework method,293 which was the 
selected qualitative methodology used to answer the qualitative research question. 
 
 




The framework approach for qualitative data analysis was used to systematically organise and 
categorise interview data to identify emerging themes and sub-themes in the following 
stages: familiarisation, identifying a thematic framework, indexing, charting, mapping and 




Stage 1-2 Transcription and Familiarisation 
 
 
Interviews were transcribed verbatim and were read and re-read several times whilst 
comparing to the original audio recordings to ensure transcripts remained true to individuals’ 
accounts. This generated a broad awareness of the data. Transcripts were highlighted and 
notes made when points of interest or of potential significance were identified. 
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Coding Stage 3-4 Developing a Framework 
 
 
Transcripts were coded line-by-line using a word or brief phrase to identify how the data was 
interpreted. Two researchers (the lead researcher and a non-clinically trained researcher) 
carried out independent coding of three transcripts. Following discussion at first meeting a 
set of codes each with a brief definition was determined. The researcher continued to code 
transcripts using this set of agreed codes. At the second meeting, both researchers decided 
that a number of codes were conceptually related and were therefore merged to form the 
coding framework. The interview guide was used to derive some thematic codes a priori; for 
example, the use of alerts was a predetermined code as it directly related to the research 
question and was an overarching question in the topic guide. However, emerging themes and 




Stage 5 Applying the framework 
 
 
MAXQDA qualitative data analysis software was used to manage data.379 The use of software 
facilitated the first stage of more in-depth analysis because it enabled preliminary ideas to 
emerge within and between data to generate initial themes. During this process some 
themes were merged and refined whilst some data organised into more than one category. 
 
Stage 6 and 7 Charting and interpreting the data 
 
 
Themes were generated from the data set by reviewing the framework matrix and making 
connections within and between categories. Central ideas embedded in the themes and 
subthemes were analysed to provide explanations of the data and illustrated by verbatim 
quotes. This included both agreeable and opposing views, to further explain the data in line 
with research objectives. A working example of the step-by-step process of the analysis can 









This section reports on the four themes derived from the analysis as summarized in Table 
5.2. The first theme presents how excessive SABA prescribing was defined and how the risk 
of excessive SABA prescribing was perceived in practice. This is followed by the second 
theme, which identifies the methods and challenges to the identification of excessive SABA 
prescribing. The third theme highlights the response to an alert for excessive SABA use in 
practice and describes how alert engagement and prescribing decisions are influenced. The 
final theme details the roles, responsibilities and relationships between primary care staff 




5.5.1 Summary of themes 
 
 
Table 5. 2 Summary of themes and subthemes 
 
 
 Theme  Subtheme (and example of relevant quote) 
 Perceptions of excessive 
 SABA use 
  Defining excessive use 
 “but then you’re tossing a coin, aren’t you?” 
 Recognising risk 
 “until someone can prove to me, that’s what we’re doing” 
 Identifying excessive use  Methods 
 “I don’t think there’s a simple way of doing it” 
 Challenges 
 “they’re not necessarily truly high users” 
 Using a SABA alert  Factors influencing engagement 
 “Alert overload...which one are you going to concentrate on?” 
 Factors influencing action 
 I’m issuing it this time but…” 
 Inter-professional practice: 
  The Three R’s 
 Roles and Relationships 
 “it’s not like it used to be, sure it’s not?” 
 Whose Responsiblility?   
 “it doesn’t matter what we think” 
175  
5.5.2 Theme 1: Perceptions of excessive SABA use 
 
 
The theme “Perceptions of excessive SABA use” is a reflection of what GPs and experts 
understand by and perceive to be the risks associated with excessive SABA use in practice. 




5.5.2.1 Defining excessive use 
 
 
“but then you’re tossing a coin, aren’t you?” 
 
 
There were wide variations in how excessive SABA use was defined by GPs and experts, with 
no consensus in regards to how much SABA was too much with contrasting definitions 
ranging from more than 12 SABAs a year to one SABA a year. 
 
There was uncertainty among both GPs and experts in regards to the number of SABA 
prescribed and the duration of use over which excessive use was determined. Table 5.3 
details the quantity and time frame of SABA use which GPs and experts defined acceptable 
with variations of between 0.5 (100 doses) and 12 SABA inhalers (2400 doses) a year. 
 
 
Table 5. 3 Definitions of acceptable SABA use offered by interviewees 
 
 
SABA use threshold  General Practitioners 
 (n=8) 
 Experts in general 
 practice (n=8) 
 Experts in hospital 
 care (n=5) 
 <3 times a week or 
 <2 SABAs a year 
 0  3  2 
 1 SABA a month  1 -   2 
 1 SABA in 6 months -   2  - 
 3 – 4 SABAs a year  1  1  - 
 12 SABAs a year  2  1  1 
 Unsure  2        -  - 
 Did not define  2  1  - 
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Excessive SABA use was defined interchangeably between daily, weekly and monthly doses 
and/or inhaler use per month or year. Asthma experts were more likely to describe excessive 
SABA use by daily/weekly/monthly doses, in contrast to GPs who were more likely to refer 
to excessive use by inhaler quantity and how the way in which SABA use was assessed 
influenced perception of excessive use. One GP was surprised that what had been perceived 
as acceptable SABA use when quantified by inhaler count was viewed as excessive when 
translated into dose equivalent: 
 
 
“Yeah, I mean that’s loads, isn’t it, 200 [doses] a month, thinking about it, that’s absolutely 
loads [Pause] 200, yeah. So, divided by…Yeah, I’d not thought of it actually…” (GP 5) 
 
 
GPs and experts expressed uncertainty regarding the appropriate time-period over which 
excessive SABA use should be determined. It was suggested that people with worsening 
symptoms potentially at risk might not be identified by monthly SABA use whilst people with 
seasonal triggers requiring increased SABA over a short time period may be inaccurately 
identified as using SABAs excessively: 
 
 
“One of the things we could do is when we are prescribing to be more mindful of how long 
we expect one inhaler to last, so is it a month or is it 3 months, which might be a more 
reasonable target” (GP 1) 
 
“how far back do you have to go to identify an individual who’s really deteriorating?...You 
can see the situations where patients for all sorts of independent reasons deteriorate and 
must use more and more bronchodilator, but that happens over a few weeks not a year or 
even three months” (Expert 2) 
 
“do you put it [overuse] at a year or do you put it at six months? I’m not quite sure. I think 
twelve months gets round the seasonal problem. Six months might be more appropriate… 
there are reasons, over short periods of time, where people might temporarily put in their 
requests, and then have nothing for the rest of the year” (Expert 3)
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Whilst there was no consensus definition in how much SABA was too much, experts were 
more likely to quantify excessive SABA use in alignment with national and international 
asthma guidelines, with use of SABAs more than twice a week suggestive of poorly controlled 
asthma: 
 
“new GINA guidelines say you shouldn’t use SABA more than twice a week…4 puffs a week, 
so one puffer a year, so tools should be used to get someone close to guideline 




There were contrasting opinions among experts, with some perceiving NRAD’s definition of 
excessive SABA use as one SABA a month or twelve SABAs a year perceived as too high: 
 
“Some people think it’s 12 a year so one a month, I think it would be even less, taking into 
account that Ventolin has 200 doses…for a month…is too much” (Expert 11) 
 
“I mean that means 200 doses in 30 days which is a hell of a lot of treatment, isn’t it? That’s 




Whilst NRAD’s recommended definition of excessive SABA use was perceived as lenient by 
some experts, other experts perceived national asthma guideline recommended use of SABA 
more than three times per week as restrictive and not realistic in practice. There was 
uncertainty regarding which definition was most appropriate, suggesting a lack of continuity 
in the evidence and application in practice: 
 
 
“I mean in an ideal world, what would you be … have your good control looks like three puffs 
in a week….So what’s that? That’s three puffs in a week and you’ve got two hundred 
[doses/year]…Yeah, I mean obviously that’s silly. So twelve is actually really, setting the 
threshold quite high; and…it’s not too low…But then you’re tossing a coin, aren’t you?” 
(Expert 3) 
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[referring to a practice nurse] “She’s new to asthma and she’s quite particular about 
guidelines, she’s very like, ‘This is the way it’s got to be done’…which I don’t think is the real 
world…” (GP 3) 
 
The choice of definition may reflect that which is transferable to practice, with NRAD’s 
definition of excessive use as 12 SABAs a year perceived as less restrictive than guideline 
recommended levels: 
 
“We use three inhalations a week…but I think that’s very stringent and that most people 
would go above that but that’s what the local guidelines say.” (Expert 10) 
 
 
Two experts questioned the evidence base for NRAD’s definition of excessive SABA use, 
suggesting that further evidence was needed to support NRAD’s findings: 
 
 
“Number one, I’ve not seen anything in the literature to support that [one SABA a month] 
and I think that is very high use.” (Expert 10) 
 
“…every sensible asthma doctor would think that an overuse of beta2-agonists would 
indicate an increased risk. But is there any [epidemiological] evidence that that is the case in 




One expert supported NRAD’s definition of excessive use citing epidemiological research 
from the Saskatchewan province in Canada that examined SABA prescribing patterns in 
asthma deaths over a ten-year period as “probably not a bad place to go.” This suggests 
uncertainty regarding the evidence base and applicability to practice, with an assessment of 
excessive use variable by clinician interpretation and patient circumstance: 
 
“the closest model is the Saskatchewan data as a prescription database, and I seem to recall 
that after more than one inhaler per month on average, the curve took off…so I would have 
thought that’s probably not a bad place to go” (Expert 4) 
 
“if we want to do something now, and I think doing something now is better than just 
waiting and waiting…,I mean that’s a subjective thing but I think twelve is as good a number 
as any because there is some evidence, if you like, circumstantial evidence, that that is 
linked to people dying from asthma…. that the figure twelve was sort of, a little bit, plucked 
out of the air. But nevertheless, it’s a good place to start” (Expert 3) 
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5.5.2.2 Recognising risk 
 
 
“Until someone can prove to me, that’s what we’re doing” 
 
 
Perceptions of the risks associated with excessive SABA use varied among interview 
participants, with expert’s regarding GPs as less likely to be aware of the risks if not their area 
of specialist interest. A number of GPs described excessive SABA use as low risk, making 
comparisons between SABAs and drugs perceived to be higher risk such methotrexate or 
opiate that are associated with increased side effects and prescribed less frequently. This 
suggests that scale of prescribing may influence what clinicians perceive as high risk: 
 
“…with something like Salbutamol which is not necessarily a drug of abuse or 
anything”…“…codeine, tramadol, you know, higher risk drugs where we’re worried about 
over use…” (GP 4) 
 
 
“In terms of methotrexate, I think it’s kind of life or death in terms of have they had their 
bloods, be aware of sore throats, whatever, but there’s only about 30, 40 patients there, 
we’ve got about 800 on the asthma register” (GP 3) 
 
 
There was variation among experts regarding the type of risk associated with excessive SABA 
use. One expert described the risks of physiological changes to the airways as a result of 
excessive SABA use, whilst another expert referred to such physiological changes as ‘theories’ 
with the greatest risk of excessive SABA use not from the direct risk of SABA use but in 
response to uncontrolled asthma as indicated by excessive SABA use: 
 
“I mean clearly the review [NRAD] has highlighted a very real problem and whatever the 
cause or consequence, which one could argue about ad nauseam, whether the Salbutamol 
overuse is causing the deterioration which I think it does in some patients or whether it’s just 
an indication of increasing severity of disease requiring other treatment, it’s a combination of 
both no doubt” (Expert 2) 
 
“…but there are other theories as well to do with beta receptor changes as a result of using 
too many beta agonists…ventolin is just a marker of control, ventolin doesn’t kill you it just 
means you aren’t treating the condition properly and therefore it gets out of control and I 
think that’s the bigger picture.” (Expert 6) 
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A number of GPs explained that excessive SABA use might be appropriate for certain patients, 
for example if required for exercise, or inevitable under certain circumstances such as 
awaiting specialist referral: 
 
“he’s now getting ridiculous levels of salbutamol which is quite inappropriate really but that’s 
what he is taking until he gets reviewed by the chest physician that’s what I’ve been giving 
him.” (GP 2) 
 
“Well, if you used it when you go for a run or if you’re doing a particular sporting activity and 
those are planned uses then I think that’s OK, it’s when you find that those are insufficient 




There was a need for further information to appropriately assess risk, with SABA use 
reviewed in isolation described as less likely to be perceived of clinical concern, but instead 
requiring additional clinical variables: 
 
“the problem is that the actual patient in front of me is unlikely to be at risk of that without 
some other warnings or some other feature, so it makes it more difficult, I think” (GP 4) 
 
“I sort of say everything is linked in so I don’t want someone to just look at asthma alone, I 
want them to also see what else are they missing? (GP 3) 
 
 
There were conflicting opinions among experts regarding the assessment of ICS use in 
conjunction with SABA use in determining at-risk patients in comparison to SABA use alone: 
 
 
“In my experience it [risk] depends on the co- use of inhaled steroids in most cases...But 
especially the mismatch between several prescriptions of SABAs without picking up the ICS, 
that should trigger the red flag. So it’s slightly more complex than just the number of SABA. 
It is in conjunction with the underuse of ICS and that’s the real problem.” (Expert 12) 
 
“you want to monitor kids who use a lot of SABA and do not use inhaled steroids, they are at 
much more risk than the ones already on inhaled corticosteroids” (Expert 13) 
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Opinions on the co-assessment of ICS use alongside SABA prescribing as a marker of potential 
risk contrasted among experts. Poor adherence to ICS treatment and the variability in 
quantity and duration of ICS dosing were challenges to the accurate capture of ICS use based 
on prescribing data and to the identification of patients potentially at risk: 
 
“I think the GINA guidelines for asthma now say if you require SABAs twice or more per 
month then you should be on an inhaled steroid. The trouble is, nobody will take an inhaled 
steroid, or quite a lot won’t” (Expert 5) 
 
“…like everywhere else in the world, people don’t use inhaled corticosteroids and 
compliance is very poor… [this is] no different to anywhere else in the world” (Expert 10) 
 
“You know, a lot of the ICS [in the] last two months, so the fact that somebody’s only having 
six canisters in a year might actually be 100% compliant” (Expert 3) 
 
 
Due to poor-adherence to ICS treatment, two experts perceived SABA on its own as a more 
reliable marker of risk, rather than co-assessment of SABA and ICS use either separately or 
as a combined prescribing ratio: 
 
“I think SABA use is most important. Of course we have to measure compliance and see what 
people do because maybe they don’t take SABA but take ICS constantly but the most 
important is to see the rescue medications of SABA in my view” (Expert 9) 
 
“some people say ICS/SABA ratios, but I don’t think that’s as good because people can keep 
giving prescriptions for the ICS at the same time they get the SABA and not use it, and I think 
at the end of the day it’s separate use is a good marker” (Expert 4) 
 
 
Experts described that prescribing data could not solely be relied upon to identify patients at 
risk. There were suggestions for prescribing data to be co-assessed with additional risk factors 
such as mental health and social wellbeing, as well as asthma severity: 
 
“the patients who have died don’t just have an overuse of Beta-agonist, they have a reduced 
frequency of access in medical care and other psycho-social adverse factors which probably 
mean those patients are not going to react in the same way when they need beta-agonists 
more frequently than many others” (Expert 2) 
 
“ You may find that people who have got significant asthma and who have got it under 
control may be using only one inhaler but that people who have got relatively insignificant 
asthma and continue to use high doses of SABA who may be in fact be more at risk of death 
than those who are not. And that may be a very difficult thing to overcome” (Expert 10)
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The theme ‘Identifying excessive SABA use’ reflects the methods used to identify excessive 
SABA use in practice, how a SABA alert is positioned among these methods and the 




5.5.3.1    Methods 
 
 




Three opportunities in which excessive SABA use could be identified in general practice were 
described; when in-consultation, when repeat prescribing or through incentivised methods 








The identification of excessive SABA use by GPs either in a consultation involved a 
combination of methods: the medication current/average usage generated within the EHR 
that presented in the medication screen (figure 5.2), the overuse warning when issuing a 
prescription (figure 5.3), the SABA alert (figure 5.4) and/or by manually checking the 
prescribing history within the EHR. 
 
GPs described commonly referring to the current/average medication usage feature (figure 
5.2) to determine a patient’s level of SABA use when reviewing medication history in 
consultation. Current and average usage were referred to interchangeably to determine 
problematic usage: 
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“…you go to the medicines page like this and it’s got this here that shows ‘current use’ and 
‘average’… if it’s massively high, obviously it comes up in, it’s already highlighted, already 
with the EMIS system, they’ve already decided their own level to flash it up in red, so you 
can see that’s overuse” [current usage over 100%] (GP 2) 
 
 




If medication use was above 200%, ‘overused’ would be displayed at point of prescribing 
(Figure 5.3). However, there was uncertainty regarding how much SABA use was reflected 
by overuse of 200% and how this was calculated within EMIS: 
 
“So…I think we have a threshold of… I’m not sure of the threshold, from memory it’s about 
200%, it seems quite a lot but if they’re shown to be overusing on the system then that 








The SABA alert, evaluated in Phase 2, presented within what was commonly referred to as 
the QOF box ‘pop up’ displayed in the bottom right hand corner of the computer screen 
(Figure 5.4). GPs were familiar with the QOF box, and all GPs, with the exception of one, were 
familiar 
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with the SABA alert. The QOF box was perceived as a useful place for reminders relating to 
outstanding care for chronic disease management, for example asthma reviews, rather than 
high-risk issues: 
 
“it’s a good reminder for what’s outstanding for that person in their year of care” (GP 5) 
 
“The QOF box where these alerts sit are just reminders really, these will be there when I am 
consulting with a patient, they will always be there. So whenever I see the patient or have 











The medication usage feature and the SABA alert were described as prompts from which to 
manually check patient records for the volume and time-period of medication use. Identifying 
excessive SABA use required clinical interpretation that was not possible with the limited 
information and context presented in an alert: 
 
“I think what’s more useful is when you right-click on the drug you can look at drug history, 
this is what I use more, ‘cause it shows you the issue dates, so I can see that this patient’s had 
an inhaler and they’ve had one in September, one in August, one in July, so they’re basically 
requesting one every month and that gives you a much better indication.” (Clinical 
Pharmacist) 
 
“I don’t think there’s a simple way of doing it really, the only real way we have is of checking 
how many prescriptions we’ve done…the most efficient way we have is of looking and seeing 




“…here for example they are using this over 100% which is very often and then I would click 












There was a move towards electronic prescribing systems (EPS) in practices to streamline 
GP’s access to patient data and improve the safety of prescribing. Repeat prescriptions 
generated in this way were referred to as an electronic ‘medicines management.’ GPs could 
assess a ‘medicines management’ in three formats: as a ‘request’, a ‘request with queries’ or 
as a repeat prescription ‘awaiting signing.’ GPs welcomed EPS as it integrated prescribing 
activities within the EHR enabling medication history to be readily viewed. GPs described 
assessing repeat prescriptions for SABAs in a number of ways before authorising, including 
checking asthma diagnosis, the frequency of request and last issue date, other medications 
prescribed and date of last annual asthma review. GP 1 described referring to the medication 
percent usage displayed within the EHR when reviewing repeat prescriptions to identify  
excessive SABA use: 
 
“So ideally, every prescription that comes in you should look at, is there a medicine review 
date, you should look at the use of the medication and so you know, is it overused, is it 
underused, is it within the authorised number of issues, all that kind of stuff which we would 
normally do in a medication review” (GP 2) 
 
“So if it’s been requested and I’m going into here (medication screen), I would go and look 
at when the medication was last issued because usually if they are on repeats they will have 
a percentage usage so we’ll straightaway know if that is more than 100%, then we know 




However, despite efforts by practices to move towards EPS, prescribing requests by paper 
continued to persist: 
 
“I’m not sure why we even still have paper prescriptions to sign, really, we’re trying to move 
towards the electronic workflow” (GP 5) 
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"when we did the prescribing review last year we said that everything should go through 
‘medicines management’ but we do have prescriptions that sit in a box each day…I don’t know 
what’s happening with those” (GP 2) 
 
 
Full adoption of EPS was described as challenging, as despite the assumed benefits to both 
practices and patients, it was suggested that patients prefer to have choice as to how they 
request their medication and electronic prescribing may not be preferred by some: 
 
“We are positively encouraging people to go down this route, so the EPS [electronic 
prescription service] medicine management, but some people don’t want to do it electronically 
straight to the chemist, they want choices. Some people for whatever reason, it comes as a 




A number of GPs described the role of receptionist in highlighting SABA use concerns. 
Receptionists had the ability to authorise repeat prescription requests for SABAs if the 
prescription was within configuration parameters as set by the prescriber. If SABAs were 
requested more frequently than the parameters set by the clinician, there was an expectation 
that receptionists would raise concerns for the attention of the GP. Receptionists had the  
potential to identify overuse electronically at point of authorisation with ‘overuse’ displayed if 
SABA use was 200% above the configured threshold. The receptionist would send the repeat 
prescription for GP authorization as a ‘request with queries’ via the medicines management 
system: 
 
(GP 8): “Just in the screen below when you are about to authorize it, it will say ‘overused’ 
underneath”… 




The receptionist could write an electronic message in conjunction with the repeat prescription 
stating SABA overuse. If the request was within prescribing parameters, the receptionist could 
authorize the prescription and send to the GP via the medicines management system to the 
‘awaiting signing’ inbox. 
 
“…so some repeats can be done by reception if they’re within clinical data and med review and 





For requests that came in paper format, receptionists described making handwritten, informal 
notes on prescriptions to highlight high SABA use for the GP’s attention: 
 
“those sort of repeat prescriptions [paper] will be done by  the front desk and they will often 
write, overusing, or something” (GP 4) 
 
 
Repeat prescription requests were processed by receptionists in both practices in varying 
ways. In one practice, a receptionist was designated with repeat prescribing duties out of 
patient view, whilst at the second practice repeat prescription duties were shared out 
between all reception staff as they carried out patient-facing duties. The aim of non-patient 
facing repeat prescribing was to minimise interruptions. However whilst this was done so 
behind a closed screen out of patient view, the receptionist was observed being interrupted 
by both patients and the practice manager. In contrast at the second practice, Receptionist 4 
explained that having been previously designated repeat prescribing tasks, receptionists felt 
pressured by patient demands to request or issue medications resulting in the repeat 
prescribing duties being shared among receptionists. 
 
 
Despite practice protocol for repeat prescribing, receptionists were often flexible with 
prescription requests, making exceptions to the repeat prescribing system in order to 
accommodate patients. At one practice, the receptionist accepted a repeat prescription 
request scribbled on a piece of paper despite this being against practice protocol. When 
observed, paper repeat prescription requests were accepted by reception despite patient 
date of birth missing or incorrect spelling of the medication. On one occasion a person of 
ethnic minority background who spoke limited English language requested a SABA for his 
father on a piece of paper stating ‘blue inhaler.’ The receptionist, opened the patient record, 
identified this as a SABA, requested this electronically and it was sent to the GP for 
authorization. The receptionist described this as necessary to meet patient need influenced 
by the receptionist- patient relationship based on familiarity: 
 
“…we don’t usually do this but the lady lost her prescription and she’s a regular so we know 
her” (Receptionist 3) 
 
 
During interview with GP 3, the receptionist interrupted with a paper repeat prescription 
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request. The GP quickly signed and handed the paper request back to the receptionist 
without referring to the electronic patient record. There was inconsistency in the assessment 
of repeat prescriptions, with medication use not assessed prior to issue and once approved 
medications prescribed on repeat were only likely to be reviewed when the patient next 
presents in- consultation: 
 
“Doctors are busy and they maybe OK a prescription without thinking about when the last 
one was given, including SABA and have no idea how often those repeats are filled” (Expert 6) 
 
“it’s end of the day, boring task of clicking through loads of prescription requests…they [GPs] 








National Health Service (NHS) policy framework and local clinical commissioning groups 
(CCGs) incentivised targets for asthma management influenced the identification of 
excessive SABA use. This included financial incentivised national Quality and Outcome 
Framework  (QOF) rewards system and Medicines Use Reviews (MURs), and local Clinical 
Commissioning Group (CCG) targets. QOF annual performance targets for annual medication 
reviews and annual asthma reviews, as well as CCG commissioned ‘enhanced asthma 
reviews’ supported at local level by the CEG. 
 
(i) Quality and Outcome Framework (QOF) performance 
 
 
Participants described using electronic searches and templates as set by the CEG in order to 
identify people with asthma using high numbers of SABA as well as to identify patients 
eligible for QOF annual asthma review or enhanced asthma review. Search templates 
assisted practices to meet target driven performance indicators and safety and effectiveness 
measures as directed by local and national initiatives. Whilst searches relied on EHR data, 
clinical interpretation was necessary to determine alert relevance for individual patients: 
 
“The CCG have that as part of our plan for the year that we have to complete, so they [CEG} 
set up a search and then I’ve imported it to our system and run that search to keep a check 
on the numbers that we’ve done…there’s a little bit of manual sifting I suppose…So the 
initial part we can get EMIS to do the searches for us, but then, it is manually then to look at 
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the details ‘cause some of these you’ll look at the patients and then when you actually click 
on them you’ll be like, ‘OK, they’re palliative, they’re … not appropriate to come in …’ and 




Annual medication reviews were described as a way to identify potential problems with 
medications, including SABAs. An annual medication review date presented in the patient 
record beside the QOF box at the bottom right hand corner of the computer screen and was 
also printed on paper repeat prescriptions (figure 5.5). 
 
 





The medication review date acted as a flag for clinicians to check SABA use, particularly if the 
review date had been exceeded: 
 
“Everyone has a different view but there are several fail-safes that we’ve got in the system 
trying to mitigate the different ways of people falling through the net. The biggest thing is 
the reviews really...So there is a review date, which is on the prescription. If the patient has 
not attended and the review date has passed I can see this and I will know I need to look at 




(ii) Pharmacist incentives 
 
 
One expert from Europe and one UK-based pharmacist described the pharmacist’s role in 
identifying excessive SABA use. Expert 12 described the role of alerts in pharmacy in Europe 
and the financial incentive for pharmacists to be responsible for the identification of 





“it [an alert] presents at the pharmacy because it happens when the pharmacy is 
preparing the medication, there will be a flagging up of misuse and then the pharmacist 
will judge whether he needs to a make a call or not [to the GP]…it is part of their financial 
incentive to be guarding these potential mistakes in daily practice and get paid for it” 
(Expert 12) 
 
“… if I click on the salbutamol that’s been done, it’ll tell me maybe they had it in January, 
March, August and October, but it won’t give me any warnings. So I could, if I wanted to, I 
could dispense the salbutamol all day to a patient and my computer wouldn’t tell me 




A Medicines Use Reviews (MURs) was an incentivized service delivered by a pharmacist, 
involving the review of a patient’s medication to improve medication adherence and to 
identify and reduce potential problems and medicines wastage. Patients eligible for MURs 
were identified via computerised searches in pharmacy systems and opportunistically in 
pharmacy at the point of patient contact: 
 
 
“…the medicine use review, it’s for any patient that takes regular medicines from you for the 
last three months, so we have targets that we try and reach, so I’d be looking to try and find 
MURs but also when you’re handing something out, I’ll always say, ‘How are you getting on 
with your medication?’ (Community Pharmacist) 
 
However obtaining patient consent was a disincentive to an MUR with the principles of 
review deemed good practice that should be delivered routinely in pharmacy without the 
need for incentives: 
 
“I think in itself it’s a very good service, but for me it’s something that I would do anyway 
without them having … ‘cause you have to sign a consent form, it’s just something that I’d 
want … if someone isn’t sure about their medication it wouldn’t bother me to sit down with 
them. I wouldn’t have to have a service that makes me do that. It’s more you care about 
your patient.” (Community Pharmacist) 
 
 
(iii) Role of incentives 
 
 
One expert expressed the limited value of an alert without motivating users to respond to an 
alert, for example by reward or by consequence to change prescribing behaviour: 
 
 “What you are trying to do is change behaviour, so this requires three things. Firstly 
motivation, either carrot or the stick, so whether getting reward for ensuring patients aren’t 
191  
using it [SABAs] that frequently or getting punished and having to explain why people are 
using more and also have confidence in asthma and understand why people are using more 
and do something about it…An alert all by itself with no motivation and nothing to improve 
the doctor’s confidence, it won’t make any difference” (Expert 6) 
 
 
Financial incentives to identify excessive SABA use were deemed necessary for both GPs and 
pharmacists to prioritise and focus areas of clinical need. Performance related incentives for 
example the benchmarking of SABA prescribing performance to that of peers was described 
as an influential motivator to improve SABA prescribing. However, as GP 4 highlights, 
remuneration for the additional workload associated with prescribing targets was expected: 
 
 
“I think that the minute you introduce some sort of payment metric around it you would see 
it go off a cliff, you know, you’re paid to have your people with asthma using less than one 
inhaler a month, say. I think you’d see a real change in prescribing. At a very crude level GPs 
are self-employed businesses and for a lot of GPs it is about the bottom line. I think for a lot 
of practices it’s about staying afloat and being sustainable and making sure that your 
income is sufficient to do that, so I think once you incentivise people I think that really does 
change practice” (GP 5) 
 
“….unfortunately it has to be [incentivised] ‘cause there’s so much we could do, someone 
has to tell us where to start” (Clinical Pharmacist) 
 
“there’s nothing like feeling that you’re doing the worst in the borough to spur you on and 
those sorts of opportunities where you look at it and say, so of the practices that are 
prescribing more than three prescriptions, because that would make you think, ‘Oh, hang on, 
where are we, why are we so bad at this?’ in the context of everyone else? …but often those 
things will come with a resource implication, so the reason that we’re getting those things is 
that there’s money attached to it or there is some sort of funding that has been applied to 














A number of challenges were described regarding the identification of excessive SABA use, 
in particular whether SABA prescribing data translates to actual overuse in patient’s lives. 
Despite knowing how much SABA has been prescribed there was no accurate was to 
determine how much of the prescribed SABA was actually used. Participants described 
situations in which excessive SABA use based on prescription data did not automatically 
equate to overuse in the context of people’s lives: 
 
“I find [the computer] it’s not the most useful thing because there’s so many different 
reasons why people would need to order medicines early or would need more, so it just 
happen all the time because people might have lost it or they’re going on holiday for two 
months so they want to order a lot early…” (GP 4) 
 
 
“…we actually did an audit in our own practice and analysed the sort of people that were on 
twelve SABAs, and then looked at those people, their characteristics, were they controlled or 
not, and what was going on…they weren’t necessarily overusing SABAs but their inhalers 
were in about five or six different places…” (Expert 3) 
 
 
It was common for children to be prescribed multiple SABAs for school and/or family social 
arrangements. This made it challenging to rely on SABA prescribing data to determine excessive 
use particularly for children and although alerted as excessive SABA use it was not always 
perceived as problematic by clinicians. A number of primary care staff and experts described the 
practice of issuing two SABA canisters per prescription. Despite being viewed as high volume 
prescribing such practice was justified as necessary when considering patient circumstances and 
may not reflect excessive use: 
 
“This is quite common in paediatrics, that you have one in school, one in the school bag, one 
at home, one with grandma and so on. And then you might be underusing even, if it is 




GP 7: “So 4 issues means 8 because they have 2 per time, which is a lot” 
GP 6: “Yes this is a lot…” 
Nurse 1: “Yeah…they might not be having 2 every time… 
GP 7: “No, all of them, it is very rare to see 1 [being issued at a time]” 
GP 6: “We offer to 2 because they need one for school or work too” 
 
 
“It [SABA alert] comes up quite a lot as well, quite a lot of patients, particularly children, 
who need quite high quantities of salbutamol…they need one for home, one for school, or 
they lose one, so they aren’t actually using them but that would trigger off the alert as well, 
and they are not necessarily truly high users but have just had a high number of salbutamol 










Concerns were expressed regarding the accuracy of the medication percent usage feature 
that was generated within the EHR and aided clinician’s identification of excessive SABA use. 
Despite being routinely used by clinicians, the percent usage displayed was dependent on 
how the SABA prescription was configured at point of prescribing. Configuration involved the 
setting of prescribing parameters, including quantity and duration of use (figure 5.6). This 
was used as a marker of medication compliance that presented as ‘current use’ and ‘average 
use’ within the medication screen of the EHR. 
 
 






Despite being commonly used by clinicians, a number of participants viewed the medication 
percent usage feature as an unreliable method to determine SABA overuse. This was due to 
variability in a) data input and b) clinician interpretation of use. 
 
The medication percent usage displayed was dependent on data manually entered in EMIS 
at point of prescribing however prescription configuration was at clinician discretion with no 
SABA prescribing parameters within the EHR. Therefore whilst two patients may be identified 
as overusing SABAs (percent usage > 100%) both prescriptions may have been configured 
differently by volume and duration. Therefore the medication percent usage feature was 




“The excessive is more difficult, I think, ‘cause you’d look on the computer screen and 
obviously EMIS records usage and there is a computer sort of monitoring of how quickly 
people are going through their inhalers. I don’t think that that is incredibly accurate because 
it’s all about the data that gets put in” (GP 4) 
 
 
“I just think the computer systems are not always that accurate because it relies on 
everything being input correctly…“It [percent usage] gives a rough indication [of medication 




The use of the medication percent usage feature to determine overuse is problematic. As 
despite 100% compliance to medication, if the prescription was configured to four SABAs in 
100 days, this would suggest excessive use. Therefore it should not be assumed that the dose 
and quantity of SABAs, as determined by the prescriber, was configured at an appropriate 
level. If no daily quantity was added, the course duration could not be automatically 
calculated (figure 5.7): 
 
“But you can leave all of that blank and if you leave all of that blank, then the computer 
system doesn’t know what the usage is supposed to be, so it can’t calculate whether they’re 












Safety nets to ensure appropriate SABA use were described by the clinical pharmacist. 
However, as two SABA inhalers were commonly prescribed per prescription, such practice 
was likely to continue unless the prescription was reconfigured when being reauthorised on 
repeat prescription. This was observed when GP 1 opened a patient record, checked the 
repeat prescription configuration and reduced the quantities of SABA to be authorised from 
two to one SABA: 
 
“So when it’s initially prescribed, ideally we’d have a review date set, number of authorised 
issues per term so the clinician’s saying I’m happy for this patient to order it two times, three 
times, four times, before we next want to review them. Or you can put the number of days, 
the minimum days before they’re allowed another one” (Clinical Pharmacist) 
 
“So the way it is set up at the moment is 4 inhalers to be used in 100 days, normally it would 
be 1 or 2 inhalers in that period of time [changes number from 4 to 2]…” (GP 1) 
 
 
There were widespread variations in how the medicines percent use was interpreted and at 
what percent of SABA use would be of clinical concern. When asked about the point at which 
SABA use would be of concern, clinicians referenced the percent usage feature with wide 
variation in responses ranging from 120% to 600%. The following excerpts highlight clinician 
uncertainty when interpreting the percent use feature with EMIS: 
 
“If you put 120 use inhaler is going to last 60 days and they’re asking for it every 30 days, 
then it will say that their usage is 200% and yet if they were using it 2 or 3 times occasionally, 
that still might not be overly concerning…o the prescription is likely to be issued unless there’s 
something… some crazy number, so if they are 100, 150%, perhaps 200%, I suspect the 
prescription would be issued. If they’ve got 600% usage or something then you’re going to 
query what on earth is happening with these inhalers” (GP 4) 
 
“it’s got this here that shows ‘current use’ and ‘average’ so we wouldn’t bother really unless 
it was going above about 120% something like that”… “Probably about 150% you know 
something above that, I don’t know what percentage of our patients that is already 
recorded at, so it’s difficult for me to say really.” (GP 2) 
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5.5.4 Theme 3: Using a SABA alert 
 
 
This section offers insight into what influences the use of a SABA alert. This seeks to help 




5.5.4.1 Factors influencing engagement 
 
 








There was concern that “alert overload” made it difficult for GPs to engage with a SABA alert, 
resulting in the alert being ignored. One GP described scrolling through the QOF box, within 
which the SABA alert presents, due to the high number of reminders for outstanding issues 
of care requiring attention. Another GP described having to prioritise alerts due to increased 
workload resulting in some alerts being ignored: 
 
 
“It comes up to here [SABA alert] for some people and they have to scroll down because 
there’s so many [alerts]” (GP 5) 
 
“people would probably ignore it ‘cause if you’ve got alert overload, you know, if you’ve got 
12 here, it’s like which one are you going to concentrate on?” (GP 3) 
 
“so they might have ten things coming up in their QOF box at the corner of the page and you 
just see it there [SABA alert] and you’re like oh no, we can’t even start to deal with all of that 
right now!...Which one do we pick to try and tick off that list” (Clinical Pharmacist) 
 
“I know that when a patient comes in to see me and five alerts go off I think well OK, maybe 
I’ll deal with this one but I can’t deal with the other four because I haven’t got half an hour 
with the patient” (Expert 1)
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A number of participants described the importance of setting an appropriate alert threshold 
to achieve a balance between alert frequency and workload. Setting the threshold 
appropriately was perceived as an important way to maximise alert impact and increase user 
engagement. If the alert threshold was set to low, thereby increasing the frequency of 
presentation and adding to clinician workload, there was a risk that users would become 
complacent to the alert. The challenge of finding a balance in the frequency of alerts was 
described by a number of experts in the following excerpts: 
 
“This [alert] could be perceived as very annoying I guess, as this hampers your daily work so I 
would aim at low frequency but high impact… the trick of the whole thing is that you make it 
not over sensitive for GPs because they will just click it away when it’s always flagging up and 
has low specificity” (Expert 12) 
 
 
“if you set the threshold low you will identify relatively large numbers of children which is an 
advantage because you won’t miss anyone at risk but you will increase the numbers of alerts 
and the GP being confronted with those alerts might not be willing or able with time 
constraints, to pick up on all these and review them. So you would have to find a balance 
between not missing out on any kid at risk on one hand and not overburdening the GP on the 
other” (Expert 13) 
 
“Of course a pop-up has to be a little less benign to make an impact but not so difficult that 
doctors are just going to ignore it completely every time because they are just too busy” 
(Expert 6) 
 
“…it needs to be a credible thing, and needs to be visible… and not set at too low a level 
because, for the reasons you said; if it fires off alerts for no apparent reason then people are 
really gonna ignore it” (Expert 3) 
 
 
GPs described how alert engagement was influenced by the frequency of a SABA alert in 
comparison to alerts for other drugs. An alert for methotrexate for example, was described 
as low frequency and high risk, in comparison to a SABA alert described as high frequency 
and low risk and therefore of lower priority. As the number of people prescribed SABAs was 
much higher than methotrexate, SABA alerts were likely to be more frequent than an alert 
for methotrexate and clinicians may be less likely to respond: 
 
“With methotrexate we’ve got about, I did a search the other day, we’ve got about 30, 40 
patients, so it’s about volume as well...“I think it’s kind of life or death in terms of have they 
had their bloods, be aware of sore throats, whatever, but there’s only about 30, 40 patients 
there, we’ve got about 800 on the asthma register” (GP 3)
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“we don’t have that many patients on Methotrexate compared to Salbutamol so you’re talking 




There was concern that an increasing number of alerts for asthma could result in alerts for 
other long-term conditions, increasing alert volume and therefore potentially disengaging 
clinicians: 
 
“there are enough clicks in the day, because if this happens with one thing it will start to 
happen with others from asthma to diabetes…” (GP 1) 
 
“My only worry is and it’s a slight worry, is at the moment we’re not getting attacked on this 
side, you know, so we have this, so Salbutamol is one area, let’s say the same for diabetes, 
let’s say the same for every time someone’s had a stroke and they’re not on aspirin and do we 
want an alert, if we start getting alerts on there as well, I can imagine that again, we might 
get ambivalent to it” (GP 3) 
 
“Well, the trouble is that these systems are over-used. So if it was the only flag that appeared 
on people’s records then obviously we’d notice it. The problem is the flags are now part of the 









The point of alert presentation was important in achieving maximum engagement with a 
variety of opinions on where a SABA alert would be best positioned. A number of GPs 
described a preference for a SABA alert to present within the QOF box due to familiarity with 
the alert and engagement at GPs discretion. GP 6 and GP 7 agreed that a SABA alert was 
positioned appropriately in the QOF box as they expected to see alerts present there. GP 1 
described the flexibility of the alert presenting with the QOF box, being able to refer to this 
at any point in workflow: 
 
“these will be there when I am consulting with a patient, they will always be there. So 
whenever I see the patient or have the patients record open I will be able to see this” (GP 1) 
199  
However, a range of interview participants perceived the QOF box as not appropriate to 
identify excessive SABA use, as clinicians were likely to ignore the QOF box, it was suggested 
that a SABA alert should present centrally on-screen: 
 
“Because the one thing about the QOF box is it’s very easy to ignore, so the central box that 
appears in the middle when you’re doing a medication or when you’re seeing that patient 
who has that, it would be more useful, I’m mindful of the fact that this business of clicking 
and saying, ‘Oh, for god sake, the person hasn’t come…’” (GP 4) 
 
“So sometimes the popup messages that come up in the middle of the screen or when you’re 
issuing drugs so you actually have to click on something, might get a bit more attention from 




Due to the context of repeat prescribing, often carried out at end of the day when the patient 
was not present, there was an increased likelihood the SABA alert being ignored. A number 
GPs and experts suggested an alert should present when authorising repeat prescriptions, at 
a clinically relevant point in workflow, for maximum influence: 
 
 
“what I’ve heard people say is they do medicine managements in the middle of the night or 
last thing before they go – Their tiredness is…. Phew! Are they interested in QOF boxes? Not 
at all. If an alert comes and says, ‘Stop, warning!’ they might be more interested” (GP 3) 
 
“not just as a flag down at the bottom [QOF box] because when I’m actually taking that 
decision I’m not even sure the flag is there on my screen when I’m dealing with an electronic 
prescription unless I choose to go and look. So I’m not sure that’s the right place for it… [The] 
way to tackle this has got to be in the repeat prescribing programme because that’s where 
the problem really arises. It’s when the patient has asked for another inhaler and it’s being 
issued as part of a repeat prescription and those come through to me to sign off...and when it 
comes through electronically it could at that point come through and say ‘this is the fourth 
prescription in as many months, are you sure you are happy to give this?’ (Expert 8) 
 
“I think it’s in the right place apart from maybe as we were talking about at the point of 
repeat prescription issue, there’s a process there” (GP 5) 
 
 
However in contrast, one GP described the limitations of an alert presenting when 






“Almost certainly of no value because the patient’s not in front of you [at point of repeat 
prescribing]” (GP 4) 
 
 
When in-consultation, the presentation of the SABA alert outside workflow resulted in the 
alert often ignored due to limited time available in-consultation and increased demands. GPs 
described that due to multiple demands in-consultation, SABA use may not be of greatest 
importance and viewed as optional rather than essential: 
 
“The only thing I would say about that is that we all see them but we’re just bombarded with 
stuff, we’ve got 10 minutes, someone comes in with three or four problems, we’ve got all of 
this to do already, it’s just overwhelming sometimes all of the different things that…we’re 
faced with. So sometimes as important as it may be, a salbutamol alert might be just pushed 
down” (GP 5) 
 
“We do telephone conversations and actually even when it pops up saying, ‘This young 
woman needs a smear,’ and I will mentally prepare myself for, ‘Must remember to talk about 
smear,’ unless I talk about it right at the beginning by the end of the consultation it will have 
escaped my memory” (GP 4) 
 
“The problem with general practice is they often come in with 2 or 3 problems and asthma 
may not be any of the presenting problems…and then you are trying to add it on as an extra 











There were contrasting opinions among GPs regarding the type of alert design that would 
promote engagement. It was suggested that clinicians would not accept a hard or modal 
alert, similar to that of methotrexate, for excessive SABA use. Such an alert that presents 
centrally on the computer screen and requires interaction was perceived as likely to deter 
clinicians from engaging with the problem of excessive SABA use. Due to competing demands 
of time and workload, financial incentives for a hard alert may be required to influence 
engagement: 
 
“once again it all depends on the number of alerts that are generated because if you make it 
mandatory to have some sort of action and you get a lot of those alerts and GPs may be less 




“you’ve got to be a little bit careful with it, because this is much more like Big Brother looking 
at you and it may mean you then not get acceptance from GPs that, ‘Why did you ignore it?’, 
‘Well I don’t want Big Brother breathing down my neck all the time; I don’t really want this.’ I 
think if it was really hammered down that Big Brother was watching you, then I’d say well, 




It was suggested that a more targeted approach to a SABA alert was required based on a 
hierarchy of SABA use rather than a universal threshold. A hard alert was proposed for 
excessive SABA use with a soft alert viewed as more appropriate for lower levels of SABA use: 
 
“Well if the patient is using ten puffs a day I think that’s a hard alert. I think if they are using 
three then maybe not” (Expert 10) 
 
 
A number of participants suggested the introduction of more comprehensive alerts to 
identify excessive SABA use that require less user interaction and facilitate patient 
engagement. Experts called for a move away from one-dimensional alerts, calling for the 




“There should be some kind of check mark box on the pop-up before you can close it that 
says ‘have reviewed,’ ‘have called,’ ‘one for gym bag, one for home and therefore need an 
extra one,’ something that gives the doctor an explanation which can then be reviewed if 
something happens, because there is a legal obligation to it as well” (Expert 6) 
 




Automated methods of communication following the identification of excessive SABA use 
were proposed. This included letters or prescription messages generated automatically 
following the triggering of a SABA alert by targeting other staff and patients to reduce 
workload and support action. The following excerpts describe how actions generated 
following the SABA alert, that inform other staff and also the patient to the problem of 




“If you think about the workload in general practice it’s quite stressful, a lot to do, so it [alert] 
needs to be facilitated in a way that makes it easy for me, generates the letter for me for 
example, or generates the message that goes on to the prescription…An alert would come up 
saying ‘do you want the message to appear’ and it would be attached to the prescription. 
That means I haven’t got to think, all I’ve got to do is say ‘yes please send the message’ 
because it takes quite a time to put messages on prescriptions and if I’m short of time it’s a 
bit of a put off” (Expert 8) 
 
 
“there must be some sort of automated system or automated reminder to the patient or to 
the clinician that no further can be issued after [an agreed number of SABAs]” (Expert 1) 
 
 
It was proposed by a number of participants that a feature that automatically invites or books 
patients overusing SABA for an asthma review would be advantageous. This would include 
the automatic form of communication with patients, either by email or text, when an alert 
triggered to alleviate pressures on GP time and workload. One expert proposed that patient 
contact was initiated to further ascertain asthma control and the need for asthma review. 
Such a response facilitated by an alert would streamline resources rather than inviting all 
alerted users to review. However the type of contact initiated would depend on patient and 




“I suppose in an ideal world to make it all fool proof would be some sort of system where it 
identified the patient and automatically booked them in for their asthma review or put them 
onto a list for somebody to call them up ‘cause then we’re targeting it directly”  
(Clinical Pharmacist) 
 
“You send an ACQ or RCP 3 questions to the patient automatically on email that the patient 
could send back, a lot of things could be done automatically here if you have people’s emails 
and if it’s bad then they need to come in (for review). How many automatic things can be 
done so the doctor doesn’t have to be in the middle of it may also improve success. However 
not all practices have this information, my practice doesn’t have the majority of email 
addresses for patients so it wouldn’t work for me and in the UK it may probably be the 
same” (Expert 6) 
 
 
(GP 7): “Could you link this alert to send a text message to the patient to advise to 
come to review? 
(GP 8): “Yeah in case we forget to say” 
203  
 




“I’m issuing it this time but…” 
 
 
The SABA alert in its recommended action to consider asthma review, to assess control and 
ultimately reduce excessive SABA use. However, the opportunity to reduce SABA prescribing 










There was no consensus regarding the appropriate prescribing response to the identification 
of excessive SABA use with suggestions that SABAs should be withheld, reduced or continue to 
be prescribed if excessive use was determined. Experts suggested that SABAs should be 
withheld  by the prescribing GP or when dispensing in pharmacy: 
 
“In my country the GPs give a lot of important to the overuse of SABA, so what I would probably 
do, I wouldn’t allow them to prescribe anything in asthma if the patient had more than the 
limit” (Expert 9) 
 
“So I think that most important…could be the stopping the giving the patient in the pharmacy 
when they have more than the limit that we put” (Expert 11) 
 
“It would be very easy to make salbutamol and terbutaline a restricted drug i.e. for the 
diagnosis of asthma it can’t be prescribed more than so many time a year without a doctor’s 
review” (Expert 6) 
 
 
However, in contrast to expert’s opinions, GPs and pharmacists showed concern regarding 
the withholding SABAs being a greater risk than that associated SABA prescribing or 
dispensing when excessive use was identified. Such concerns appeared to be altruistic in 
that failing to prescribe/dispense SABAs may result in the patient having no emergency relief 
in the event of an asthma attack. SABAs were perceived as an essential medicine that was 
unethical to refuse: 
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“so with all of these things whatever they might be overusing you’ve got to think about what 
are the risks of them not having it if you’re not prescribing it. I mean Salbutamol is probably 
the best example of that, you don’t want someone to have an asthma attack by refusing 
them Salbutamol even if their asthma isn’t that controlled and they’re not using the therapy 
appropriately, so I don’t think I would ever not issue it” (GP 5) 
 
“I don’t think I would ever deny someone one! In the short-term if they have an asthma attack 
where they can’t breathe, it’s essentially a life-saving medication for them. I suppose it’s 
better to save that life in the short-term and maybe keep giving it to them, even though we 
know that these people with poorly controlled asthma, the outcomes still aren’t good longer-
term but I suppose it’s better than nothing” (Practice Pharmacist) 
 
“Because people use it to relieve the breath, there’s really almost no excuse for me to ever 
refuse somebody, because they end up having an asthma attack…I would not be comfortable 
with having a restriction on it...” (Community Pharmacist) 
 
 
Concerns regarding health care professional liability influenced decisions to issue or not to 
issue or dispense SABAs. The withholding of SABAs was viewed as a “medicolegal minefield” 
with concerns regarding potential litigation if a person came to harm due to not having SABAs 
for emergency symptom relief. Expert 12 commented that prescribing SABA in high numbers 
was ‘clinically defendable’ when made in conjunction with the assessments of ICS prescribing. 
This suggests clinician’s concerns regarding accountability for clinical decisions to prescribe 
or not to prescribe SABAs: 
 
“It’s an essential medicine. We’re not gonna [sic] deny anyone it, we’d probably get sued if 
they then have an asthma attack” (Community Pharmacist) 
 
“And this is the medicolegal … minefield. I didn’t give the patient the medication because it 
was in the patient’s best interest. The patient died because you didn’t give them the 
medication they wanted, in his best interest – so how do you square that circle?” (Expert 1) 
 
“it could be possible if you use your ICS but still need SABA inhalers maybe 2 or 3 per month, 
then it is clinically defendable” (Expert 12) 
 
 
GPs described that two SABA devices were commonly prescribed per prescription rather than 
one. Following the SABA alert, it was proposed that quantities should be reduced rather than 
withheld, with configuration altered from two to one SABAs per prescription. This required 
clinicians to input or alter the prescribing configuration, as discussed earlier in the chapter, 
when making or authorising prescriptions. GP 3 described that reducing the number of SABAs 
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was one way to ensure patients attended asthma review: 
 
“We do do things like for example if somebody’s requesting two inhalers or we’ve always 
given them two at a time, I would have no problem in reducing that down to one inhaler and 
saying, ‘We’ve reduced your quantity because we really need you to come in, before the next 
prescription’” (Practice Pharmacist) 
 
“In fact I went around changing two Ventolin inhalers on prescriptions to one, to try and get 
the message that you shouldn’t be using your blue inhaler unless you’re out of control, and if 
you’re out of control you should come and see me and we can talk about it” (Expert 1) 
 
 
 “We can reduce the quantity… have your review and we’ll try and get your management 
better, it might be you don’t have to use this many inhalers.’ But a lot of people just want 








GPs and experts described an asthma review as an opportunity to both confirm and explore 
the reasons for excessive SABA use. At the earliest opportunity of suspected SABA overuse, 
an asthma review was recommended to review medications, check inhaler technique, and 
assess patient understanding and reasons for overuse as well as developing a plan to improve 
asthma management: 
 
“But the purpose of the review is why the patient using so many. And an awful lot of people use 
their SABAs as a prop…and if they need a prop, find out what they need propping up for and 
then tackle that problem in a more appropriate manner” (Expert 1) 
 
“Yeah. I think with this sort of thing you need that space, you need a dedicated piece of time to 
really… especially with asthma, you really need that dedicated asthma review, I think, to go 
through things properly ‘cause I think there’s massive variation on what people understand, 




Despite an asthma review being the recommended form of action in response to the alert, a 
number of challenges were raised regarding review availability and attendance with no clear 
plan on how to address these issues. GP 3 described that timely review is not always possible 
due to varying appointment availability and practice resources: 
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 “so until you’ve got a good protocol and each practice will need different protocols, some 
are, ‘See practice nurse in three weeks’ time,’ ours are, ‘See practice nurse tomorrow,’ that’s 
how good our access is” (GP 3) 
 
 
Clinicians described the challenge of patient non-attendance for review perceiving their 
asthma as well controlled or not prioritised around day-to-day life: 
 
“But I think, I tried to act on this alert and sometimes I’m surprised because patients don’t 
realize they are overusing because they feel their asthma is controlled by using like three 
inhalers per month and I explain we can change the preventer but they are not aware of 
that and that’s why they don’t come for their review” (GP 7) 
 
“we had [patients] who rated their asthma as very well controlled when they were using 
their reliever inhaler about 10-12 times a day. So the concept of good control, or what was 
adequate control was very, very different” (Expert 10) 
 
 
“I don’t know why asthma in particular seems impossible to get people in for their reviews. I 
think a lot of them are young working people so they don’t necessarily prioritise coming in 
for their reviews, even if they perceive that their asthma is under control, when it may not 
necessarily be or they’re not using their inhalers appropriately, so that’s another big battle, I 




Significant practice resources were required to follow up people for an asthma review, whilst 
generating increased workload for GPs. GP 5 describes the additional workload following the 
identification of excessive SABA use whilst GP 4 highlights the challenges that such increased 
workload brings to general practice: 
 
 
“And to pick someone up on it at the moment that involves quite a lot of effort, so it 
involves dictating a letter, writing to the [patient]… or sending a task to reception to 
book an appointment” (GP 5) 
 
“there are resource implications in that that in a small practice to commit a member of staff 
to doing that, writing letters to every patient, do we think that letters are the most effective 
way of communicating with people? Not really. We’re certainly not going to commit a doctor 
to ringing every one of those people and saying, ‘Would you like to come in?’ because of the 




It was commonly the responsibility of other primary care staff including the receptionist, 
nurse and/or pharmacist to ensure that asthma reviews were offered and attended. This was 
often at considerable effort, involving ringing patients and sending letters. Such methods 
were viewed as time consuming and resource intensive, with an expectation of review to 
each alerted patient viewed as overstretching resources: 
 
“the only thing we don’t do is go round their doors” (Receptionist 1) 
 
 
“…you can do as much chasing as you can possibly do. You can ring them, I write letters to 
them to come in if they DNA, you know that sort of thing...” (Nurse 2) 
 
“it also kills us with if you overload it [reviews], we’ve got patient demand there asking for 
access, we’ve got what we need to do asking for access and then you’ve got chronic disease 
access, so they don’t even want to be seen but we need to see them, the asthma, the COPD, 




However, given the high levels of non-attendance for routinely offered annual asthma 
reviews, an additional review for excessive SABA use was regarded as challenging to deliver 
in practice: 
 
“everybody already gets an asthma review annually although many people don’t take the 
offer of one up, and so you could, but then there are resource implications in that that in a 
small practice to commit a member of staff to doing that, writing letters to every patient, do 









Acting on excessive SABA use identified when repeat prescribing presented a number of 
challenges due to the context of repeat prescribing as an the end of the day task with limited 
time and resources to follow-up. GP 2 described a lack of motivation when carrying out 




“So all my medicines management stuff gets left to the end of the day…then it is much more 
difficult to follow up any kind of issues from it. So it’s done at the end of the day, you are 
knackered, you know you just want to get home, you’re not necessarily going to give it 
everything that you could…we know what we should do, but this is the problem at the 
moment in general practice, we know what we should do, we want to do what we should do, 
but we haven’t got a hope in hell of doing it all because there is just too much pressure. So 
that’s the kind of issues” (GP 2) 
 
 
Although reception highlighted concerns regarding potentially problematic SABA use, GP 4 
described difficulty in determining potentially problematic SABA use due to the repeat 
prescribing process that involved a flagging of concerns by receptionists and without the 
patient present: 
 
“those sort of repeat prescriptions will be done by the front desk and they will often write, 
overusing, or something but in the context of current general practice, speaking honestly, it’s 
very difficult sometimes to then drill into that and decide if there is something else that you 
need to be doing….it’s about whether the patient’s with you or are they, you know…?” So you 
can’t read into it too much, I think without speaking to the patient and knowing the reasons” 
(GP 4) 
 
“…the alert comes up like a pop-up but the problem can be when you cannot see the patient 









As described by both GP 4 and expert 11, acting on excessive SABA use was challenging with 
no strategy for GPs, receptionists and pharmacists in responding to excessive SABA use. 
Expert 8 describes the lack of a clear plan for following-up of patients identified when repeat 
prescribing: 
 
“ Looking at my appointment system and I have no appointments left and I’m thinking ‘now 
what’s going to happen?’ Do I try to bring this person in at the end of an evening surgery 
because there are no appointments left and it was me who generated the request to be 
seen, the patient wants their inhaler by the weekend. So what’s going to happen? The 
receptionist will say you wanted to see this patient and we’ve put them on after the end of 






GP 4 further described the challenge of navigating the repeat prescribing process with no 
clear guidance on how to respond to medication concerns at this point, with the system a 
source of frustration for both patient and prescriber: 
 
“And partly that’s to do with the way the system works, so we deny, we refuse the 
prescription, the patient doesn’t know that, they come in to the front desk going, ‘Where’s my 
prescription?’ Reception may not… the communication between us and reception is simply, 
‘There’s no prescription,’ or maybe a scrawled note on the prescription or a computer’s 
message saying, ‘Needs to talk to doctor.’ So then they’ll need to make a phone call, our 
system is a phone call based system, so they then need to book for a phone call, by the time 
they’re actually talking to a clinician often they’re [the patient] just annoyed ‘Why haven’t I 
not got this?’ and you’re then having to negotiate” (GP 4) 
 
 
GPs and experts described a responsibility to find a balance between what may be clinically 
appropriate from a medical perspective and that was appropriate to individual patient 
circumstances. For example there may be many reasons why SABAs are requested for 
example, to circumvent the cost of individual SABA prescriptions, additional SABAs for school, 
home, lifestyle or family situations, or by mistake when requesting other medications. 
However, there was no clear pathway to help GPs manage these situations. 
 
GP 3 reiterated clinician uncertainty on how to respond to the SABA alert commenting, “we 
need to just work out in our heads what do we want to do.” Expert 7 described an absence of 
clear guidance and support for clinicians on how to proceed following the SABA alert which 
needed to be clarified: 
 
“What should you do then? Should you send a message to the patient to give them an 
appointment, should you give this information to the nurse that is supposed to call the 
patient to check ‘how are you?’ ” (Expert 7) 
 
 
The absence of a plan of action was described as likely to deter clinicians from engaging with 
the alert: 
 
“the clinician needs a strategy for dealing with the problem. Alerting me to a problem is not 
very helpful if I don’t know what to do about it….if I wasn’t interested in asthma I might not 
know really what I’m going to do about it. And strategies for helping both in the short term, 





“Something has to happen as a result of the alerts, so it’s that thing about having a plan 




One nurse described the variable role of reception at highlighting medication concerns, with 
no clear protocol on when or how this should be done. When processing repeat prescriptions, 
Receptionist 3 described that despite noticing a medication review was overdue, it was outside 
the scope of a receptionist’s role to discuss with the patient or to inform a clinician, but that 
‘hopefully’ a clinician would pick this up. One nurse described the receptionist’s role as variable 
by practice priorities: 
 
 
“It’s usually what’s flavour of the month and there’s so much overload if information 
that we have to, or the girls have to provide patients at the front desk, it’s not always 
just about medications, there are other things going on as well that are priorities…a 
lot of the girls would mention that [SABA use] but it’s not set in stone so it won’t be at 




A number of experts reiterated a need to support receptionists in the identification of 
excessive SABA use with a plan to support: 
 
“There has to be a pathway about what to do with the alert when it comes up at the 
receptionist level perhaps when it’s requested, so that somebody can have a dialogue 
with the patient explaining the importance of having the review rather than just say, 







5.5.5 Theme 4 Inter-professional Practice: The 3 R’s 
 
 
The theme ‘Inter-professional practice’ addresses how the roles, responsibilities and 
relationships of primary care staff contribute to the identification and management of 
excessive SABA use. 
 
5.5.5.1 Roles and relationships 
 
 









Despite an expectation among some GPs that receptionists would highlight SABA concerns, 
on the contrary the identification of excessive SABA use was perceived as a clinical task 
beyond  the role of non-clinically trained staff and not something with which receptionists 
should be expected to engage: 
 
“To be honest I don’t think that admin people that do scanning pay any attention to that 
anyway ‘cause it’s all really clinical stuff” (GP 5) 
 
“So I can imagine reception are not looking at it enough, I’m sure if you’ve spoken to them 
they’ll say they never do” (GP 3) 
 
(GP 7): “I don’t think the receptionists really look at what’s in the [QOF] box anyway…” 
(GP 8): “No…” 
(Interviewer): “Should they be looking at it?” 
(GP 7): “Probably not” 
(GP 6): “No, No” 
(GP 8): “It’s quite medical isn’t it?” 
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Since the introduction of electronic prescribing, the role of receptionists in prescribing had 
changed. GP 2 described the changing role of reception in highlighting medication concerns 
since the introduction of electronic prescribing: 
 
“[Reception] will highlight overuse or whatever, they would bring that up…it’s not been 
happening as much now, but they rely on the medicines management systems and they don’t 




One expert described the changing role of reception in one European country following the 
introduction of electronic prescribing. A receptionist could have previously authorised a 
prescription that a GP would authorise, however electronic prescribing has resulted in all 
control of prescriptions as solely the responsibility of a GP: 
 
“Often a patient would come to consultation with a packet of boxes and they say please 
renew this for me and the receptionist made the prescription and the doctor just signed, this 
is no more happening, because we have full electronic prescription all over Spain and a very 
good system…” (Expert 11) 
 
 
When observing receptionists carrying out repeat prescribing task, two receptionists were 
discussing their changing role, one receptionist questioned rhetorically “it’s not like it used to 
be, sure it’s not?.” This reflected a sense of depreciation in their ability and experience to 
identify concerns or mistakes with prescriptions that was now deemed a clinical task outside 
their scope of practice despite routinely doing so prior to the introduction of the EHR and 
electronic prescribing. They described that prior to the introduction of electronic prescribing 
receptionists had greater ‘clinical’ input into the repeat prescribing process but their role to 
interpret and alter prescriptions had gradually declined. Receptionists spoke of contradictory 
expectations in their role in the management of repeat prescriptions since the introduction of 
electronic prescribing. This had resulted in a shift in responsibility for reviewing prescriptions 
from receptionists to GPs. However there remained an expectation that receptionists would 
continue to raise concerns regarding SABA use when requested in paper format. One 
receptionist described contradictory roles and responsibilities as determined by GPs, with 
years of experience negated with the introduction of electronic prescribing: 
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“it was fine before [electronic prescribing] and they [GPs] are happy for you to do something 




One GP suggested the potential for an increased role of receptionists in the management of 
SABAs that involved the triaging and signposting of patients when high SABA use was 
identified. This however was dependent on a GP’s ability and propensity to support 
receptionists in an increased role: 
 
“ that’s our problem, we [GPs] haven’t empowered them [receptionists]. Believe it or not 
that would work really… I think I’m just about… my next meeting is about empowering our 
reception staff and we’re very good at normally doing that and I think they’re actually now 
in a position of feeling that they could really try and get involved with patient care in more 
than just a, ‘Let’s give them an appointment, let’s triage them, let’s work out, signpost 
them,’ of actually where are they in this field? And I think having teams of people… almost 




There was a lack of continuity described in relationships between receptionists and other 
primary care staff. Receptionist 1 was unaware of how GPs and pharmacists manage the 
repeat prescriptions initially processed by receptionist, whilst conversely, GP 5 described 
uncertainty as to how receptionist process repeat prescriptions and the potential ways 
receptionists identify SABA overuse. In one practice, the receptionists described a number of 
challenges when contacting GPs about repeat prescribing issues. Methods of communication 
between reception and GPs were often informal and opportunistic. Receptionists previously 
attached hand-written notes onto a repeat prescription request by paper but these were no 
longer allowed as all GP communication was to be made electronically: 
 
“…the communication between us and reception is…maybe a scrawled note on the 




However Receptionist 1 explained that following complaints from GPs, electronic messages 
were appropriate for certain, but not all, queries due to interruption in clinical practice. In 
one example, Receptionist 1 explained she was no longer being able to send electronic 
messages to remind a GP that repeat prescriptions awaiting signing were nearing the 48 hour 
processing deadline. When GPs made decisions to reject medications, communication to 
other staff involved in the repeat prescribing process was not a prerequisite but instead at 
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GP discretion. GP 1 describes the rejecting a medication without providing an explanation to 
reception despite being the likelihood that a patient would question this with reception, as 
highlighted in section 5.12.2, would likely be unhappy with decisions made: 
 
“that’s rejected because she has requested all her medications but there’s one that she got a 
couple of days ago so she doesn’t need it. But if I wanted I could reply and leave a note to with 
reception and explain” (GP 1) 
 
 
However, there were conflicting opinions from allied health care professionals and reception 
staff regarding the potential to increased role of receptionist in the identification and 
management of SABA use. There was surprise from one pharmacist and one nurse in regards 
to current GP expectations on receptionists managing repeat prescriptions. Extending the role 
of reception presented potential challenges including possible confusion around the numerous 
types of inhalers for asthma and the competing demands on reception due to having a patient 
facing role and the first point of contact in practice: 
 
 
“but then receptionists might get the colours muddle up, there’s always a lot of other stuff 
that goes on and they aren’t medically trained…they could always highlight [SABA overuse] 
but then they have such a heavy task because a lot of things are frontline…it’s alot of 
responsibility for people that aren’t medically trained]” (Nurse 2) 
 
 
“I think myself and other colleagues ...are just amazed that the receptionists are doing 









There were variations in the roles and relationships between pharmacists and general 
practice in Europe in comparison to the UK. Experts described an active role of pharmacists 
in Europe  in identifying concerns with SABA use but also in regards to prescribing for other 
long-term conditions including diabetes and hypertension.  
 
Internationally, pharmacists were described as increasingly supported and respected by GPs 
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in the raising of prescribing concerns. Support was also available in the form of financial 
incentives and integrated computer systems between pharmacy and general practice: 
 
“there is quite a strong link between pharmacists and GPs in Holland. In general, pharmacist 
will be linked to the electronic system used by GPs and usually they would have 
arrangements in place that would cover the over prescribing of SABA but also other issues in 
terms of prescribing…in respiratory they are strong but also in diabetes and cardiovascular 
disease and now geriatric patients, for example in decreasing the number of medications for 
the patient. So, a number of fields in healthcare have been claimed by pharmacists and as a 
result they have an increased role” (Expert 12) 
 
“pharmacists play a role in the prescription refill process by identifying people being given to 
many SABA and deciding whether this is appropriate or not” (Expert 6) 
 
“for example when a new warning comes up for people with hypertension that we must be 
careful because some hypertensive emergencies have happened and an alert comes from 
the Ministry of Health that every patient (unclear) should be checked for blood pressure 
frequently. The pharmaceutical people in our health service they look for the patients on this 
prescription and they put an email to you (the doctor) saying “please Doctor you have X 
number of patients on this treatment and they should be checked for their blood pressure so 
please make an appointment” (Expert 11) 
 
 
Pharmacy was viewed as having a prominent role in the identification and management of 
excessive SABA use that was presently underutilized. One of the main roles of pharmacy was 
to ensure that patients received safe and accurate medication, acting as a firewall to 
troubleshoot prescribing issues prior to medication being dispensed: 
 
“so that’s why we are in conjunction with pharmacists because they work in a much more risk 
adverse situation than GPs who usually work on an 80% feasibility basis in my experience so 
they could now and then make the mistake of overprescribing SABA and then it is very helpful 
to have a different type of healthcare provider who will double check it and give you a call 
because this person is in a risk zone” (Expert 12) 
 
 
However pharmacy was viewed as opportune to identify excessive SABA use. There was no 
plan of support for pharmacists if excessive SABA use was identified with current action to 
dispense SABAs and signpost the patient back to general practice. However, there were calls 
for pharmacists to take further action such as carry out a medication use review with the 
patient in pharmacy. GP 4 welcomed the increased involvement of pharmacy in asthma care, 
described as the ‘farming out’ of the GP role: 
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“…they may flag it to us or more often they will tell the patient to come in and have their 
medication reviewed” (GP 1) 
 
 
“So this is again the farming out of what traditionally would be a GP role, so there’s nothing 
wrong with a pharmacist having a conversation and saying, ‘You really need to go and talk 
to the GP,’ or, ‘You’re ordering three a month or three every three months,’ and that would 




GP 5 proposed that rather than refer a patient back to general practice, pharmacists had a 
responsibility to take specific action on SABA overuse for example by reviewing a patient in 
a MUR: 
 
“I think pharmacists know how much Salbutamol they’re giving to someone, so I think the 
more conscientious pharmacists probably do spot that and maybe that could be a cue for 




One expert commented that signposting of patients back to general practice for review was an 
underutilization of the role of pharmacy. Expert 1 commented that pharmacy should be able 
to review and optimise medications yet due to prescribing policies the power to do so remains 
confined to GPs and the potential of community pharmacy is unmet: 
 
“the pharmacist has a prescription record of how often something’s going in, so they could act 
as a break on it and say, ‘You need to see your GP for review.’ But I think that the prime role 
of the pharmacist is checking inhaler technique…What they’re missing is they haven’t got the 
ability or the permission to prescribe an alternative inhaler…I keep saying to loads of people, 
pharmacists have the ability. There are tasks which they are well suited to perform… And I 
think it’s unlikely, unless CCG decides under some sort of patient group directive, that 




The point of contact when dispensing medication was viewed as a prime opportunity for a 
pharmacist to address concerns regarding SABA use, which was not possible for GPs in the 
process of repeat prescribing due to the patient not being present: 
 
 
“there is a role for the pharmacist because at the moment the SABA is handed over, that’s the 




A number of experts suggested that excessive SABA use should be identified in pharmacy at the 
point when SABAs are dispensed. One expert in Europe described how an alert system 
presented in both general practice and pharmacy, whilst two experts described the importance 
of such a system and what it should entail. A pharmacist should have greater  
responsibility for bringing concerns regarding SABA use to the GP’s attention. It was 
perceived that an alert when dispensing SABAs was more likely to be acted upon given the 
challenge of responding to the high volume of alerts in general practice: 
 
“[an alert] presents at the pharmacy because it happens when the pharmacy is preparing the 
medication, there will be a flagging up of misuse and then the pharmacist will judge whether 
he needs to a make a call or not. The same system is actually in place in the GP’s office so he 
could have known in the majority of cases that something is wrong but it flags up so often 
that in my experience usually you click that screen away because you are in a hurry to see 
your next patient, so that’s where things go wrong” (Expert 12) 
 
 
“Yes what could be done is that pharmacy can see all prescriptions that have been made on 
their register. They could then send an alert to more than one physician that this patient is 
collecting more than he or she is supposed to do based on individual prescriptions…And then 
the pharmacy would see you have collected six canisters and not two during the last month 
then of course if you had electronic alert system this could go to all three of the GPs telling 
them this patient has collected more than you have prescribed” (Expert 7) 
 
 
“So an alert in the pharmacy that this patient has taken SABA from a different pharmacy and 
also to oblige them to take measures on that. This is something that depends on the health 
system of the country of course. And I think there must also be some connection between the 
different pharmacists and primary care” (Expert 9) 
 
 
There was no set method to identify excessive SABA prescribing in pharmacy. A number of 
factors affected the pharmacist’s ability to identify excessive SABA use including the 
robustness of the dispensing system and the ability of the staff involved. Medication was 
often prepared by a non-clinically trained dispenser, with final checks carried out by a 
pharmacist often involving the cross checking of prescription details but not frequency of use: 
 
“What happens is you get a prescription in and then the dispenser will dispense it, so they’ll 
put it into the computer, put the labels on, and then the pharmacist checks it. So I’m 
involved in the final checking bit, which doesn’t involve looking at when they last had it, so 
it’s relying on the fact that I checked this two days ago, why am I checking the same thing 
again…And if it’s not me, we have five pharmacists that work within here, if it’s someone 
else they’re not gonna know that” (Community Pharmacist) 
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In one European country primary care systems have moved to reduce power imbalances 
between pharmacy and GPs facilitated by integrated health care systems. Such systems 
increased community pharmacist’s role in primary care and improved working relationships. 
However in the NHS primary care appeared to be built on hierarchies of power, as headed 
by GPs, which influence and determine the relationships between primary care staff. Expert 
6 reiterated the fragmented relationship and balance of power between community 
pharmacy and GPs in which communication initiated by pharmacists was not reciprocated by 
GPs: 
 
“when I speak with the pharmacist they say ‘well I tried calling but the doctor says that’s my 
problem, not yours so leave me alone’” (Expert 6) 
 
“So I left a message with the doctor to just say, ‘Are you sure you want him to be having this 




However GP 1 noted inconsistent communication from pharmacists when raising concerns 
about SABA use. However, as described by the community pharmacist, this stemmed from a 
reluctance to question GP prescribing, with the GP viewed as holding responsibility for 
prescribing decisions, for which pharmacists were responsible for enacting: 
 
“it depends on the pharmacist, [contact is] not very often, but they may flag it to us or more 
often they will tell the patient to come in and have their medication reviewed” (GP 1) 
 
 
“it can’t be the pharmacy’s’ responsibility to control when they get the medication ‘cause 
that’s not our role. The doctor decides how often to give the medication... and to question a 
doctor sometimes … not in my experience, we’ve found they’ve been OK, but sometimes you 







Expert 6 described the importance of closer working relationships with pharmacy, however 
the success of systems identifying high SABA use are dependent on patient relationships and 
a team effort that includes the patients is required. A team approach between general 
practice, pharmacy and the patient was essential to ensure the accurate identification of 
SABA overuse and to reinforce key messages regarding the significance of high SABA use as 
a as a marker of poor asthma control and a risk factor for asthma attack: 
 
“it’s about the team approach with each other, it’s the connection between the patient, 
between the clinician and the patient, the rappor…” (Nurse 2) 
 
“I would think this has to be a three-way conversation between the patient and family, the 
pharmacist and physician…You are hoping you are going to have a relationship between the 
pharmacist, the patient and the doctor to ensure how the information is being tracked 
properly” (Expert 6) 
 
“the more often the same message was delivered [to the patient] the more effect we could 





Relationships between primary care staff and patients varied. Staff who held patient-facing 
roles, such as receptionists or pharmacists, were likely to have closer relationships with 
patients than GPs. GP 3 described the challenge of building patient relationships whilst 
relying on computers, quipping that patients are likely to have a better relationship with 
receptionists: 
 
“as much as computers are very helpful, meaning the relationships of… probably the patient 
knows the receptionist actually now better than me because they’re probably seeing them 
three times, they’ve ordered, prescribed, come in, seen Johnny, whatever….” (GP 3) 
 
 
There was a limited GP-patient relationship when requesting and obtaining SABAs through 
repeat prescribing. The receptionist acted as go-between for patients often relaying GP 
prescribing decisions. However clinical information transmitted by reception on behalf of GPs 
was described as a potential source of frustration for patients who often preferred to engage 
directly with a GP rather than non-clinical staff communicating clinical information: 
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“Yeah and also patients open up to you more, they don’t want a discussion with the 
receptionist they want a discussion with someone they see in their room on a regular basis, 
who they trust” (Nurse 2) 
 
 
One receptionist spoke about the difficulty of being first point of contact for patients and the 
challenge of meeting patient expectations. In one practice, a designated receptionist carried 
out repeat prescribing tasks behind shutters that acted as a barrier between patent and 
receptionist. On observation, both patients and the practice manager knocked on the closed 
shutters whilst she carried out repeat prescribing tasks interrupting the receptionist. In a 
second practice, receptionists shared the processing of repeat prescriptions on an ad hoc 
basis when concurrently carrying out general receptionist duties due to the pressure from 
patients when this task was done individually. Receptionist 4 explained that repeat 
prescriptions could previously be left in a designated box at the reception desk but patients 
often had numerous questions and receptionists described feeling pressured.  It was decided 
that rather than have a designated receptionist for repeat prescribing tasks, repeat 
prescriptions could be handed to any receptionist and duties shared between reception staff. 
Receptionists had a prominent role repeat prescribing but this came with a certain degree of 
pressure: 
 
“patients are so used to getting their own way, it’s difficult to change when they’ve been 
allowed to do things a certain way for so long” (Receptionist 3) 
 
 
In both community and clinical pharmacy, intervening on excessive SABA use depended on 
the willingness of the patient to engage. This was influenced by the patient-pharmacist 
relationship, with community pharmacists often relying on opportunism and intuitive ability 
to determine when and how to raise issues or concerns with a patient: 
 
“also when you’re handing something out, I’ll always say, ‘How are you getting on with your 
medication?’ and that gives people a chance and they’ll say really good or really bad, or they 
might have a particular question, and you can usually tell when someone wants to talk a little 
bit more” (Community Pharmacist) 
 
 
Nurse 2 described the reluctance of patients to engage with community pharmacists on 
clinical matters, whilst GP 5 reflected on the mixed patient feedback of a clinical pharmacist’s 
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when reviewing asthma medications: 
“…what one patient may say is ‘I don’t want everyone to know my business,’ I had that 
situation recently but he’s happy to talk to me but not happy to talk to the pharmacist, 
because it’s not as accepted” (Nurse 2) 
 
“To be honest I had mixed feedback from patients about that, so some just didn’t engage with 
it at all, some found it all a bit patronising ‘cause they thought they can manage their asthma 




Patients were described as having a responsibility for their own SABA use, with SABA use 
unlikely to change if patient behaviours cannot be changed. However, it was acknowledged 
that primary care staff had a responsibility to support and empower patients to take 
responsibility for SABA use, enabling patients to identify when asthma is not well controlled 
and how to act: 
 
“It’s down to the patients responsibility as well really, isn’t is, you can do as much chasing as 
you can possibly do. You can ring them, I write letters to them to come in if the DNA, you know 
that sort of thing” (Nurse 2) 
 
“in the end I think we probably don’t give patients enough support and responsibility that 
they’d be willing to take for themselves, provided they receive the right training and they 
should be the people who are given all the information they need and the support to be able 
to recognise that something’s going wrong and somehow almost the alert needs to be on 
the inhaler itself that shines out at the patient every time they use it” (Expert 2) 
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5.5.5.2 Who’s responsible? 
 
 
  “it doesn’t matter what we think” 
 
 
There were varying opinions in regards to who in primary care held responsibility for SABA 
overuse. It was suggested that other staff members could assist in the identification and 
management of excessive SABA use to relieve pressures on GPs. However there was 
uncertainty regarding whom should take overall responsibility. GP 3 believed the 
responsibility for the identification and management of SABA overuse rested with the GP but 
that the problem of high SABA use required a team effort to adequately address and manage 
the problem: 
 
“Well, it could be a nurse, I mean anybody who has received the appropriate training, it 
could be any kind of lay person provided they’re appropriately trained, but I think the issue 
is who takes the responsibility” (Expert 2) 
 
 
“Definitely not them, it’s me, nobody else, and as much as what I would say is I can only be as 




Expert 13 suggested that identification of SABA overuse is a GP responsibility, with pharmacy 
responsible for alerting systems potentially presenting at point of dispensing. Whilst 
pharmacy had a responsibility to identify high SABA use Expert 12 explained that for systems, 
such as alerts, to be succe9ssful, GPs needed to retain overall responsibility with an ability to 
overrule pharmacists: 
 
“I would say the final responsibility lies with the prescriber. Certainly the pharmacy could be 
used as a second firewall so to speak, if before dispensing medication 
there would be a second surveillance system popping up ‘hey this patient might be at risk, 
please review with the prescriber’ that might be useful” (Expert 13) 
 
 
“But this is the classic mismatch about giving responsibility but not ability. [Here] the GP is still 
in charge because otherwise they are unlikely to accept the system, so the GP is responsible but 
the pharmacist is responsible for advising the GP. The GP can always overrule and can always 
say no if there is a special case etc, etc, “I’m doing this because of that”...using clinical insight 
but the pharmacist is responsible for flagging up” (Expert 12) 
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Expert 9 and Expert 12 believed pharmacy had a responsibility to distribute SABAs and 
double- check the safety of GP prescribing, raising concerns where appropriate: 
 
“I think most of this responsibility lies with the pharmacist regarding the distribution. But 
regarding the first steps, because a patient who had to take a SABA continuously lets say, is 
a patient that is not well controlled, so the responsibility goes back to the doctor” (Expert 9) 
 
“The majority of GPs consider the pharmacist to be in a unique position to do so [identify 
SABA overuse] and it means you have less of a worry as a GP you can be clinically 
responsible and you know you have an extra check the moment you send that prescription, 
by the pharmacist” (Expert 12) 
 
However, community pharmacist believed pharmacists were not responsible for the 
identification of high SABA and the flagging of concerns to GPs but rather a pharmacist was 
responsible for enacting GP decision-making, and did not have authority to question GP 
prescribing decisions: 
 
“The thing is, it’s not something that I feel is really the pharmacy’s responsibility to control 
how often somebody is taking the medication, ‘cause we don’t authorise the medication. If 
the doctor wants to give somebody six months, it doesn’t matter what we think, then give 
them six months, and to question a doctor sometimes … not in my experience, we’ve found 
they’ve been OK, but sometimes you can get people that would be like, ‘Why are you asking; 
is it like I don’t know what I’m doing?’” (Community Pharmacist) 
 
 
GPs being solely responsible for the monitoring and identification of high SABA use, including 
electronic alerts, was contextualized within the current challenges of general practice: 
 
 
“Well it depends on the resources in primary care, because general practitioners have got so 
many other things to monitor and I think to do that and expect the GP to be responsible for 
that is still quite a lot” (Expert 10) 
 
“If you only put the responsibility at the GP’s desk, such a system will be a failure because 






This qualitative study explored primary care staff and experts views regarding an alert to 
identify excessive SABA prescribing in primary care. Four key themes were established within 
the present analysis that reflected the broad issues regarding an alert for excessive SABA 
prescribing. The four themes were: perceptions of excessive SABA use, identifying excessive 
use, using a SABA alert and inter-professional practice. The findings will be summarised 




5.6.1 Summary of findings 
 
 
This study established that despite the evidence, discrepancies exist between how GPs and 
experts define excessive SABA prescribing. Excessive SABA use was more likely to be 
perceived as high risk if presented alongside additional risk factors rather than as a sole 
marker of risk. Clinicians used a combination of methods to identify excessive SABA 
prescribing with the SABA alert intermittently used alongside automatic EHR features and 
the manual checking of prescription records. The ability of the alert to influence SABA 
prescribing was dependent on clinician engagement with the alert and ensuing action. 
Findings suggest that SABA alert use was variable as the alert was not aligned with prescribing 
workflow, with no clear management strategy on how to respond to the SABA alert 
particularly when repeat prescribing. 
 
There were conflicting views between experts and GPs regarding action following the 
identification of excessive SABA prescribing, with experts more likely to suggest that SABAs 
are withheld, whilst GPs deemed this inappropriate instead preferring to prescribe SABAs and 
invite patients for asthma review to assess asthma control. However, the provision of timely 
review following the identification of excessive SABA prescribing was challenging due to the 






Both receptionists and pharmacists were involved in the identification of excessive SABA use 
to varying degrees. GPs often relied on receptionists to highlight excessive SABA use when 
processing repeat prescriptions despite being neither a formally recognised nor supported 
role. In comparison to Europe, pharmacists in this study were an underutilised resource in 
asthma management. The need for a collective approach to the identification and 
management of excessive SABA prescribing across primary care was expressed among both 
GPs and experts but was yet to be realised in practice. Increased patient education and 
asthma self-management was deemed necessary for excessive SABA prescribing to be 
reduced rather than the sole targeting of prescribing behaviour. These findings will be further 
discussed in the following section and alongside findings from Phase 1 and Phase 2 of the 
thesis in the next chapter. 
 
 
5.6.2 Strengths and limitations 
 
 
In Chapter 2, the general strengths and limitations of qualitative research methods were 
reviewed. This section describes the specific strengths and limitations of Phase 3 of the thesis 
presented in this chapter. 
 
 
5.6.2.1  Strengths  
 
One of the strengths of the qualitative findings was its inclusion of various members of 
primary care staff rather than GPs. This provided a broad understanding of the challenges 
faced in the identification of excessive SABA use in the wider context of primary care. Using 
what Kelly257 refers to as generic qualitative research enabled a broad analysis of the issues 
surrounding the identification of excessive SABA use in practice. Conducting face-to-face 
interviews with GPs in practice allowed for wider discussions around the use of the EHR in 
identifying high SABA use. GPs were able to refer to the EHR when describing methods used 
to identify high SABA use was carried out in practice. Furthermore, rather than simply 
referring to the AUK medicines management alert, GPs were able to demonstrate the ways 
in which excessive use was identified within the EHR. Telephone interviews facilitated access 
to a wide range of experts worldwide with knowledge, experience and perspectives of a 
variety of healthcare systems. Observations with receptionists gave an insight into the 
varying processes and roles in the primary care management of SABA prescribing in real time, 
unlikely to be accurately captured in interview. 
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5.6.2.2  Limitations  
 
Although the study included a variety of primary care staff to provide broad insight into the 
research topic, findings are not representative of all primary care staff and experts due to the 
variable participant numbers. Despite a convenience sample of fourteen practices identified 
as likely to participate in the project, only 2 practices agreed to both clinicians and 
receptionists to take part, one with clinicians only and the final practice declined but one GP 
agreed to take part following snowball sampling. There may be a number of reasons for poor 
uptake; by restricting the study to a convenience sampling strategy of those who were easily 
accessible380 and the challenge on clinician time during working hours. Uptake may have been 
higher had practices been incentivised to participate, in particular for GPs who are likely the 
most time deprived, financial incentives may have increased participation outside of their 
working day.  Observations with clinicians may have provided greater insight into the role of 
an alert in repeat SABA prescribing however given the challenges of recruitment, interviews 
were judged to be more easily accessible than observations. As the study was carried out in 
an inner city, ethnically diverse population findings are not generalisable to wider primary 
care. Observations with receptionists were of limited duration and may not be reflective of 
the role of receptionists in other practices, whilst limited pharmacist input does not provide 
depth in understanding of the role of pharmacists. In utilising a ‘generic qualitative research’ 
approach in the absence of a theoretical underpinning, a larger sample size may have been 
required to grant sufficient information power.262 GP interviews may not have accurately 
reflected the processes that GPs would adopt when prescribing SABAs in practice. Observing 
GPs when repeat prescribing SABAs may have helped to overcome some of these limitations 
however may have impacted on practice uptake. Furthermore, observations such as with 
receptionists may have influenced repeat prescribing practice and may lack 
generalisability.381 Telephone interviews may have limited the depth and quality of data 
collected in comparison to face-to-face interviews.  
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(i) Theme 1: Perceptions of excessive SABA use 
 
 
Despite the association between excessive SABA use and risk of exacerbation and asthma 
related death presented in Chapter 1, inconsistencies existed among GPs and expert’s 
understanding and application of asthma guideline evidence into practice. GPs and experts 
expressed conflicting opinions regarding how much SABA was too much in contrast to the 
most recent evidence presented in BTS/SIGN52 and NRAD.25 There may be a number of 
reasons for contrasting definitions of excessive SABA use. As highlighted in Chapter 1, there 
is a lack of consistency in how excessive SABA use is defined in the literature. Both NRAD25 
and BTS/SIGN52 recommend that people prescribed more than one SABA a month (200 doses) 
or 12 SABAs a year, should be invited for asthma review, whilst BTS/SIGN52 further describe 
that SABA use of more than three times a week (24 doses a month), at a much lower quantity 
of one SABA a month (200 doses a months), is a potential sign of poor asthma control. The 
lack of clarity and consistency in both guidelines and wider evidence to determine what 
constitutes ‘too much’ SABA has been highlighted in the recent IPCRG initiative ‘Asthma Right 
Care’ described in Chapter 1.65 
 
 
GPs were more likely to refer to NRAD’s threshold for excessive SABA use suggesting that GPs 
were less likely to follow guideline recommendations than experts which may reflect the 
challenge of guideline implementation.382 Findings indicate that defining excessive SABA use 
involved a subjective balancing of the evidence with what was practical: NRAD’s 
recommendations too lenient yet guidelines recommendations too restrictive in practice. 
Despite current evidence highlighted in Chapter 1,1,25–27,52 both GPs and experts questioned 
the risks associated with excessive SABA prescribing particularly when SABA use was used as 
a sole marker of risk. GPs described a hierarchy of prescribing risk with commonly prescribed 
SABAs perceived low risk in contrast to higher risk, less frequently prescribed drugs such as 
methotrexate. The frequency of SABA prescribing may have implications for alerts as the 
more commonly prescribed, the more frequently an alert may present, potentially 




GPs and experts viewed the co-assessment of ICS use in conjunction with SABA use as 
increasingly important in determining risk and prompting intervening action in practice. GPs 
and experts also described additional markers of risk such as oral steroid use, hospital 
admissions and emergency department attendances as necessary to identify those with 
current poor asthma control and at future risk. This suggests that further clinical indicators 
are required to identify at-risk patients and influence prescribing behaviour that may not 
result from an alert based on a sole assessment of SABA prescribing. A number of more 
targeted approach to the identification of potentially at-risk patients identified on SABA 
prescribing alone, have been described in the literature. 
 
As described in Chapter 1, Schatz et al.18 used a stratified approach to SABA prescribing to 
target patients with poor asthma control rather than determining risk based on a definitive 
SABA use threshold. The co-assessment of SABA and ICS prescribing as a marker of risk is 
reflective of NRAD’s findings, implicating excessive SABA use and underuse of ICS in asthma 
deaths,25 as well as reflective of Hull et al’s13 recommendations for the identification of those 
under-prescribed ICS and excessively prescribed SABAs which account for the majority of 
hospital admissions. Whilst CDSSs to improve clinician’s adherence to guidelines offers 
potential to improve prescribing,304 if clinicians do not agree with the content, for example 
the SABA alert threshold and/or do not perceive this threshold as indicative of risk, then the 
alert is unlikely to influence prescribing. The SABA alert design and factors influencing the 
use of an alert are discussed later in this section. 
 
 
(ii) Theme 2: Identifying excessive SABA prescribing 
 
 
There were two main opportunities to identify excessive SABA use either in-consultation 
(acute prescribing) or when repeat prescribing. The most commonly described method to 
identify excessive SABA use was the EHR generated medication percent usage, with the SABA 
alert an adjunct method rather than as the primary tool to identify problematic SABA 
prescribing. GPs described using the medication percent usage to identify problematic SABA 
use, as calculated within the EHR using the quantity, dose and time frame of use entered by 




However, given the variability in the definitions and perceptions of excessive SABA identified 
in this study, it cannot be assumed that SABA prescriptions are appropriately and consistently 
configured to reflect guideline recommendations. Therefore people with potentially poor 
asthma control may not be appropriately identified in practice using this method. 
 
When repeat prescribing, GPs did not routinely refer to the SABA alert, often relying on 
receptionists to highlight concerns in the absence of further clinical checks. This suggests a 
lack on continuity in prescribing activity in a time sensitive clinical environment. Furthermore 
that GPs are not adequately supported by current electronic methods to identify excessive 
SABA use particularly when repeat prescribing. However, it remains unclear to what extent 
an alert can influence repeat SABA prescribing, with Duerden et al.,383 recommending that 
electronic methods to identify potential problems at point of repeat prescribing are explored. 
 
It is questionable as to whether the presentation of the SABA alert in the QOF box is 
appropriate given that the QOF box is commonly associated with ‘reminders’ for incentivised 
quality of care indicators and administrative tasks. Furthermore, inconsistent use of the SABA 
alert may reflect overlap with incentivised measures such as the QOF annual asthma review, 
both positioned within the QOF box and with asthma review the recommended action 
following the alert. In an evaluation of an intervention to improve prescribing safety, Grant 
et al.,384 reported that GPs perceived ‘asthma control’ as the least important safety concern 
due to the overlap with QOF indicators, associated with the management of long term 
conditions more commonly the responsibility of nurses. Furthermore positioning of the SABA 
alert in the QOF box with non-urgent tasks raises questions about the appropriate design and 
presentation of the SABA alert, the characteristics that differentiate an alert from a reminder 








(iii) Theme 3: Using a SABA alert 
 
 
The use of the SABA alert was dependent on two mutually existing factors: the ability of 
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clinicians to engage and act on the SABA alert. Engagement with the SABA alert was 
influenced by three factors: the volume of alerts, alert presentation and alert design. 
Clinicians described ‘alert fatigue’ from the volume of alerts presenting in practice, resulting 
in the prioritising of issues deemed of higher clinical importance above excessive SABA use. 
The reflects both the literature that a high volume of alerts deemed of variable clinical 
importance may result in clinician disengagement,144 and findings of Theme 1, that alerts 
presented on the sole marker of SABA prescribing were not perceived as high risk and 
therefore less likely to be used. In the ARISSA study, alerts to identify severe asthma patient’s 
at-risk, were based on a range of guideline criteria rather than one component of the 
guideline.160 However, the at-risk alert had no effect on exacerbations with the alert design 
deemed a likely contributor.  
 
CDSSs should present “the right information, in the right format, at the right time, without 
requiring special effort,”126 with the literature in Chapter 1 highlighting the importance of 
alerts integrated both with workflow and at point of decision making.122,123,137,141 However, in  
its presentation within the QOF box the SABA alert was neither aligned with workflow nor 
decision-making and therefore at increased risk of being over-looked. Furthermore as the 
SABA alert was activated when a patient’s medical record was opened and not specifically at 
point of decision-making, engagement with the alert may be less likely. This may explain the 
use of the SABA alert as an adjunct method to the identification of excessive SABA 
prescribing. In its presentation in the QOF box with informative, optional recommendations 
that did not require additional user interaction, the SABA alert was representative of a ‘soft’ 
or non-modal alert design. This was in contrast to ‘hard’ or modal alerts for methotrexate 
that presented in the centre of the computer screen that required user engagement to exit 
the alert before progressing through the EHR. ‘Soft’ alerts that have optional rather than 
required engagement suggest non-urgency and may be likely perceived as a reminder rather 
than an urgent high-risk concern. It is more likely that this type of alert is overlooked rather 
than prioritised and therefore of limited opportunity to influence SABA prescribing 
behaviour. 
 
As described in Chapter 1, an alert should consist of a signal word for example, ‘information’, 
‘warning’, or ‘stop’ to differentiate between levels of priority, including instructions on the 
hazard and an explanation of consequences of the alert.144  
However the current SABA alert fails to provide information on the risks of excessive SABA 
use, instruction on how to respond to the alert and the consequences of inaction, therefore 
offering little persuasion for clinicians to engage. The use of the SABA alert was dependent 
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on a number of factors including the context in which the alert presents, the type of action 
to be taken, how and by whom. GPs described problems on acting on excessive SABA use 
both in consultation and when repeat prescribing. There were challenges in-consultation due 
to time constraints due to the number of clinical issues that may already require attention, 
in addition to excessive SABA use. GPs agreed that improved resourcing of existing services 
was necessary to provide time for an appropriate assessment and review of asthma control 
and patient education. There was uncertainty regarding how excessive SABA use should be 
responded to particularly if identified when repeat prescribing, with no guidance for GPs or 
receptionists on how to respond within the repeat prescribing process. A number of experts 
in European and International primary care suggested SABAs should be withheld if excessive 
use was identified. This was in contrast to primary care staff who did not view the withholding 
of SABAs as an option due to concerns regarding risk of patients coming to harm and 
professional liability. The SABA alert did not provide advice and support for GPs on how to 
respond to the alert in such situations. This raises question whether the recommended action 
to invite patients for review is appropriate in its present form. Due to resource constraints 
and the already well-documented challenges of patient attendance at annual asthma review, 




(iv) Theme 4: Inter-professional practice 
 
 
The role of receptionists in the management of repeat SABA prescriptions is reflective of 
Swinglehurst et al’s71 findings that repeat prescribing is complex, technology-supported 
social practice between clinicians and receptionists. However one of the main differences 
between this study and that of Swinglehurst et al,71 has been the introduction of the 
electronic prescription service. The aim of the EPS was to reduce non-clinical staff 
involvement by streamline prescribing to improve the processing and authorisation of 
prescriptions by clinicians. Despite a drive towards the EPS, variable practice uptake means 
that receptionists continue to process and manage repeat SABA prescriptions to differing 
extents. This was in contrast to the decreased role of receptionists in primary care in Europe 
following the introduction of electronic prescribing as described by a number of asthma 
experts. The variable uptake of EPS described in this study may explain the continued reliance 
on receptionists to raise prescribing concerns for GP’s attention. However, despite the EPS, 
GP’s described carrying out variable repeat prescribing checks prior to authorisation, often 
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dependent on time of day repeat prescribing was carried out and the volume of repeat 
prescribing requests received. As the SABA alert was not integrated with electronic 
prescribing workflow it raises questions regarding at what point in prescribing the SABA alert 
has greatest impact and on whom. The role of receptionists may vary by practice or CCG 
priorities as in some practices receptionists have increased ownership of QOF “pop ups.”385  
Therefore, in its current presentation, it is possible the SABA alert is noted by receptionists 
rather than clinicians. However in observations with receptionists, none of the receptionists 
referred to the QOF box when carrying out either repeat prescribing tasks or patient-facing 
duties as this was not perceive this as part of their role. 
 
Despite varying perceptions regarding the appropriateness of receptionists to flag SABA 
prescribing concerns, the receptionist’s role in other areas of primary care is increasing and 
evolving to include the identifying and signposting of patients. Initiatives to enhance the role 
of receptionists including in the identification and signposting of patients eligible for 
screening programmes386,387 has been recommended by the NHS England’s ‘General Practice 
Forward View.’388 There remains potential for an increased role of receptionists in actively 
signposting patients with excessive SABA use for review however this requires a clear plan 
for the identification and management of SABA in primary care. 
 
Both GPs and experts described a need for an increased role of pharmacists in the 
identification and management of excessive SABA use. This reflects on-going calls for an 
increased role of community pharmacists in the delivery of primary care services.389,390 GPs 
and experts viewed pharmacists as a ‘backstop’ for prescribing safety however, the 
pharmacist’s role in the identification of potentially problematic SABA prescribing was 
neither clearly defined nor supported. The action taken by pharmacists when SABA use 
concerns were identified, involved the dispensing and signposting of patients back to general 
practice for asthma review. This is reflective of the literature in Chapter 1 that described the 
challenge of intervening in prescribing decisions downstream rather than upstream at point 
of prescribing. 
 
Furthermore, this highlights a lack of clear support for community pharmacists in the 
management of SABA prescribing, reflective of the underutilisation of community pharmacy 
described in Chapter 1. Despite the Murray Review90 identifying an increasing potential for 
community pharmacists in the management of long-term conditions in England, such 
initiatives have not been forthcoming. The Murray Review90 described the potential for MURs 
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to be extended to full clinical reviews in community pharmacy,89 with pharmacists in Scotland 
already managing long term conditions such as asthma through the CPRS service.391 However 
study findings showed no supported mechanism by which pharmacists could identify and 
respond to excessive SABA prescribing. Furthermore, pharmacist’s signposting of patients 
back to general practice may intensify rather than resolve the challenge of timely patient 
review, by failing to address the problem at point of identification, with a number of GPs and 
experts suggesting pharmacists should be able to act on problematic SABA use for example 
through a medication review in pharmacy. 
 
GPs described prescribing SABAs irrespective of the identification of excessive SABA use due 
to concerns of withholding SABAs without first reviewing the patient. Recent evidence has 
demonstrated the effectiveness of community pharmacists at improving outcomes for 
people with asthma through the delivery of asthma specific reviews. In the UK, a study of a 
community pharmacy asthma review service (CPARS)392 and the Italian Medicines Use Review 
(I-MUR) service393 identified the potential for asthma reviews to be delivered by pharmacists 
rather than in general practice. In a proof-of-concept study, patients who had not attended 
for annual asthma review were identified in general practice and referred to CPARS. Twenty-
seven patients were reviewed by pharmacists using the structured SIMPLES review 
technique394 in addition to standard MUR questions. In the three months following review 
the number of patients requesting 2 and 3 SABAs decreased, with an increase patients 
requesting 1 SABA and an increase in preventer inhalers. CPARS reduced general practice 
time and resources required to follow-up patients for review, issues identified by GPs in this 
study as problematic following the SABA alert. The absence of linked pharmacy and general 
practice records, and the inability of pharmacists to change medications were described as 
limitations to CPARS. These issues were also expressed as potential limitations by number of 
experts in this study when discussing the increased role of community pharmacists in the 




Due to the inability of pharmacists to change prescriptions, pharmacists delivering CPRAS 
referred patients to general practice if changes to medications were required. This echoes 
current practice of community pharmacist’s signposting patients to general practice if 
concerns with SABA use were suspected. However in CPARS patients signposted back to 
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general practice had an allocated review unlike current practice. 
 
Initiatives such as CPARS offer community pharmacists the potential to intervene and triage 
patients for the more appropriate utilisation of both general practice resources and 
enhanced utilisation of community pharmacy. It was not possible to determine if the costs 
associated with patient referral back to general practice in CPARS were offset by improved 
quality of life, reductions in hospitalisation, and unplanned GP visits following the community 
pharmacy service. However, the RCT tested I-MUR service393 demonstrated the potential 
effectiveness and cost-effectiveness of community pharmacy medication reviews. Other RCT 
tested interventions delivered in pharmacy show improvements in asthma control, 
medication adherence, inhaler technique395 and reductions in SABA use.396–398 The methods 
by which patients eligible for pharmacist-intervention are identified varies, with eligible 
patients most commonly identified by pharmacists or through audit searches in general 
practice for pharmacist follow-up.392,393 The real-time identification of patients in response to 
a CDSS alert aligned with GP prescribing workflow has yet to be explored. 
 
However pharmacist-GP relationships may not be well established in primary care and may 
require an overcoming of inter-professional barriers.68,399,400 A number of international 
experts described the increasing role of pharmacists in the management of asthma in Europe 
in comparison to England. Experts described the pharmacist’s role as being supported at both 
local and national and local level, with working relationships based on mutual respect 
supported by clear channels of communication. The lack of consistency or support for the 
identification and management of excessive SABA use across primary care identified in this 
study is likely to reflect contrasting infrastructure, roles and relationships in primary care 
nationally in comparison to internationally. It is likely that success of the I-MUR study393 at 
improving asthma control and adherence was due to a significant cultural shift in the roles of 
Italian community pharmacy to more patient-centred and clinically orientated role as 
supported by the Italian Government/Ministry of Health. It is therefore questionable to what 
extent the Murray Review recommendations are likely to improve the management of long- 
term conditions if implemented in silos in primary care given the continued absence of a 
national strategy for respiratory disease in England. In the absence of integrated computer 
systems, pharmacists are is limited in their ability to make clinical decisions and remain 
dependent on relationships with general practice.399 
 
Both GPs and experts described the need for increased patient responsibility in asthma self- 
235  
management to reduce excessive SABA use. GPs described it challenges in responding to 
excessive SABA prescribing, influenced by patient’s lack of awareness regarding asthma 
control and patient expectations, particularly when repeat prescribing, as the patient is not 
present.  As described in Chapter 1 there is discrepancy in what patients perceive by well 
controlled asthma, often tending to believe their asthma is under control even despite 
frequent symptoms, regular SABA use, or having had an acute exacerbation within the last 
year.28,401,402 Inconsistency between patients' perceptions of their asthma as being well 
controlled in relation to asthma guideline definition of asthma control is an international 
issue.403–406 Therefore, rather than targeting clinician behaviour alone, interventions should 




5.7     Conclusion 
 
This study provides insight into the role of an alert to reduce excessive SABA prescribing in 
primary care. Whilst GPs and experts were receptive to an alert for excessive SABA 
prescribing, the impact of an alert was likely to be limited for a number of reasons including 
the variable definitions and perceptions of excessive SABA use in contrast to the SABA alert, 
inadequate alert design and presentation to facilitate engagement and action and lack of 
management strategy to support the use of the SABA alert. This was representative of the 
absence of a strategy for the identification and management of excessive SABA use in wider 
primary care. 
 
Divergent perspectives among GPs and experts on excessive SABA prescribing and associated 
risks, in contrast to asthma guidelines, suggests that an alert based solely on SABA prescribing 
alone may not be appropriate method to identify people with asthma potentially at risk. 
Current methods used to identify excessive SABA prescribing in practice are inconsistent and 
unreliable. The SABA alert was aligned neither with prescribing workflow nor with point of 
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decision-making and therefore of limited influence to change prescribing behaviour. There 
was an expectation that receptionists and pharmacists would identify SABA prescribing 
concerns yet this role was neither formally recognised nor supported in primary care. 
 
There is a lack of management strategy to support GPs in responding to excessive SABA 
prescribing identified when the patient is not present at point of repeat prescribing. An alert 
should be optimised using additional risk factors for a targeted approach to the identification 
of patients at potentially at risk. An alert should be aligned with repeat prescribing workflow 
and designed to facilitate engagement and action as part of a collaborative approach to the 
identification and follow-up of at-risk patients across primary care. 
 
 
5.8    Recommendations for practice 
 
The findings of this chapter raise a number of issues for consideration in regards to the 
identification and management of excessive SABA prescribing and the use of an alert in 
primary care. Clarity and consistency is required in how excessive SABA prescribing is defined 
and framed by clinicians delivering asthma care at local, national and international levels, and 
how excessive use is defined and framed between HCPs and patients. This should form part 
of wider discussion regarding increased education and awareness aimed at change attitudes 
towards the risk of excessive SABA use and towards overall management of asthma.  
 
This requires action in two ways: (1) clarification regarding the configuration of SABA 
prescriptions to raise awareness among GPs when prescribing or a restriction on the number 
of SABA devices that may be configured per prescription. However, any changes to SABA 
prescribing should be clearly explained to the patient and may be prescribed at GP 
discretion. (2) Future SABA alerts should be optimised within prescribing workflow, with a 
hard alert more likely to be accepted if additional clinical indicators are used to identify at-
risk patients. Routine searches of EHRs for at-risk patients may not identify patients in timely 




Findings suggest that an alert should facilitate and support both engagement and action 
if it is to influence SABA prescribing behaviour. Alternative ways to facilitate asthma 
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reviews should be explored to ensure people at risk have their asthma control. This will 
require clearly defined roles and responsibilities in the identification and management of 
potentially at-risk patients across primary care supported by a clear process for action at 
local level. However, at national level, the UK is experiencing an unprecedented crisis in 
the provision of primary care primarily due to underfunding of services. To enable those 
in primary care to deliver safe and effective asthma care, staffing, workload and resource 

































6.1 Recap of the thesis aim 
 
The overall aim of the project was to explore the use of an electronic alert to identify 
excessive SABA prescribing for people with asthma in primary care in east London. 
 
The main objectives of the study were as follows: 
 
 
Phase 1: To systematically review the literature on the use of CDSS alerts to reduce excessive 
SABA prescribing for people with asthma in primary care and determine the features of alert 
systems that have the potential to improve process outcomes for healthcare providers and 
clinical outcomes for people with asthma. 
 
Phase 2: To evaluate the impact of the Asthma Medicines Management alert to reduce SABA 
prescribing and secondary process measures and clinical outcomes of asthma care within 
general practices in east London. 
 
Phase 3: To explore the views of primary care staff and asthma experts on how they define 
and perceive excessive SABA prescribing, the role of an alert to identify excessive SABA 
prescribing, the factors influencing the use of an alert and the roles and relationships 
between primary care staff in the management of excessive SABA prescribing. 
 
 
6.2 Recap of thesis findings 
 
In Phase 1 (Chapter 3), the systematic review of the literature identified limited evidence that 
when delivered as a multicomponent intervention in an integrated health care system, alerts 
may potentially reduce excessive SABA prescribing.189 The greatest effect on SABA 
prescribing occurred when clinicians were alerted to excessive SABA prescribing outside of 
prescribing workflow when facilitated by intervening actions including referral to an allergy 
specialist and  a patient information letter in an integrated health care system.314 
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In Phase 2 (Chapter 4), a single component alert intervention resulted in a small but 
potentially clinically significant reduction in SABA prescribing in the 12 months following the 
SABA alert. The alert had no effect on exacerbations but a reduction in primary care 
consultations was observed. Exploratory subgroup analysis identified a reduction in repeat 
SABA prescribing, with variable effect by CCG and time frame. 
 
In Phase 3 (Chapter 5) four themes regarding primary care staff and asthma expert’s views 
on a SABA alert were identified. These include Theme 1: Perceptions of excessive SABA use, 
Theme 2: Identifying excessive SABA use Theme 3: Using a SABA alert and Theme 4: Inter- 
professional practice. Theme 1 identified varying definitions of excessive SABA use and 
application of guideline evidence on the risks of excessive SABA use among clinicians. Theme 
2 established the SABA alert as one of a number of informal methods, inconsistently used by 
clinicians, to identify excessive SABA use. Theme 3 determined the SABA alert did not align 
with repeat prescribing workflow with no clear pathway of action to support its use. Theme 
4 highlighted an absence of clearly defined roles for receptionists and pharmacists in the 




6.3 Addressing gaps in the literature 
 
This thesis responds to two gaps identified in the literature as described in Chapter 1. Firstly, 
recommendations have called for clinicians to be alerted to the excessive prescribing of 
SABAs in primary care but the evidence supporting alerts in this context is unclear. Secondly, 
the literature on the use of alerts to change prescribing behaviour has focused on the 
presentation of alerts at point of decision making when in consultation but not when repeat 
prescribing. 
 
The systematic review in Phase 1 of the thesis addressed the first gap in the literature, 
identifying that an alert delivered as multicomponent intervention can reduce excessive 
SABA prescribing. However, none of studies included repeat SABA prescribing as an outcome 
measure. Phase 2 of the thesis addressed the second gap in the literature, reporting a small 
reduction in repeat SABA prescribing following the use of a single component alert 
intervention. Further analyses indicate that a reduction in SABA prescribing is a result of 
asthma reviews generated in response to the alert rather than a direct result of the alert at 
influencing prescribing behaviour at the point of prescribing. 
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In this section, the findings of Phases 1, 2 and 3 of the thesis are presented and discussed in 
relation to the gaps in literature identified in Chapter 1. More specifically, Phase 1 and Phase 
3 findings will be discussed in relation to the findings of Phase 2 to explore the potential 
reasons for variability of the effect of the alert on SABA prescribing and to understand how 
the alert may have influenced repeat prescribing behaviour. 
 




Chapter 1 highlighted variations in the literature on how the problem of SABA use is framed 
in practice. This included variations between national asthma guidelines definition of poor 
asthma control as 6 puffs of SABAs per week in contrast to NRADs definition of excessive 
SABA use as more than 1 SABA inhaler a month or alternatively 6 puffs daily, approximately 
7 times higher than guideline recommended levels. A number of studies have used a targeted 
approach to the identification of poor asthma control and risk by capturing ICS prescribing in 
conjunction with SABA prescribing rather than SABA use on its own as a marker of risk. In the 
systematic review of the literature in Phase 1 (Chapter 3), two of the four studies variably 
defined excessive SABA use. In Tamblyn et al.313 excessive SABA use as was defined as more 
than the equivalent of 250 doses in a 3-month period (2.7 puffs daily) whilst Zeiger et al.314 
defined excessive SABA use as seven SABAs per year equating to (four puffs daily). Both 
definitions were higher than national guideline recommended use for the identification of 
poor asthma control but less that the daily dose equivalent identified by NRAD as a risk factor 
for exacerbation and asthma related death. 
 
In Phase 3 theme 1 Perceptions of excessive SABA use, clinicians quantified excessive SABA 
use by differing thresholds. Experts more likely to define problematic SABA use in accordance 
with guideline recommendations whilst GPs were more likely to define in accordance with 
higher threshold of NRAD. Theme 1 further identified that irrespective of evidence, a number 
of GPs and experts did not equate excessive SABA use as high risk. Additional risk factors such 
as ICS use, exacerbations, hospitalisations and AED were perceived necessary, in association 
with SABA use, to determine risk. This raises questions regarding both a lack of awareness 
among 
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GPs of the guideline evidence for excessive SABA use and the suitability of an alert to identify 
poor asthma control based on one component of current asthma control rather than 
components of future risk and overall asthma control. Findings highlight the challenge of 
setting an alert threshold with which GPs will respond as if end users do not perceive the 
alert as indicative of excessive SABA and high-risk use, then it is unlikely to influence SABA 
prescribing behaviour. 
 
In Phase 1 of the thesis, the intervention in Zeiger et al.,314 was triggered on excessive SABA 
use alone, and resulted in a reduction in SABA prescribing for patients without prior specialist 
asthma care. This raises questions as to how an intervention based solely on excessive SABA 
use reduced SABA prescribing, whilst in Phase 3 clinicians did not perceive excessive SABA 
use as high risk when presented alone. This was likely due to the alert in Zeiger et al.,314 
forming part of a multicomponent intervention in an integrated health system that facilitated 
a specialist allergy referral and placed responsibility on patients rather than clinicians alone. 
Clinicians were alerted to the problem of excessive SABA use in real-time based on dispensing 
data for information purposes only and did not attempt to influence prescribing behaviour 
at point of decision making. Through an allergy review and patient education, the 
multicomponent intervention sought to optimise asthma management and improve asthma 
control resulting in decreased need for symptom relief in turn reducing clinician SABA 
prescribing. In this way, the intervention in Zeiger et al.,314 negated the problem identified by 
Hayward et al.,124 in Chapter 1, that alerts often do not present within prescribing workflow 
at and therefore have limited influence on decision making. 
 
Chapter 1 highlighted the interchangeable language in the literature used to describe 
problematic SABA use as overuse, inappropriate use, high use and excessive use. In its current 
format, the SABA alert described the threshold of three SABAs in three months as high use. 
SABAs are commonly framed in terms of ‘use’ as determined by prescribing data, yet in Phase 
3, clinicians expressed concern that excessive use based on prescribing data may not be 
reflective of actual use. As patient’s SABA ‘use’ is dependent on what has been prescribed, 
framing the problem as SABA use appropriates blame to the patient, maintaining reinforcing 
clinician power in what Bourdieu describes as the social institutions of medicine.408,409 A shift 
in language from SABA ‘use’ to ‘prescribing’ refocuses responsibility of the problem upon 
clinicians who facilitate excessive use through prescribing. Patient SABA use and clinician 
SABA prescribing are not mutually exclusive with changing the behaviours of both patients 
and clinicians required to improve asthma management and patient outcomes. However this 
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raises questions regarding how alert semantics may influence how clinicians engage with the 
problem in practice. It is important to consider not just how SABA use is quantified but how 
the language used to describe and define the problem shapes meaning and influences how 
the SABA alert may be used. 
 
 




Chapter 1 highlighted that no clear distinction is made between CDSS features such as 
“reminders”, “alerts”, and “prompts,” with terms used interchangeably in the literature. In 
Phase 1, each of the studies systematically reviewed used different terminology to describe 
CDSS components, with both McCowan et al.,156 and Eccles et al.,153 referencing the use of 
prompts whilst Tamblyn et al.,313 and Zeiger et al.,314 referred to alerts. The prompts used in 
Eccles et al.,153 and McCowan et al.,156 offered suggestions to clinicians on how to respond 
when in consultation, similar to the SABA alert evaluated in Phase 2, that recommending the 
patient was invited for asthma review. However, the alerts in Tamblyn et al.,313 and Zeiger et 
al.,314 went beyond suggestions, instead facilitating actions to improve asthma control. In 
Tamblyn et al.,313 an alert enabled clinician access to an asthma profile with the option to 
enrol patients in a home care nurse-monitoring programme, whilst in Zeiger et al.,314 both 
patients and allergy department were alerted to excessive SABA use as well as clinicians, to 
facilitate referral and inform/educate patients. This suggests that an alert is inherently 
different from a prompt or reminder based on the actions generated. This suggests the SABA 
alert was akin to reminder rather than an alert in its recommendation for review rather than 
facilitating action for review. These issues are explored further below. 
 
 




Phase 3 interviews support the differentiation of alerts from prompts or reminders. In Phase 
3 Theme 3 Using a SABA alert, two key features distinguished an alert from a prompt or 
reminder: engagement and action. 
 
 The importance of both alert engagement and action and how this relates to the SABA alert 
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The literature in Chapter 1 described that CDSSs do not guarantee user engagement, with 
alerts often ignored or overridden by users. In Phase 1 of the thesis, two of the four studies 
included in the systematic review captured CDSS user engagement, with one reporting that 
engagement with the CDSS was poor with several instances of zero interactions, whilst the 
other reported clinicians failed to interact with the intervention in approximately 60% of 
cases. However, neither study explored the potential reasons for poor engagement. In Phase 
3 of this thesis qualitative findings showed that clinicians did not routinely use the SABA alert 
and it was often ignored when prescribing. As discussed in Chapter 1, workflow commonly 
refers to processes or activities carried out in consultation however CDSS use is dependent 
on the ‘thought-flow’ (clinical decision-making) and the ‘workflow’ (the clinical pathway) that 
often occur at different points when prescribing in consultation or in repeat prescribing 
activities outside of consultation. Phase 3, Theme 3 Using a SABA alert identified that 
engagement with the alert was dependent on alert presentation, alert design and alert 
volume. Yet, in its presentation within the QOF box, the alert is not conducive with both 
thought-flow and work-flow. Such failure is a result of alert design but also a result of 
‘thought-flow’ limited by ‘work-flow’ time constraints in primary care consultations.  
 
Furthermore, the QOF box is commonly associated with reminders for administration tasks 
or outstanding issues for routine care in the management of chronic conditions. The SABA 
alert presentation, coupled with design as a non-modal or soft alert with optional rather than 
essential engagement, is likely to reinforcing existing attitudes from Phase 3 Theme 1, that 
excessive SABA use is non-urgent and a low risk concern. As SABA alert design and 
presentation is not conducive to thought-flow or workflow, this may explain why in the 
qualitative study in Tower Hamlets, clinicians did not routinely use the SABA alert, as 
reflected in the very small reduction in SABA prescribing in exploratory analysis in this CCG in 





Phase 3 Theme 3 identified that use of the SABA alert was dependent on the type of action, 
the point of action and the support for action. An asthma review was the recommended 
action following the SABA alert, with clinicians describing the need for asthma review prior 
to changing SABA prescribing. In Phase 2 of the thesis, a lack of increase in the number of 
reviews and time to review in the 3 months following the SABA alert is likely dependent 
on practice follow-up and review availability as well as patient attendance, which the alert 
fails to address. Phase 3 Theme 3 highlighted that point of action was challenging if excessive 
use was identified when repeat prescribing, outside of consultation, as the patient was not 
present. In Zeiger et al.,314 in Phase 1, clinicians were alerted to excessive SABA use outside 
of consultation, however success of the intervention was likely due to the additional 
components supporting action by alerting both allergy services and patients, rather than an 
alert requiring solely clinicians action. 
 
As described in Chapter 1, the ARISSA study of at-risk register alerts for severe asthma failed 
to reduce exacerbations. Despite the intervention consisting of an at-risk alert customised to 
practices and supported by education and training, the alert had limited influence on 
receptionist’s ability to prioritise appointments for patients identified as at-risk. Smith et 
al.,160 suggest the lack of reduction in exacerbations was due to combination of training and 
electronic flagging of at-risk patients. However, the study did not explore the time between 
alert presentation and review, the components of review and by whom reviews were carried 
out. If timely reviews do not occur following the alert, opportunities to maximise 
management and improve outcomes are delayed. 
 
Phase 2 of the thesis, the greatest reduction in SABAs coincided with asthma review however 
the lack of a clear plan of action on how to proceed following the identification of excessive 
SABA use, particularly when repeat prescribing, was described as challenging due to general 
practice capacity and workload. The findings of Phase 2 and the ARISSA study160 highlight the 
potential challenge of providing reviews in general practice in response to an alert and may 
explain the variability in the number of reviews carried out across CCGs. 
 
In contrast the ELECTRA study,410 an RCT of a specialist nurse intervention for high-risk 
asthma patients in Tower Hamlets and Newham consisted of review of at-risk asthma 
patients in a specialist nurse-led clinic. This included educational outreach and promotion of 
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asthma guidelines to primary care clinicians. In contrast to the challenge of reviewing 
patients following the SABA alert in Phase 2 and 3 of the thesis, patients in the ELECTRA 
study410 were reviewed immediately by a specialist nurse after at-risk status was identified, 
resulting in delayed presentation for unscheduled care and a reduction in exacerbations. In 
Phase 1, Zeiger et al.,314 a multicomponent intervention including an alert that presented to 
clinicians outside of workflow reduced excessive SABA prescribing, despite only 30% of the 
intervention patients availing of an allergy review. The delivery of a multicomponent 
intervention in both Zeiger et al.314 in a managed health care organisation and the ELECTRA 
study in the NHS410 was facilitated by increased resource availability beyond that of routine 
NHS primary care. Furthermore the qualitative findings in Phase 3 identified a desire among 
clinicians to be supported in  both the identification of at risk patients and management of 
asthma across primary care. This suggests that a combination of approaches targeting 
clinicians, primary care staff and patients may have greater potential to reduce SABA 







Phase 3 Theme 2 Identifying excessive SABA use highlighted the varying role of receptionists 
in the repeat prescribing process in the practices in Tower Hamlet. As highlighted in Theme 
4 Interprofessional practice, there was variable expectation and contrasting opinion among 
clinical staff that receptionists could and should raise SABA prescribing concerns with GPs. 
Furthermore, receptionists were not observed engaging with the QOF box where the SABA 
alert is positioned, instead associating the QOF box with clinical issues beyond the scope of 
their role. Therefore it remains unclear how the SABA alert that is not positioned within 
repeat prescribing workflow influenced SABA prescribing. It may be that other staff such as 
receptionists responded to the SABA alert when managing repeat prescriptions rather than 
clinicians at point of repeat prescribing. As described in Chapter 1, receptionists contribute 
to the quality and safety of repeat prescribing and often have increased ownership of ‘clinical’ 
issues presenting within the QOF box. This may result in receptionists having an increased 
awareness of and engagement with the SABA alert, passing on concerns to prescribers rather 
than the alert influencing behaviour at the point of prescribing. As repeat prescribing is often 
adapted to local contexts and the receptionists role is likely to vary with differences in 




As described in Chapter 1, the introduction of EPS intended to streamline the process by 
which GPs received, authorised and communicated repeat prescriptions may have reduced 
informal role of receptionists in highlighting prescribing concerns to improve the safety of 
repeat prescribing. However, the uptake of EPS was variable and repeat prescription requests 
by paper remained. In both Theme 2 and Theme 3 clinicians described an intermittently 
assessing repeat prescriptions prior to authorisation, with varied engagement with the QOF 
box at this point. It may be that uptake of EPS varied between practices however this was 
not captured in Phase 2 evaluation of the SABA alert. Furthermore, Chapter 1 highlights the 
increasing role of clinical pharmacists in the identification and management of repeat 
prescribing in primary care with clinical pharmacists delegated responsibilities for the 
management of repeat prescribing. However, it is not clear to what extent clinical 
pharmacists were employed in general practices across CCGs. In a recent analysis on health 
care improvement, Braithwaite et al.366 argue that changing behaviours in health care 
requires consideration of local contexts including the repeat prescription process and how 
and by whom asthma reviews are followed by and delivered. National distribution of the 
SABA alert in EMIS practices fails to consider the influence of local contexts on SABA alert 
use. As the qualitative study in Phase 3 of the thesis involved limited research in three primary 
care practices in Tower Hamlets and did not include practices in Newham where the effects 
of the greatest effects SABA alert were observed, it was not possible to determine the 








● Clarity and consistency 
 
 
Urgent action is required to change attitudes and perceptions towards problematic SABA use 
among those involved in the delivery of asthma care at all levels. This should involve three 
areas: clarity of the evidence on how much SABA is too much, support for the application of 
evidence into practice, and uniformity in the language used to frame the problem in practice. 
This should include one UK national asthma guideline to provide clear and consistent advice 
to clinicians in the primary care management of asthma and the identification of at-risk 
patients. A combined effort of both top-down and bottom-up approaches is required to 
change perceptions around SABAs. This should be supported by a national strategy for 
respiratory disease in England that prioritises asthma care. Findings of this thesis support 
bottom-up approaches such as the recent IPCRG Asthma Right Care Slide Rule pilot 
initiative,65 described in Chapter 1, that seek to increase awareness, challenge attitudes and 
educate both primary care staff and patients on guideline-based evidence of excessive SABA 
use and the associated risks. Clearer and consistent use of language and messaging is required 
to appropriately distinguish between chronic ongoing excessive SABA use as a marker for 
poor asthma control and a risk factor for adverse outcomes in contrast to excessive SABA use 
in the management of acute asthma attacks. Failure to do so raises the risk that both health 
care professionals and patients fail to identify poor asthma control, whilst creating a 
reluctance to use salbutamol in appropriate situations.  
 
 
● Distinction between alerts and reminders 
 
 
Findings of this thesis recommend a differentiation between alerts and reminders in practice. 
When determining whether to implement an alert or reminder, consideration should be 
given to the intended target, point of presentation, time of present, level of engagement and 
action required. An alert should be reserved for clinical concerns that require HCP 
engagement, presenting centrally on screen, aligned to workflow at point of decision-making 




In contrast, reminders/pop ups/flags should be reserved for non-urgent concerns that may 
be addressed by HCPs and non-clinical staff, which do not require alignment with workflow 
or decision-making and for which engagement and action is optional. Distinctions are needed 
in the design of CDSSs to promote consistency in practice to reduce alert fatigue and promote 




● Alerting to at-risk patients 
 
 
An alert to identify potentially at risk patients should utilise additional markers of risk rather 
than SABA use alone. In the absence of linked EHRs to capture secondary care asthma related 
data, prescribing data should be used to identify ICS underuse and excessive SABA use. 
Additional risk factors such as asthma-related hospitalisations and AED attendance data 
should be captured in primary care systems for a targeted approach to the identification of 
at-risk patients. 
 
● Alert design and presentation 
 
 
Findings of this thesis recommend the optimisation of the design and presentation of an alert 
to identify patients with poor asthma control who may be potentially at-risk. As SABAs remain 
the most commonly prescribed inhaler for asthma issued on repeat prescription, alerts 
should be aligned with clinician’s repeat prescribing workflow. Rather than presenting within 
the QOF box, an alert should contain the three features as recommended by Phansalkar et 
al.,144 including a signal word to determine the purpose of the alert, a description of the risks 
of underuse of ICS and excessive use of SABAs and an explanation of consequences of the 





An alert should go beyond information instead facilitating action for review following alert 
presentation. Without action, the alert merely serves as a reminder. As the majority of SABAs 
are issued by repeat prescription, an alert should facilitate action at this point. Following the 
challenge of timely review of patients in general practice identified in Phase’s 2 and 3 of this 
thesis, an alert should facilitate a structured review that is not restricted to general practice. 
The role of community pharmacists in the structured delivery of asthma review, for example 
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using the SIMPLES394 approach, as part of a multicomponent intervention, should be 




● Multicomponent alert intervention 
 
 
Findings suggest that success of an alert to reduce excessive SABA prescribing is dependent 
timely review of patients. As Phase 3 identified apprehension among GPs and pharmacists to 
withhold SABAs, an alert should enable the prescriber to generate a pharmacist-delivered 
asthma review upon the patient’s SABA collection at pharmacy. In response to Phase 3 
Theme 4 findings, the ownership of an alert should be a GP responsibility with GPs 
communicating the need for review to the receptionist, the pharmacist and the patient in 
real-time response to the alert (figure 6.1). Such action addresses both the challenge of 
patient follow-up in general practice whilst addressing the current underutilisation and lack 
of guidance for community pharmacists in the management of excessive SABA use. This also 
offers an alternative to the current signposting of patients from pharmacy back to general 
practice for review. 
 
Following alert presentation at point of repeat prescribing, an electronic message may be 
sent to pharmacy using the “message to dispenser” field on the left hand side of EPS. This 
can provide patient specific information for the attention of the pharmacist. This should be 
documented on the patient’s EHR so the receptionist is aware in the event of patient queries. 
This information should also be relayed to the patient so they are informed that an asthma 
review is required in pharmacy prior to SABA being obtained. If poor asthma control is 
identified following pharmacist’s review, an urgent review should be scheduled with a GP. 
The potential for such an intervention should be further explored with community and CCG 
















● Adapation at local level 
 
 
Implementation of a multicomponent alert should be tailored to the local area in which it is 
applied rather than a one-size-fits-all approach at national level. Primary care is increasingly 
influenced by local cultures, relationships and management that may vary by practices 
and/or CCG. The implementation of an intervention will require support at all levels. 
Therefore it is recommended that to increase acceptability, primary care staff should be 
central in the planning phase to identify and address potential challenges to delivery, to 
clarify staff roles and responsibilities and to strengthen channels of communication between 
primary care staff and patients. This thesis has highlighted the need for continuity of care in 
prescribing and asthma management. At local level there remains potential to enhance 
asthma management through multidisciplinary working across primary care, in particular 




● Standardised coding and reporting 
 
 
Homogeneity in the defining and reporting of asthma outcomes within EHR studies is 
required. As identified in Phase 1, this includes standardisation in asthma outcomes including 
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how outcomes are defined and captured in EHR based evaluations. Variations make the 
design, implementation and evaluations of EHR interventions challenging due to the lack 
of comparability between studies. This further supports recommendations by Al Sallakh et 
al.,330 for improvements in the capturing and coding of asthma-related data at the point of 
care and reporting clarity among studies using EHRs using the RECORD Statement. 
 
 




● Optimising alert specificity 
 
 
(i) Defining ICS/SABA parameters 
 
 
The relationship between patient demographics and varying SABA and ICS parameters 
associated with AED visits and hospitalisation data will be explored within the same dataset 








In primary care data sets the use of ICS and combination inhaler data is commonly captured 
by inhaler count data despite variations in strength and potency. As acknowledged in Phase 
2 of the thesis, it was not possible to include an analysis of ICS and combination inhaler 
prescribing data due to the challenges of calculating BDP equivalent prescribing in routine 
primary care data.  
 
In response to the problem identified, data mining algorithms were developed in the course 
of this thesis to aide the translation of ICS prescribing to BDP equivalent dosing. The rationale 
was to standardise prescribing data within the EHR, to provide a targeted approach to the 
identification of problematic prescribing care and potentially at-risk patients in primary care. 
 
Matching algorithms that can detect the name of the ICS or collective ICS medication, the 
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individual dose of the ICS and collective therapy and the number of times the dose is 
prescribed daily were developed. The algorithm translates ICS to BDP equivalent dose using 
R language software and guidance on steroid dosage from NICE.108 Although dosages are not 
strict equivalences they may be used as a guide to similar clinical effectiveness (see figure 6.1 
for algorithm pipeline).  
 
Over 65 algorithmic rules were created in order to convert raw routine steroid prescribing data 
into BDP equivalent from primary care data. These rules can be used to create three new 
variables and return these in an excel format that can be used for further analysis (see table 
6.1).  The predictive sensitivity and specificity for the algorithms requires further testing. 
Further research is required to determine how the calculation of BDP equivalent corticosteroid 
prescribing to SABA prescribing impacts on the identification and management at-risk patient 
patients in primary care.  
 
 
Table 6. 1 Output variables from inhaled steroid data mining algorithm  
 
Steroid Name Dose  BDP equivalent 
Beclometasone 200mcg 2 puffs twice daily 800 
Fluticasone 125mcg  2 puffs twice daily 1000 
Beclometasone + formoterol 100/6mcg 2 puffs twice daily 1000 











Steroid Name and Dosage Steroid dose delivered 
Medication type 
Steroid dose per puff Number of puffs Times per day 
(ICS or combination) 
Medication name 




(iii) Determining optimal workflow presentation 
 
 
Whilst the ideal alert should demonstrate the following characteristics: provision of the right 
(correct) information, to the right person, in the right format, through the right channel, and 
at the right time,114 the correct workflow must first be defined. As the majority of SABAs are 
issued on repeat prescription both inside or outside of consultation, the system capabilities 
for alerts presenting within repeat prescribing workflow will explored in collaboration with 
the CEG.  
 
● Feasibility of pharmacist review 
 
 
Following an exploration for the potential of alerts aligned with repeat prescribing workflow, 
the acceptability and feasibility of pharmacists in delivering an asthma review to patients 
identified by a repeat prescribing alert as potentially at risk. The feasibility of both paper and 
electronic repeat prescribing requests will be explored. This will include a review of the 
channels of communication between pharmacy and GPs that could be utilised in the delivery 
of a multicomponent intervention. This will involve a review of EPS use and capabilities as it 
is currently unclear the extent to which EPS supports reverse flow for messages from 
dispensers to prescribers. This work will add to the body of recent evidence assessing the 
increased role of pharmacy in the management of asthma and in particular the delivery of 
asthma reviews. Pharmacist’s training needs will be identified prior to intervention delivery. 
Unlike recent studies, this work will explore the feasibility of a review in response to the real 
time identification of potentially at-risk patients at point of repeat prescribing rather than 
the identification of patients by general practice audit searches or opportunistic 
identification in pharmacy described in Chapter 1 section 1.2.3. Further research is required 
to determine the role of online pharmacies in excessive SABA prescribing including the 
current or potential methods to identify and manage excessive SABA prescribing through 
online platforms. 
 
● Patient input 
 
 
Further research should include interviews and/or focus groups with patients identified by 
excessive SABA prescribing to explore SABA use and asthma management from the patient 
perspective. This will support the design and development of interventions for healthcare 
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professionals to improve asthma prescribing, management and support for people with 
asthma. Exploration of the feasibility and acceptability of patients being alerted to excessive 




6.7 Critical appraisal of the research process 
 
The specific strengths and limitations of the three Phases of the thesis have been discussed 
in Chapter 3 (Phase 1), Chapter 4 (Phase 2) and Chapter 5 (Phase 3) respectively with each 
phase contributing to the literature on the use of an alert for excessive SABA prescribing in 
primary care. A mixed methods study design enhanced this thesis through three Phases that 
complement and converge. Firstly, the qualitative findings of Phase 1 (Chapter 3) and Phase 
3 (Chapter 5) complemented the quantitative findings of Phase 2 (Chapter 4) by providing an 
understanding for the variable impact of a SABA alert across the 3 CCGs included in the study. 
Secondly, both quantitative and qualitative methods converged in this chapter, with 
qualitative data used to corroborate and confirm findings.285 A mixed methods approach 
utilised the views, perceptions and experiences of primary care staff to provide 
understanding for the effect of the SABA alert on primary and secondary outcomes. 
Addressing the research question using mixed methods enhanced the credibility of the 
research process to strengthen the overall thesis outcome.286 
 
In terms of limitations, it was not possible to determine potential reasons for the variable 
effect of the intervention between practices, as qualitative work was carried out in Tower 
Hamlets only. A sequential mixed methods approach would have been more appropriate 
with qualitative work influenced by quantitative findings, for example, qualitative work in 
both Newham and Tower Hamlets may have explained why SABA prescribing reduced in one 
CCG but not the other. The concurrent mixed methods approach rather than a sequential 
mixed methods approach was applied due to project time constraints. The original proposed 
thesis was to collaborate with EMIS health to develop and pilot an alert for excessive SABA  
prescribing. However EMIS implemented an alert nationally in June 2015 prior to 
collaboration and the thesis plan evolved to an evaluation project facilitated by CEG. To 
adequately capture 12 months intervention and follow-up data, Phase 2 data could only be 
extracted towards the latter part of the final year of the project. Furthermore, the alert 
implemented by EMIS was not coded for evaluation therefore a number of meetings over 
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2016-2017 were required to ensure robust methods and extraction of data were applied to 
meet the study aims and in a suitable format for statistical analysis. 
 
Findings are neither comprehensive nor irrefutable evidence of the structures and processes 
for SABA prescribing/repeat prescribing in primary care given the limited variety in the 
numbers of primary care staff included. Pharmacists were recruited by affiliation with 
practices. However, the involvement of primary care staff was restricted despite initial access 
gained. For example, access was gained in practice 3 and 4 (Figure 5.1 Participant recruitment 
flow chart) for interviews but not reception staff. Furthermore, access to the one community 
pharmacist was gained through strong relationships with Practice 1 however this was not 
reflected in the additional 3 practices. Some of the issues raised by primary care staff included 
conjectures about the roles of other staff in the prescribing process. Such issues can only be 
sufficiently addressed by involving these staff members directly, which may not have been 
sufficiently captured in this thesis, in particular the role of pharmacists. Flexibility and 
adaptability was required in data collection to accommodate GPs. This resulted in a 
discussion with clinicians within a clinical lunchtime meeting due to time constraints in 
practice. Challenges in primary care recruitment experienced in this study reiterate Riis et 
al’s.,287 process evaluation of the recruitment process in primary care that calls for a more 
systematic approach to support the recruitment of healthcare professionals in research. The 
study included only primary care staff and not patients as PPI members are not research 
participants but advisors. To deliver the project within time frame, people with asthma were 
not included as active research participants however patients should be incorporated into 
subsequent research to optimise and enhance the credibility of a future intervention.  
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6.8     Reflexive practice 
 
This section provides a reflexive account detailing the lead researcher’s professional and 
personal background and experience of the research process. As described in Chapter 2, it is 
recommended that researchers acknowledge and embrace the ‘subjectivity’ that may 
influence the research process including] personal and professional backgrounds.288 
 
The researcher is a registered nurse held two clinical nursing positions during the research 
process: as a specialist respiratory and allergy nurse in a tertiary care centre and as an asthma 
nurse specialist at Asthma UK. The lead researcher had neither professional experience of 
primary care nor experience with EHR records including electronic alerts but was familiar 
with concerns in both practice and the literature regarding excessive SABA use. The lead 
researcher’s role was explicit at all points of the data collection process. In the literature, the 
influence of researcher identity on the research process, in particular health research is 
commonly undertaken by clinically trained researcher interviewing health care professional 
peers.411 A shared identity may increase the openness of HCPs being interviewed, however 
there is potential for responses to be researcher-led rather than being participant driven. 
There is a possibility that responses of clinically trained participants may not have been fully 
expressed assuming the lead researcher had ‘insider’ knowledge of the topic being 
researched, and due to apprehension of having one’s practice judged. Furthermore, the 
researcher not having a primary care background may have resulted in interview probing and 
missed opportunities in direction of questioning due to a lack of understanding of primary 
care roles and organisational structures. However in contrast given the researcher had no 




6.9 Overall conclusion 
 
  
Four years after NRAD recommendations, findings of this thesis indicate a continued 
complacency and uncertainty among healthcare professionals in regards to excessive SABA 
use. Despite promising reductions in excessive SABA prescribing, an alert focusing solely on 
clinician’s prescribing behaviour fails to address how decisions to prescribe SABAs are 
influenced in practice and the complexity of asthma management in primary care. Strong 
leadership is required to promote consistent application of the evidence base for SABA use 
and to challenge the ways in which health care professionals think about asthma. Clear and 
consistent guidance on excessive SABA use is required, with further research needed on how 
this can be translated into practice. This thesis provides a base for alert optimisation to meet 
the needs of primary care and the challenges of asthma management. This should involve an 
intervention that supports both the identification and follow-up of potentially at-risk patients 
that is not limited to SABA prescribing. This will require a collaborative effort involving people 
with asthma and wider primary care to help identify those with poor asthma control who are 
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Appendix 3. 1 Detailed intervention characteristics 
 
 
Features of CDSSs McCowan Eccles Zeiger Tamblyn 
Context 
Clinical setting Primary Care (NHS) Primary care (NHS) Primary Care (Kaiser Permanente 
Managed Care Organisation) 
Primary Care 
(Insured Health care system) 
Clinical task Asthma management Asthma management SABA use Asthma management 
Unit of optimization Process and patient outcomes Process and patient outcomes Process and patient outcomes Process and patient outcomes 
Relation to point of care In-consultation In-consultation Non-specific In-consultation 
External behavior 
modification programs 
Not reported Not reported Not reported Not reported 
Potential barriers Double data entry required Method of intervention trigger None identified Non-asthma specific 
consultation 
Knowledge and data source 
Clinical knowledge 
source 
British Asthma Guidelines Study developed guidelines National Asthma Education & Prevention 
Programme/Global Initiative 
for Asthma 
Canadian consensus guidelines 
Data source Manually entered Electronic health record Research data warehouse Electronic health record 
Data coding Not reported Not reported Not reported Not reported 
Degree of 
customisation 
Generic Generic Personalised Personalised 







Decision Support McCowan Eccles Zeiger Tamblyn 
Type of system Asthma Crystal Byte 
Computer decision support 
based on asthma guidelines, 
clinical scenarios and 
reminders. 
Computer decision support 
system (CDSS) 
Asthma management and 
prescribing suggestions based 
on guidelines, clinical scenarios 
and health record 
information 
Real-time outreach 
Real-time identification, notification, 
and facilitated allergy specialist referral 
for excessive SABA users. 
Asthma Decision Support (ADS) 
A dashboard alert, decision 
support for evidence-based 
asthma management and 
asthma home care and 
monitoring programme. 
Reasoning method Not reported Not reported Not reported Not reported 
Alert activation Specific presentation 
complaints or features 
would trigger a series 
of prompts based on a 
previously determined 
protocol, which would have 




suggestions were triggered 
when an asthma morbidity 
code was entered. 
An electronic message within the 
electronic medical record system was 
sent to a patient’s primary care 
provider, once-only, when a patient with 
excessive SABA use was identified. 
Alert automatically activates 
upon opening the medical record 
of a patient with out-of- control 
asthma. Out-of-control asthma 
defined as having had an ER visit 
or a hospitalisation for 
respiratory-related problems in 
the past 3 months and/or the 
excess use (>250 doses 
dispensed) of fast-acting b- 
agonist (FABA) in the past 3 
months. 
Clinical urgency Not reported Not reported Not reported Not reported 
Recommendation 
explictness 
Explicit Explicit Explicit Explicit 
Logistical complexity Simple Simple Simple Simple 







Information delivery McCowan Eccles Zeiger Tamblyn 
Delivery format Electronic Electronic Electronic Electronic 
Delivery mode Voluntary Voluntary Voluntary Voluntary 
Integration No-the programme was 
delivered on a 3 ½ inch floppy 
disk to be installed on 
participants Microsoft 
Windows compatible 
computer desktop to be used 
for asthma consultations. 
No-the CDSS was a programme 
accessible from within the 
main computerised operating 
system of the two suppliers. 
The guideline was a separate 
pathway within the 
clinical system. 
Yes-the asthma out-reach used the 
standard Kaiser Permanente Southern 
California (KPSC) electronic medical 
record system and electronic registry 
that allows physicians access to 
dispensing data and hospital data in a 
managed care organisation (MCO). 
Yes-the ADS can be accessed 
from a tab in the electronic 
health record for intervention 
physicians or from the 
dashboard alert, when it 
appears. 
Explanation availability The research team constructed 
non-judgemental feedback and 
management suggestions 
based on British Asthma 
Guidelines but it is not clear if 
the rationale 
behindrecommendations was 
presented to physicians. 
It was unclear whether 
clinicians were informed of 
the guideline evidence when 
recommendations were 
presented or whether the 
recommendations prompted 
the clinician to access the 
separate pathway for the 
guideline. 
Physicians- ‘Kaiser Permanente and 
other groups have documented this 
amount of albuterol is a sign of 
uncontrolled asthma…’ 
Patients- ‘Kaiser Permanente and other 
groups have shown that care by 
allergists helps to improve asthma 
control’; ‘too much use of [reliever] may 
indicate your asthma control could be 
better.’ 
Dashboard alert: ‘since the last 
time you accessed the record, 
new information is available.’ 
Decision support for evidence- 
based asthma management: 
provides physicians with access 
to Canadian asthma guidelines, 
including translation into 
assessment tools and 
recommendations. 
Provision of a 
recommendation not 
just an assessment 
Prompts included e.g. ‘check 
inhaler technique,’ ‘review 
compliance,’ ‘consider 
increasing dose of preventer 
inhaler.’ 
The system offered 
suggestions for management 
including prescribing. 
Included recommendations for 
treatment e.g. commence preventer 










Information delivery McCowan Eccles Zeiger Tamblyn 
Recommendations 
executed by noting 
agreement i.e. click ‘OK’ 
Not reported Not reported Not applicable Dashboard alert- ‘Click here to 
enrol your patient in the 
Asthma Assist Program 
immediately’; ‘update 
suggested treatment’; ‘proceed 
with changes.’ 
Decision support- patient 
specific recommendations 
generated and once selected, 
prescriptions and action plans 
where automatically generated. 
Request documentation 
of reasons if CDSS 
recommendations not 
followed 
Not reported Not reported Electronic message was sent to 
physicians informing of the patient’s 
uncontrolled asthma status but did 
provide recommendations for the 
physician to act upon. 
The dashboard alert could be 
exited however no further 
information was reported. 
Interactive delivery Yes Yes Not applicable Yes 
Additional clinical data 
entry not required 
No- the system used data 
entered on a specialised data 
entry screen. 
Yes-the system anticipated 
clinicians’ requirements by 
using the information 
contained within a patient’s 
computerised record. 
Yes-patients were identified using 
computer algorithm data collected in 
the KPSC research data warehouse. No 
clinician input was necessary. 
Yes-patient’s asthma control 
was determined dynamically, 
based on a daily retrieval of 
newly dispensed prescriptions 
and physician visit information 
from the provincial health 
insurance databases at the 








Workflow McCowan Eccles Zeiger Tamblyn 
System user General practitioner Doctor or nurse Physician Physician 
Target decision maker General practitioner Doctor or nurse Physician and patient Physician 
Data input intermediary General practitioner Doctor or nurse Not required Not required 
Output intermediary Not required Not required Not required Not required 
Workflow integration Intervention software ran 
alongside practice software 
To access guidelines the 
clinical system had to be 
exited 
Generated within KPSC electronic 
medical record system 
Integrated with clinician 
workflow 
Auxiliary features     
Local user involvement 
in development process 
The Asthma Crystal Byte 
software was designed and 
developed by a project team, 
reviewed over an 18 month 
period by a steering group; 
‘The General Practitioners in 
Asthma Group.’ 
Not reported Not reported Not reported 
Provision of decision 
support to patients as 
well as providers 
Customised self-management 
plans and patient advice 
sheets 
Not reported Physicians were contacted by electronic 
message and patients by letter 
Asthma action plans were 
automatically generated when 
recommendation accepted 
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9S and 9i 
Read Codes 









British or mixed British 
 
9i0 
1. British or Mixed 
British 
 









1. British or Mixed 
British 
 






Ethnic White British 
 
9i0 
1. British or Mixed 
British 
 






Ethnic White British Other 
 
9i0 
1. British or Mixed 
British 
 






Bangladeshi or British Bangladeshi 
 
9i9 
10. Bangladeshi or 
British Bangladeshi 










10. Bangladeshi or 
British Bangladeshi 




9iA Other Asian 9iA 11. Other Asian Other Asian South Asian 
9iA1 Other Asian Punjabi 9iA1 11. Other Asian Other Asian South Asian 
9iA2 Other Asian Kashmiri 9iA2 11. Other Asian Other Asian South Asian 
9iA3 Other Asian East African Asian 9iA3 11. Other Asian Other Asian South Asian 
9iA4 Other Asian Sri Lankan 9iA4 11. Other Asian Other Asian South Asian 
9iA5 Other Asian Tamil 9iA5 11. Other Asian Other Asian South Asian 
9iA6 Other Asian Sinhalese 9iA6 11. Other Asian Other Asian South Asian 
9iA7 Other Asian Caribbean 9iA7 11. Other Asian Other Asian South Asian 







9iA9 Other mixed Asian 9iA9 11. Other Asian Other Asian South Asian 
9iAA Other Asian or Asian unspecified 9iAA 11. Other Asian Other Asian South Asian 
 
9SA6 










9S and 9i 
Read Codes 




NS 16+1 text Final coding 
categories 
9SA7 Other Ethnic Indian sub-continent 9iA 11. Other Asian Other Asian South Asian 
9SA8 Other Ethnic Other Asian 9iA 11. Other Asian Other Asian South Asian 
9SH Other Ethnic Asian 9iA 11. Other Asian Other Asian South Asian 
9iB Caribbean 9iB 12. Caribbean Caribbean Black 
9S2 Ethnic Black Caribbean 9iB 12. Caribbean Caribbean Black 
9iC African 9iC 13. African African Black 
9S3 Ethnic Black African 9iC 13. African African Black 
9S44 Black other African country 9iC 13. African African Black 
9SA5 Other Ethnic African 9iC 13. African African Black 
9iD Other Black 9iD 14. Other Black Other Black Black 
9iD0 Somali 9iD0 14. Other Black Other Black Black 
9iD1 Nigerian 9iD1 14. Other Black Other Black Black 
9iD2 Black British 9iD2 14. Other Black Other Black Black 
9iD3 Black mixed 9iD3 14. Other Black Other Black Black 
9iD4 Black other 9iD4 14. Other Black Other Black Black 
9S4 Black other non-mixed 9iD 14. Other Black Other Black Black 
9S41 Black British 9iD2 14. Other Black Other Black Black 
9S42 Black Caribbean / W.I. / Guyana 9iD 14. Other Black Other Black Black 







9S45 Black E African / Indo-Caribb 9iD 14. Other Black Other Black Black 
9S46 Black Indian sub-continent 9iD 14. Other Black Other Black Black 
9S47 Black other Asian 9iD 14. Other Black Other Black Black 
9S48 Black other 9iD 14. Other Black Other Black Black 
9S5 Black other mixed 9iD 14. Other Black Other Black Black 
 
9SA3 










9SG Other Ethnic Black 9iD 14. Other Black Other Black Black 
9iE Chinese 9iE 15. Chinese Chinese Other 
9S9 Chinese 9iE 15. Chinese Chinese Other 
9iF Other 9iF 16. Other Other Other 
9iF0 Other Vietnamese 9iF0 16. Other Other Other 
9iF1 Other Japanese 9iF1 16. Other Other Other 
9iF2 Other Filipino 9iF2 16. Other Other Other 
9iF3 Other Malaysian 9iF3 16. Other Other Other 
9iF4 Other Buddhist 9iF4 16. Other Other Other 
9iF5 Other Hindu 9iF5 16. Other Other Other 
9iF6 Other Jewish 9iF6 16. Other Other Other 
9iF7 Other Muslim 9iF7 16. Other Other Other 
9iF8 Other Sikh 9iF8 16. Other Other Other 
9iF9 Other Arab 9iF9 16. Other Other Other 
9iFA Other North African 9iFA 16. Other Other Other 
 
9iFB 
Other Mid Eastern (excl. Isreali, 









9iFC Other Isreali 9iFC 16. Other Other Other 







9iFE Other Kurdish 9iFE 16. Other Other Other 
9iFF Other Moroccan 9iFF 16. Other Other Other 
9iFG Other Latin American 9iFG 16. Other Other Other 
9iFH Other South & Central American 9iFH 16. Other Other Other 
 
9iFJ 
Other Mauritian / Seychellois / 









9iFK Other unspecified 9iFK 16. Other Other Other 
9SA Other Ethnic non-mixed 9iF 16. Other Other Other 
9SA1 Other Ethnic British Specific Minor. 9iF 16. Other Other Other 
9SA2 Other Ethnic British Unspecific Minor. 9iF 16. Other Other Other 
9S and 9i 
Read Codes 




NS 16+1 text Final coding 
categories 
9SA4 Other Ethnic N African Arab / Iranian 9iFA 16. Other Other Other 
9SAA Other Ethnic Greek / Greek Cypriot 9iF 16. Other Other Other 
9SAB Other Ethnic Turkish / Turkish Cypriot 9iF 16. Other Other Other 
9SAC Other Ethnic European 9iF 16. Other Other Other 
9SAD Other Ethnic EEC 9iF 16. Other Other Other 
9SC Vietnamese 9iF0 16. Other Other Other 
9SJ Other Ethnic 9iF 16. Other Other Other 
9iG Not stated 9iG 17. Not Stated Not Stated Not Stated 
9SD Patient refused 9iG 17. Not Stated Not Stated Not Stated 
9SE Not Recorded 9iG 17. Not Stated Not Stated Not Stated 
9SZ Ethnic groups NOS 9iG 17. Not Stated Not Stated Not Stated 
9i1 Irish 9i1 2. Irish Irish White 
9S11 Ethnic White Irish 9i1 2. Irish Irish White 







9i2 Other White 9i2 3. Other White Other White White 
9i20 White English 9i20 3. Other White Other White White 
9i21 White Scottish 9i21 3. Other White Other White White 
9i22 White Welsh 9i22 3. Other White Other White White 
9i23 White Cornish 9i23 3. Other White Other White White 
9i24 White Northern Irish 9i24 3. Other White Other White White 
9i26 White Cypriot 9i26 3. Other White Other White White 
9i27 White Greek 9i27 3. Other White Other White White 
9i28 White Greek Cypriot 9i28 3. Other White Other White White 
9i29 White Turkish 9i29 3. Other White Other White White 
9i2A White Turkish Cypriot 9i2A 3. Other White Other White White 
9S and 9i 
Read Codes 




NS 16+1 text Final coding 
categories 
9i2B White Italian 9i2B 3. Other White Other White White 
9i2C White Irish Traveller 9i2C 3. Other White Other White White 
9i2D White Traveller 9i2D 3. Other White Other White White 
9i2E White Gypsy Romany 9i2E 3. Other White Other White White 
9i2F White Polish 9i2F 3. Other White Other White White 
9i2G White Estonian 9i2G 3. Other White Other White White 
9i2H White Russian 9i2H 3. Other White Other White White 
9i2J White Kosovan 9i2J 3. Other White Other White White 
9i2K White Albanian 9i2K 3. Other White Other White White 
9i2L White Bosnian 9i2L 3. Other White Other White White 
9i2M White Croatian 9i2M 3. Other White Other White White 







9i2P White Former Yugoslavia 9i2P 3. Other White Other White White 
9i2Q White Mixed Irish & Other 9i2Q 3. Other White Other White White 
9i2R White Other European 9i2R 3. Other White Other White White 
9i2S White Mixed 9i2S 3. Other White Other White White 
9i2T White Unspecified 9i2T 3. Other White Other White White 
9S12 Ethnic White Other 9i2 3. Other White Other White White 




White and Black Caribbean 
 
9i3 
4. White + Black 
Caribbean 
 






Other Ethnic Black Caribbean & White 
 
9i3 
4. White + Black 
Caribbean 
 






White and Black African 
 
9i4 
5. White + Black 
African 
 






Other Ethnic African & White 
 
9i4 
5. White + Black 
African 
 
White + Black African 
 
Black 
9S and 9i 
Read Codes 




NS 16+1 text Final coding 
categories 
9i5 White and Asian 9i5 6. White + Asian White + Asian South Asian 
9SB2 Other Ethnic Asian and White 9i5 6. White + Asian White + Asian South Asian 
9i6 Other mixed 9i6 7. Other Mixed Other Mixed Other 
9i60 Other mixed Black and Asian 9i60 7. Other Mixed Other Mixed Other 
9i61 Other mixed Black and Chinese 9i61 7. Other Mixed Other Mixed Other 
9i62 Other mixed Black and White 9i62 7. Other Mixed Other Mixed Other 
      
9i63 Other mixed White and Chinese 9i63 7. Other Mixed Other Mixed Other 







9i65 Other mixed or mixed unspecified 9i65 7. Other Mixed Other Mixed Other 
9S51 Black other Black and White 9i62 7. Other Mixed Other Mixed Other 
9S52 Black other Black and Asian 9i6 7. Other Mixed Other Mixed Other 
9SB Other Ethnic mixed 9i6 7. Other Mixed Other Mixed Other 
9SB1 Other Ethnic Black and White 9i62 7. Other Mixed Other Mixed Other 
9SB3 Other Ethnic mixed White 9i6 7. Other Mixed Other Mixed Other 




Indian or British Indian 
 
9i7 
8. Indian or British 
Indian 
 









8. Indian or British 
Indian 
 






Pakistani or British Pakistani 
 
9i8 
9. Pakistani or British 
Pakistani 










9. Pakistani or British 
Pakistani 




9i Incomplete 9i Unclassified Unclassified Not Stated 
9S Others Others Unclassified Unclassified Not Stated 
9i00 White British 9i0 1. British or mixed British or Mixed British White 
9S and 9i 
Read Codes 




NS 16+1 text Final coding 
categories 
9i10 White Irish 9i1 2. Irish Irish White 
9i25 Ulster Scots - ethnic category 2001 census   White 
9S42-1 Black Caribbean    Black 
9S43-1 Black North African    Black 
9S43-2 Black Arab    Black 







9SA4-1 North African Arab (NMO)    Other 
9SAA-1 Greek (NMO)    Other 
9SAA-2 Greek Cypriot (NMO)    Other 
9SAB-1 Turkish (NMO)    Other 
9SAB-2 Turkish Cypriot (NMO)    Other 
9SI Irish traveller    White 
9S42-2 Black West Indian    Black 
9S42-3 Black Guyana    Black 
9SA3-3 Guyana (NMO)    Black 
EMISNQNE35     Not Stated 
PCSDT4523_13274    Not Stated 
SITE1AS1     Not Stated 
SITE1BR1     Not Stated 
SITE1BR2     Not Stated 
9SA4-2 Iranian (NMO)    Other 
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Appendix 4. 2 Inhaled corticosteroids for inclusion 
 
 
Steroid 60 puffs Name, Dosage and Quantity 
Flixotide 100micrograms/dose Accuhaler (GlaxoSmithKline UK Ltd) 
Flixotide 500micrograms/dose Accuhaler (GlaxoSmithKline UK Ltd) 
Flixotide 50micrograms/dose Accuhaler (GlaxoSmithKline UK Ltd) 
Fluticasone 100micrograms/dose dry powder inhaler 
Fluticasone 250micrograms/dose dry powder inhaler 
Fluticasone 500micrograms/dose dry powder inhaler 
Fluticasone Propionate Dry Powder Breath-Actuated Inhaler 500 micrograms 
Fluticasone propionate 100micrograms/dose dry powder inhaler 
Fluticasone propionate 250micrograms/dose dry powder inhaler 
Fluticasone propionate 500micrograms/dose dry powder inhaler 
Steroid 100 puffs Name, Dosage and Quantity 
Beclometasone 200micrograms/dose dry powder inhaler 
Steroid 120 puffs Name, Dosage and Quantity 
Flixotide 250micrograms/dose Evohaler (GlaxoSmithKline UK Ltd) 
Fluticasone 125micrograms/dose inhaler CFC free 
Fluticasone 250micrograms/dose inhaler CFC free 
Fluticasone 50micrograms/dose inhaler CFC free 
Steroid 200 puffs Name, Dosage and Quantity 
Asmabec 100 Clickhaler (Focus Pharmaceuticals Ltd) 
Beclometasone Breath-Actuated Inhaler (Cfc-Free) 100 micrograms/actuation 
Beclometasone Cfc-free inhaler 100 micrograms/actuation~(c66W.) 
Beclometasone 100micrograms/dose breath actuated inhaler CFC free 
Beclometasone 100micrograms/dose inhaler CFC free 
Beclometasone 200micrograms/dose dry powder inhaler 
Beclometasone 50micrograms/dose inhaler CFC free 
Clenil Modulite Cfc-Free Inhaler 100 micrograms/actuation 
314  
Appendix 4.2. Inhaled corticosteroids for inclusion (continued) 
 
 
 Steroid 200 puffs Name, Dosage and Quantity 
Clenil Modulite Cfc-free inhaler 100 micrograms/actuation~(c66d.) 
Clenil Modulite Cfc-Free Inhaler 200 micrograms/actuation 
Clenil Modulite Cfc-Free Inhaler 250 micrograms/actuation 
Clenil Modulite Cfc-Free Inhaler 50 micrograms/actuation 
Clenil Modulite 100micrograms/dose inhaler (Chiesi Ltd) 
Clenil Modulite 200micrograms/dose inhaler (Chiesi Ltd) 
Clenil Modulite 250micrograms/dose inhaler (Chiesi Ltd) 
Clenil Modulite 50micrograms/dose inhaler (Chiesi Ltd) 
Easyhaler Beclometasone 200micrograms/dose dry powder inhaler 
(Orion Pharma (UK) Ltd) 
Qvar 100 Autohaler Cfc-Free Breath-Actuated Inhaler 100 micrograms/dose 
Qvar 100 Autohaler (Teva UK Ltd) 
Qvar 100 inhaler (Teva UK Ltd) 
Qvar 100micrograms/dose Easi-Breathe inhaler (Teva UK Ltd) 
Qvar 50 Autohaler (Teva UK Ltd) 
Qvar 50 inhaler (Teva UK Ltd) 
Qvar 50micrograms/dose Easi-Breathe inhaler (Teva UK Ltd) 
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Appendix 4. 3 Long-acting beta2-agonist inhalers for inclusion 
 
 
 Long–acting beta2-agoinist Name, Dosage and Quantity 
Foradil 12microgram inhalation powder capsules with device (Novartis 
Pharmaceuticals UK Ltd) 
Oxis 6 Turbohaler (AstraZeneca UK Ltd) 
Oxis 12 Turbohaler (AstraZeneca UK Ltd) 
Formoterol Dry Powder Inhaler 12 micrograms/actuation, 60 dose 
Formoterol 6 micrograms/dose dry powder inhaler 
Formoterol 12micrograms/dose dry powder inhaler 
Serevent 50micrograms/dose Accuhaler (GlaxosmithKline UK Ltd) 
Salmeterol 50micrograms/dose dry powder inhaler 
Salmeterol 50 microgram inhalation powder blisters 
Atimos Modulite 
Formoterol 12micrograms/dose inhaler CFC free 
Formoterol Dry Powder Inhaler 12micrograms/actuation, 120 dose 
Formoterol Easyhaler 12micrograms/dose dry powder inhaler (Orion Pharma 
(UK) Ltd) 
Serevent 25micrograms/dose Evohaler (GlaxoSmithKline UK Ltd) 
Serevent 25micrograms/dose inhaler (GlaxoSmithKline UK Ltd) 





Appendix 4. 4 ICS/LABA Combination inhalers for inclusion 
 
Compound 120 puffs Name, Dosage and Quantity 
 
Budesonide 100micrograms/dose / Formoterol 6micrograms/dose dry powder inhaler / 
Budesonide 200micrograms/dose / Formoterol 6micrograms/dose dry powder inhaler 
Budesonide And Formoterol Dry Powder Inhaler 100 micrograms + 6 micrograms/actuation 
Budesonide And Formoterol Dry Powder Inhaler 200 micrograms + 6 micrograms/actuation 
DuoResp Spiromax 160micrograms/dose / 4.5micrograms/dose dry powder inhaler (Teva UK Ltd) 
Fluticasone 125micrograms/dose / Formoterol 5micrograms/dose inhaler CFC free/ 
Fluticasone 125micrograms/dose / Salmeterol 25micrograms/dose inhaler CFC free / 
Fluticasone 250micrograms/dose / Formoterol 10micrograms/dose inhaler CFC free 
Fluticasone 250micrograms/dose / Salmeterol 25micrograms/dose inhaler CFC free/ 
Fluticasone 50micrograms/dose / Formoterol 5micrograms/dose inhaler CFC free / 
Fluticasone 50micrograms/dose / Salmeterol 25micrograms/dose inhaler CFC free / 
Fluticasone And Salmeterol Cfc-Free Inhaler 125 micrograms + 25 micrograms/actuation/ 
Fluticasone And Salmeterol Cfc-Free Inhaler 250 micrograms + 25 micrograms/actuation / 
Fluticasone And Salmeterol Cfc-free inhaler 250 micrograms + 25 micrograms/actuation~(c1Dw.) / 
Fluticasone Propionate And Salmeterol Cfc-Free Inhaler 125 micrograms + 25 micrograms/actuation / 
Fluticasone Propionate And Salmeterol Cfc-Free Inhaler 250 micrograms + 25 micrograms/actuation / 
Fluticasone Propionate And Salmeterol Cfc-Free Inhaler 50 micrograms + 25 micrograms/actuation 
Flutiform 125micrograms/dose / 5micrograms/dose inhaler (Napp Pharmaceuticals Ltd) 
Fostair 100micrograms/dose / 6micrograms/dose inhaler/ Fostair 200micrograms/dose/6micrograms/dose inhaler (Chiesi Ltd) 
Seretide 125 Evohaler (GlaxoSmithKline UK Ltd) / Seretide 250 Evohaler Cfc-Free Inhaler / Seretide 250 Evohaler (GlaxoSmithKline UK Ltd) 
/Seretide 50 Evohaler (GlaxoSmithKline UK Ltd) 






Appendix 4.4. ICS/LABA Combination inhalers for inclusion (continued) 
 
 
Compound 30 puffs Name, Dosage and Quantity 
Relvar Ellipta 92micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 
Compound 60 puffs Name, Dosage and Quantity 
Budesonide 400micrograms/dose / Formoterol 12micrograms/dose dry powder inhaler Fluticasone 
100micrograms/dose / Salmeterol 50micrograms/dose dry powder inhaler Fluticasone 
250micrograms/dose / Salmeterol 50micrograms/dose dry powder inhaler Fluticasone 
500micrograms/dose / Salmeterol 50micrograms/dose dry powder inhaler Fluticasone And 
Salmeterol Dry Powder Inhaler 500 micrograms + 50 micrograms/actuation Fluticasone propionate 
100micrograms/dose / Salmeterol 50micrograms/dose dry powder inhaler Fluticasone propionate 
250micrograms/dose / Salmeterol 50micrograms/dose dry powder inhaler Fluticasone propionate 
500micrograms/dose / Salmeterol 50micrograms/dose dry powder inhaler 
Fluticasone Propionate And Salmeterol Dry Powder Inhaler 500 micrograms + 50 micrograms/actuation 
Seretide 100 Accuhaler (GlaxoSmithKline UK Ltd) /Seretide 250 Accuhaler (GlaxoSmithKline UK Ltd) 
Seretide 500 Accuhaler Dry Powder For Inhalation /Seretide 500 Accuhaler (GlaxoSmithKline UK Ltd) 
Symbicort 400/12 Turbohaler (AstraZeneca UK Ltd) 
318  
Appendix 4. 5 Oral steroids for inclusion 
 
 
 Oral Steroid Name, Dosage and Quantity 
Prednisolone 2.5mg gastro-resistant tablets 
Prednisolone 5mg gastro-resistant tablets 
Prednisolone 25mg tablets 
Prednisolone 1mg tablets 
Prednisolone 2.5mg tablets 
Prednisolone 5mg/5ml oral solution unit dose 
Prednisolone 20mg tablets 
Prednisolone 10mg tablets 
Prednisolone 15mg/5ml oral solution 
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Appendix 4. 8 The Reporting of Observational Studies in Epidemiology (STROBE) and the Reporting of studies Conducted using Observational Routinely 




STROBE items Location in 
manuscript 
where items are 
reported 
RECORD items Location in 
manuscript 
where items are 
reported 
Title and abstract 
 1 (a) Indicate the study’s design 
with a commonly used term in 
the title or the abstract (b) 
Provide in the abstract an 
informative and balanced 
summary of what was done 
and what was found 
 
Chapter 4 
RECORD 1.1: The type of data used 
should be specified in the title or 
abstract. When possible, the name of 
the databases used should be 
included. 
 
RECORD 1.2: If applicable, the 
geographic region and timeframe 
within which the study took place 
should be reported in the title or 
abstract. 
 
RECORD 1.3: If linkage between 
databases was conducted for the 
study, this should be clearly stated in 




Background rationale 2 Explain the scientific 










  the investigation being 
reported 
   
Objectives 3 State specific objectives, 






Study Design 4 Present key elements of 
study design early in the 
paper 
Chapter 2: section 
2.4.2; Chapter 4: 
Section 4.2 
  
Setting 5 Describe the setting, locations, 
and relevant dates, including 
periods of recruitment, 
exposure, 
follow-up, and data collection 
Chapter 4: section 
4.2.1 and 4.2.2 
  
Participants 6 (a) Cohort study - Give the 
eligibility criteria, and the 
sources and methods of 
selection of participants. 
Describe methods of follow- 
up 
Case-control study - Give the 
eligibility criteria, and the 
sources and methods of case 
ascertainment and control 
selection. Give the rationale 
for the choice of cases and 
controls 
Cross-sectional study - Give 
the eligibility criteria, and the 
(a) Chapter 4: 
section 4.2.2 
RECORD 6.1: The methods of study 
population selection (such as codes or 
algorithms used to identify subjects) 
should be listed in detail. If this is not 
possible, an explanation should be 
provided. 
 
RECORD 6.2: Any validation studies of 
the codes or algorithms used to select 
the population should be referenced. If 
validation was conducted for this study 
and not published elsewhere, detailed 
methods and results should be 
provided. 
Section 4.2.1 and 
4.2.2; appendix 







  sources and methods of 
selection of participants 
 
(b) Cohort study - For matched 
studies, give matching criteria 
and number of exposed and 
unexposed Case-control study 
- For matched studies, give 
matching criteria and the 










RECORD 6.3: If the study involved 
linkage of databases, consider use of a 
flow diagram or other graphical display 
to demonstrate the data linkage 
process, including the number of 
individuals with linked data at each 
stage. 
 
Variables 7 Clearly define all outcomes, 
exposures, predictors, 
potential confounders, and 
effect modifiers. Give 
diagnostic criteria, if 
applicable. 
Chapter 4: section 
4.2.3 
RECORD 7.1: A complete list of codes 
and algorithms used to classify 
exposures, outcomes, confounders, 
and effect modifiers should be 
provided. If these cannot be reported, 






8 For each variable of interest, 
give sources of data and 
details of methods of 
assessment (measurement). 
Describe comparability of 
assessment methods if there 
is more than one group 
Chapter 4: section 
4.2.3 and 
appendices 4.1 – 
4.7 
  
Bias 9 Describe any efforts to 
address potential sources of 
bias 
Chapter 2: Section 
2.4.4 
  
Study size 10 Explain how the study size 
was arrived at 









Quantitative variables 11 Explain how quantitative 
variables were handled in the 
analyses. If applicable, 
describe which groupings 
were chosen, and why 
Chapter 4: Section 
4.2.5 
  
Statistical methods 12 (a) Describe all statistical 
methods, including those 
used to control for 
confounding 
(b) Describe any methods 
used to examine subgroups 
and interactions 
(c) Explain how missing data 
were addressed 
(d) Cohort study - If 
applicable, explain how loss 
to follow-up was addressed 
Case-control study - If 
applicable, explain how 
matching of cases and 
controls was addressed 
Cross-sectional study - If 
applicable, describe analytical 
methods taking account of 
sampling strategy 
(e) Describe any sensitivity 
analyses 
Section 4.2.5   
Data access and 
cleaning methods 
 ..  RECORD 12.1: Authors should describe 
the extent to which the investigators 
Chapter 4: 







    had access to the database population 
used to create the study population. 
 
RECORD 12.2: Authors should provide 
information on the data cleaning 
methods used in the study. 
section 4.2.4 
Linkage  ..  RECORD 12.3: State whether the study 
included person-level, institutional- 
level, or other data linkage across two 
or more databases. The methods of 
linkage and methods of linkage quality 
evaluation should be provided. 
N/A 
 Results 
Participants 13 (a) Report the numbers of 
individuals at each stage of 
the study (e.g., numbers 
potentially eligible, examined 
for eligibility, confirmed 
eligible, included in the study, 
completing follow-up, and 
analysed) 
(b) Give reasons for non- 
participation at each stage. 
(c) Consider use of a flow 
diagram 
Chapter 4: section 
4.3.1 
RECORD 13.1: Describe in detail the 
selection of the persons included in 
the study (i.e., study population 
selection) including filtering based on 
data quality, data availability and 
linkage. The selection of included 
persons can be described in the text 




Descriptive data 14 (a) Give characteristics of 
study participants (e.g., 
demographic, clinical, social) 
and information on 









  exposures and potential 
confounders 
(b) Indicate the number of 
participants with missing 
data for each variable of 
interest 
(c) Cohort study - summarise 
follow-up time (e.g., average 
and total amount) 
   
Outcome data 15 Cohort study - Report Chapter 4: Section   
  numbers of outcome events 4.3.1 
  or summary measures over  
  time  
  Case-control study - Report  
  numbers in each exposure  
  category, or summary  
  measures of exposure  
  Cross-sectional study - Report  
  numbers of outcome events  
  or summary measures  
Main results 16 (a) Give unadjusted estimates Chapter 4: section   
  and, if applicable, 4.3 and 4.4.1 
  confounder-adjusted  
  estimates and their precision  
  (e.g., 95% confidence  
  interval). Make clear which  
  confounders were adjusted  
  for and why they were  







  (b) Report category 
boundaries when continuous 
variables were categorized 
(c) If relevant, consider 
translating estimates of 
relative risk into absolute risk 
for a meaningful time period 
   
Other analyses 17 Report other analyses 
done—e.g., analyses of 
subgroups and interactions, 
and sensitivity analyses 




Key results 18 Summarise key results with 
reference to study objectives 
Chapter 4: section 
4.4 and 4.5 
  
Limitations 19 Discuss limitations of the 
study, taking into account 
sources of potential bias or 
imprecision. Discuss both 
direction and magnitude of 
any potential bias 
Chapter 4: section 
4.5.2 
RECORD 19.1: Discuss the implications 
of using data that were not created or 
collected to answer the specific 
research question(s). Include discussion 
of misclassification bias, unmeasured 
confounding, missing data, and 
changing eligibility over time, as they 
pertain to the study being 
reported. 
Chapter 4 section 
4.5 
Interpretation 20 Give a cautious overall 
interpretation of results 
considering objectives, 
limitations, multiplicity of 
analyses, results from similar 
studies, and other relevant 









  evidence    
Generalisability 21 Discuss the generalisability 
(external validity) of the 
study results 
Chapter 4 section 
4.5 
  
 Other Information 
Funding 22 Give the source of funding 
and the role of the funders 
for the present study and, if 
applicable, for the original 
study on which the present 
article is based 
   
Accessibility of 
protocol, raw data, 
and programming 
code 
   RECORD 22.1: Authors should provide 
information on how to access any 
supplemental information such as the 
study protocol, raw data, or 
programming code. 
N/A 
*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working 




*Checklist is protected under Creative Commons Attribution licence
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Using too many blue inhalers may mean that asthma is not well controlled and that people may be at 
high risk of an asthma attack and may end up in hospital. To avoid this, when too many blue relievers 
(blue inhalers) are prescribed, an alert may appear in the GP computer to warn that a person needs to 
have an asthma review as they may be at high risk of having an asthma attack. As an alert may impact 
on how many relievers a person may be prescribed it is important to get the patient and public 
perspective on how you feel about this and an alert. Your feedback will help focus the questions for 
primary care staff and may help inform a patient focus group. 
 
Question Response 
What are your thoughts about an alert in GP practices that identifies 
when patients have been prescribed too many blue inhalers? 
 
An alert will be triggered when patients have been using too many blue 
inhalers and are at high risk of an asthma attack. The patient will be 
invited for Asthma Review. Do you think there would be any problems 
with this? If so, please explain. 
 
What do you feel would be the best way to ‘alert’ the patient that they 





How many blue inhalers do you, or the person you care for, use in a 
month? 
 
Has anyone told you or the person you care for that you are using too 
many blue inhalers? If so, what was done about it? 
 
Have you obtained blue reliever inhalers by repeat prescription, either 
for yourself or the person you care for? If so, please tell me what 
process you go through. 
 
 
What suggestions would you have to improve the repeat prescription process? 
Finally, if a focus group was conducted what other questions do you believe would be 




Shauna McKibben - Postgraduate Research Student 
Asthma UK Centre for Applied Research/Queen Mary University London 
334 
Appendix 5. 2 Queen Mary Ethics of Research Committee correspondence 
Queen Mary, University of London Room W117 
Queen’s Building 
Queen Mary University of London Mile End Road 
London E1 4NS 
Queen Mary Ethics of Research Committee 
c/o Professor Chris Griffiths 
Room 1.21 - Centre for Primary Care 
Queen Mary University of London Yvonne 
Carter Building 
Turner Street 
Mile End Road, London 27th September 2017 
To Whom It May Concern: 
Re: QMREC2061a –The use of electronic alerts to identify excessive prescribing of short 
acting beta₂-agonists for people with asthma in primary care: a mixed methods study. 
I can confirm that Shauna McKibben has completed a Research Ethics Questionnaire with regard 
to the above work, and also referred to; and taken advice on, Health Research Authority 
guidance. N.B. This liaison having taken place prior to the commencement of any analyses. 
The result of which was the conclusion that her proposed work does not present any ethical 
concerns; is extremely low risk; and thus does not require the scrutiny of the full Queen Mary 
Research Ethics Committee. 
Yours faithfully 
Ms Hazel Covill – QMERC Administrator Patron: Her Majesty the Queen Incorporated 
by Royal Charter as Queen Mary and Hazel 
Covill Research Ethics Administrator Westfield College, University of London 
Tel: +44 (0) 20 7882 7915
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Please complete this form after you have read the Information Sheet and/or listened to an 
explanation about the research. 
Title of Study: Evaluation of an electronic alert to identify the excessive use of short acting beta2-
agonist (SABA) inhalers in patients with asthma: a qualitative study of the views of primary care 
staff. 
Thank you for agreeing to participate in this research. The person organising the research must 
explain the project to you before you agree to take part. 
If you have any questions please ask the researcher before you decide to take part. 
You will be given a copy of this Consent Form to keep and refer to at any time. 
 
• I consent to the processing of my personal information for the purposes of this 
research study which may include anonymised audio recording and/or handwritten observations 
taken by the researcher. I understand that such information will be treated as strictly confidential 
and handled in accordance with the provisions of the Data Protection Act 1998. 
• I consent to anonymised audio and/or handwritten observations being used as 
part of a doctorate degree (PhD) and may contribute to research papers published in an academic 
journal. 
• I understand that if I decide at any other time during the research that I no 
longer wish to participate in this project, I can notify the researchers involved and be withdrawn 




I  agree that the research project 




I  confirm that I have explained the nature 
and demands of the proposed research to the participant. 
Signed: Date: 
Contact: Shauna McKibben Email: s.m.mckibben@qmul.ac.uk 
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Appendix 5. 4 Interview topic guide 
 
 
Topic guide for interviews 




How would you define excessive SABA use? Excluding pre-exercise use. 
PROMPT: volume and duration, evidence e.g. National Review of Asthma 
Deaths, BTS/GINA guidelines, other research 
How do you identify patients prescribed high numbers of SABA inhalers? 
PROMPT: methods: computerised/manual and context, task: 
consultation/repeat prescribing, workflow 
What happens if high SABA prescribing is identified? PROMPT: type of 
action, challenges to action, who is involved 
Who is involved in identifying and managing high SABA use? PROMPT: the 
role of reception, pharmacy, nurse, patient 
Alerts to 
identify 
high SABA use 
What are your thoughts on an alert to identify patients being prescribed 
excessive SABA? PROMPT: current EMIS medicines management alert 
How do you use this alert? 
PROMPT: In what context, how do you respond 






What are your thoughts on recommendations for electronic surveillance of 
SABA prescribing in primary care practices? PROMPT: National Review of 
Asthma Deaths, current EMIS medicines management alert 
How do you feel this could best be done? 
What do you view as challenges to such a system? How could these 
challenges be overcome? 
Who should such a system involve? 





Appendix 5. 5 Observation guide 
 
 
Observation guide for reception staff 
Categories Issues to consider 
Space: Layout of the physical 
setting when repeat 
prescribing; rooms, space 
What is the general environment in particular the area in which repeat prescribing tasks are carried out? What aspects of the space 
facilitate/hinder monitoring of prescribing? Why? How is the room/area laid out? How does receptionist’s personal space correlate 
with professional space in repeat prescribing tasks? Do people consider the impact of space of relevance to the task of repeat 
prescribing? 
Staff: 
People involved in repeat 
prescribing and interactions 
Who are the different actors? Age, gender, ethnicity, profession? How do they interact with each other? Who speaks to whom and 
for how long? What is the hierarchy? With what other staff do they discuss tasks? Do staff have multiple roles? How do they 
demonstrate what role they are playing at any one time? What behaviours make their role/status apparent? 
Activities: Type of activities 
including but not limited to 
repeat prescribing tasks 
What activities do staff have responsibility for? Who decides what activities they do? Is their behaviour different from what they 
say their activities are? What activities are considered more important than others? Are some activities ‘performed’ more than 
others? Are there visible and invisible activities? What is the gravity of acts in repeat prescribing? E.g. clinical input, decision making, 
assessment, interpretation 
Objects: Computers, 
furniture etc. in repeat 
prescribing 
What objects are involved in repeat prescribing? Are there ‘unofficial’ objects that people use? How do people use them? What 
significance is attached to them? Are all objects understood and used in the same way? What objects help or hinder repeat 
prescribing? 
Time: The sequence of events 
of repeat prescribing 
What is the sequence of events in repeat prescribing tasks? Who decides on sequencing? Is timing considered important? By 
whom? For what reasons? Who controls the timing of events? What happens if a sequence is interrupted? 
Goals: What are staff 
attempting to accomplish 
when managing SABA repeat 
prescriptions 
What are explicit and implicit goals? Personal and group goals? How are goals decided upon? What is the work people do to achieve 
goals? How do goals change over time? What happens if goals aren’t achieved? What is considered success? How is success 
celebrated? 
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The following is an illustrative example of the use of the Framework Method used in Chapter 5 “A 
qualitative study on the use of electronic alerts to identify excessive prescribing of short acting beta2-
agonist (SABA) inhalers in people with asthma: the views of asthma experts and primary care staff.” 
 
 
In this study, we used semi-structured interviews and observations to collect data from 32 participants 
including clinicians (GPs and asthma experts) nurses, pha rmacists, reception staff. Using the 
Framework Method themes were developed inductively from the experiences and views of 
interviewees. This working example demonstrates how the Framework method was used to critically 
explore participant responses, identify deviant cases and interpret themes. The following is an example 
to illustrate how the Framework method was applied during this study. 
 
 
Section 1: Transcription 
 
Of the 25 audio recorded interviews 15 were transcribed by the researcher and 10 were transcribed by 
a by a transcription specialist from Penguin Transcription services, as recommended by Queen Mary 
University of London. The researcher validated transcripts by comparing the completed transcript 
against the audio recordings. Each interview was numbered and line numbers were added to the typed 
transcripts. Any initial notes made during observations were written-up into detailed field notes by 




Section 2: Familiarisation with the interview 
 
The researcher thoroughly read and re-read each transcript, and listened back to the audio- recorded 
interviews to become familiar with the whole data set. Initial impressions were documented for 
example where participants expressed exceptionally strong or contrasting views. One such example 
was a pharmacist who believed it was not their responsibility to refuse to dispense salbutamol inhalers 
that were prescribed by the GP. Yet it was suggested by 
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a number of asthma experts that pharmacists had a responsibility to do so. Familiarisation through 
reading and making notes in this way also enabled us to find our way easily around hundreds of pages 
of transcript later in the analysis. 
 
 
Section 3: Coding 
 
Coding was carried out by the researcher and supported by a second coder. Both the researcher and 
second coder independently coded the same three transcripts. Segments of interest within the text 
were assigned a label or code alongside notes and ideas, including questions raised, ideas to explore 
or patterns emerging. An excerpt of open coding from one interview is included below. The participant, 
a GP, describes the role of reception staff could be expanded to support GPs in identifying and 
managing high SABA use and how this could be done. The researcher’s underlining emphasises data of 






Coding example: GP 3 
Coding labels       Notes and Ideas 
157 So I can imagine reception are not looking at it enough, I’m sure if you’ve spoken to them they’ll say 
 
158 they never do and we haven’t… that’s our problem, we haven’t empowered them. Believe it or not that 
 
159 would work really… I think I’m just about… my next meeting is about empowering our reception staff 
 
160 and we’re very good at normally doing that and I think they’re actually now in a position of feeling 
 
161 that they could really try and get involved with patient care in more than just a, ‘Let’s give them an 
 
162  appointment, let’s triage them, let’s work out, signpost them,’ of actually where are they in this field? 
 
163 And I think having teams of people… almost saying to every receptionist, before you’re taking the 
 
164 prescription request look and see…So that’s me with this alert but then they could also be before 
 
165  you’re printing off if it’s a repeat, have a look at this alert, which I think you’re talking about would 
 
166 flash up. And then in my head, and it depends if we want to be paperless or not, it would be great if 
 
167 they could almost stamp the prescription or do something saying, ‘Doctor beware,’ because if they 
 
168 don’t issue it, then again, we’re getting a clog going on but they need to be just highlighting to us 
 






















What is the role of 
reception? GP 
expectation? Do 

















alert, applying clinical 
judgement? Increased 
role in decision 
making 
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After two researchers had each open coded the same three transcripts, we met to discuss coding 
progress. One full working day was spent reviewing the three transcripts. Discussion included why each 
section had been coded as such, why it had been interpreted as meaningful and what it told us about 
the identification and management of high SABA use in primary care and the role of alerts in this 
process. There was significant overlap in how researchers coded text, however, sometimes 
interpretations of the content was expressed in different ways. For example risk was coded in the text 
as of ‘’risk categorisation’ by one researcher and ‘recognising the risk’ by the other. Following 
discussion it was agreed to label this code as ‘recognising risk’, as shown in table A, to reflect 
participant’s interpretation of risk rather than determined by others. 
 
 
The initial framework underwent a process of application and refinement until the research questions 
aims were met and further data was not contributing any new data to address the research question. 
The analytical framework was repeated by the primary researcher until additional data collection was 
unlikely to generate new findings. This was influenced by no new codes emerging and no new 
definitions of high SABA use being introduced. The framework was discussed at a second meeting 
including codes and initial interpretations and no new codes were added to the framework. The final 
framework consisted of 7 sub-codes clustered into four themes. The following example shows how the 




Initial codes Subcode 
Defining overuse Volume and time frame 
EMIS alert 









SABA Prescribing Prescription type 
System 
Volume and time frame 
Assessment 
Challenges 
















Defining excessive use How high use is defined and perceived in relation to 
evidence 
Risk perceptions The perceived risk of high SABA and how the risk is 
contextualized by other drugs and evidence 
Identifying 
excessive use 
Methods The methods used to identify high SABA use and the 
influences on identification 
Challenges The human and systems factors influencing the 
identification of high SABA use 
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Section 5: Applying the analytical framework 
 
 
The final analytical framework was applied to each transcript using MAXQDA 2018. In practice, this 
meant importing transcripts to the software for indexing. The lead researcher systematically went 
through each transcript, highlighting each meaningful passage of text and selecting and attaching an 
appropriate code from the final analytical framework. Below is an excerpt from GP 4’s transcript in 
which the participant discussed high SABA use. The example below shows the application of the 






37 The excessive is more difficult, I think, ‘cause you’d look on the 
 
38 computer screen and obviously EMIS records usage and there is a sort 
 
39 of monitoring of how quickly people are going through their inhalers. 
 
40 I don’t think that that is incredibly accurate because it’s all about the 
 
41 data that gets put in. If you put 120 use inhaler is going to last 60 days 
 
42 and they’re asking for it every 30 days then it will say that their usage is 
43 200% and yet if they were using it 2 or 3 times occasionally, that still 
44 might not be overly concerning. 
35 particular sporting activity and those are planned uses then I think 
 
36 that’s OK, it’s when you find that those are insufficient that that makes 
 
37 me concerned. 
   Challenge  
    Methods  
32 So excessive is harder to define over concerning, so I’d start with if 
 
33 you’re using it as prescribed, so twice a day, and you’re not needing to 
 
34 use it on, well, if you used it when you go for a run or if you’re doing a 
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Once data had been coded using the framework, data was imported by theme from MAXQDA into 
Microsoft Excel. Data was presented by participant and code, and summarised it using verbatim words 
and inserted it into the corresponding cell in the matrix. Software enabled quick and easy retrieval of 
indexed data for specific codes within each transcript. Once the data was coded using the analytical 
framework, we summarized the data in a matrix for each theme using Microsoft Excel. Table 1 
documents the charting of codes from the Themes ‘Perceptions of excessive SABA use’ and ‘Identifying 






Table 1. Charting data into the Framework matrix 
 
 
 Defining excessive use Risk perceptions Methods Challenges 
GP 3 “Anyone who has more 
than 12 short-acting 
agonists a year, SABAs a 
year, should be 
highlighted” [p1, 15-17] 
“I think it’s no way on the same level. 
With methotrexate we’ve got about, 
I did a search the other day, we’ve 
got about 30, 40 patients, so it’s 
about volume as well, so I don’t think 
it is… [p11, 274-277] 
“We are positively encouraging 
people to go down this route, so 
the EPS medicine management, 
but some people don’t want to do 
it electronically straight to the 
chemist, they want choices” 
[p8, 192-196] 
“The QOF box works for me but 
I’m aware I’m the partner, the 
overseer, I’m the one that’s got 
that eye.” 
[p15, 400-401] 
‘”cause they’re probably just 
taking it with a panic attack 
rather than ‘cause they’ve 
got a genuine asthma” [p11, 
272-273] 
GP 4 “if you’re using it as 
prescribed, so twice a day, 
and you’re not needing to 
use it on… Well, if you used 
it when you go for a run or 
if you’re doing a particular 
sporting activity and those 
are planned uses then I 
think that’s OK” [p2, 33-37] 
“the actual patient in front of me is 
unlikely to be at risk of that without 
some other warnings or some other 
feature, so it makes it more difficult, I 
think” [p5, 121-125] And the vast 
majority of our patients who have 
asthma are unlikely to come to 
significant harm from it and it’s 
balancing those two priorities, which 
is challenging, I think” [p4, 115-117] 
“So either it comes as a paper 
prescription that we’ll sign or 
medicine management on the 
computer” [p6, 160-161] 
“you’d look on the computer 
screen and obviously EMIS 
records usage and there is a 
computer sort of monitoring of 
how quickly people are going 
through their inhalers” [p2, 38- 
40] 
“I don’t think that that is 
incredibly accurate because 
it’s all about the data that 
gets put in” [p2, 41-42] 
Expert 8 “A well-controlled asthmatic 
shouldn’t need more than 
one every six months so 
twelve a year is quite a high 
threshold.” 
[p7, 291-293] 
 “So the receptionist sort of deals 
with the paper-work side if you 
like but it has to come through to 
me to sign either on paper or 
increasingly these days almost 
electronic” [p4, 147-149] 
“The electronic prescribing bit is 
sort of separate to the patient 
record...it will tell me when the 
last prescription was but it wont 
tell me the ones before” [p7, 
302-307] 
“So the first thing I would 
say is to check the default 
setting, I don’t think EMIS 
has got it in quite the same 
way, that is it set to one” 
[p5, 214-215] 
Pharmacist 1 “The one we’ve got set up 
at the moment is more than 
six relievers in a year, so 
that’d be one every two 
months” [p4, 123-125] 
 “I tend to do the ones [repeat 
prescriptions] where the doctor’s 
on holiday or annual leave or not 
in that day and I get the extra 
ones. They come to me by 
default” [p9, 317-321] 
 “I just think the computer 
systems are not always that 
accurate because it relies on 
everything being input 
correctly” [p10, 357-362] 
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Themes were generated from the data set by reviewing the matrix and making connections within and 
between participant and categories. The generation of Theme 1 ‘Perceptions of excessive SABA use’ 
and Theme 2‘ Identifying excessive SABA use’ has been documented in this illustrative example (table 
C). This process was influenced both by the original research objectives and by new concepts generated 
inductively from the data. One of the research questions in the topic guide enquired how excessive 
SABA use was identified in practice. However this was interpreted in the context of the wider data to 
determine significance to the research question. Ideas were generated and explored beyond 




Whilst the methods used to identify high SABA use was of key importance when addressing the 
research question, it became apparent from the data that a number of issues influence  and impact on 
the ways in which excessive SABA use was identified. For example, the code ‘Defining excessive SABA 
use’ highlighted the methods used in practice and was conceptually related to ‘Risk perceptions’ which 
together formed the overarching category named ‘Perceptions of excessive SABA use.’ Whilst the 
codes ‘Methods’ and ‘Challenges’ formed the theme ‘Identifying excessive SABA use.’ 
 
 
• Defining excessive use 
High SABA use will be identified based on how one perceives high use. However there were variations 
between participants in regards to what constituted high use. For example there was contrasting 
opinions between experts and GPs regarding the definition of high use; “anyone who has more than 
12 short-acting agonists a year, SABAs a year, should be highlighted” [GP 3 p1, 15-17] in contrast to 
“a well-controlled asthmatic shouldn’t need more than one every six months so twelve a year is quite 
a high threshold.” [Expert 8, p7, 291- 293]. 
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• Risk perceptions 
This suggests a lack of certainty in how high SABA use is interpreted raising questions regarding the 
impact on variable interpretations of high use and associated risk. It is questionable as to whether 
those who define high use as 12 or more SABAs a year perceive high use as low risk. GP 3 described 
high use as 12 SABAs a year and did not perceive high use as problematic without further evidence: 
“so don’t think it is [of concern]… It would be if, and touch wood it hasn’t happened, you know, if 





Prescriber’s views on high SABA use and the associated risk, combined with varied methods to obtain 
SABAs, may result in inconsistent identification of high SABA use. As GP 4 explains, “once the 
prescription is done there is no review process…well, the next time will be when they next have a 
clinical encounter” (p6, 175-177). Furthermore there is no one standardised way of managing repeat 
prescriptions as GP 2 describes “when we did the prescribing review last year we said that everything 
should go through medicines management but we do have prescriptions that sit in a box each day…I 
don’t know what’s happening with those.” 
 
 
The methods used to obtain SABAs i.e. electronic or paper prescription, influence how high use is 
identified in practice. When SABAs were requested on repeat prescription GP 1 describes checking the 
EHR to identify the extent of high use: “I would go and look at then the medication was last issued 
because usually if they are on repeats they will have a  percentage usage so will straightaway know 
if that is more than 100%, then we know they are using it often, so that is like a flag for us.” In 
contrast, GP 4 describes manual checking the EHR as computerised indicators for usage were 
unreliable:  “I don’t think there’s a simple   way of doing it really, the only real way we have is of 
checking how many prescriptions we’ve done…” This raises questions about the reliance on 
computers to identify high SABA use, suggesting that the ways in which high SABA use is established 
depends on both human and systems factors. 
348  
• Challenges 
Human and systems factors presented challenges to the identification of high SABA use. For example 
whilst GPs relied on EHR systems to identify and present high use to the clinician, the EHR system relied 
on clinician data input to do so: “I don’t think that that is incredibly accurate because it’s all about 
the data that gets put in” [GP 4, p2, 41-42]. 
 
 
Whilst electronic methods to identify high SABA use are increasingly relied upon the  usefulness will 
depend on the context in which it presents, for example when repeat prescribing the patient is not 
present and can restrict response: “…the alert comes up like a pop-up but the problem can be when 
you cannot see the patient for days” (Expert 11) 
 
 
Despite the computer system identifying a patient as overusing SABAs, clinicians respond to overuse 
in different ways based in their interpretations of high use. In the following, GP 4 describes high SABA 
use as open to interpretation and would continue to prescribe based on his own interpretations: “So 
the prescription is likely to be issued unless there’s something… some crazy number, so if they are 
100, 150%, perhaps 200%, I suspect the prescription would be issued. If they’ve got 600% usage or 






Points for further consideration 
 
Why does GP 4 suspect the prescription would still be issued? What 
influences the perception of high SABA use as low risk? What type of 
action occurs when high SABA use is identified? How might an alert 
assist with this? 
